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Ineleganolide, horiolide, kavaranolide, sinulochmodin C, scabrolide A, scabrolide 
B, and yonarolide are related polycyclic furanobutenolide norcembranoid natural 
products that exhibit potent biological activity, and feature highly oxygenate carbocyclic 
scaffolds with complex stereochemical frameworks. Herein, we describe a unified 
synthetic approach toward ineleganolide and the related furanobutenolide 
norcembranoids. Assembly of the tetracyclic scaffold of ineleganolide is accomplished in 
a convergent manner from (R)-carvone and an enantioenriched cis-1,3-cyclopentenediol 
fragment, which is constructed by a key enantioselective allylic alkylation. From the 
combined product of the two major fragments, we employ a tandem intramolecular 
cyclopropanation/Cope rearrangement to furnish the cycloheptene carbocyclic core 
characteristic of ineleganolide.  
Synthetic manipulations of this carbocyclic core are extensively investigated; 
several constitutional isomers of ineleganolide are synthesized through these studies. 
Many approaches are explored to assist in the completion of the synthesis. Computational 
studies inform our understanding of the conformational bias of late-stage intermediates. 
The retroaldol-aldol carbocyclic isomerization from the core of ineleganolide to the core 
of sinulochmodin C is also investigated.  
Additionally, our work on the (3 + 2) cycloadditions of heterocumulenes with 
donor–acceptor cyclopropanes and with N–H- and N–sulfonyl aziridines is disclosed. The 
exploration of substrate scope, reaction mechanism, and the enantiospecific formation of 
heterocyclic products in investigated.   
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Furanobutenolide Cembranoid and Norcembranoid Natural Products: 
Biosynthetic Connections and Synthetic Efforts 
 
 
1.1   Introduction 
The cembranoid natural products are a vast family of marine and terrestrial 
diterpene natural products found throughout the world.  This structurally diverse and 
highly oxygenated class of metabolites is produced in vast numbers by an array of 
gorgonian octocorals and soft coral species.  Considering the relatively few marine fauna 
that prey upon gorgonian and soft corals, it has been hypothesized that marine 
cembranoids serve to defend against competing and/or predatory organisms.1  Indeed, the 
isolation and investigation of the biological activity of cembranoids has led to the 
discovery of a vast range of structurally diverse, biologically active compounds 
possessing potent cytotoxicity.2  
Among the most biologically active members of the cembranoids is the subclass of 
furanobutenolides, including the macrocyclic furanobutenolide C20-cembranoids 
lophotoxin (1), bipinnatin D (2), and bipinnatin I (3) as well as the C19-norcembranoids 
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sinuleptolide (4) and 5-episinuleptolide (5, Figure 1.1.1).  Lophotoxin is a potent 
neurotoxin, functioning as an irreversible antagonist of the nicotinic acetylcholine 
receptor.3  Alternatively, bipinnatin D (2) is active against P-388 murine leukemia in 
vitro4 and bipinnatin I (3) is strongly cytotoxic (µM GI50) against a variety of cancer cell 
lines including variants of melanoma and colon cancer. 5   The norcembranoids 
sinuleptolide (4) and 5-episinuleptolide (5) also possess antitumor and cytotoxic 
properties toward human KB human oral epidermoid cells, Hepa59T/VGH human liver 
carcinoma cells, and a panel of squamous cell carcinomas (µM IC50).6 
Figure 1.1.1. Characteristic Macrocyclic Furanobutenolide Cembranoids and Norcembranoids 
 
Among the vast numbers of macrocyclic furanobutenolides are a small subset of 
congested, stereochemically complex, and extensively oxygenated polycyclic diterpenes 
and norditerpenes (Figure 1.1.2).  Example polycyclic diterpenes include 
bielschowskysin (BSK, 6), the cytotoxic cyclobutanoid that is highly active against 
EKVX nonsmall cell lung cancer (GI50 < 0.01 µM),7 as well as the mildly cytotoxic 
intricarene (7)8 and rameswaralide (8).9  The polycyclic norcembranoid diterpenes are 
highlighted by the antileukemic ineleganolide (9)10 and the isomeric sinulochmodin C 
(10),11 which are both highly compact, cycloheptanone-derived ketofurans.  The beauty 
and complexity of these structures, paired with their pertinent and variable bioactivity, 
has and continues to entice synthetic chemists to pursue their syntheses and further 
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Figure 1.1.2. Characteristic Polycyclic Furanobutenolide Cembranoids and Norcembranoids 
 
 
1.2   Statement of Purpose  
The purpose of this review is not to present a comprehensive catalog of the 
literature surrounding the cembranoid family of natural products. 12  A tremendous 
amount of research has been performed previously by Trauner13 and Pattenden,1a,14 among 
others,2c,15 to compile a series of scholarly works covering the known members of the 
cembranoid natural products, their biological activity, and the elaborate details of their 
biosynthetic relationships.  Rather, the focus of this chapter will be on the polycyclic 
furanobutenolide members of the cembranoid natural product family and the array of 
approaches taken toward their syntheses.  Including semisynthetic studies and de novo 
synthetic efforts, we have gathered this body of knowledge to gain insight into the 
reactivity and constraints of these compact and highly oxygenated polycyclic structures. 
1.3   Polycyclic Furanobutenolide Cembranoids and Norcembranoids 
The polycyclic furanobutenolide natural products can be separated into two 
categories: cembranoid and norcembranoid (Figure 1.3.1).  The former is derived from 
macrocyclic furanobutenolide scaffold 11, which is derived from the linear tetraisoprene 
geranylgeranyl diphosphate and has retained all 20 carbons.1a Comparatively, the 
norcembranoid furanobutenolide natural products are based on macrocyclic lactone 
precursors related to furan 12, which contains only 19 carbons.  It has been postulated 
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The absolute stereochemistry of the polycyclic cembranoids is biosynthetically derived 
from oxygenated derivatives of scaffolds 11 and 12, which contain the isopropenyl and 
butenolide groups in the C(1)-(R)- and C(10)-(S)-configurations, respectively, as 
drawn.11,16  
Figure 1.3.1. Cembranoid and Norcembranoid Macrocyclic Scaffolds 
 
There are 10 polycyclic furanobutenolide cembranoids, including macrocycles BSK 
(6) and verrillin (13), polycycles intricarene (7), rameswaralide (8), havellockate (14), 
and the closely related plumarellides and mandapamates (15–19, Figure 1.3.2).  
Decorated by a variety of oxygenation states and patterns, these furanobutenolide 
diterpenes display a variety of complex, highly compact, stereochemically dense 
architectures.  In a similar fashion, the biosynthetically related furanobutenolide 
norcembranoids include ineleganolide (9), horiolide (20), kavaranolide (21) all possess a 
central heptacycle.  In comparison, the remaining members of the polycyclic 
furanobutenolide norcembranoids dissectolide (22), sinulochmodin C (10), scabrolide B 
(23), scabrolide A (24), and yonarolide (25) are all constructed around a central 6-
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Figure 1.3.2. Polycyclic Cembranoid Furanobutenolide Natural Products 
 
Figure 1.3.3. Polycyclic Norcembranoid Furanobutenolide Natural Products 
 
1.4   Brief Summary of Biosynthetic Connections 
Despite the breadth of complexity found within the family of polycyclic 
furanobutenolide diterpenes and norditerpenes, these natural products are typically co-
isolated with (and hypothesized to be derived from) the more simplified furanobutenolide 
macrocycles.  Before discussing synthetic strategies, it is critical to establish the context 
of the interconnected nature of these polycycles derived from the postulated biosynthetic 
routes.  While the comprehensive review of the biosynthesis of the cembranoid and 
norcembranoid natural products can be found elsewhere,1a,13,14,15 a brief overview of 
postulated biosynthetic routes to these molecules is presented before exploring the in 
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1.4.1   Biosynthesis of Polycyclic Furanobutenolide Cembranoids  
Bielschowskysin (BSK, 6) is a rare cyclobutane-containing cembranoid that is 
highly biologically active, showing excellent cytotoxicity against EKVX nonsmall cell 
lung cancer (GI50 < 0.01 µM) and CAKI-1 renal cancer (GI50 = 0.51 µM) as well as 
antiplasmodial activity.7 The majority of synthetic efforts toward entry into the polycyclic 
cembranoids have focused on the synthesis of BSK, owing the attention to its unique 
carbocyclic scaffold paired with its bioactivity profile (vida supra).  Biosynthetically, 
BSK is believed to be derived from bipinnatin J (26, Scheme 1.4.1.1).1a,13 Oxidation at 
C(13) and C(16) followed by intramolecular lactolization would provide acetate 27.  
Oxidation of the Δ7,8 bond would afford epoxide 28 and subsequent doubly vinylogous 
transposition across the furan ring would furnish hydroxyfuran 29.  Butenolide 29 is then 
positioned to undergo a light-induced [2 + 2] cycloaddition to construct the characteristic 
cyclobutane ring and complete BSK (6).   
Scheme 1.4.1.1. Biosynthetic Proposal for the Construction of Bielschowskysin (BSK, 6) 
 
The furanobutenolide verrillin (13),17 similarly based around a central ether-bridged 
macrocycle, is also likely derived from bipinnatin J (26, Scheme 1.4.1.2).1a,13 Alternative 
oxidation of butenolide 26 would not only oxidizes C(13) and the isopropenyl group, but 
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oxidative opening of the furan ring.  Intramolecular Michael addition within vinylogous 
diketone 30 would construct the C(7)–C(11) bond, furnishing polycycle 31 after 
transposition of the acetate group to reveal an oxyanion at C(13).  Ultimately, sequential 
ketalization of diol 31 through the vinylogous diketone system and hydrolysis of the enol 
acetate moiety would provide verrillin (13).   
Scheme 1.4.1.2. Biosynthesis of Verrillin (13) 
 
Bipinnatin J also likely serves as the biosynthetic precursor for the contrasting 
pentacyclic cytotoxic cembranoid intricarene (7).1a,8,13,18  Oxidative cleavage of the furan 
ring affords homoallylic alcohol 32 (Scheme 1.4.1.3).   Equilibration of alcohol 32 
through hemiketal 33 would access oxocarbenium 34.  The charge separated aromatic 
ring within macrocycle 34 is proposed to participate in an intramolecular [5 + 2] 
cycloaddition, forming the furan-bridged cycloheptenone ring and completing the 
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Scheme 1.4.1.3. Biosynthetic Speculation Concerning the Formation of Intricarene (7) 
 
Bipinnatin J (26), however, is not the progenitor of every polycyclic cembranoid.  
Macrocycle 35, which in comparison to bipinnatin J is oxidized at C(18) rather than C(2) 
and has an extra unit of unsaturation between C(13) and C(14), is the proposed precursor 
to the hemolytic cembranoids plumarellide (15) and plumarellate (16, Scheme 
1.4.1.4.A).1a,13,19 Oxidation across the Δ7,8 bond followed by olefin transposition would 
afford intermediate hemiketal 36.  Diene 36 could proceed through an intramolecular [4 + 
2] cycloaddition with the transannular enol moiety to construct the central cyclohexene 
ring and complete plumarellide (15).  Ethanolysis of the lactone by ethanol would 
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Scheme 1.4.1.4. Proposed Biosynthetic Construction of the Plumarellides and Mandapamates 
 
Analogs of the plumarellides, the cembranoid natural products mandapamate (17)20 
and isomandapamate (18),21 and bishomoisomandapamate (19),22 are expected to arise 
from a related biosynthetic route (Scheme 1.4.1.4.B and 1.4.1.4.C).1a,13,20,21 Each of these 
three natural products would be formed from a derivative of macrocycle 37, a C(8) 
epimeric analog of intermediate 36, that has been oxidized to the acid oxidation state at 
C(18), and possesses methyl ketal rather than a hemiketal at the furan ring (i.e., C(3)).  
Mandapamate (17) would be constructed by the intramolecular [4 + 2] cycloaddition for 
the E-enol isomer of 37 (Scheme 1.4.1.4.B).  Isomandapamate (18, R = Me) and 
bisohomoisomandapamate (19, R = Et) would be formed in an analogous manner from 
the Z-enol isomer of ketal 37 (Scheme 1.4.1.4.C). 
The biosynthetic formation of the remaining two members of the polycyclic 
cembranoid natural product family remains unclear.   Havellockate (14) contains a related 
tricyclic core to the plumarellides and the mandapamates that is flanked by a spirocyclic 
butyrolatone whose relative stereochemistry was unambiguously established upon initial 
isolation (Figure 1.4.1.1).23  Comparatively, the cytotoxic diterpenoid rameswaralide (8) 
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cycloheptenone.9,24  Both havellockate (14) and rameswaralide (8) bear similarities to the 
plumarellides and the mandapamates, although they are both epimeric at C(8) compared 
to the former and epimeric at C(7) compared to the later.  Multiple biosynthetic proposals 
have been described, hypothesizing that havellockate (14) and rameswaralide (8) may 
arise either from the cyclization cembranoids related to macrocycles 36 and 37 with the 
proper C(8) stereochemistry or from rearrangement cascades directly forming the 
plumarellides and mandapamates.1a,13,24,25 
Figure 1.4.1.1. Structural Comparison of Havellockate (14) and Rameswaralide (8) to Plumarellide 
(15) and Mandapamate (17) 
 
 
1.4.2   Biosynthesis of Polycyclic Furanobutenolide Norcembranoids 
The furanobutenolide norcembranoid natural products are exclusively found in soft 
corals of the genus Sinularia.1a,14  The progenitors of all of these C19 natural products are 
speculated to be the sinuleptolides (4 and 5), being epimeric at C(5) and likely in 
equilibrium via epimerization in vivo (Figure 1.4.2.1).1,11,14 The biosynthetic derivation of 
macrocyclic cembranoids to the antitumor norcembranoids sinuleptolide (4) and 5-
episinuleptolide (5) has been described in detail elsewhere and will not be discussed 
here.1,6,14  
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The biosynthesis of the antileukemic norditerpenoid ineleganolide (9)10 and the 
related cycloheptanone natural products horiolide (20)26 and kavaranolide (21)27 are 
proposed to arise from ketofuran 38, which is formed after the intramolecular Michael 
addition of 5-episinuleptolide (5) and sequential dehydration (Scheme 1.4.2.1).1a,14 
Subsequent 5-exo-trig Michael addition would forge the C(7)–C(19) bond and complete 
ineleganolide (9).   
Scheme 1.4.2.1. Biosynthesis of Ineleganolide (9), Horiolide (20), and Kavaranolide (21) 
 
Ineleganolide could subsequently undergo a retro-oxa-Michael addition, opening 
the ketofuran ring, followed by a retro-Michael addition to provide methyl ketone 
intermediate 39.  Considering ketone 39 has yet to be isolated and described from natural 
sources, it is proposed to rapidly undergo an intramolecular Michael addition to construct 
the C(5)–C(9) bond and furnish horiolide (20).  Ultimately, isomerization of horiolide by 
elimination of the β-acetoxy group would generate the unsaturated methyl ketone found 
within kavaranolide (21).   
In a similar fashion, 5-episinuleptolide (5) could serve as the biosynthetic 
progenitor to sinulochmodin C (10),11 scabrolide B (23),6d scabrolide A (24),6d and 
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intramolecular Michael cyclization to construct the characteristic peripheral 
cycloheptanone ring of these related norcembranoids and furnish intermediate 40 after 
dehydration.  Ketofuran 40 would furnish sinulochmodin C (10) after a second Michael 
addition to construct the bond between C(7) and C(11).   
Scheme 1.4.2.2. Biosynthetic Formation of Sinulochmodin C (10), Scabrolide B (23), Scabrolide A 
(24), and Yonarolide (25) 
 
 
Scabrolide B (23) could be biosynthetically produced by one of two possible routes.  
First, scabrolide B could be formed after a retro-oxa-Michel addition from sinulochmodin 
C (10).  Alternatively, direct conversion of biosynthetic intermediate 40 to scabrolide B 
could occur by a retro-oxa-Michael addition and subsequent intramolecular Michael 
addition.  From scabrolide B (23), olefin isomerization from a trisubstituted vinylogous 
diketone to a tetrasubstituted enone would furnish scabrolide A (24).  Ultimately, 
sequential dehydration would provide the dienone norcembranoid yonarolide (25). 
The exact biosynthetic process for the construction of the remaining member of the 
polycyclic norcembranoids, dissectolide A (22), is less clear.29 Two plausible biosynthetic 
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bears remarkable similarity to the mandapamate and plumarellide cembranoids (see 
Scheme 1.4.1.4), perhaps suggesting that intermediate 41, with the Δ13,14 bond in the trans 
configuration, undergoes a [4 + 2] cycloaddition with the C(6)–C(7) enol tautomer of the 
ketofuran ring to directly construct the central cyclohexene moiety of tetrahydrofuran 42.  
Macrocycle 41 could alternatively proceed to intermediate furan 42 in a stepwise manner 
through a Michael addition between C(7) and C(11) and subsequent vinylogous aldol 
cyclization of the resultant enolate to construct the C(14)–C(6) bond.  Proposed 
intermediate 42 would then only need to undergo the hydrolytic opening of the furan ring 
in an SN2 fashion to complete the biosynthesis of dissectolide A (22).   
Scheme 1.4.2.3. Biosynthetic Conjectures for the Formation of Dissectolide A (22) 
 
1.5  Synthetic Studies Toward Polycyclic Cembranoids and 
Norcembranoids 
 
A testament to the synthetic challenge of accessing the complex structures of the 
polycyclic furanobutenolide cembranoid and norcembranoid natural products is that the 
syntheses of only a handful of members of this family have been completed. This article 
will explore the literature concerning the synthetic efforts toward the polycyclic 
furanobutenolide cembranoid and norcembranoid natural products in an effort to 
condense the knowledge surrounding these natural products and explore the limitations 
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1.5.1   Synthetic Efforts Toward Bielschowskysin (BSK, 6) 
Bielschowskysin (BSK, 6) has been the most studied member of either the 
polycyclic cembranoid or norcembranoid family of natural products, piquing the interest 
of the scientific community with its unique cyclobutane scaffold and potent biological 
activity.7  Six different research groups have reported synthetic studies toward BSK, five 
of them employing a light-induce cyclobutane formation.  While the total synthesis of 
BSK has not yet been reported, a tremendous amount of work toward the 
functionalization of the BSK scaffold has been accomplished.  Because of this large body 
of literature, this chapter will be limited to a brief summary of each approach taken and 
the limitations that prevented each method from advancement to BSK.   
1.5.1.1  Photo [2 + 2] Approaches to Bielschowskysin 
 The majority of approaches toward the synthesis of BSK have hinged on a photo-
induced [2 + 2] cycloaddition to construct the characteristic fused cyclobutane moiety.  In 
that sense, there are two directions to retrosynthetically disconnect the central 
cyclobutane within building block 43 (Scheme 1.5.1.1.1).   The most commonly 
employed retrosynthetic disconnection of the four-membered carbocycle has been along 
the axis of the [4,5]-bicycle (Pathway A, green arrow) to furnish retron 44. 
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The utility of this synthetic approach was explored by Ghosh and coworkers.30 
Early synthetic studies to explore the planned copper-catalyzed [2 + 2] 
photocycloaddition were performed on a model system that was available in an 
enantiopure fashion after three synthetic transformations from a known reported 
derivative of α-D-glucofuranose (Scheme 1.5.1.1.2.A).  Copper(I) triflate-catalyzed [2 + 
2] cycloaddition of 1,6-diene 46 proceeded smoothly to furnish cyclobutane 47 in 75% 
yield as a single diastereomer.  The cycloaddition is hypothesized to proceed exclusively 
through the copper-coordinated intermediate 48, accounting for the observed 
stereoselectivity.  Attempting to extend the developed cycloaddition to a functionalized 
system more closely related to BSK, Ghosh and coworkers synthesized allylic alcohol 49 
(Scheme 1.5.1.1.2.B).  Under the same copper-catalyzed light-induced [2 + 2] 
cycloaddition conditions, cyclobutane 50 was isolated in a comparable 66% yield.  
Unfortunately, while the substrate has dictated the formation of many of the stereocenters 
as required for BSK, the configuration at C(8) and C(10) were epimeric to those found in 
BSK. 
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The development of a method for the tandem epimerization of C(8) and C(10) was 
procured on the closely related allylic alcohol 51 (Scheme 1.5.1.1.3).  Photocycloaddition 
again under copper(I)-catalyzed conditions produced cyclobutane 52 in 78% yield.  A 
five step redox procedure from trans-1,3-cyclopentanediol 52 accomplished the inversion 
of configuration at both C(8) and C(10) by a tandem oxidation-elimination pathway, 
setting their relative stereochemistry as required for BSK.  To date, protected trans-diol 
53 represents the most advanced published compound produced by Ghosh and coworkers 
in their work toward BSK.   




Sulikowski and coworkers also envisioned accessing BSK by a similar 
retrosynthetic strategy (Scheme 1.5.1.1.4).31  Simplifying BSK to scaffold 54, they 
planned to construct the core central cyclobutane through an intramolecular [2 + 2] 
photocycloaddition of dibutenolide 55.  Diastereoselective control of this cycloaddition 
depends on both the geometry of the exocyclic olefin as well as the steric encumbrance of 
the butenolide-substituted olefin cycloaddition partners.   
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Development of the reaction conditions for the desired photochemical [2 + 2] 
cycloaddition began with the model butenolide 56, where the steric congestion at the 
butenolide cycloaddition partner was reduced from optimal (Scheme 1.5.1.1.5).  Lactone 
56 was available in an enantiospecific fashion from (–)-malic acid.  Intramolecular 
cycloaddition of enoate 56 proceeded smoothly, furnishing spirocycle 57 in 50% yield as 
a single diastereomer.  UV light was not required in order to induce the desired 
cycloaddition and  the choice of acetone for the solvent was critical for the minimization 
of impurity formation.  The stereoselective formation of cyclobutane 57 accomplished 
solely by substrate control to provide the desired scaffold that mirrors the relative 
stereochemistry found in BSK (6).   
Scheme 1.5.1.1.5. Model System for Intramolecular Butenolide [2 + 2] Cycloaddition (Sulikowski) 
 
Having succeeded in selectively forming the tetracyclic scaffold of BSK, 
Sulikowski and coworkers turned their attention to the construction of a more densely 
functionalized cyclobutane for synthetic advancement toward BSK.  Thus the [2 + 2] 
cycloaddition of substrate 58 was explored, where the butenolide cycloaddition partner 
has been functionalized with a side chain produced in an enantiospecific fashion from D-
glyceraldhyde (Scheme 1.5.1.1.6).  Fully elaborated butenolide underwent a visible light-
induced [2 + 2] cycloaddition to provide cyclobutane 59 in 81% yield over two steps after 
the removal of the benzyl ether by hydrogenolysis.  Pleasingly, like cyclobutane 57, 
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the fully elaborated fused cyclobutane polycyclic portion of BSK and represents the most 
advanced intermediate detailed by the Sulikowski group to date. 
Scheme 1.5.1.1.6. Intramolecular [2 + 2] Cycloaddition with Elaborated Butenolide (Sulikowski) 
 
Mulzer and coworkers envisioned accomplishing the construction of the 
cyclobutane moiety from an even more functionalized, late-stage synthetic intermediate.32  
Access to BSK (6) was planned by the late-stage oxidation of exocyclic olefin 60 
(Scheme 1.5.1.1.7).  Construction of the central macrocycle would be accomplished by 
an intramolecular Heck reaction of vinyl bromide 61.  Olefin 61 would be constructed by 
an intramolecular light-mediated [2 + 2] cycloaddition of allene 62 to construct the 
characteristic 4-membered carbocycle. 
Scheme 1.5.1.1.7. Mulzer’s Retrosynthesis of BSK Employing an Allene [2 + 2] Cycloaddition 
 
Asymmetric access to late-stage allene 62 was achieved in an enantiospecific 
fashion, in a similar fashion to other synthetic approaches, beginning with (–)-malic acid 
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homologation of a terminal alkyne and carried through a number of synthetic 
transformations to access to butenolide 63.  Intramolecular [2 + 2] cycloaddition induced 
by UV-C light in cyclohexane provided cyclobutane 64 as a single diastereomer, 
furnishing the stereochemistry around the periphery of the cyclobutane as required for 
BSK.   
Scheme 1.5.1.1.8. Allene [2 + 2] Cycloaddition (Mulzer) 
 
Subsequently, the construction of the central macrocycle would be necessary in 
order to progress toward BSK.  Unfortunately, under Heck cyclization conditions, desired 
cyclononene 67 was not isolated (Scheme 1.5.1.1.9).  Surprisingly, Mulzer and 
coworkers observed a cyclization to produce cyclooctane 66, which has undergone a 
concomitant acetoxylation of the 1,1-disubstituted olefin to provide a neopentyl acetate.  
Although this type of reactivity had previously been unknown for a 1,1-disubsitited 
olefin, the direct advancement of vinyl bromide 65 toward BSK was thwarted.  While 
Mulzer and coworkers continue to explore the utility of cyclooctane 66 as a synthetic 
intermediate en route to BSK, they have pursued a series of alternative retrosynthetic 
strategies in their pursuit of the total synthesis of BSK (vide infra). 
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In comparison to Mulzer’s planned late-stage formation of the central macrocycle 
after construction of the cyclobutane moiety, Nicolaou and coworkers explored the 
potential to accomplish the formation of the 4-membered carbocycle after completion of 
the macrocyclic scaffold in a manner reminiscent of the proposed biosynthesis of BSK 
(see Scheme 1.4.1.1).33  Retrosynthetically, BSK was simplified to a model core scaffold 
68, retaining the required functionalization or providing a functional group handle at 
C(2), C(3), and C(8) (Scheme 1.5.1.1.10.A).  Synthesis of polycycle 68 would be 
accomplished by the transannular photochemical [2 + 2] cycloaddition of alkene 69. 




Enantioselective synthesis of the macrocyclic cycloaddition precursor 69 began 
with the coupling of furan 70 and β-ketoester 71 (Scheme 1.5.1.1.10.B).  Furanyl alcohol 
70 was produced with 92% enantiomeric excess (ee) by asymmetric reduction of the 
corresponding α-ketofuran precursor.  Over the following three synthetic 
transformations, the (S)-configuration at C(2) dictated the stereochemistry at the 
remaining chiral centers, furnishing desired diastereomer 69 in 20% yield from alcohol 
70 with  the minor diastereomer 72 also possessing an anti relationship between the C(3)-
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The potential of both furan macrocycles 69 and 72 to undergo an intramolecular [2 
+ 2] photocycloaddition was subsequently explored. Furan 69, when exposed to UV-B 
light in either benzene or chloroform, produced cyclobutane 68 in high yield as a single 
diastereomer (Scheme 1.5.1.1.11.A).  The new fused carbocycle contained the desired 
relative stereochemistry, furnishing the spirocyclic furan as found in BSK.  Under 
identical photocyclization conditions, diastereomeric macrocycle 72 produced carbocycle 
73 as the sole product (Scheme 1.5.1.1.11.B).  The relative stereochemistry of furan 72 
dictated enantiomeric formation of the stereocenters on the periphery of the cyclobutane 
in comparison to polycycle 68, constructing the spirocyclic furan in the opposite and 
undesirable sense for advancement toward BSK.  Although cyclobutane contains the 
proper spirocycle relative to BSK and a series of functional group handles, the Nicolaou 
group has not disclosed any further studies to date concerning its advancement toward 
BSK. 
Scheme 1.5.1.1.11. Stereochemical Outcome of Macrocyclic [2 + 2] Cycloaddition (Nicolaou) 
 
By a comparative approach toward BSK, Lear and coworkers additionally 
envisioned late-stage construction of the cyclobutane moiety from a fully elaborated 
macrocyclic precursor 74 by a tandem [2 + 2]-oxidative [4 + 2] cycloaddition (Scheme 
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hydroxyl group and subsequent isomerization.  In the forward sense, allene 74 would 
proceed toward BSK by first undergoing a light-induced [2 + 2] cycloaddition to furnish 
cyclobutane intermediate 76 (Scheme 1.5.1.1.13).  Diene 76 would then undergo a 
photochemical [4 + 2] cycloaddition with singlet oxygen to construct peroxide 77.  
Homolytic cleavage of the peroxide bond by cobalt(II) would result in the formation of 
elaborated BSK scaffold 78.   
Scheme 1.5.1.1.12. Lear’s Macrocyclic Tandem [2 + 2] and [4 + 2] Cycloaddition Strategy  
 
Scheme 1.5.1.1.13. Planned Tandem [2 + 2] and [4 + 2] Cycloaddition in the Forward Sense (Lear) 
 
Initial exploration of the planned tandem cycloaddition strategy focused on the 
potential to accomplish the [2 + 2] cycloaddition of a tethered allene and butenolide 
system.  Model allene 79 was available in an enantiospecific fashion from (–)-malic acid 
in 10 synthetic steps, constructing the allene moiety by a homologation of an alkyne 
(Scheme 1.5.1.1.14).  Irradiation of allene with UV light in a 1:1 mixture of hexane and 
dichloromethane furnished the desired cyclobutane tricycle (80) in 70% yield as a single 
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acid as the starting material has endowed the cyclobutane tricycle with both the relative 
and absolute stereochemistry as required for BSK.  These initial studies concerning the 
formation of allene 79 and its success in a [2 + 2] cycloaddition as desired informed the 
aforementioned synthetic strategy of Mulzer and coworkers (see Scheme 1.5.1.1.7).32  
Scheme 1.5.1.1.14. Model System Studies on Allene Cycloaddition with a Butenolide (Lear) 
 
With this result in hand, Lear and coworkers aimed to construct the fully elaborated 
system and test the efficacy of the proposed tandem [2 + 2] and [4 + 2] cycloaddition.  
Enantiospecific access to macrocycle 81 was achieved from (–)-malic acid paired with a 
known derivative of α-D-glucofuranose (Scheme 1.5.1.1.15).  The central macrocycle 
was stitched together using a Sonogashira coupling and subsequent macrolactonization.  
Unfortunately, progress toward BSK was halted at intermediate 81 because cyclization 
between the primary chloride and the α-position of the β-ketoester could not be achieved.  
Without the ability to form the butenolide moiety, the tandem oxidative cycloaddition 
cascade could not be investigated.   
Scheme 1.5.1.1.15. Model System Studies on Allene Cycloaddition with a Butenolide (Lear) 
 
Although these synthetic approaches toward BSK had provided numerous methods 
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elusive.  As a result, Mulzer and coworkers developed an alternative retrosynthetic 
strategy for the construction of the BSK core 83 (Scheme 1.5.1.1.16).35  Rather than 
bisecting the cyclobutane along the axis of the [4,5]-bicycle like each of the previous 
synthetic approaches, they envisioned accessing the 4-membered carbocycle by an 
intramolecular photo-induced [2 + 2] cycloaddition between an α,β-unsaturated ester and 
a cyclopentenyl olefin.   
Scheme 1.5.1.1.16. Alternative Retrosynthetic Analysis of Cyclobutane Moiety of BSK (6, Mulzer) 
 
Investigation of the desired [2 + 2] cycloaddition began with the assessment of a 
cyclopentene diol (85) in a [2 + 2] photocycloaddition (Scheme 1.5.1.1.17.A).  
Cyclopentene 85 underwent [2 + 2] cycloaddition with maleic anhydride in the presence 
of UV-A light, furnishing cyclobutane 86. Unfortunately, nearly every attempt to 
construct functionalized tricycle 87 was unsuccessful, including systems containing an 
ester conjugated with substituted allenes, ketenes, ketene acetals, ketene iminium salts, 
aryl groups, and butenolides in the presence of either a sun lamp, UV-A, or UV-B light or 
under thermal conditions (Scheme 1.5.1.1.17.B).  Successful [2 + 2] cycloaddition could 
only be accomplished with allene 89 generating tetrahydrofuran 90 in 60% yield (Scheme 
1.5.1.1.17.C).  Rather than explore the advancement of tricycle 90 toward BSK, the 
authors chose to explore an alternative route through which the cyclobutane moiety was 
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Scheme 1.5.1.1.17. Limitations of Targeted [2 + 2] Cycloaddition (Mulzer) 
 
1.5.1.2  Non-Photochemical Approaches to Bielschowskysin 
In the face of the challenges encountered in their efforts toward BSK (6), Mulzer 
and coworkers designed a 3rd generation synthetic strategy toward BSK hinging on the 
production of core scaffold 91 from a cyclobutane-containing feedstock (93, Scheme 
1.5.1.2.1).35,36  Enantioselective access to tricycle 91 was envisioned from cyclobutanol 
(+)-92.  Bicycle (+)-92 could be synthesized over four steps from racemic ketone 93 by a 
classical resolution.  Thus the cyclobutane moiety within BSK was available from 
commercially available ketone 93. 
Scheme 1.5.1.2.1. Mulzer’s 3rd Generation Retrosynthetic Analysis of BSK (6) 
 
Cyclobutanol (+)-92 was advanced toward BSK through a series of stereoselective 
alkylations and redox manipulations over 16 steps to furnish the enantioenriched tricyclic 
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advancement of aldehyde 91 toward BSK was found to be infeasible.  Attempts to 
functionalize the 1,1-disubstitued olefin with carbon nucleophiles in a productive manner 
failed.  As a result, intermediate 95, encountered en route to aldehyde 91, was utilized for 
further elaboration (Scheme 1.5.1.2.2.B).  From cyclobutane 95, installation of the 
spirocyclic furan was accomplished as desired for BSK and the complimentary furan was 
synthesized in an enantiospecific fashion from α-D-glucofuranose and installed by a 
chromium(II)-mediated coupling, furnishing polycycle 96 in 13% yield over eight steps.  
Although Mulzer and coworkers envision advancement of ketal 96 to BSK over a few 
additional synthetic transformations, and they briefly explored an additional strategy for 
the formation of core 91 by a ring contraction strategy without any success,32b they have 
instead chosen to actively pursue their light-induced [2 + 2] cycloaddition strategy for 
continued efforts toward BSK (see Scheme 1.5.1.1.8). 
Scheme 1.5.1.2.2. Advancement of Enantioenriched Cyclobutanol (+)-92 Toward BSK (Mulzer) 
 
The final strategy for the synthesis of BSK presented in the literature to date is a 
cyclopropane fragmentation-Michael addition strategy developed by Stoltz and 
coworkers.37  Access to BSK (6) was envisioned through the highly functionalized core 
cyclobutane-centered polycycle 97 (Scheme 1.5.1.2.3).  Construction of the cyclobutane 
was planned through an intramolecular Michael addition of enolate 98 into the extended 
oxocarbenium fragment.  Generation of charge-separated intermediate would be achieved 
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Scheme 1.5.1.2.3. Stoltz’s Retrosynthetic Analysis of BSK Core Scaffold 97 
 
Investigation of the planned cyclopropane fragmentation began with the 
enantioselective synthesis of furan-substituted cyclopentenediol 100 by palladium-
catalyzed aerobic oxidative kinetic resolution (Scheme 1.5.1.2.4).  By this method, diol 
100 was accessible in 93% ee.  Cyclopropane 101 was then synthesized from diol 100 in 
29% yield over four steps.  Unfortunately, advancement of the cyclopropane was plagued 
by nonproductive translactonization after liberation of the free hydroxyl group at C(8) 
independent of the identity of and conditions used to remove the protecting group.  For 
example, saponification of acetate 101 results in translactonization, liberating a free 
hydroxyl at C(10), which underwent oxidation by DMP and after cyclopropane 
fragmentation, regenerated the bicyclic lactone scaffold as ketal 102.  Ultimately, like all 
of the other synthetic methods disclosed to date, Stoltz and coworkers were not 
successful in the completion of their efforts toward BSK (6), as they were unable to 
develop conditions for the successful advancement of any cyclopropane scaffold related 
to 101 to the desired cyclobutane intermediate. Bicyclic lactone 102, however, could still 
be employed as an intermediate toward the total synthesis of verrillin (13).   











































































1) K2CO3, MeOH, 0 °C
2) DMP, CH2Cl2
3) La(OTf)3
    MeOH, 55 °C






Chapter 1 –Furanobutenolide Cembranoid and Norcembranoid Natural Products 28 
1.5.2   Synthetic Efforts Toward Verrillin (13) 
The total synthesis of the closely related macrocycle verrillin (13) has only been 
attempted by Theodorakis and coworkers (Scheme 1.5.2.1).38  Retrosynthetically, they 
envisioned completion of verrillin (13) by late-stage oxidation of furan 103 to complete 
the sequential bridging ketals and the second lactone from the isopropenyl side chain.  
Convergent assembly of furan 103 would be accomplished by the coupling of three 
components: aldehyde 104, furan 105 and cis-1,3-cyclopentenediol 106.  The relative 
stereochemistry throughout the synthesis would be derived from the stereochemistry of 
the 1,3-cis-cyclopentenediol building block.   
Scheme 1.5.2.1. Retrosynthetic Analysis of Verrillin (Theodorakis) 
 
Theodorakis and coworkers pursued the synthesis of racemic verrillin (13) 
beginning with furanyl alcohol 107.  Conversion of furan 107 to racemic vinyl iodide 106 
was accomplished in 21% yield over 4 steps (Scheme 1.5.2.2).  Eschenmoser–Claisen 
rearrangement from tertiary alcohol 106 with amide acetal 108 followed by removal of 
the TBS ether with concomitant lactonization provided bicycle 109.  Addition of lactone 
109 into aldehyde 104 provided alcohol 110 as a 1.7:1 mixture of diastereomers at C(13) 
in favor the desired diastereomer as shown.  After protecting group manipulation, vinyl 
iodide 111 was coupled with furanyl stannane 105.  Subsequent Appel halogenation 
provided bromide 112, which could be cyclized to provide macrocycle 113 in 39% 
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desired anti configuration between C(1) and C(2) as required for verrillin (13).  The 
completion of the furanyl core of the natural product marked the end of the only reported 
synthetic studies toward the total synthesis of verrillin.   
Scheme 1.5.2.2. Theodorakis’ Synthetic Approach Toward Verrillin (13) 
 
1.5.3   Synthetic Efforts Toward Havellockate (14) 
Havellockate (14), which contains the same C(8)/C(10) relative stereochemistry 
found in verrillin (13), has been targeted by two laboratories through two distinct 
synthetic strategies. Mehta and coworkers disclosed the first synthetic studies toward 
havellockate in 2001.39  They envisioned access to havellockate (14) could be achieved 
through tetracycle 114 after addition of the isopropenyl side chain and ultimate oxidation 
(Scheme 1.5.3.1).  Spirocyclic lactone 114 would in turn be derived from the oxidation of 
spirocyclic furan 115. 
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Targeting core tetracycle 115, synthetic advancement toward racemic havellockate 
(14) was pursued from ketal 116 (Scheme 1.5.3.2).  Synthesis of cis-1,3-cyclopentanediol 
117 was achieved after eight synthetic transformations comprised mainly of a series of 
stereoselective redox manipulations in 16% overall yield.  Baeyer–Villager oxidation of 
ketone 117 furnished lactone 118 as a single product.  Reductive opening of lactone 118 
followed by sequential selective silyl ether formation and oxidation furnished enone 119.  
Formation of the targeted spirocyclic furan was accomplished after 1,2-addition of a 
vinyl nucleophile into the enone, allylic alkylation of the resultant tertiary alcohol, and 
ring-closing metathesis to provide spirocycle 120 in 49% yield over three steps.  Silyl 
ether cleavage, oxidation, and olefin isomerization supplied aldehyde 121, which was 
globally hydrogenated and oxidized afforded tetrahydrofuran 115, the targeted core 
polycycle of havellockate (14) with the proper stereochemistry installed at each ring 
junction.  Mehta and coworkers did not advance furan 115 further toward havellockate. 
Scheme 1.5.3.2. Construction of the Havellockate Core (Mehta) 
 
More recently, in 2010, Barriault and workers disclosed their progress toward the 
racemic total synthesis of havellockate.40  Access to havellockate (14) was envisioned 















































0 °C → 23 °C
(45% yield)
1) LiAlH4, THF, 0 °C
2) TBDMSCl, imidazole
    DMAP, CH2Cl2
3) PCC, 4 Å MS
    CH2Cl2 , 0 °C → 23 °C
(56% yield, 3 steps)
1) vinyl–MgBr
   THF, 0 °C → 23 °C
2) allyl–Br, NaH, 
    (n-Bu)4NI, THF, 0 °C
3) Grubbs Gen. I
    CH2Cl2
  (49% yield, 3 steps)
1) TBAF, THF
     0 °C → 23 °C
2) PCC, 4 Å MS
    CH2Cl2 , 0 °C
3) DBU, CH2Cl2
    0 °C → 23 °C
(27% yield, 3 steps)
1) H2, Pd–C
    EtOAc
2) PCC, 4 Å MS
    CH2Cl2
    0 °C → 23 °C
(35% yield, 2 steps)
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Enone 122 would be available from bicycle 123 after oxidation and functionalization of 
the cyclohexene.  Bicycle 123 would in turn be formed through a Diels–Alder 
cycloaddition of diene 124. 
Scheme 1.5.3.3. Barriault’s Retrosynthesis of Havellockate (14) 
 
In the forward sense, furanyl alcohol 107 was advanced to racemic cis-1,3-
cyclopentenediol 124 over five steps in 10% overall yield.  Hydroxyl-directed Diels–
Alder cycloaddition of diene 124 with acrolein in the presence of excess magnesium(II) 
bromide followed by global reduction furnished cyclohexanol 125.  Oxidation of polyol 
125 furnished silyl ether 126 after concomitant lactonization.  Addition of a vinyl 
nucleophile to ketone 126 followed by the addition of acetic anhydride provided acetate 
127 in 42% yield.  Ozonolysis, aldol condensation, and ultimate silyl ether cleavage 
provided spirocycle 128 after in situ translactonization.  Tetracycle 128 is the fully 
elaborated core of havellockate lacking the appropriate oxidation state and the 
isopropenyl side chain flanking the cyclohexane as well as the β-hydroxyl group within 
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Scheme 1.5.3.4. Synthesis of Elaborated Core Tetracycle of Havellockate (14, Barriault) 
 
While direct advancement of tetracycle 128 toward havellockate (14) proved 
unfruitful, cyclohexanone 126 proved amenable to functionalization of the cyclohexane 
(Scheme 1.5.3.5).  Two-step oxidative desaturation of cyclohexanone 126 furnished 
enone 129 in 34% yield.  Stille coupling of stannane 130 with the vinyl iodide of enone 
129 afforded diene 131.  Installation of the spirocyclic dihydrofuran was accomplished 
by a method derived from Mehta and coworkers (see Scheme 1.5.3.2) to provide alcohol 
132 after PMB ether cleavage in 44% yield over four steps.  Vinylation of allylic alcohol 
132 followed by Claisen rearrangement furnished aldehyde 133 in 53% yield as a 1:1 
mixture of C(1) diastereomers.  The successful installation of the isopropenyl side chain 
produced another late-stage, highly functionalized intermediate that stands as the 
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(18% yield, 3 steps)
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Scheme 1.5.3.5. Alternative Synthetic Approach Toward Havellockate (14, Barriault) 
 
1.5.4   Synthetic Efforts Toward Intricarene (7) 
The biomimetic asymmetric total synthesis of intricarene (7) was accomplished by 
both the Pattenden18b,c and Trauner18 laboratories in 2013, representing two of the rare 
examples of a completed synthesis of a member of the polycyclic furanobutenolide 
cembranoid and norcembranoid natural family.  The biosynthesis of intricarene (7) had 
been proposed from bipinnatin J (26, Scheme 1.5.4.1).  Oxidative cleavage of the furan 
moiety followed by isomerization would produce the hypothesized biosynthetic 
intermediate 34.  Subsequent dipolar [5 + 2] cycloaddition would then complete the 
construction of intricarene (7).  In order to confirm this speculated biosynthetic pathway, 
which has been explored computationally as well,41 both Pattenden and Trauner sought 
initially to complete the asymmetric total synthesis of bipinnatin J (26). 
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Both laboratories took similar routes toward the asymmetric total synthesis of 
bipinnatin J (26).  Pattenden and coworkers began their enantiospecific synthesis with 
epoxide 134, which was available five steps from (+)-glycidol (Scheme 1.5.4.2.A).  
Coupling of epoxide 134 with selenide 135 provided alkene 136 in 60% yield.  
Sequential lactonization, selenide oxidation and elimination, and silyl ether cleavage 
furnished vinyl iodide 137 in 62% yield over three steps.  Alternatively, Trauner and 
coworkers pursued the enantioselective synthesis of bipinnatin J (26) beginning with 
alkyne 138, which was available in with 92% ee after the asymmetric 1,2-reduction of the 
ketone precursor (Scheme 1.5.4.2.B).  Conversion of silyl alkyne 138 into alkynoate 139 
was accomplished in four steps in high yield.  Butenolide 141 was formed from ester 139 
through a ruthenium-catalyzed Alder ene reaction, followed by olefination of the 
resultant aldehyde to furnish lactone 141.  Redox manipulation of ester 141 again 
provided vinyl iodide 137.  
Scheme 1.5.4.2. Synthesis of Common Intermediate Vinyl Iodide 137 (Pattenden and Trauner) 
 
Advancement of iodide 137 was accomplished by both Pattenden (Scheme 
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iodide 137 and furfural stannane 105 and subsequent Appel halogenation of the primary 
allylic alcohol produced allylic bromide 142.  Chromium(II)-mediated macrocycle 
formation was then employed to couple the allylic bromide and furanyl aldehyde to 
complete the asymmetric synthesis of bipinnatin J (26).   




With the asymmetric total synthesis of bipinnatin J (26), both Pattenden (Scheme 
1.5.4.4.A) and Trauner (Scheme 1.5.4.4.B) turned their attention to the investigation of 
the biomimetic synthesis of intricarene (7).  Pattenden and coworkers proceeded with the 
vanadium-catalyzed epoxidation of allylic alcohol 26 followed by acetylation of the 
resultant hemiketal to provide enone 143 in 30% yield from polycycle 26.  Alternatively, 
Trauner and coworkers accomplished the epoxidation of furan 26 with m-CPBA.  
Acetylation of the intermediate hemiketal furnished enone 143 in an improved 81% yield 
from bipinnatin J (26). 
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Advancement of acetate 143 was accomplished under basic conditions.  Pattenden 
and coworkers found that exposure of ketal 143 to DBU in refluxing acetonitrile 
furnished intricarene (7) in 10% yield, proposing the reaction proceeded through 
intermediate dipole 34 and ultimate [5 + 2] cycloaddition.  Similarly, Trauner and 
coworkers found that in the presence of TMP in DMSO at 150 °C, acetate 143 was 
converted to intricarene (7) in 26 % yield, again invoking the intermediacy of the same 
charge separated and speculated biosynthetic precursor 34.  These studies led the authors 
to conclude that the biosynthetic speculations surrounding the formation of intricarene (7) 
from macrocycle 34 are likely correct and the production of intricarene likely happens 
spontaneously in vivo directly from bipinnatin J (26). 
1.5.5   Synthetic Efforts Toward Rameswaralide (8) 
Several approaches to the core structure of rameswaralide (8) have been described, 
although the synthesis of rameswaralide itself has not yet been achieved.  Mehta and 
coworkers envisioned access to rameswaralide (8) through core tricycle 144 after Diels–
Alder cycloaddition (Scheme 1.5.5.1). 42   Cycloheptenone 144 would in turn be 
synthesized by a ring-closing metathesis from diene 145.  Access to enone 145 would be 
accomplished by the functionalization of bicyclic lactone 146, a derivative of the Corey 
lactone.   
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The pursuit of (±)-rameswaralide was accomplished from bicyclic ketone 148, 
which was available from acetate 147 in 49% yield over six steps (Scheme 1.5.5.2).  
Baeyer–Villager oxidation of ketone 148 provided lactone 149 as a single product in 
excellent yield.  Silyl ether cleavage and subsequent iodolactonization furnished bicyclic 
iodide 150.  Global silyl ether formation followed by reduction of the secondary iodide 
provided lactone 151 in 85% yield over two steps from halide 150. 
Scheme 1.5.5.2. Synthesis of Corey Lactone Derivative 151 (Mehta) 
 
Advancement of lactone 151 was then accomplish by alkylation with either allyl or 
propargyl bromide (Scheme 1.5.5.3).  Sequential selective primary silyl ether cleavage 
and oxidation of the resultant primary alcohol provided intermediate bicycle 152 as a 
single diastereomer independent of the identity of the α-lactone substituent.  Addition of 
an vinyl nucleophile to aldehyde 152 followed by oxidation of the intermediate secondary 
alcohol provided allyl-substituted lactone 153 and propargyl-substituted lactone 154 in 
47% and 41% yield, respectively, over five steps from bicycle 152. 
Scheme 1.5.5.3. Synthesis of Bicyclic Metathesis Substrates 153 and 154 (Mehta) 
 
Pleasingly, exposure of allylic bicycle 153 to Grubbs generation II catalyst 
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1.5.5.4.A).  Unfortunately, all attempts to advance dienophile 155 toward rameswaralide 
through a Diels–Alder cycloaddition were unfruitful.  In an attempt to alternatively 
access rameswaralide, Mehta and coworkers sought to complete the more extensively 
functionalized core of rameswaralide (156) by the enyne metathesis of alkyne 154 
(Scheme 1.5.5.4.B).  Unfortunately, this synthetic approach could not be successfully 
employed for the formation of the characteristic 7-membered ring integral to the 
carbocyclic scaffold of rameswaralide. 
Scheme 1.5.5.4. Construction of the Rameswaralide Tricyclic Core (Mehta) 
 
Comparatively, Srikrishna and coworkers envisioned the use of a ring-closing 
metathesis to access two different rameswaralide core bicycles 157 and 158 (Scheme 
1.5.5.5).43  The [6,7]-core scaffold 157 would arise directly from olefin 159 by ring-
closing metathesis.  Alternatively, synthetic access to [5,7]-core scaffold 158 was also 
envisioned from olefin 159 after ring contraction and subsequent ring-closing metathesis.   
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butenyl bromide 162 in the presence of lithium metal and oxidative 1,3-allylic 
transposition of the intermediate tertiary alcohol provided enone 163 in 80% yield over 
two steps.  Ring-closing metathesis of tetraene 163 furnished 157 in 98% yield as the 
core [6,7]-bicycle of rameswaralide, possessing the proper relative anti configuration 
between the isopropenyl substituent and the fused cycloheptene.   
Scheme 1.5.5.6. Synthesis of the [6,7]-Bicyclic Core of Rameswaralide (Srikrishna) 
 
Construction of the complimentary [5,6]-bicyclic core of rameswaralide began with 
the diastereoselective reduction and sequential diastereo- and chemoselective epoxidation 
to provide alcohol 164 in 62% yield over two steps (Scheme 1.5.5.7).  Oxidation of 
secondary alcohol followed by a Favorskii-type ring contraction produced cyclopentane 
165.  Ultimate ring-closing metathesis furnished bicyclic cycloheptene 158 in 95% yield 
from cyclopentanol 165.  Although the core carbocyclic scaffold of the cycloheptene 158 
contains a portion of the core bicyclic structure of rameswaralide (8), the substitution and 
oxidation pattern would need to be greatly altered in order to utilize bicycle 158 in total 
synthetic efforts toward the natural product.   
Scheme 1.5.5.7. Formation of the [5,7]-Bicyclic Core of Rameswaralide (Srikrishna) 
 
A third approach to the core scaffold of rameswaralide (8) was disclosed by Trost 
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radical cyclization and epoxidation of selenide 167 (Scheme 1.5.5.8).  Acylselenide 167 
would be produced by the acylation of secondary alcohol 168.  Construction of bicycle 
168 could be achieved by the intramolecular [5 + 2] cycloaddition of allylic cyclopropane 
169. 
Scheme 1.5.5.8. Trost’s Retrosynthetic Approach Toward Rameswaralide Core 166 
 
Synthesis of the racemic core tricycle of rameswaralide commenced with known 
cyclopropane 170 (Scheme 1.5.5.9).  Stereoselective 1,2-reduction of enone 170 
furnished syn-1,3-diol 171 in a 20:1 diastereomeric ratio in favor of the desired product 
as shown.  Subsequent ruthenium-catalyzed intramolecular [5 + 2] cycloaddition 
provided cycloheptadiene 172 in 73% yield.  Acylselenide 173 was then formed over two 
steps from secondary alcohol 172 in high yield.  Reductive radical cyclization of 
acylselenide 173 furnished tricycle 174 in 88% yield.  Epoxidation of allylic alcohol 174 
provided tetracycle 175, which was advanced to sulfoxide 176 over two steps.  
Ultimately, elimination of sulfoxide 176 by heating in toluene at 90 °C provided two 
isomeric forms of the desired core of rameswaralide, 177 and 178, although further 
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Scheme 1.5.5.9. Trost’s Construction of the Rameswaralide Tricyclic Scaffold (Trost) 
 
1.5.6  Synthetic Efforts Toward Rameswaralide (8), Mandapamates (17–
19), and Plumarellides (15–16) 
 
Pattenden and coworkers also developed synthetic access to the core of 
rameswarellide during their pursuit of a unified biomimetic approach to the 
mandapamates and plumarellides.45  The mandapamates (17–19) and plumarellides (15 
and 16) share a common carbocyclic scaffold (Figure 1.5.6.1).  Although they are varied 
to a different extent in overall oxidation state and relative configuration at the spirocyclic 
furan ring juncture, Pattenden and coworkers sought to test their biosynthetic hypotheses 
for the construction of each of these 5 natural products through related mechanisms.   
Figure 1.5.6.1. Mandapamate and Plumarellide Natural Products 
 
Hypothesizing that each of the mandapamates and plumarellides arises in vivo from 
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macrocycle 35 to plumarellide (15), Scheme 1.5.6.1), Pattenden and coworkers designed 
a series of model substrates (179–182) to explore the propensity of related systems to 
construct the desired carbocyclic scaffold.  Acyclic diastereomeric diols 179 and 180 
were synthesized through an asymmetric dihydroxylation route while macrocyclic ester 
181 and acetate 182 were each constructed in an enantiospecific fashion from (–)-malic 
acid.    
Scheme 1.5.6.1. Substrates for Exploration of Proposed Biosynthesis (Pattenden) 
 
Exposure of acetonide 180 to TFA resulted in the cleavage of the ketal and 
subsequent intramolecular rearrangement (Scheme 1.5.6.2).  Based on the isolated 
products, Pattenden and coworkers hypothesize that under the reaction conditions, furan 
180 proceeds through intermediate 183 en route to allylic cation 184 after intramolecular 
cyclization.  Cation 184 would then undergo nucleophilic attack from either C(6) or C(5) 
of the furan ring to furnish cyclohexene 185 or cycloheptene 186, respectively.  
Cyclohexene 183, the minor product, represents the core structure of the mandapamates 
with the lactone found in plumerallide still intact.  Pentacycle 185 is epimeric to the 
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the core structure of rameswaralide (8), containing all of the required relative 
stereochemistry. 
Scheme 1.5.6.2. Synthesis of the Mandapamate and Rameswaralide Core Scaffolds (Pattenden) 
 
In an effort to construct the plumarellide core, diastereomeric diol 179 was 
subjected to identical reaction conditions (Scheme 1.5.6.3).  Surprisingly, the only 
observed product was the C(7) and C(8) diastereomer of the rameswaralide core 189.  
This empirical evidence suggests that the influence of C(8) stereochemistry is critical for 
the productive formal intramolecular cycloaddition of the nonmacrocyclic substrates 179 
and 180. 
Scheme 1.5.6.3. Formation of Rameswaralide Core from Diol 179 (Pattenden) 
 
Macrocyclic substrates 181 and 182 were then exposed to aqueous TFA and both 
selectively furnished unexpected tetracycle 192 as the sole product without any trace of 
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arise from the formal cycloaddition between C(4) and C(5) of the vinylogous diketone 
moiety and the 1,3-diene between C(11) and C(14).  Plumarellide core 193, the expected 
product, would have been produced by the proposed biomimetic [4 + 2] cycloaddition 
between the olefin at C(6) and C(7) of macrocycle 190 with the diene moiety before 
isomerization to vinylogous diketone 191. 
Scheme 1.5.6.4. Synthesis of Unexpected Novel Cembranoid Core (Pattenden) 
 
Although these results did not disprove the originally proposed biosynthesis of the 
mandapamates and plumarellides, Pattenden and coworkers began exploring alternative 
biosynthetic pathways for the formation of these two natural product families.  One such 
alternative, considering the biosynthesis of plumarellide, for example, would begin with 
macrocyclic cembranoid 35 (Scheme 1.5.6.5).  Oxidation of the olefin between C(7) and 
C(8) followed by olefin transposition and intramolecular Michael addition would provide 
intermediate ketal 194.  Subsequent vinylogous aldol addition would complete 
plumarellide.  Although the exact biosynthesis of the mandapamates and plumarellides 
remains unknown, the work done by Pattenden and workers has provided a wealth of 
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Scheme 1.5.6.5. Alternative Proposal for Biosynthesis of Mandapamates and Plumarellides  
 
1.5.7  Synthetic Efforts Toward Mandapamates (17–19), Plumarellides 
(15–16), and Dissectolide (22) 
 
The only other work toward the mandapamates and plumarellides was carried out 
by Mehta and coworkers in their pursuit of a unified strategy to the carbocyclic core of 
both families of cembranoids as well as the furanobutenolide norcembranoid dissectolide 
(22, Scheme 1.5.7.1).46  Synthetic access to the common [7,6,5]-carbocyclic core 195 was 
envisioned through the intramolecular Diels–Alder cycloaddition of diene 196.  
Vinylogous diketone 196 would in turn be synthesized by the oxidative cleavage of furan 
197. 
Scheme 1.5.7.1. Retrosynthesis of Common Carbocyclic Core (Mehta) 
 
Synthetic advancement began with furfural derivative 198 (Scheme 1.5.7.2).  
Coupling of alkyl zinc 199 followed by nucleophilic addition of bromide 200 into the 
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reduction, Stille coupling, and ring-closing metathesis yielded macrocycle 202 in 14% 
yield over three steps.  This synthetic route only provides access to the cis-macrocyclic 
product 202 with no trace to trans-macrocycle 197.  
Scheme 1.5.7.2. Synthesis of Macrocyclic Diene 202 (Mehta) 
 
Advancement of cis-macrocycle 202 by oxidative cleavage of the furan moiety 
provided cis-vinylogous diketone 203 in excellent yield (Figure 1.5.7.3).  Diene 202 was 
then heated in toluene in order to induce an intramolecular Diels–Alder cycloaddition.  
Under the reaction conditions, the cis-dienophile isomerized to the trans-vinylogous 
diketone, as evidenced by the resulting trans-stereochemistry in tricycle 204, which was 
isolated as the sole product from diene 203 after in situ opening of the lactone.  Tricycle 
205 represents the most advanced intermediate synthetized by Mehta and coworkers.  
Unfortunately, core scaffold 205 possesses the improper relative stereochemistry at 
C(7) in comparison to plumarellide (15) and dissectolide (22) and at C(11) as required for 
all three natural products (i.e., 15, 17, and 22). While the epimerization of configuration 
at C(7) can easily be envisioned, the correction of the anti-relationship between C(11) 
and C(14) to the desired syn configuration would be nontrival. This anti-relationship is 
dictated by the cis-configuration of the Δ13,14 bond formed during the macrocyclization of 
lactone 202 by ring-closing metathesis. As such, alternative formation of macrocycle 202 
would need to be established in order for this synthetic route to warrant further 
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Scheme 1.5.7.3. Construction of Tricycle 205 by Diels–Alder Cycloaddition (Mehta) 
 
1.5.8   Synthetic Efforts Toward Yonarolide (25) 
The synthesis of yonarolide (25) has only been studied by Ito and coworkers in their 
development of a strategy for the construction of the tricyclic portion if its core scaffold 
(203, Scheme 1.5.8.1).47  Cyclopentene 206 would be formed after intramolecular aldol 
condensation of methyl ketone 207.  Synthesis of bicyclic cyclohexenone 207 would be 
constructed by the Diels–Alder cycloaddition of bisenol ether 208 and butenolide 209.  
Scheme 1.5.8.1. Retrosynthetic Analysis of Yonarolide (25, Ito) 
 
In the forward sense, Ito and coworkers pursued the racemic synthesis of the core 
structure of yonarolide beginning with butenolide 209, which was available from β-
ketoester 210 in 65% yield over four steps.  Diels–Alder cycloaddition of dienol ether 
211 with butenolide 209 proceeded smoothly in the presence of trimethylaluminum and 
bis(trifluoromethanesulfonyl)methane.  Subsequent ketal cleavage provided methyl 
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Scheme 1.5.8.2. Diels–Alder Cycloaddition of Butenolide 209 (Ito) 
 
Although methyl ketone 212 contained the wrong relative stereochemistry at the 
lactone carbinol, exposure of the substrate to TFA in toluene at elevated temperature 
resulted in the isomerization of configuration at this stereocenter (likely through a retro-
conjugate addition and cyclization pathway) and induced the desired aldol condensation 
to furnish the yonarolide core (206) in 55% yield (Scheme 1.5.8.3).  No trace of 
undesired core 213 was observed.  By this synthetic route, Ito and coworkers showed the 
viability of their retrosynthetic strategy for accessing the core of yonarolide (206), 
however, the employment of this method in further advancement toward yonarolide has 
not yet been disclosed.   
Scheme 1.5.8.3. Synthesis of the Yonarolide Core by Tandem Isomerization-Aldol Cyclization (Ito) 
 
1.5.9  Synthetic Efforts Toward Ineleganolide (9) and Sinulochmodin C (10) 
Three different methods for the total synthesis of ineleganolide (9) have been 
disclosed in the literature.  The first example was presented by Moeller and coworkers, 
however, the studies on their model system failed to generate even the bicyclic core of 
ineleganolide. 48  The second was a biomimetic, semisynthetic approach taken by 
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Scheme 1.5.9.1).49  Previously, Pattenden and coworkers had postulated the biosynthesis 
of both ineleganolide (9) and sinulochmodin C (10) occurred through sequential 
transannular Michael additions from 5-episinuleptolide (5, see Schemes 1.4.2.1 and 
1.4.2.2).1a,14  




To explore this hypothesis, the authors took a portion of 5-episinuleptolide (5) 
isolated from the natural source for exploratory semisynthetic studies.  It is noteworthy 
that, to date, there are no reports of the total synthesis of 5-episinuleptolide.  Acetylation 
of secondary alcohol 214 was accomplished in 92% yield using standard conditions.  
Exposure of acetate 214 to LHMDS over an extended reaction time, warming to 0 °C 
furnished both ineleganolide (9) and sinulochmodin C (10) as predicted in 22% yield and 
9% yield, respectively.   
Additionally, Pattenden and coworkers sought to accomplish the biomimetic 
semisynthesis of another norcembranoid diterpene natural product horiolide (20)26 by 
exposure of acetate 214 to modified strongly basic conditions (Scheme 1.5.9.2).  Despite 
their efforts, only novel norcembranoid derivative 215 was isolated as a product of the 
reaction.  No trace of either horiolide (20) or kavaranolide (21), which has only been 
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Scheme 1.5.9.2. Attempted Biomimetic Semisynthesis of Additional Norcembranoids (Pattenden) 
 
The second example of the synthetic pursuit of ineleganolide comes from the 
Vanderwal laboratory and their work toward the asymmetric total synthesis of the natural 
product. 50   Retrosynthetically, access to ineleganolide (9) was envisioned after 
construction of the central heptacycle by cyclization of tetracycle 216 (Scheme 1.5.9.3).  
Ketofuran 216 would in turn be synthesized from desmethylcarvone (217) and tricycle 
218 after intermolecular Michael addition.   
Scheme 1.5.9.3. Vanderwal’s Retrosynthetic Analysis of Ineleganolide (9) 
 
For the purpose of synthetic development, the enantiomer ent-ineleganolide (ent-9) 
was targeted.  Advancement toward the natural product began with the asymmetric 
deprotonation and subsequent rearrangement of epoxide 219 to furnish cis-1,3-
cyclopentenediol 221 in 79% yield with 89% ee (Scheme 1.5.9.4).  Oxidation of allylic 
alcohol (+)-221 with PCC provided the cyclopentenone building block (+)-222 in 97% 
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Scheme 1.5.9.4. Synthesis of Enantioenriched Cyclopentenone (+)-222 (Vanderwal) 
 
Advancement of enantioenriched cyclopentenone (+)-222 proceeded with the 1,2-
addition of methyl lithium into the conjugated system (Scheme 1.5.9.5).  Alkylation of 
the resultant tertiary alcohol and cleavage of the silyl ether provided propargyl alcohol 
223 in 87% yield over three steps from enone (+)-222.  Functionalization of secondary 
alcohol 223 with ethyl vinyl ether in the presence of NBS provided bromide 224 in 87% 
yield as a 1:1 mixture of diastereomers.  Radical cascade cyclization of cyclopentene 224 
furnished tricycles 225 and 226 in a 1:1 mixture after sequential ozonolysis in a 
combined 78% yield over two steps.51 
Scheme 1.5.9.5. Construction of Ketofurans 225 and 226 (Vanderwal) 
 
Fortuitous equilibration of epimers 225 and 226 toward lactol 226 in a 19:1 ratio 
enabled the triflation of the ketofuran moiety and efficient advancement of material, as 
epimer 225 would not undergo this desired transformation (Scheme 1.5.9.6).  Oxidation 
of acetal 227 to lactone 228 provided the desired tricyclic coupling partner in 88% yield.   
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The asymmetric synthesis of complimentary enone (+)-217 began with racemic 
cyclohexanone 229 (Scheme 1.5.9.7).  Diastereoselective reduction of the carbonyl 
followed by enzymatic acetylation provided both alcohol (+)-230 and acetate (+)-231 in 
greater than 95% ee.52  Advancement of desired diastereomer (+)-231 was accomplished 
by saponification and oxidation of the intermediate secondary alcohol.  Oxidative 
desaturation of the resultant cyclohexanone was accomplished over two steps to provide 
enone (+)-217 in 69% yield from acetate (+)-231 as the complimentary coupling partner. 
Scheme 1.5.9.7. Asymmetric Synthesis of Complimentary Cyclohexenone (+)-217 (Vanderwal) 
 
Coupling of the two fragments of ineleganolide was accomplished using a 
Mukaiyama–Michael addition, beginning with formation of the silyl enol ether of lactone 
228 (Scheme 1.5.9.8).   Subsequent exposure of the intermediate enol ether to enone (+)-
217 in the presence of lanthanum(III) triflate induced the planned Mukaiyama-Michael 
addition, providing tetracycle 232 in 91% yield in high diastereoselectivity as the 
undesired epimer at the α-position of the lactone moiety.  Despite screening a variety of 
conditions, Vanderwal and coworkers were unable to accomplish the desired 
epimerization to furnish tetracycle 233. 
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Exploring alternative approaches toward ent-ineleganolide (ent-9), tetracycle 232 
would be advanced by saponification of the lactone moiety, followed by protection of the 
secondary alcohol and carboxylic acid to furnish ketone 234 in 45% yield over three steps 
(Scheme 1.5.9.9).  Bromination of silyl enol ether 234 with NBS furnished α-
bromoketone 235 as a mixture of diastereomers.  Unfortunately, samarium(II) iodide-
mediated cyclization conditions failed to produce desired ketofuran 237, forming instead 
tetrahydrofuran 236 in high yield.  Despite attempting a number of alternative routes, 
Vanderwal and coworkers were unable to complete the total synthesis of ent-
ineleganolide (ent-9). 
Scheme 1.5.9.9. Alternative Advancement Toward Ineleganolide (Vanderwal) 
 
1.6   Conclusion 
The synthetic efforts toward ineleganolide are a tremendous representation of the 
pattern of successes and failures around the synthetic studies of the furanobutenolide 
cembranoid and norcembranoid natural products.  The extremely limited examples of 
completed syntheses of members of this natural product family have been exclusively 
biomimetic synthetic or semisynthetic studies.  Not a single de novo synthesis of a 
furanobutenolide cembranoid and norcembranoid has been completed to date.  A number 






















1) NaOH, MeOH, CH2Cl2
2) TMS•imidazole
3) MeI, DBU, MeCN









































Chapter 1 –Furanobutenolide Cembranoid and Norcembranoid Natural Products 54 
have been disclosed, revealing valuable information about the chemistry of these core 
structures.  The fact that not one of these synthetic routes has yielded the targeted natural 
product, however, highlights the need for further investigations. The continued 
investigation of these elegant, biologically active, stererogenically complex, and highly 
oxygenated family of natural products will require the development of new synthetic 
methods for the synthetic manipulations of compact and highly oxidized polycycles.  
Success in this area and completion of the syntheses of the polycyclic furanobutenolide 
cembranoids and norcembranoids will benefit not only other areas of synthetic chemistry 
through methodological development, but also medicinal chemistry and chemical 
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Enantioselective Synthesis of a 
Hydroxymethyl-cis-1,3-cyclopentenediol Building Block† 
 
 
2.1   Introduction 
Functionalized cyclopentanol frameworks are an important structural motif in 
organic chemistry.  Scaffolds of this type are found in many biologically active natural 
products,1 pharmaceuticals,2 and nucleoside analogs.3  In particular, cis-1,3-cyclopentane-
diols (238) have been extensively employed in the synthesis of medicinally relevant 
natural and non-natural compounds (Figure 2.1.1).3,4  For example, the biologically active 
prostaglandin (e.g., 239 and 240),2,5 furanocembranoid diterpene (e.g., 8 and 13), and 
norcembranoid diterpene families of natural products (e.g., 9 and 10)1d,6 all contain the 
cis-1,3-cyclopentanediol motif. 
Typically, enantioenriched carbocycles of this type have been accessed by kinetic 
enzymatic7 or classical8 resolutions.  The utility of cis-1,3-cyclopentanediols that contain 
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a tertiary alcohol is severely limited due to the challenges associated with the 
stereocontrolled formation of such chiral centers.  Literature examples of the asymmetric 
synthesis of this moiety are limited to substrate-controlled diastereoselective alkylation4b 
or asymmetric oxidation of prochiral substrates.9  To the best of our knowledge, the 
enantioselective synthesis of the cis-1,3-cyclopentanediol scaffold has not been 
accomplished through asymmetric alkylation.  As such, in concert with our research 
program dedicated to the development and application of the palladium-catalyzed 
asymmetric allylic alkylation,10 we developed an efficient and general route for the 
enantioselective synthesis of cis-1,3-cyclopentanediol building block 238. 
Figure 2.1.1. Representative Natural Products Possessing cis-1,3-Cyclopentanediol Scaffold 
 
2.2   Retrosynthetic Analysis 
We envisioned that a catalytic asymmetric preparation of a cis-1,3-cyclopentanediol 
core (238) with additional functional handles would serve as an enabling technology for 
various total synthetic efforts.  Specifically, we targeted diol 241, which can be 
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cleavage (Scheme 2.2.1).  Intramolecular cyclization of dioxanone 243 would afford 
cyclopentenone 242.  In turn, chiral dioxanone 243 would be prepared by palladium-
catalyzed asymmetric allylic alkylation of silyl enol ether 244. 
Scheme 2.2.1. Retrosynthetic Analysis of cis-1,3-Cyclopentenediol 241 
 
2.3   Intramolecular Aldol Cyclization 
Our synthetic approach to cis-1,3-cyclopentenediol 241 was inspired by our 
previous report of the synthesis of related enone 247 (Scheme 2.3.1.A).10a–b,e  The 
palladium-catalyzed asymmetric alkylation of enol ether 245 afforded allyl ketone 246 in 
95% yield with 87% ee.  Wacker oxidation of the allyl fragment to the intermediate 
methyl ketone followed by intramolecular aldol condensation generated cyclopentenone 
247 in 73% yield over two steps from allylic alkylation product 246. 




Similarly, acetonide 248 was converted to chiral ketal 249 in 86% yield and 87% ee 
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(Scheme 2.3.1.B). 11   However, employment of the sequential Wacker oxidation–
intramolecular aldol cyclization conditions were found to be ineffective for the 
preparation cyclopentenone ketal 250.  Despite extensive exploration of alternative 
conditions for this transformation, formation of enone 250 was never observed by this 
approach.12 
2.4   Intramolecular Wittig Cyclization 
Faced with this challenge, we envisioned preparation of cyclopentenone 250 by an 
intramolecular Wittig cyclization (Scheme 2.4.1).13  The introduction of an oxidized allyl 
fragment during the alkylation event to generate ketone 251 could facilitate the olefinic 
oxidation.  Subsequent nucleophilic substitution with a phosphine would generate Wittig 
precursor 252.  Exposure to basic conditions could generate the phosphonium ylide, 
thereby enabling an intramolecular Wittig cyclization to form cyclopentenone 250. 




To explore this pathway, we began with chloroallylketone 254, which was prepared 
by palladium-catalyzed asymmetric allylic alkylation in 82% yield and 91% ee by a 
known procedure (Scheme 2.4.2).14  Epoxidation of ketone 254 with m-CPBA generated 
intermediate epoxide 255.  Nucleophilic epoxide opening then formed the α-
phosphinoketone in situ, enabling the construction of enone 250 by intramolecular Wittig 
cyclization.  Although the yield for the two-step sequence was low and varied 
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Scheme 2.4.2. Construction of Enone 250 by Epoxidation of Chloroallylketone 254 
 
Having accomplished a proof of principle, we turned our attention to optimization.  
Despite the fact that a variety of epoxidation conditions had been screened,15 the 
synthesis of intermediate 255 proved difficult and remained low yielding.  The Wittig 
cyclization had similar constraints, furnishing cyclopentenone 250 in variable, 
unsatisfactory yields.  
In spite of these failed attempts, we remained inspired by the successful isolation of 
the desired enone 250.  As an alternative, we decided to explore the synthesis of other 
Wittig cyclization precursors.  One appealing option was to target intermediate α-
bromoketone 256 (Scheme 2.4.3).13  Oxidative bromination of vinyl chloride 254 with 
NaOBr in AcOH resulted in the formation of intermediate bromide 256.  In situ 
displacement of the bromide by triphenylphosphine and subsequent intramolecular Wittig 
cyclization furnished cyclopentenone 250 with no erosion of enantiomeric excess, albeit 
in unpredictable yields. 
Scheme 2.4.3. Construction of Enone 250 by Oxidative Bromination of Chloroallylketone 254 
 
Synthetic advancement of dioxanone 254 through α-bromoketone 256 was plagued 
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a range of yields from 0% to 82%.  A variety of oxidative bromination conditions were 
attempted,15 yet consistent yields could not be achieved.  Importantly, when intermediate 
256 was successfully formed,16 conversion to cyclopentenone 250 could be reproducibly 
achieved with moderate success, indicating that the oxidative bromination was the 
problematic step in the sequence. 
Upon closer inspection of the oxidative α-bromination procedure, we identified two 
possible sources of inconsistency.  First, we suspected that exposure of substrate 254 and 
intermediate 256 to acetic acid was causing the ketal cleavage of both compounds 
throughout the reaction, resulting in decomposition.  Direct observation of this hypothesis 
was challenging, as the cleavage of the acetonide simply generated additional quantities 
of the reaction solvent, acetone.  An additional source of variability arose as the scale of 
the reaction was increased.  During prolonged reaction times, a consequence of operating 
on greater scale (ca. 2 h), the bright yellow NaOBr solution suspended over the reaction 
flask in an addition funnel (Figure 2.4.1.A) decomposes due to the acetic acid vapors in 
the reaction headspace (Figure 2.4.1.B).  This decomposition hinders reproducibility and 
lowers the reaction yield. 
Figure 2.4.1. Decomposition of NaOBr Stock Solution 
 
A. B.
T = 0 h  Addition begins, stock solution is
              bright yellow, homogenous
T = 1 h  Stock solution has become hetero-
              genous with white precipitate
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In order to address these concerns, we first sought to alter the ketal.  The 
introduction of additional steric bulk was hypothesized to impart additional stability to 
the protecting group and thus its tolerance to the oxidative bromination conditions.  
Gratifyingly, the selection of the cyclohexyl ketal proved to have no deleterious effects 
on the asymmetric allylic alkylation of enol ether 257 (Scheme 2.4.4).17  Under optimized 
conditions,18 chloroallylketone 258 was generated in a greatly improved 82% yield and 
increased 92% ee in comparison to acetonide allylic alkylation product 254. 
Scheme 2.4.4. Synthetic Route Enabled by the Crucial Choice of the Cyclohexyl Ketal Group 
 
With vinyl chloride 258 in hand, we set about developing an improved procedure 
for the formation of α-bromoketone 259.  In order to avoid suspending the NaOBr stock 
solution over the headspace of the reaction for any prolonged period, we divided vinyl 
chloride 258 into equal portions in a solution of acetone and AcOH among a series of 
vials cooled to 0 °C (Figure 2.4.2.A).  The addition of NaOBr was then accomplished 
dropwise from a needleless plastic syringe, adding one drop (ca. 40 µL) of the bright 
yellow stock solution to each vial every 30 seconds.19  As the addition commences, the 
transparent colorless solution of vinyl chloride 258 immediately took the bright yellow 
color of the NaOBr stock solution (Figure 2.4.2.B).  As the addition proceeded, the vials 
progressed through light orange (Figure 2.4.2.C) to deep red-orange (Figure 2.4.2.D) at 
the completion of the addition.  Attempts to convert cyclohexyl ketal 258 to α-
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complete conversion could be reliably accomplished under optimized conditions, 
affording bromide 259 in nearly quantitative yield.20 
Figure 2.4.2. Improved Technique for Conversion of Vinyl Chloride 258 to α-Bromoketone 259 
 
With α-bromoketone 259 in hand, the silica sensitive intermediate was immediately 
advanced as a crude oil to cyclopentenone 260.  Application of standard conditions for 
this transformation afforded enone 260, albeit in 35–40% yield.21  Modification of these 
conditions, including the use of (n-Bu)3P, enabled the conversion of bromide 259 to the 
desired cyclopentenone 260 in 94% yield over two steps from chloroallylketone 258. 
2.5   Completion of Hydroxymethyl-cis-1,3-cyclopentenediol 262 
With the establishment of a scalable, reliable route for the production of 
cyclopentenone 260, we sought to advance toward the desired cis-1,3-cyclopentenediol 
241.  Diastereoselective 1,2-reduction of enone 260 with diisobutylaluminum hydride 
(DIBAL) smoothly furnished allylic alcohol 261 in excellent yield as a single 
A. B.
C. D.
Reaction Setup Addition of NaOBr Commences
Addition of NaOBr 50% Complete Addition of NaOBr 100% Complete
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diastereomer (Scheme 2.5.1).22  Sequential benzoylation of alcohol 261 and fumaric acid-
mediated ketal cleavage yielded provided alcohol 262, a surrogate for the targeted 
cyclopentene 241.  This three-step transformation from cyclopentenone 260 not only 
provided cis-1,3-cyclopentenediol building block 262 in 97% yield but also proved to be 
scalable, allowing access the desired product in multi-gram quantities.23 




2.6  Conclusion 
In summary, this chapter discloses a highly efficient and scalable route for the 
construction of a cis-1,3-cyclopentenediol building block, enabling access to such 
frameworks found in a variety of natural products and analogs.  The enantioselective 
palladium-catalyzed allylic alkylation has been used effectively to generate the desired 
chiral tertiary alcohol stereocenter.  Judicious choice of the ketal protecting group, along 
with an improved procedure for the formation of the requisite α-bromoketone 
intermediate, allowed for successful optimization of the diastereoselective formation of 
the cis-1,3-diol framework, generating diol 262 in 91% yield over 5 steps from allylic 
alkylation product 258.  Efforts are currently underway to employ this building block in 














1. Bz2O, DMAP, Et3N
    CH2Cl2 , 0 °C, 13.5 h
2. fumaric acid, HC(OMe)3
    MeOH, 0 °C → 35 °C, 18 h
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2.7  Experimental Methods and Analytical Data 
2.7.1  Materials and Methods 
Unless stated otherwise, reactions were performed at ambient temperature (23 °C) in 
flame-dried glassware under an argon atmosphere using dry, deoxygentated solvents 
(distilled or passed over a column of activated alumina)24 stirring with a Teflon®-coated 
magnetic stirring bar.  Commercially available reagents were used as received unless 
otherwise noted.  TBAT was triturated with bench-top EtOAc (25 g batches, 2 x 100 mL 
washes) under a cone of argon, dried in vacuo (ca. 0.30 torr) for 24 hours, and then stored 
in a nitrogen-filled glovebox.  Et3N was distilled from calcium hydride immediately prior 
to use.  MeOH was distilled from magnesium methoxide immediately prior to use.  
Reagent grade acetone was obtained from Sigma-Aldrich and used as received.  Purified 
H2O was obtained using a Barnstead NANOpure Infinity UV/UF system.  4 Å molecular 
sieves were oven-dried at 120 °C for a minimum of 24 h and cooled in a desiccator to 
ambient temperature immediately prior to use.  (S)-t-BuPhox (263),10a,25 (S)-5,5-diphenyl-
i-PrPhox (264), 26  (R)-5,5-dimethyl-i-PrPhox (265), 27  2-bromo-5-(trifluoromethyl)-
benzoyl chloride (266), 28  (R)-3-amino-2,4-dimethylpentan-2-ol hydrogen chloride 
(267),26,27 bis(4-(trifluoromethyl)phenyl)phosphine oxide (268),28 and tris(4,4’-
methoxydibenzylideneacetone)-dipalladium(0) (Pd2(pmdba)3)29 were prepared by known 
methods.  Reactions requiring external heat were modulated to the specified temperatures 
using an IKAmag temperature controller.  Thin-layer chromatography (TLC) was 
performed using E. Merck silica gel 60 F254 precoated plates (250 nm) and visualized by 
UV fluorescence quenching, potassium permanganate, or p-anisaldehyde staining.  
Silicycle SiliaFlash P60 Academic Silica gel (particle size 40-63 nm) was used for flash 
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chromatography.  1H and 13C NMR spectra were recorded on a Varian Inova 500 (500 
MHz and 126 MHz, respectively) and a Varian Mercury 300 spectrometer (300 MHz and 
76 MHz, respectively) and are reported in terms of chemical shift relative to residual 
CHCl3 (in CDCl3, δ 7.26 and δ 77.16, respectively) or C6D5H (in C6D6, δ 7.16 and δ 
128.06, respectively).  19F and 31P NMR spectra were recorded on a Varian Mercury 300 
spectrometer (282 MHz and 121 MHz, respectively) and are reported in terms of absolute 
chemical shift according to IUPAC standard recommendations from CFCl3 and H3PO4, 
respectively.30   Data for 1H NMR spectra are reported as follows: chemical shift (δ ppm) 
(multiplicity, coupling constant (Hz), integration).  Infrared (IR) spectra were recorded on 
a Perkin Elmer Paragon 1000 Spectrometer and are reported in frequency of absorption 
(cm-1).  Analytical chiral gas chromatography was performed with an Agilent 6850 GC 
using a G-TA (30 m x 0.25 cm) column (1.0 mL/minute carrier gas flow).  Analytical 
chiral HPLC was performed with an Agilent 1100 Series HPLC utilizing a Chiralcel OB-
H column (4.6 mm x 25 cm) obtained from Daicel Chemical Industries, Ltd. with 
visualization at 254 nm.  High resolution mass spectra (HRMS) were obtained from the 
Caltech Mass Spectral Facility using a JEOL JMS-600H High Resolution Mass 
Spectrometer in fast atom bombardment (FAB+) or electron ionization (EI+) mode or 
acquired using an Agilent 6200 Series TOF with an Agilent G1978A Multimode source 
in atmospheric pressure chemical ionization (APCI) or mixed (MultiMode ESI/APCI) 
ionization mode.  Optical rotations were measured on a Jasco P-2000 polarimeter using a 
100 mm path length cell at 589 nm. 
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2.7.2  Experimental Procedures 
 
Cyclopentenone Acetonide 250: A solution of chloroallylketone 254 (0.157 g, 0.72 
mmol, 1.00 equiv) in CH2Cl2 (4.5 mL) was distributed evenly among three oven-dried 
one-dram vials. Solid m-CPBA (0.252 g, 1.46 mmol, 2.00 equiv) was divided into three 
equal portions and added to each vial. After 9 days, the reaction vessels were 
simultaneously cooled to 0 °C, filtered individually through celite plugs, rinsing with 
pentane. The organics were then combined, concentrated in vacuo (>300 torr) and 
purified immediately by column chromatography (5% Et2O in pentane eluent) to afford 
volatile intermediate epoxide 255 (0.051 g, 30 % yield) as a pale yellow oil which was 
immediately carried onto the sequential reaction.31 
Epoxide 255 (0.051 g, 0.22 mmol, 1.00 equiv) was added as a solution in toluene 
(2.5 mL) to a Schlenk flask. Upon the subsequent addition of Ph3P (0.123 g, 0.47 mmol, 
2.15 equiv) as a solid at ambient temperature, the reaction immediately turned bright 
yellow. The mixture was allowed to stir for 1 h, at which time the addition of Et3N (0.13 
mL, 0.91 mmol, 4.15 equiv) was accomplished dropwise. The reaction vessel was 
immediately sealed with a Teflon® stopcock and introduced to a preheated 110 °C bath. 
After 4.5 h, the reaction was removed from the bath, cooled to ambient temperature (ca. 
23 °C), and purified by silica gel column chromatography (5%→10% Et2O in pentane 
eluent) to furnish volatile cyclopentenone acetonide 250 (0.008 g, 20% yield) as a yellow 
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1H), 4.95–4.81 (m, 2H), 2.60 (d, J = 17.7, 1H), 2.47 (d, J = 17.7, 1H), 1.62 (s, 3H), 1.42 
(s, 3H), 1.37 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 203.4, 175.9, 125.4, 100.8, 77.8, 
60.9, 53.5, 30.2, 28.6, 25.4; IR (Neat Film, NaCl) 3072, 2991, 2937, 2861, 1723, 1639, 
1445, 1408, 1382, 1372, 1349, 1316, 1267, 1226, 1200, 1169, 1139, 1094, 1060, 1010, 
983, 952, 920, 903, 848, 831, 772, 752 cm-1; HRMS (EI+) m/z calc’d for C10H14O3 
[M•]+:182.0943, found 182.0941; [α]D23.6 –19.8° (c 1.53, CHCl3). 
 
 
Cyclopentenone Acetonide 250: To a stirred solution of NaOH (0.942 g, 23.6 mmol, 
17.2 equiv) in H2O (12 mL) at 0 °C (ice/H2O bath) was added Br2 (0.40 mL, 7.81 mmol, 
5.70 equiv) dropwise through a needleless plastic syringe. The resulting yellow solution 
of NaOBr was stirred for 30 minutes at 0 °C.  
A flask was charged with a solution of chloroallylketone 254 (0.300 g, 1.37 mmol, 
1.00 equiv), acetone (12 mL), and acetic acid (7.10 mL, 124 mmol, 90.5 equiv). The 
colorless solution was cooled to 0 °C (ice/H2O bath).  The reaction was treated with 
NaOBr (8.20 mL, 5.44 mmol, 4.00 equiv) dropwise using a needleless plastic syringe 
over 1 h. At the completion of the addition, the reaction progress was monitored by TLC 
(1:1 Et2O:Hexanes eluent). If the reaction was not immediately complete, further addition 
of NaOBr (up to 1 mL) was carried out at the same rate.  Upon complete consumption of 
the starting material as determined by TLC, the reaction mixture was diluted with CH2Cl2 
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and Na2S2O3•5H2O (2.084 g) in H2O (10 mL). Quenching resulted in the vigorous 
evolution of gas and the dissipation of the orange color, affording two colorless phases. 
The aqueous layer was further diluted with H2O (15 mL) and extracted with CH2Cl2 (3 x 
25 mL). Combined organic layers were dried over MgSO4 for 1 minute, filtered, and 
concentrated under reduced pressure until around 2 mL of solution remained. The 
solution was diluted with heptane (10 mL), and the reaction was concentrated under 
reduced pressure until around 0.6 mL of solution remained.  The reaction was quickly 
purified through an SiO2 plug (10% Et2O in hexanes eluent) and partially concentrated 
under reduced pressure to give the desired α-bromoketone 256 as a yellow solution, 
which was promptly diluted with anhydrous toluene (1 mL) and immediately employed.32 
A 250 mL Schlenk flask and stir bar was charged with powdered Ph3P (0.893 g, 
3.40 mmol, 2.48 equiv) and toluene (10 mL). The colorless solution was treated dropwise 
with the solution of α-bromoketone 256 and rinsed with additional toluene (4 mL).  The 
colorless solution was then treated dropwise with Et3N (0.29 mL, 2.08 mmol, 1.50 equiv). 
The reaction vessel was immediately sealed with a Teflon® stopcock and introduced to a 
preheated 110 °C bath. After 5 h, the reaction was removed from the bath, cooled to 
ambient temperature, and purified directly by column chromatography (25%→50% Et2O 
in pentane eluent) to furnish the volatile cyclopentenone acetonide 250 (0.205 g, 82% 
yield) as a yellow oil. 33  See above for characterization data. Additionally, the 
enantiomeric excess of enone 250 generated by this procedure was determined by 
analytical chiral HPLC (Chiralcel OB-H column, 3:7 i-PrOH:Hexanes, 1 mL/minute, 
major retention time: 12.7 minutes, minor retention time: 16.5 minutes, 92% ee). 
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Aminoalcohol 271: To a suspension of Trizma•HCl (270, 45.0 g, 286 mmol, 1.00 equiv) 
in DMF (365 mL) were added cyclohexanone dimethyl ketal (269, 50.0 mL, 329 mmol, 
1.15 equiv) and p-toluenesulfonic acid monohydrate (p-TsOH, 1.63 g, 8.57 mmol, 0.03 
equiv) in one portion with stirring. After 17 h, a distillation apparatus was attached 
directly to the reaction flask and the volatiles were distilled off (75 °C/6 torr). The 
semisolid residue was triturated with Et2O (700 mL) until white solid precipitated. The 
resulting heterogeneous solution was filtered, washed with EtOAc (4 x 100 mL), and 
dried under high vacuum (0.50 torr) to afford a white solid.  
To a portion of the resulting crude white solid (19.7 g, 82.9 mmol, 1.00 equiv) as a 
suspension in EtOAc (276 mL) was added Et3N (13.9 mL, 99.4 mmol, 1.20 equiv) 
dropwise with stirring. After 11 h, the reaction mixture was filtered, the solids washed 
with EtOAc (4 x 20 mL) and resuspended in EtOAc (150 mL) to which Et3N (5.0 mL, 
35.9 mmol) was added dropwise. The suspension was stirred for 48 h and then filtered 
and the solids were washed with EtOAc (4 x 120 mL). Combined organic filtrate was 
concentrated in vacuo to give aminoalcohol 271 (16.68 g, 94% yield from 270) as a white 
solid: Rf = 0.17 (1:4 MeOH:CH2Cl2 eluent); 1H NMR (500 MHz, CDCl3) δ 3.80 (d, J = 
11.9 Hz, 2H), 3.54 (d, J = 11.9 Hz, 2H), 3.49 (s, 2H), 1.87–1.64 (m, 7H), 1.59–1.52 (m, 
2H), 1.52–1.46 (m, 2H), 1.42 (q, J = 6.0 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ 98.7, 
66.5, 65.2, 50.7, 34.0, 31.0, 25.8, 22.7; IR (Neat Film, NaCl) 3350, 3294, 2937, 2857, 
1) p-TsOH
    DMF
2) Et3N
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1618, 1448, 1331, 1284, 1255, 1160, 1087, 918 cm-1; HRMS (MM: ESI-APCI) m/z calc’d 
for C10H20NO3 [M+H]+: 202.1438, found 202.1434. 
 
 
Dioxanone 272: Aminoalcohol 271 (14.7 g, 73.0 mmol, 1.00 equiv) was dissolved in a 
solution of KH2PO4 (11.9 g, 87.6 mmol, 1.20 equiv) in H2O (243 mL) and cooled to 0 °C 
(ice/H2O bath). To the resultant stirred homogenous solution was added a solution of 
NaIO4 (15.6 g, 73.0 mmol, 1.00 equiv) in H2O (243 mL) dropwise over 2.5 h through a 
250 mL additional funnel. The reaction was then allowed to stir at temperature for 40 
minutes before being allowed to warm to ambient temperature. The starting material was 
consumed after an additional 4 h as determined by TLC (1:4 MeOH:CH2Cl2 eluent). 
Na2S2O3•5H2O (18.1 g, 73.0 mmol, 1.00 equiv) was then immediately added in one 
portion. The solution was allowed to stir for 40 minutes at which time the reaction 
mixture was extracted with CH2Cl2 (11 x 150 mL). Combined organic layers were dried 
over Na2SO4, filtered, and concentrated in vacuo (26 °C/100 torr) to afford dioxanone 272 
(12.4 g, >99% yield) as a pale yellow oil. This compound was carried to the next step 
without further purification: Rf = 0.80 (1:4 MeOH:CH2Cl2 eluent);  1H NMR (500 MHz, 
CDCl3) δ 4.12 (s, 4H), 1.72–1.65 (m, 4H), 1.59–1.51 (m, 4H), 1.44–1.35 (m, 2H); 13C 
NMR (126 MHz, CDCl3) δ 208.3, 100.0, 66.7, 32.6, 25.3, 22.9; IR (Neat Film, NaCl) 






H2O, 0 °C → 23 °C
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1118, 1079, 1058, 1028, 922, 847, 825 cm-1; HRMS (EI+) m/z calc’d for C9H14O3 [M•]+: 
170.0943, found 170.0961. 
 
 
Methyldioxanone 273: A solution of dioxanone 272 (12.4 g, 73.0 mmol, 1.00 equiv) in 
toluene (243 mL) was charged with 4 Å molecular sieves (14.9 g, 1.20 equiv by mass) 
and cyclohexylamine (16.2 mL, 142 mmol, 1.94 equiv). After 13 h, the reaction mixture 
was filtered over celite, rinsing with toluene, and concentrated in vacuo to give the crude 
cyclohexylimine.  
In a separate three-neck flask with an internal temperature probe, a solution of 
freshly prepared lithium diisopropylamine (LDA, 0.60 M in THF, 1.00 equiv) was cooled 
to –78 °C (dry ice/i-PrOH bath). To the solution of LDA was added crude 
cyclohexylimine as a solution in THF (73 mL) dropwise through a cannula with an 
overpressure of argon. After 5 minutes, the reaction flask was introduced to a –15 °C bath 
(ice/MeOH) and after 1.75 h was cooled back to –78 °C. To the reaction mixture was 
then added methyl iodide (4.77 mL, 76.7 mmol, 1.05 equiv) at a rate of 2.00 mL/h with a 
syringe pump, ensuring the internal temperature did not exceed –70 °C. Upon completion 
of addition, the reaction was allowed to stir for 30 minutes before being allowed to 
slowly warm to ambient temperature. Upon reaching ambient temperature, the reaction 
was quenched with saturated aqueous NH4Cl (150 mL) and stirred for 14 h. The reaction 
mixture was then extracted with Et2O (4 x 150 mL). Combined organic layers were then 
OO
O
1) H2NCy, 4 Å m.s.
    toluene
2) LDA, MeI 
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washed with H2O (50 mL), brine (50 mL), dried over Na2SO4, filtered, and concentrated 
in vacuo to afford an orange-tan oil. Purification of this residue by flash chromatography 
(10% Et2O in hexanes eluent) furnished methyldioxanone 273 (9.77 g, 73% yield) as a 
clear, colorless oil: Rf = 0.30 (1:9 Et2O:Hexanes eluent); 1H NMR (500 MHz, CDCl3) δ 
4.38 (qd, J = 6.8, 1.5 Hz, 1H), 4.28 (dd, J = 17.2, 1.5 Hz, 1H), 4.02 (d, J = 17.2 Hz, 1H), 
1.84–1.76 (m, 1H), 1.76–1.66 (m, 3H), 1.62–1.54 (m, 4H), 1.47–1.39 (m, 2H), 1.31 (d, J 
= 6.7 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 210.4, 100.8, 70.8, 66.3, 33.3, 33.0, 25.4, 
23.1, 23.0, 14.4; IR (Neat Film, NaCl) 2935, 2859, 1748, 1447, 1365, 1339, 1278, 1255, 
1164, 1151, 1133, 1118, 1072, 1045, 991, 928, 846, 825 cm-1; HRMS (EI+) m/z calc’d for 
C10H16O3 [M•]+: 184.1100, found 184.1129. 
 
 
Silyl enol ether 257: A 250 mL round bottom was soaked in a 20:1 i-PrOH:toluene bath 
saturated with KOH for 12 h, rinsed with deionized H2O, acetone, and allowed to dry. To 
a solution of methyldioxanone 273 (9.77 g, 53.0 mmol, 1.00 equiv) in CH3CN (88 mL) in 
a flame-dried 250 mL base-bathed round bottom flask with stir bar were added sodium 
iodide (10.3 g, 68.9 mmol, 1.30 equiv) in a single portion and Et3N (11.8 mL, 84.8 mmol, 
1.60 equiv) dropwise with stirring. After 5 minutes, triethylsilyl chloride (TESCl, 11.6 
mL, 68.9 mmol, 1.30 equiv) was added dropwise. After 18 h, consumption of starting 
material was complete as determined by TLC (1:9 Et2O:Hexanes eluent) and the reaction 
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with H2O (100 mL), brine (100 mL), dried over Na2SO4, filtered, and concentrated in 
vacuo to produce a yellow oil. Purification of this residue by flash chromatography (1.0% 
Et2O / 0.5% Et3N in hexanes eluent) on base–treated silica furnished silyl enol ether 257 
(8.68 g, 55% yield) as a faintly pink, clear oil: Rf = 0.31 (1:19 Et2O:Hexanes eluent); 1H 
NMR (500 MHz, CDCl3) δ 4.03 (q, J = 2.0 Hz, 2H), 1.78 (t, J = 2.0 Hz, 3H), 1.74–1.69 
(m, 4H), 1.58–1.50 (m, 4H), 1.45–1.38 (m, 2H), 0.98 (t, J = 8.0 Hz, 9H), 0.64 (q, J = 8.0 
Hz, 6H); 13C NMR (126 MHz, CDCl3) δ 134.1, 125.7, 98.5, 60.4, 33.0, 25.7, 22.8, 14.0, 
6.8, 5.5; IR (Neat Film, NaCl) 2953, 2937, 2877, 1718, 1448, 1412, 1395, 1362, 1289, 
1253, 1219, 1203, 1154, 1133, 1096, 1055, 1012, 946, 923, 866, 848, 830, 745 cm-1; 
HRMS (MM: ESI-APCI) m/z calc’d for C16H31O3Si [M+H]+: 299.2037, found 299.2031. 
 
 
Chloroallylmesylate 253: A flask was charged with 2-chloroallyl alcohol (274, 4.78 mL, 
60.0 mmol, 1.00 equiv), THF (120 mL), and Et3N (17.2 mL, 120 mmol, 2.00 equiv) and 
cooled to 0 °C (ice/H2O bath) with stirring. To the solution was added methanesulfonyl 
chloride (6.96 mL, 90.0 mmol, 1.50 equiv) dropwise. After 2 h, the reaction was 
quenched with saturated aquesous NaHCO3 (120 mL). The reaction mixture was warmed 
to ambient temperature and extracted with Et2O (3 x 180 mL). Combined organic layers 
were washed with 1 N HCl (120 mL), saturated NaHCO3 (120 mL), brine (120 mL), 
dried over MgSO4, filtered, and concentrated in vacuo to provide a crude tan oil. The 
residue was purified by bulb-to-bulb distillation using a Kügelrohr apparatus (150 °C/3.5 
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0.34 (2:1 EtOAc:Hexanes eluent); 1H NMR (300 MHz, CDCl3) δ 5.65 (d, J = 0.5 Hz, 
1H), 5.55 (d, J = 0.5 Hz, 1H), 4.77 (s, 2H), 3.10 (s, 3H); 13C NMR (76 MHz, CDCl3) δ 
134.3, 117.9, 71.1, 38.6; IR (Neat Film, NaCl) 3652, 3570, 3267, 3119, 3033, 2943, 
2523, 2310, 2089, 1832, 1639, 1454, 1415, 1360, 1175, 1010, 923, 830, 757 cm-1; HRMS 
(EI+) m/z calc’d for C4H735ClO3S [M•]+: 169.9804, found 169.9811. 
 
 
Chloroallyl ketal 258: A 500 mL Schlenk flask was soaked in a 20:1 i-PrOH:toluene 
bath saturated with KOH for 12 h, rinsed with deionized H2O, acetone, and allowed to 
dry. To a flame-dried 500 mL base-bathed Schlenk flask in a nitrogen-filled glovebox 
were charged Bu4NPh3SiF2 (TBAT, 7.53 g, 13.9 mmol, 1.00 equiv), Pd2(pmdba)3 (230 
mg, 0.21 mmol, 0.015 equiv),  (S)-t-BuPhox (190 mg, 0.49 mmol, 0.035 equiv), and 
toluene (280 mL, 0.0015 M in Pd). The reaction vessel was immediately removed from 
the glovebox, introduced to an argon atmosphere and placed in a preheated 35 °C bath 
with stirring. After 20 minutes, a yellow-brown solution was observed. 
Chloroallylmesylate 253 (2.85 g, 16.7 mmol, 1.20 equiv) was added quickly dropwise 
affording a blue-green solution. After 3 minutes, silyl enol ether 257 (4.16 g, 13.9 mmol, 
1.00 equiv) was added quickly dropwise over 3 minutes. The resultant blue-green 
reaction mixture was allowed to stir for 20 h. The resultant yellow-brown reaction was 
then allowed to cool to ambient temperature, filtered through a pad of SiO2 using hexanes 
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with Et2O, to isolate the volatile reaction products. The filtrate was concentrated in vacuo 
to furnish a bright yellow oil which was subsequently purified by flash chromatography 
(1%→3%→5% Et2O in hexanes eluent) to afford volatile chloroallyl ketal 258 (2.95 g, 
82% yield) as a clear, colorless oil: Rf = 0.41 (19:1 Et2O:Pentane eluent); 1H NMR (500 
MHz, CDCl3) δ 5.30 (d, J = 1.1 Hz, 1H), 5.23 (q, J = 0.8 Hz, 1H), 4.36 (d, J = 17.9 Hz, 
1H), 4.20 (d, J = 17.9 Hz, 1H), 2.87 (dd, J =14.6, 0.9 Hz, 1H), 2.74 (d, J = 14.6 Hz, 1H), 
1.84–1.76 (m, 2H), 1.76–1.69 (m, 2H), 1.66–1.58 (m, 2H), 1.57–1.50 (m, 2H), 1.47 (s, 
3H), 1.45–1.41 (m, 1H), 1.41–1.36 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 210.2, 137.1, 
116.9, 100.5, 81.1, 66.5, 48.2, 36.2, 35.0, 25.3, 25.2, 23.1, 23.0; IR (Neat Film, NaCl) 
2937, 2862, 1743, 1635, 1447, 1364, 1332, 1280, 1258, 1245, 1172, 1159, 1113, 1052, 
1005, 943, 889, 826 cm-1; HRMS (APCI) m/z calc’d for C13H2035ClO3 [M+H]+: 259.1095, 
found 259.1092; 92% ee (analytical chiral GC, G-TA column, 120 °C isotherm, major 




Cyclopentenone Cyclohexyl Ketal 260: To a stirred solution of NaOH (3.25 g, 81.2 
mmol, 18.0 equiv) in H2O (54 mL) at 0 °C (ice/H2O bath) was added Br2 (1.39 mL, 27.1 
mmol, 6.00 equiv) dropwise through a needleless plastic syringe. The resulting yellow 
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A solution of chloroallyl ketal 258 (1.17 g, 4.51 mmol, 1.00 equiv) in acetone (45 
mL) was distributed equally to eight 20 mL scintillation vials with stir bars. Each vial 
was capped loosely with a septum and cooled to 0 °C open to air. AcOH (23.2 mL, 406 
mmol, 90.0 equiv) was distributed between the eight reaction vessels in a dropwise 
fashion. After 5 minutes, addition of NaOBr (28.0 mL, ca. 3.0 equiv) was accomplished 
by adding one drop (ca. 40 µL) every 30 seconds to each reaction vessel through a 
needleless 1 mL plastic syringe.34 Upon completion of addition (approximately 80 
minutes), the bright orange reactions were allowed to stir for 10 minutes, at which time 
the consumption of starting material was complete as determined by TLC (1:4 
EtOAc:Hexanes eluent). If the consumption of starting material was determined 
incomplete, additional NaOBr (2.00 mL, ca. 0.21 equiv) was added by the previously 
specified procedure and allowed to react for a maximum of 5 additional minutes. The 
reactions were then diluted with CH2Cl2 at 0 °C, quickly combined in a separatory funnel 
with additional CH2Cl2 (100 mL total), and carefully quenched with a solution of 
Na2S2O3•5H2O (11.2 g, 45.1 mmol, 10.0 equiv) and K2CO3 (12.5 g, 90.2 mmol, 20.0 
equiv) in H2O (54 mL). Quenching resulted in the vigorous evolution of gas and the 
dissipation of the orange color, affording a cloudy, white organic layer. The aqueous 
layer was washed with CH2Cl2 (3 x 100 mL). The combined organic layers were dried 
over MgSO4 for 1 minute, filtered, concentrated in vacuo, and azeotroped with heptane (4 
x 30 mL) to ensure thorough removal of AcOH and afford crude bromide 259 (1.440 g, 
>99% yield) as a white, viscous, opaque oil which was immediately subjected to the 
subsequent reaction conditions without further purification.35  
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To a clear, colorless solution of neat (n-Bu)3P (2.25 mL, 9.02 mmol, 2.00 equiv) in 
toluene (30 mL) in a Schlenk flask was added crude bromide 259 (1.440g, 4.51 mmol, 
1.00 equiv) as a solution in toluene (15 mL) dropwise affording a clear, gold solution. 
After 90 minutes Et3N (0.94 mL, 6.77 mmol, 1.50 equiv) was added dropwise, generating 
white precipitate on the first drops. The reaction was allowed to stir for 5 minutes, after 
which the vessel was sealed with a Teflon® stopcock and introduced to a preheated 110 
°C bath. The reaction solution was allowed to stir vigorously for 16 h, after which the 
dark brown reaction mixture was removed from the bath and allowed to cool to ambient 
temperature with stirring. The vessel was then opened to the atmosphere in a well-
ventilated fume hood and allowed to stir for an additional hour. The reaction mixture was 
filtered through a pad of SiO2 using hexanes to remove toluene at which time separate 
fractions were collected, eluting with Et2O, to isolate the volatile reaction products. The 
filtrate was concentrated in vacuo (>100 torr) and the resultant dark brown oil was 
purified by column chromatography (40% Et2O in hexanes eluent) to furnish the volatile 
cyclopentenone cyclohexyl ketal 260 (0.939 mg, 94% yield) as a light yellow oil: Rf = 
0.28 (2:3 Et2O:Hexanes eluent); 1H NMR (300 MHz, CDCl3) δ 5.92–5.82 (m, 1H), 4.95–
4.76 (m, 2H), 2.60 (app d, J = 17.6 Hz, 1H), 2.46 (app d, J = 17.7 Hz, 1H), 1.92–1.62 (m, 
2H), 1.60 (s, 3H), 1.57–1.15 (m, 8H); 13C NMR (126 MHz, CDCl3) δ 203.4, 176.4, 125.0, 
101.0, 77.3, 60.2, 53.4, 39.0, 34.3, 28.7, 25.1, 23.4, 22.9; IR (Neat Film, NaCl) 3509, 
3419, 2936, 2857, 1717, 1639, 1446, 1408, 1366, 1286, 1235, 1198, 1147, 1096, 1081, 
1035, 984, 933, 855, 755 cm-1; HRMS (EI+) m/z calc’d for C13H18O3 [M•]+: 222.1256, 
found 222.1262; [α]D25.0 –55.9° (c 13.02, CHCl3). 
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Allylic Alcohol 261: To a pale yellow solution of cyclopentenone cyclohexyl ketal 260 
(840 mg, 3.78 mmol, 1.00 equiv) in THF (38 mL) at –78 °C (i-PrOH/dry ice bath)  was 
added a solution of DIBAL (1.35 mL, 7.56 mmol, 2.00 equiv) in THF (7.6 mL) dropwise. 
After 30 minutes, the gold reaction mixture was removed from the bath and allowed to 
warm slowly. After an additional 30 minutes, the consumption of starting material was 
complete as determined by TLC (1:4 EtOAc:Hexanes eluent) and the reaction mixture 
was cooled to 0 °C (ice/H2O bath). The reaction was subsequently quenched with a 1:1 
solution of saturated aqueous NH4Cl and saturated aqueous Rochelle salt (35 mL) 
dropwise, vigorously evolving gas on the first drops. The mixture was then diluted with 
CH2Cl2 (250 mL) and H2O (30 mL). The aqueous layer was then extracted with CH2Cl2 
(3 x 60 mL). The combined organics were dried over Na2SO4, filtered, and concentrated 
in vacuo to provide crude allylic alcohol 261 (0.848 g, >99% yield), which was used 
without further purification.  
 
 
Benzoylated Alcohol 275: To a stirred solution of crude allylic alcohol 261 (2.05 g, 9.14 
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2.233 g, 18.3 mmol, 2.00 equiv) and Et3N (10.2 mL, 73.1 mmol, 8.00 equiv). The light 
yellow reaction mixture was cooled to 0 °C (ice/H2O bath) at which time benzoic 
anhydride (Bz2O, 4.135 g, 18.28 mmol, 2.00 equiv) was added in one portion. After 30 
minutes, the reaction was removed from the bath and allowed to warm to ambient 
temperature. After an additional 13 h, at which time the consumption of starting material 
was complete as determined by TLC (3:2 EtOAc:Hexanes eluent), the reaction was again 
cooled to 0 °C (ice/H2O bath) and quenched with saturated aqueous NH4Cl (150 mL). 
The biphasic solution was further diluted with CH2Cl2 (240 mL) and H2O (200 mL). The 
organics were separated and the aqueous was extracted with CH2Cl2 (2 x 240 mL). The 
combined organics were washed with saturated NH4Cl (5 x 500 mL), dried over Na2SO4, 
filtered, and concentrated in vacuo to afford benzoylated alcohol 275 (3.002 g, >99% 
yield) as a light gold oil that was typically utilized without further purification. A 
characterization sample of benzoylated alcohol 275 was obtained through purification by 
column chromatography (1% Et3N in CH2Cl2 eluent) to afford a clear colorless oil: Rf = 
0.63 (1:4 EtOAc:Hexanes eluent); 1H NMR (500 MHz, CDCl3) δ 8.03 (dt, J = 8.2, 1.0 
Hz, 2H), 7.55 (td, J = 7.4, 1.3 Hz, 1H), 7.43 (td, J = 7.6, 1.1 Hz, 2H), 5.79 (ddq, J = 6.9, 
3.8, 1.8 Hz, 1H), 5.64 (q, J = 1.6 Hz, 1H), 4.74–4.58 (m, 2H), 2.67 (dd, J = 12.7, 6.8 Hz, 
1H), 2.12 (dd, J = 12.7, 6.7 Hz, 1H), 2.06–1.93 (m, 1H), 1.74–1.51 (m, 6H), 1.48 (s, 3H), 
1.46–1.34 (m, 2H), 1.33–1.21 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 166.5, 147.1, 
133.1, 130.3, 129.7, 128.4, 121.5, 100.6, 80.6, 76.6, 59.7, 49.4, 38.9, 34.8, 28.8, 25.4, 
23.6, 23.1; IR (Neat Film, NaCl) 2934, 2858, 1719, 1450, 1367, 1266, 1110, 1095, 1026, 
984, 712 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C20H25O4 [M+H]+: 329.1747, 
found 329.1745; [α]D25.0 +48.7° (c 6.09, CHCl3). 
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Diol 262: To a flask containing benzoylated alcohol 275 (1.12 g, 3.40 mmol, 1.00 equiv) 
were added MeOH (68 mL) and HC(OMe)3 (3.35 mL, 30.6 mmol, 9.00 equiv). The 
reaction mixture was cooled to 0 °C (ice/H2O bath) with stirring, at which time the 
addition of fumaric acid (0.988 g, 8.51 mmol, 2.50 equiv) was accomplished in one 
portion. After 10 minutes, the reaction was removed from the cold bath and immediately 
introduced to a preheated 35 °C bath. After 18 h, the consumption of starting material 
was complete as determined by TLC (1:4 EtOAc:Hexanes eluent) and the reaction was 
allowed to cool to ambient temperature (ca. 23 °C). The reaction mixture was diluted 
with EtOAc (150 mL) and poured over saturated aqueous NaHCO3 (150 mL). The 
organics were separated and the aqueous was extracted with EtOAc (3 x 150 mL). 
Combined organic layers were washed with brine (100 mL), dried over MgSO4 for 2 
minutes, filtered, and concentrated in vacuo to generate a yellow oil. The crude residue 
was then purified by column chromatography (50% EtOAc in hexanes eluent) to afford 
diol 262 (0.816 g, 97% yield) as a pale yellow oil: Rf = 0.18 (1:1 EtOAc:Hexanes eluent); 
1H NMR (500 MHz, CDCl3) δ 8.03–7.94 (m, 2H), 7.54–7.47 (m, 1H), 7.41–7.35 (m, 2H), 
5.85 (q, J = 1.7 Hz, 1H), 5.66 (ddq, J = 7.8, 3.8, 1.8 Hz, 1H), 4.39 (td, J = 14.5, 1.7 Hz, 
1H), 4.31 (td, J = 14.6, 1.3 Hz, 1H), 3.29 (bs, 2H), 2.64 (dd, J = 14.2, 7.3 Hz, 1H), 2.17 
(dd, J = 14.2, 4.2 Hz, 1H), 1.39 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 166.6, 153.2, 
133.2, 130.1, 129.7, 128.4, 125.6, 81.2, 76.3, 58.8, 48.3, 26.6; IR (Neat Film, NaCl) 
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(FAB+) m/z calc’d for C14H17O4 [M+H]+: 249.1127, found 249.1132; [α]D25.0 115.1° (c 
6.90, CHCl3). 
 
2.7.3  Ligand Synthesis  
The synthesis of (R)-CF3-5,5-dimethyl-i-PrPhox proceeded as follows: 
 
 
Amide 276:36 To a stirred solution of the hydrogen chloride salt of aminoalcohol 267 
(1.00 g, 5.96 mmol, 1.00 equiv) in p-dioxane (20 mL) was added Et3N (2.50 mL, 17.9 
mmol, 3.00 equiv). The reaction mixture was then cooled to 0 °C (ice/H2O bath) followed 
by the addition of acid chloride 266 (1.971 g, 6.86 mmol, 1.15 equiv) as a solution in p-
dioxane (13 mL) slowly dropwise. After 15 minutes, the reaction was removed from the 
cooling bath and allowed to warm to ambient temperature (ca. 23 °C). After 4 h, the 
consumption of starting material was complete as determined by TLC (1:9 
MeOH:CH2Cl2 eluent). The reaction mixture was concentrated in vacuo, dissolved in 
Et2O and filtered through a pad of silica gel, eluting the product with Et2O. The filtrate 
was then concentrated in vacuo and the crude white solid residue was purified by silica 
gel column chromatography (20% acetone in hexanes eluent) to provide amide 276 (1.79 
g, 79% yield) as an amorphous white solid: Rf = 0.20 (1:4 Acetone:Hexanes eluent); 1H 
NMR (CDCl3, 500 MHz) δ 7.78–7.71 (m, 2H), 7.52 (ddt, J = 8.3, 2.3, 0.7 Hz, 1H), 6.40 













0 °C → 23 °C
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1.37 (s, 3H), 1.34 (s, 3H), 1.08 (d, J = 6.8 Hz, 3H), 1.00 (d, J = 6.8 Hz, 3H); 13C NMR 
(CDCl3, 126 MHz) δ 167.0, 139.4, 134.3, 130.4 (q, J = 33.5 Hz), 127.7 (q, J = 3.6 Hz), 
126.6 (q, J = 3.8 Hz), 123.5 (q, J = 272.3 Hz), 123.2 (q, J = 1.5 Hz), 73.8, 60.9, 29.9, 
28.8, 27.7, 22.5, 17.2; 19F NMR (CDCl3, 282 MHz) δ –62.8 (s); IR (Neat Film, NaCl) 
3413, 3299, 2964, 1638, 1540, 1332, 1311, 1173, 1132, 1080, 1033, 828 cm–1; HRMS 
(MM: ESI-APCI) m/z calc’d for C15H20O279BrF3N [M+H]+: 382.0624, found 382.0633; 
[α]D25.0 –3.9° (c 0.895, CHCl3). 
 
 
Oxazoline 277:36 To a solution of amide 276 (1.41 g, 3.70 mmol, 1.00 equiv) in CH2Cl2 
(93 mL) at 0 °C (ice/H2O bath) was added methanesulfonic acid (MsOH, 1.44 mL, 22.2 
mmol, 6.00 equiv) dropwise over 10 minutes. The flask was subsequently removed from 
the cooling bath, topped with a reflux condenser, and introduced to a preheated 50 °C 
bath. After 17 h, the consumption of starting material was complete as determined by 
TLC (1:4 Acetone:Hexanes eluent). The refluxing solution was removed from the heating 
bath and allowed to cool to ambient temperature (ca. 23 °C). The yellow reaction mixture 
was then diluted with CH2Cl2 (100 mL) and poured onto saturated aqueous NaHCO3 (100 
mL). The organics were separated and washed with H2O (40 mL), brine (40 mL), dried 
over MgSO4, filtered and concentrated in vacuo. The crude gold oil was purified by silica 
gel column chromatography (5%→10% acetone in Hexanes eluent) to provide oxazoline 













0 °C → reflux
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NMR (CDCl3, 500 MHz) δ 7.92–7.88 (m, 1H), 7.77–7.72 (m, 1H), 7.52–7.46 (m, 1H), 
3.53 (d, J = 8.1 Hz, 1H), 1.94 (dhept, J = 8.0, 6.6 Hz, 1H), 1.56 (s, 3H), 1.45 (s, 3H), 1.16 
(d, J = 6.5 Hz, 3H), 1.05 (d, J = 6.6 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 160.4, 
134.6, 131.6, 129.8 (q, J = 33.4 Hz), 128.4 (q, J = 3.8 Hz), 127.9 (q, J = 3.6 Hz), 126.1 
(q, J = 1.7 Hz), 123.5 (q, J = 272.8 Hz), 88.2, 81.0, 29.4, 29.2, 21.4, 21.3, 20.7; 19F NMR 
(CDCl3, 282 MHz) δ –62.8 (s); IR (Neat Film, NaCl) 2973, 1652, 1608, 1472, 1343, 
1306, 1173, 1133, 1077, 1028, 830 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for 
C15H18O79BrF3N [M+H]+: 364.0518, found 364.0535; [α]D25.0 +33.1° (c 6.050, CHCl3). 
 
 
CF3-(R)-5,5-dimethyl-i-PrPhox (279):37 To a multineck reaction vessel fitted with a 
reflux condenser were added CuI (377 mg, 1.98 mmol, 1.00 equiv) and phosphine oxide 
268 (870 mg, 2.57 mmol, 1.30 equiv) as solids. The reaction vessel was then evacuated 
and backfilled with argon (3 x 5 minute cycles). Toluene (8 mL) was then added and 
stirring commenced. N,N’-Dimethylethylenediamine (DMEDA, 0.64 mL, 5.94 mmol, 
3.00 equiv) was then added dropwise causing the yellow heterogeneous reaction mixture 
to become dark green and homogeneous. After 20 minutes, oxazoline 277 (721 mg, 1.98 
mmol, 1.00 equiv) was added as a neat oil dropwise followed by Cs2CO3 (2.39 g, 7.33 
mmol, 3.70 equiv) as a solid in single portion. The reaction vessel was then introduced to 
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as determined by TLC (1:9 Et2O:Hexanes eluent). The refluxing solution was removed 
from the heating bath and allowed to cool to ambient temperature (ca. 23 °C). The crude 
reaction mixture was concentrated in vacuo and the crude brown solid was purified by 
silica gel column chromatography (25%→50% EtOAc in hexanes eluent) to provide 
phosphine oxide 278 (778 mg, 63% yield) as an amorphous white solid that was carried 
directly into the next transformation. 
Solid phosphine oxide 278 (778 mg, 1.25 mmol, 1.00 equiv) was added to a 
sealable pressure vessel, which was then evacuated and backfilled with argon (3 x 5 
minute cycles). To the flask was then added Ph2SiH2 (1.63 mL, 8.76 mmol, 7.00 equiv) 
with stirring. The reaction vessel, containing a homogeneous yellow solution, was then 
sealed and introduced to a preheated 140 °C bath. After 48 h, the consumption of starting 
material was complete as determined by TLC (1:1 EtOAc:Hexanes eluent). The refluxing 
solution was removed from the heating bath and allowed to cool to ambient temperature 
(ca. 23 °C). The crude reaction mixture was directly purified by silica gel column 
chromatography (20% CH2Cl2 in hexanes eluent) to furnish CF3-(R)-5,5-dimethyl-i-
PrPhox (279, 614 mg, 81% yield) as an amorphous white solid: Rf = 0.27 (1:4 
CH2Cl2:Hexanes eluent); 1H NMR (C6D6, 500 MHz) δ 8.57 (dd, J = 3.3, 2.0 Hz, 1H), 
7.41–7.36 (m, 4H), 7.21–7.15 (m, 4H), 7.10 (dd, J = 8.2, 2.0 Hz, 1H), 6.78 (dd, J = 8.0, 
3.0 Hz, 1H), 3.22 (d, J = 8.4 Hz, 1H), 1.55 (ddt, J = 13.0, 8.3, 6.5 Hz, 1H), 1.21 (s, 3H), 
1.08 (s, 3H), 0.99 (d, J = 6.5 Hz, 3H), 0.75 (d, J = 6.5 Hz, 3H); 13C NMR (C6D6, 126 
MHz) δ 159.1 (d, J = 4.0 Hz), 143.5 (t, J = 14.8 Hz), 142.7 (d, J = 30.6 Hz), 134.5 (dd, J 
= 21.3, 15.7 Hz), 133.7 (d, J = 19.5 Hz), 131.1 (q, J = 33.1 Hz), 131.0 (dq, J = 32.3, 4.4 
Hz), 127.1 (q, J = 3.6 Hz), 126.4–126.1 (m), 125.5 (dp, J = 7.5, 3.8 Hz), 124.8 (dq, J = 
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272.0, 3.3 Hz), 124.4 (q, J = 272.6 Hz), 87.2, 81.7 (d, J = 1.5 Hz), 29.1, 28.8, 21.1, 20.8, 
20.8 (d, J = 1.8 Hz); 19F NMR (C6D6, 282 MHz) δ –62.6 (s), –62.9 (s); 31P NMR (C6D6, 
121 MHz) δ –7.1 (s); IR (Neat Film, NaCl) 2974, 1652, 1606, 1397, 1323, 1165, 1128, 
1060, 1017, 832, 756 cm–1; HRMS (FAB+) m/z calc’d for C29H26OF9NP [M+H]+: 
606.1608, found 606.1585; [α]D25.0 +9.5° (c 3.200, CHCl3). 
 
2.7.4 Ligand Screen in Palladium-Catalyzed Intermolecular 
Enantioselective Allylic Alkylation 
 
 
General Procedure for Ligand Screen 
A 20 mL scintillation vial was soaked in a 20:1 i-PrOH:toluene bath saturated with 
KOH for 12 h, rinsed with deionized H2O, acetone, and allowed to dry in a 120 °C oven 
for an additional 12 h. To this oven-dried 20 mL scintillation vial in a nitrogen-filled 
glovebox were charged Bu4NPh3SiF2 (TBAT, 216 mg, 0.40 mmol, 1.00 equiv), 
Pd2(pmdba)3 (7 mg, 0.006 mmol, 0.015 equiv),  ligand (0.014 mmol, 0.035 equiv), and 



















Cost per gram ($)
S - Enantiomer - R
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0.60            6
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a Configuration at chiral center of product 258. b measured by analytical chiral GC
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block with stirring. After 20 minutes, a yellow-brown solution was observed. 
Chloroallylmesylate 253 (82 mg, 0.48 mmol, 1.20 equiv) was added quickly dropwise 
affording a blue-green solution. After 3 minutes, silyl enol ether 257 (120 mg, 0.40 
mmol, 1.00 equiv) was added quickly dropwise. The resultant blue-green reaction 
mixture was allowed to stir for 20 h, at which time the consumption of starting material 
was complete as determined by TLC (1:19 Et2O:Hexanes eluent). The resultant yellow-
brown reaction was then allowed to cool to ambient temperature (ca. 23 °C), filtered 
through a pad of SiO2 using hexanes as the eluent to remove toluene, at which time 
separate fractions were collected, eluting with Et2O, to isolate the volatile reaction 
products. The filtrate was concentrated in vacuo to a bright yellow oil which was 
subsequently purified by flash chromatography (1%→3%→5% Et2O in hexanes eluent) 
to afford volatile chloroallyl ketal 258 as a clear, colorless oil. The yield of each reaction 
was not determined. The ee of each product was determined by analytical chiral GC (G-










Chapter 2 – Enantioselective Synthesis of 1,3-Cyclopentenediol Building Block 93 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2.8  Notes and References 
1.  For selected examples, see: (a) Herdewijn, P.; Balzarini, J.; De Clercq, E.; 
Vanderhaeghe, H. J. Med. Chem. 1985, 28, 1385–1386. (b) King, S. B.; Ganem, 
B. J. Am. Chem. Soc. 1991, 113, 5089–5090. (c) Ono, M.; Nishimura, K.; 
Tsubouchi, H.; Nagaoka, Y.; Tomioka, K. J. Org. Chem. 2001, 66, 8199–8203. 
(d) Kamel, H. N.; Slattery, M. Pharm. Biol. 2005, 43, 253–269. 
2.  Collins, P. W.; Djuric, S. W. Chem. Rev. 1993, 93, 1533–1564.  
3.  (a) Perigaud, C.; Gosselin, G.; Imbach, J. L. Nucleosides Nucleotides 1992, 11, 
903–945. (b) Boyer, S. J.; Leahy, J. W. J. Org. Chem. 1997, 62, 3976–3980. 
4.  (a) Bisacchi, G. S.; Chao, S. T.; Bachard, C.; Daris, J. P.; Innaimo, S.; Jacobs, G. 
A.; Kocy, O.; Lapointe, P.; Martel, A.; Merchant, Z. Slusarchyk, W. A.; Sundeen, 
J. E.; Young, M. G.; Colonno, R.; Zahler, R. Bioorg. Med. Chem. Lett. 1997, 7, 
127–132. (b) Tsuna, K.; Noguchi, N.; Nakada, M. Angew. Chem., Int. Ed. 2011, 
50, 9452–9455.  
5.  Corey, E. J.; Weinshenker, N. M.; Schaaf, T. K.; Huber, W. J. Am. Chem. Soc. 
1969, 91, 5675–5677.  
6.  (a) Roethle, P. A.; Trauner, D. Nat. Prod. Rep. 2008, 25, 298–317. (b) Li, Y.; 
Pattenden, G. Nat. Prod. Rep. 2011, 28, 1269–1310. 
7.  (a) Nakashima, H.; Sato, M.; Taniguchi, T.; Ogasawara, K. Tetrahedron Lett. 
2000, 41, 2639–2642. (b) Audran, G.; Acherar, S.; Monti, H. Eur. J. Org. Chem. 
2003, 92–98.  
8.  Corey, E. J.; Schaaf, T. K.; Huber, W.; Koelliker, U.; Weinshenker, N. M. J. Am. 
Chem. Soc. 1970, 92, 397–398. 
Chapter 2 – Enantioselective Synthesis of 1,3-Cyclopentenediol Building Block 94 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
9.  Niidu, A.; Paju, A.; Eek, M.; Müürisepp, A.-M.; Pehk, T.; Lopp, M. Tetrahedron: 
Asymmetry 2006, 17, 2678–2683.  
10.  (a) Behenna, D. C.; Stoltz, B. M. J. Am. Chem. Soc. 2004, 126, 15044–15045. (b) 
McFadden, R. M.; Stoltz, B. M. J. Am. Chem. Soc. 2006, 128, 7738–7739. (c) 
Mohr, J. T.; Stoltz, B. M. Chem. Asian J. 2007, 2, 1476–1491. (d) Enquist, Jr., J. 
A.; Stoltz, B. M. Nature 2008, 453, 1228–1231. (e) Day, J. J.; McFadden, R. M.; 
Virgil, S. C.; Kolding, H.; Alleva, J. L.; Stoltz, B. M. Angew. Chem., Int. Ed. 
2011, 50, 6814–6818.  
11.  Seto, M.; Roizen, J. L.; Stoltz, B. M. Angew. Chem., Int. Ed. 2008, 47, 6873–
6876. 
12.  A variety of conditions were found to be ineffective in the formation of desired 
product 250 including: KOH/xylenes/110 °C, NaH/110 °C, 
Ba(OH)2•8H2O/H2O/methoxyethanol, LDA/THF/–78 °C, NaOt-Bu/HOt-Bu, 
KF/18-crown-6/xylenes, TMSOTf/EtN(i-Pr)2/0 °C then TBAF. 
13.  (a) Trost, B. M.; Curran, D. P. J. Am. Chem. Soc. 1980, 102, 5699–5700. (b) 
VanBrunt, M. P.; Ambenge, R. O.; Weinreb, S. M. J. Org. Chem. 2003, 68, 
3323–3326.  
14.  The procedure for the conversion of silyl enol ether 248 to chloroallylketone 254 
with the associated characterization data has been reported by our group, see 
reference 11, and: Roizen, J. L. Progress Toward an Enantioselective Total 
Synthesis of Ineleganolide.  Ph.D.  dissertation, California Institute of 
Technology, Pasadena, CA, 2010. 
15.  For full details and optimized procedure, see section 2.7.2. 
Chapter 2 – Enantioselective Synthesis of 1,3-Cyclopentenediol Building Block 95 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
16.  Determined by 1H NMR studies of the crude mixture. 
17.  For details concerning the synthesis of silyl enol ether 257, see Section 2.7.2. 
18. Optimized conditions for the transformation of silyl enol ether 257 to 
chloroallylketone 258 are displayed in Scheme 2.4.4. For full details, see Section 
2.7.2.  
19.  For the experimental procedure and full details, see Section 2.7.2. 
20.  This transformation has been performed on scales up to 1.40 g of starting material 
258. For full details, see Section 2.7.2. 
21.  See Scheme 2.4.3. Also, see reference 13. 
22.  Only one diastereomer is observed as a product. The stereochemistry of the 
reduction has been confirmed by NOE studies of alcohol 261 after benzoylation. 
See Section 2.7.2. and Appendix 1. 
23. This transformation has been performed on scales up to 3.30 g of starting material 
260. For full details, see Section 2.7.2.  
24. Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. 
Organometallics 1996, 15, 1518–1520. 
25. (a) Peer, M.; de Jong, J. C.; Kiefer, M.; Langer, T.; Rieck, H.; Schell, H.; 
Sennhenn, P.; Sprinz, J.; Steinhagen, H.; Wiese, B.; Helmchen, G. Tetrahedron 
1996, 52, 7547–7583. (b) Krout, M. R.; Mohr, J. T.; Stoltz, B. M. Org. Synth. 
2009, 86, 181–193. 
26. Bélanger, E.; Pouliot, M.-F.; Courtemanche, M.-A.; Paquin, J.-F. J. Org. Chem. 
2012, 77, 317–331. 
27. Bélanger, E.; Pouliot, M.-F.; Paquin, J.-F. Org. Lett. 2009, 11, 2201–2204. 
Chapter 2 – Enantioselective Synthesis of 1,3-Cyclopentenediol Building Block 96 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
28. White, D. E.; Stewart, I. C.; Grubbs, R. H.; Stoltz, B. M. J. Am. Chem. Soc. 2008, 
130, 810–811. 
29. (a) Ukai, T.; Kawazura, H.; Ishii, Y.; Bonnet, J. J.; Ibers, J. A. J. Organomet. 
Chem. 1974, 65, 253–266. (b) Fairlamb, I. J. S.; Kapdi, A. R.; Lee, A. F.  Org. 
Lett.  2004, 6, 4435–4438. 
30. (a) Harris, R. K.; Becker, E. D.; Cabral de Menezes, S. M.; Granger, P.; Hoffman, 
R. E.; Zilm, K. W. Pure Appl. Chem. 2008, 80, 59–84. (b) Harris, R. K.; Becker, 
E. D.; Cabral de Menezes, S. M.; Goodfellow, R.; Granger, P. Pure Appl. Chem. 
2001, 73, 1795–1818. 
31. The epoxidizing conditions tested include: Oxone®, magnesium 
monoperoxyphthalate hydrate (MMPP•6H2O), t-BuOOH/SiO2, t-
BuOOH/VO(acac)2, m-CPBA, m-CPBA/Jacobsen’s catalyst. 
32. A variety of conditions were found to be ineffective in the formation of the 
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33. Repetition of this procedure provided cyclopentenone 250 in yields ranging from 
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34. It was observed that slow addition via addition funnel of the bright yellow, 
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discoloration of solution remaining in the funnel. We believed that the vapors in 
the headspace of the reaction vessel were facilitating this apparent decomposition 
and lowering the yield in the process. 
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35. Although storage of this intermediate in a benzene matrix is possible for extended 
periods, purification by silica gel chromatography results in moderate 
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36. Procedure adapted from reference 26.   
37. Procedure adapted from: McDougal, N. T.; Streuff, J.; Mukherjee, H.; Virgil, S. 
C.; Stoltz, B. M. Tetrahedron Lett. 2010, 51, 5550–5554. 
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1) H2NCy, 4 Å m.s.
    toluene, 13 h
2) LDA, MeI 
    THF, –78 °C, 5 h




























110 °C, 16 h
(94% yield 
 2 steps) 260259
TBAT
Pd2(pmdba)3 (1.5 mol %)
(S)-t-BuPhox (3.5 mol %)
toluene 
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 Figure A2.2. Infrared spectrum (Thin Film, NaCl) of compound 250. 
 
 Figure A2.3. 13C NMR (126 MHz, CDCl3) of compound 250. 
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Figure A2.5. Infrared spectrum (Thin Film, NaCl) of compound 271. 
Figure A2.6. 13C NMR (126 MHz, CDCl3) of compound 271. 

























































































Figure A2.8. Infrared spectrum (Thin Film, NaCl) of compound 272. 
Figure A2.9. 13C NMR (126 MHz, CDCl3) of compound 272. 

























































































Figure A2.11. Infrared spectrum (Thin Film, NaCl) of compound 273. 
Figure A2.12. 13C NMR (126 MHz, CDCl3) of compound 273. 



























































































Figure A2.14. Infrared spectrum (Thin Film, NaCl) of compound 257. 
Figure A2.15. 13C NMR (126 MHz, CDCl3) of compound 257. 
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Figure A2.17. Infrared spectrum (Thin Film, NaCl) of compound 253. 
Figure A2.18. 13C NMR (76 MHz, CDCl3) of compound 253. 
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Figure A2.20. Infrared spectrum (Thin Film, NaCl) of compound 258. 
Figure A2.21. 13C NMR (126 MHz, CDCl3) of compound 258. 
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Figure A2.23. Infrared spectrum (Thin Film, NaCl) of compound 260. 
Figure A2.24. 13C NMR (126 MHz, CDCl3) of compound 260. 
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Figure A2.26. Infrared spectrum (Thin Film, NaCl) of compound 275. 
Figure A2.27. 13C NMR (126 MHz, CDCl3) of compound 275. 














































































































































































Figure A2.30. Infrared spectrum (Thin Film, NaCl) of compound 262. 
Figure A2.31. 13C NMR (126 MHz, CDCl3) of compound 262. 













































































































Figure A2.33. Infrared spectrum (Thin Film, NaCl) of compound 276. 
Figure A2.34. 13C NMR (126 MHz, CDCl3) of compound 276. 
































































































































































































Figure A2.37. Infrared spectrum (Thin Film, NaCl) of compound 277. 
Figure A2.38. 13C NMR (126 MHz, CDCl3) of compound 277. 



































































































































































































Figure A2.41. Infrared spectrum (Thin Film, NaCl) of compound 279. 
Figure A2.42. 13C NMR (126 MHz, C6D6) of compound 279. 











































































































































































Alternative Construction of Hydroxymethyl-cis- 
1,3-cyclopentenediol Building Block by Ring-Closing Metathesis 
 
 
A3.1   Alternative Approach to 1,3-cis-Cyclopentenediol Building Block 
During the development of the ultimately successful and highly efficient route to 
hydroxymethyl-cis-1,3-cyclopentenediol building block 241 through intramolecular 
Wittig cyclization, 1  we concurrently investigated an alternative procedure (Scheme 
A3.1.1).  Retrosynthetically, we envisioned access to cyclopentenediol 241 through the 
same key cyclopentenone intermediate 242.  Bicycle 242 would be accessed by the 1,3-
allylic transposition of tertiary alcohol 280.  Cyclopentenol 280, in turn, could be 
constructed by a ring-closing metathesis from vinyl alcohol 281.  Synthesis of vinyl 
alcohol 281 was envisioned to be accomplished by the 1,2-addition of a vinyl group into 
ketone 243.  Although the stereochemistry of the 1,2-vinyl addition is ultimately 
inconsequential for the synthesis of cyclopentenone 242, we hypothesized that only syn-
281 will only undergo productive ring-closing metathesis to form the cis-fused [5,6]-
bicycle 280.  Thus, we planned to accomplish the vinyl addition into ketone 243 in a 
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diastereoselective fashion.  Access to allyl dioxanone 243 would be accomplished in an 
asymmetric fashion through the enantioselective palladium-catalyzed allylic alkylation of 
enol ether 244. 
Scheme A3.1.1. Alternative Retrosynthetic Analysis of Hydroxymethyl-cis-1,3-cyclopentenediol 
Building Block 241 
 
 
A3.2   Synthesis of Diethyl Ketal Analog 
Exploration of the proposed synthetic route to access to hydroxymethyl-cis-1,3-
cyclopentenediol 241 began with the evaluation of the influence of the identity of the 
ketal protecting group on the diastereoselective 1,2-addition of a vinyl nucleophile into 
dioxanone 243 (Scheme A3.2.1).   We had previously established synthetic access to 
acetonide 2832 as well as cyclohexyl ketal 284,1 but had not explored the synthesis of 
diethyl ketal variant 285. 
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Synthesis of diethyl ketal 285 was accomplished by modification of the procedure 
employed for the synthesis of cyclohexyl ketal 284,1 beginning with the transketalization 
of 3,3-dimethoxypentane (286)3 with the hydrogen chloride salt of amino alcohol 270 
(Scheme A3.2.2).  Exposure of the intermediate ammonium salt to excess Et3N furnished 
aminoalcohol 287 in 19% yield over two steps.  Subsequent oxidative cleavage of amine 
287 using NaIO4 provided ketodioxanone 288 in 67% yield.  Ketone 288 was then 
alkylated by a two-step procedure beginning with cyclohexylimine formation followed by 
deprotonation using LDA to furnish methylated dioxanone 289 in 44% yield.  
Thermodynamic enolization of ketone 289 afforded enol ether 290 as the allylic 
alkylation substrate in 53% yield.  Ultimately, palladium-catalyzed allylic alkylation of 
TES enol ether was smoothly accomplished using mesylate 253 as the external 
electrophile to furnish chloroallylketone 291 in 73% yield.4 
Scheme A3.2.2. Synthesis of Diethyl Ketal Allylic Alkylation Product 291 
 
A3.3   Attempted Deprotection of Kinetic Enol Ether Byproducts 
The formation of enol ether 290 from diethylketal 289, as with the acetonide 291 
and cyclohexyl ketal 273, was complicated by the competing formation of the undesired 
kinetic silyl enol ether 294 (Table A3.3.1).  In order to improve the overall yield of 
thermodynamic enol ether 293, we attempted to develop conditions for the deprotection 
O O
1) p-TsOH
    DMF
2) Et3N
    ethyl acetate














1) H2NCy, 4 Å m.s.
    toluene
2) LDA, MeI 




















(44% yield, 2 steps)
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silyl enol ether 295 back to ketone 273 (Table A3.3.2).  Unfortunately, even using the 
more robust cyclohexyl ketal 295, we were never able to accomplish the removal of the 
TES group.  The majority of reaction conditions screened resulted in cleavage of the ketal 
group or complete decomposition of the reactant.  No trace of ketone 273 was observed. 
Table A3.3.1. Enolization of Ketodioxanone 292 
 
Table A3.3.2. Attempted Deprotection of Undesired Kinetic Silyl Enol  
 
A3.4   Exploration of Diastereoselective Vinyl Addition 
Nevertheless, with the acetonide, diethyl, and cyclohexyl ketal variants of ketone 
243 in hand, we explored the diastereoselectivity of nucleophilic vinyl addition (Table 
A3.4.1).  The addition of the vinyl Grignard reagent directly into ketone 243 routinely 
produced a complex mixture of products.  Alternatively, the use of LaCl3•2LiCl as a 
stoichiometric additive facilitated nucleophilic addition the vinyl nucleophile, furnishing 






























Entry Conditions Result a
1 TBAF, THF Decomposition
2 TBAF, DMF Ketal Cleavage
3 HF•pyridine, pyridine, THF Ketal Cleavage
4 DBU, THF No reaction
5 ZnBr2, H2O, CH2Cl2 Decomposition
a All results assessed by crude 1H NMR.
295 273
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of the vinyl nucleophile into allyl acetonide 249 furnished a 1.2:1.0 mixture in favor of 
the undesired diastereomer anti-vinyl alcohol 297.   
Table A3.4.1. Effect of Ketal Identity on Diastereoselective Grignard Addition  
 
Fortunately, switching from allylketone 249 to chloroallylketone 254 furnished syn-
vinyl alcohol 298 as the major product in a 2.8:1.0 ratio with anti-vinyl alcohol 299.  
Switching the identity the ketal to the diethyl ketal slightly improved the product ratio, 
while the cyclohexyl ketal variant provided an intermediate product ratio.  Ultimately, we 
decided to explore the advancement of chloroallylalcohol 302, because of the improved 
stability of the cyclohexyl ketal, along with allylalcohol 296. 
A3.5   Ring-Closing Metathesis 
We were pleased to find the ruthenium-catalyzed ring-closing metathesis of syn-
allylalcohol 296 proceeded smoothly to furnish bicyclic cyclopentene 305 in 95% yield 
(Scheme A3.5.1.A).  Similarly, the cyclization of syn-chloroallylketone 298 could be 
accomplished under the same reaction conditions to provide vinyl chloride 306 in 89% 
yield (Scheme A3.5.1.B).  As we hypothesized, the exposure of anti-chloroallylketone 
299 provided no trans-fused product 307 even after prolonged exposure to the ruthenium-
catalyzed conditions that were highly effective for the cyclization of its diastereomer (i.e., 
















































Appendix 3 – Alternative Construction of Hydroxymethyl-1,3-cis-cyclopentenediol Framework 137 
Scheme A3.5.1. Ring-Closing Metathesis of Allyl Dioxanones 
 
A3.6   1,3-Allylic Transposition of Bicyclic Cyclopentenes 
With cyclopentenes 305 and 306 in hand, we began exploring the potential to 
accomplish a 1,3-allylic transposition and convert the allylic alcohols into the 
corresponding cyclopentenones.  We began by exploring the potential to rearrange 
cyclopentene 305 to either allylic alcohol 308 under redox neutral conditions or 
cyclopentenone 309 employing oxidative 1,3-allylic transposition reaction manifolds 
(Scheme A3.6.1).  Unfortunately, no trace of any allylic transposition product was 
observed employing SO3•pyridine,7 IBX,8 or PCC.9  In fact, we most typically observed 
decomposition of the substrate, most likely due to the labile nature of the acetonide 
protecting group.6  One of the few isolable products we encountered was simply the result 
of an intramolecular transketalization in the presence of PCC to provide spirocyclic 
acetonide 311 (Scheme A3.6.2).10  Without any success, we turned our attention to the 
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Scheme A3.6.1. Attempted 1,3-Allylic Transposition of Bicyclic Acetonide 305  
 
Scheme A3.6.2. Isomerization of Acetonide 306 
 
Having installed an oxidized allyl fragment earlier in the synthetic route with a 
chloroallyl electrophile to provide vinyl chloride 311, we needed only to accomplish a 
1,3-allylic transposition under redox neutral conditions to directly furnish bicyclic 
cyclopentenone 242 (Table A3.6.1).  Under rhenium catalysis, the substrate protected 
with an acetonide ketal decomposed (Entries 1 and 2) and the cyclohexyl ketal variant 
failed to react (Entry 3).11  Comparatively, the use of PCC (Entry 4)9 and SO3•pyridine 
(Entry 5)7 failed to induce any reactivity at all, resulting in the quantitative recovery of 
starting material.  Fortunately, we found that exposure of vinyl chloride 311 (R,R = 
(CH2)5, Entry 6) to SO3•pyridine followed by a phosphate buffer produced traces of 
cyclopentenone.12  Although we were encouraged by this result, we quickly discovered 
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Table A3.6.1. 1,3-Allylic Transposition of Vinyl Chloride 311 
 
Despite our best attempts, we were unable to access the required cyclopentenone 
fragment 242 for further advancement toward the hydroxymethyl-cis-1,3-
cyclopentenediol building block 241.  We did establish the substitution at the 2-position 
of the allyl fragment of allylic alkylation product 243 has a profound impact on the 
diastereoselective addition of a vinyl group in a 1,2-fashion into the carbonyl moiety.  
Additionally, we showed that only the syn-vinyl products undergo a ring-closing 
metathesis to build bicyclic cyclopentenes.  Although these intermediates were not 
immediately useful for the purposes of our synthesis of cis-1,3-cyclopentadiol-containing 
natural products, these easily accessible, enantioenriched, highly oxygenated 












Entry Reaction Conditions Outcome
1 ReO3Me, Ph3SiOHEt2O, 0 °C
Decomposition
2 ReO3(OSiPh3), Et2O, 23 °C
Decomposition




3 ReO3(OSiPh3), Et2O, 23 °C
No Reaction a(CH2)5
4 PCC, Et3NCH2Cl2, 50 °C
No Reaction a






then phosphate buffer, 60 °C
Trace 242 b(CH2)5
a Quantitative recovery of starting material. b Trace of enone 242 by 
LCMS, however no isolated product was obtained. Instead, mostly 
decomposition of vinyl chloride 312 was observed.
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A3.7  Experimental Methods and Analytical Data 
A3.7.1  Materials and Methods 
Unless stated otherwise, reactions were performed at ambient temperature (23 °C) 
in flame-dried glassware under an argon atmosphere using dry, deoxygentated solvents 
(distilled or passed over a column of activated alumina) 13  using a Teflon®-coated 
magnetic stirring bar.  Commercially available reagents were used as received unless 
otherwise noted.  Et3N was distilled from calcium hydride immediately prior to use. 
Purified H2O was obtained using a Barnstead NANOpure Infinity UV/UF system.  4 Å 
molecular sieves were oven-dried at 120 °C for a minimum of 24 h and cooled in a 
desiccator to ambient temperature immediately prior to use.  (S)-t-BuPhox (263),14 tris-
(4,4’-methoxydibenzylideneacetone)-dipalladium(0) (Pd2(pmdba)3),15 and LaCl3•2LiCl5 
were prepared by known methods.  Reactions requiring external heat were modulated to 
the specified temperatures using an IKAmag temperature controller.  Thin-layer 
chromatography (TLC) was performed using E. Merck silica gel 60 F254 precoated 
plates (250 nm) and visualized by UV fluorescence quenching, potassium permanganate, 
or p-anisaldehyde staining.  Silicycle SiliaFlash P60 Academic Silica gel (particle size 
40-63 nm) was used for flash chromatography.  1H and 13C NMR spectra were recorded 
on a Varian Mercury 300 spectrometer (300 MHz and 76 MHz, respectively) and are 
reported in terms of chemical shift relative to residual CHCl3 (in CDCl3, δ 7.26 and δ 
77.16, respectively).  Data for 1H NMR spectra are reported as follows: chemical shift (δ 
ppm) (multiplicity, coupling constant (Hz), integration).  Infrared (IR) spectra were 
recorded on a Perkin Elmer Paragon 1000 Spectrometer and are reported in frequency of 
absorption (cm-1). High resolution mass spectra (HRMS) were acquired using an Agilent 
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6200 Series TOF with an Agilent G1978A Multimode source in atmospheric pressure 
chemical ionization (APCI) or mixed (MultiMode ESI/APCI) ionization mode or 
obtained from the Caltech Mass Spectral Facility using a JEOL JMS-600H High 
Resolution Mass Spectrometer in fast atom bombardment (FAB+) or electron ionization 
(EI+) mode.  Optical rotations were measured on a Jasco P-2000 polarimeter using a 100 
mm path length cell at 589 nm. 
 
A3.7.2  Experimental Procedures 
 
Aminoalcohol 287: To a suspension of Trizma•HCl (270, 11.8 g, 74.8 mmol, 1.00 equiv) 
in DMF (83 mL) were added 3-pentanone dimethyl ketal (286, 10.9 g, 82.3 mmol, 1.15 
equiv) and p-toluenesulfonic acid monohydrate (p-TsOH, 427 mg, 2.24 mmol, 0.03 
equiv) in one portion with stirring. After 17 h, a distillation apparatus was attached 
directly to the reaction flask and the volatiles were distilled off (75 °C/6 torr). The 
semisolid residue was triturated with Et2O (700 mL) until white solid precipitated. The 
resulting heterogeneous solution was filtered, washed with EtOAc (4 x 75 mL), and dried 
under high vacuum (0.50 torr) to afford a white solid.  
To the crude white solid as a suspension in EtOAc (300 mL) was added Et3N (11.0 
mL, 74.8 mmol, 1.00 equiv) dropwise with stirring. After 11 h, the reaction mixture was 
filtered and the solids washed with EtOAc (4 x 20 mL). The combined organic filtrate 
was concentrated in vacuo to give aminoalcohol 287 (2.72 g, 19% yield from 270) as a 
white solid: Rf = 0.16 (4:1 CH2Cl2:MeOH eluent); 1H NMR (300 MHz, CDCl3) δ 3.82–
O O
1) p-TsOH
    DMF
2) Et3N
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3.72 (m, 2H), 3.55–3.49 (m, 2H), 3.48 (s, 2H), 2.03 (s, 3H), 1.73 (app qd, J = 7.5, 2.7 Hz, 
4H), 0.90 (app dt, J = 14.2, 7.5 Hz, 6H). 
  
 
Dioxanone 288: Aminoalcohol 287 (2.72 g, 14.4 mmol, 1.00 equiv) was dissolved in a 
solution of KH2PO4 (3.91 g, 28.8 mmol, 2.00 equiv) in H2O (48 mL) and cooled to 0 °C 
(ice/H2O bath). To the resultant stirred homogenous solution was added a solution of 
NaIO4 (3.07 g, 14.4 mmol, 1.00 equiv) in H2O (48 mL) dropwise over 2 h through a 250 
mL additional funnel. The reaction was then allowed to stir at temperature for 40 minutes 
before being allowed to warm to ambient temperature (ca. 23 °C). The starting material 
was consumed after an additional 16 h as determined by TLC (1:4 MeOH:CH2Cl2 eluent). 
Na2S2O3•5H2O (3.57 g, 14.4 mmol, 1.00 equiv) was then immediately added in one 
portion. The solution was allowed to stir for 40 minutes at which time the reaction 
mixture was extracted with CH2Cl2 (11 x 75 mL). Combined organic layers were dried 
over Na2SO4, filtered, and concentrated in vacuo (26 °C/100 torr) to afford dioxanone 288 
(1.53 g, 67% yield) as a pale yellow oil. This compound was carried on to the next step 
without further purification: Rf = 0.80 (1:4 MeOH:CH2Cl2 eluent);  1H NMR (300 MHz, 
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Methyldioxanone 289: To a solution of dioxanone 288 (1.15 g, 7.29 mmol, 1.00 equiv) 
in toluene (24 mL) were added 4 Å molecular sieves (1.14 g, 1.00 equiv by mass) and 
cyclohexylamine (1.62 mL, 14.1 mmol, 1.94 equiv). After 13 h, the reaction mixture was 
filtered through celite, rinsing with toluene, and concentrated in vacuo to give the crude 
cyclohexylimine.  
In a separate three-neck flask with an internal temperature probe, a solution of 
freshly prepared lithium diisopropylamine (LDA, 0.60 M in THF, 1.00 equiv) was cooled 
to –78 °C (dry ice/i-PrOH bath). To the solution of LDA was added crude 
cyclohexylimine as a solution in THF (7.3 mL) dropwise through a cannula with an 
overpressure of argon. After 5 minutes, the reaction flask was the cooled to 0 °C  
(ice/H2O bath) and after 1.75 h was cooled back to –78 °C. To the reaction mixture was 
then added methyl iodide (0.45 mL, 7.30 mmol, 1.00 equiv) at a rate of 2.00 mL/h with a 
syringe pump, ensuring the internal temperature did not exceed –70 °C. Upon completion 
of addition, the reaction was allowed to stir for 30 minutes before being allowed to 
slowly warm to ambient temperature. Upon reaching ambient temperature, the reaction 
was quenched with saturated NH4Cl (100 mL) and stirred for 14 h. The reaction mixture 
was then extracted with Et2O (4 x 50 mL). The combined organic layers were then 
washed with H2O (25 mL), brine (25 mL), dried over Na2SO4, filtered, and concentrated 
in vacuo to afford an orange-tan oil. Purification of this residue by flash chromatography 
(10% Et2O in hexanes eluent) furnished methyldioxanone 289 (547 mg, 44% yield) as a 
clear, colorless oil: Rf = 0.28 (9:1 hexanes:Et2O eluent); 1H NMR (300 MHz, CDCl3) δ 
1) H2NCy, 4 Å m.s.
    toluene
2) LDA, MeI 
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4.41–4.33 (m, 1H), 4.27 (dd, J = 17.3, 1.4 Hz, 1H), 4.01 (d, J = 17.3 Hz, 1H), 1.82–1.62 
(m, 4H), 1.30 (d, J = 6.7 Hz, 3H), 1.00–0.85 (m, 6H). 
 
 
Silyl Enol Ether 290: A 50 mL round bottom was soaked in a 20:1 i-PrOH:toluene bath 
saturated with KOH for 12 h, rinsed with deionized H2O, acetone, and allowed to dry. To 
a solution of methyldioxanone 289 (547 mg, 3.18 mmol, 1.00 equiv) in CH3CN (5.3 mL) 
in a flame-dried 50 mL base-bathed round bottom flask with stir bar were added sodium 
iodide (619 mg, 4.13 mmol, 1.30 equiv) in a single portion and Et3N (0.71 mL, 5.08 
mmol, 1.60 equiv) dropwise with stirring. After 5 minutes, triethylsilyl chloride (TESCl, 
0.69 mL, 4.13 mmol, 1.30 equiv) was added dropwise. After 18 h, consumption of 
starting material was complete as determined by TLC (1:9 Et2O:Hexanes eluent) and the 
reaction mixture was extracted with pentane (4 x 100 mL). Combined organic layers were 
washed with H2O (50 mL), brine (50 mL), dried over Na2SO4, filtered, and concentrated 
in vacuo to produce a yellow oil. Purification of this residue by flash chromatography 
(1.0% Et2O / 0.5% Et3N in hexanes eluent) on base-treated silica furnished silyl enol 
ether 290 (485 mg, 53% yield) as a faintly pink, clear oil: Rf = 0.28 (1:19 Et2O:Hexanes 
eluent); 1H NMR (300 MHz, CDCl3) δ 4.02 (q, J = 2.0 Hz, 2H), 1.77 (t, J = 2.0 Hz, 3H), 
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Chloroallyl Ketal 291: A 500 mL Schlenk flask was soaked in a 20:1 i-PrOH:toluene 
bath saturated with KOH for 12 h, rinsed with deionized H2O, acetone, and allowed to 
dry. To a flame-dried 500 mL base-bathed Schlenk flask in a nitrogen-filled glovebox 
were charged Bu4NPh3SiF2 (TBAT, 642 mg, 1.19 mmol, 1.00 equiv), Pd2(pmdba)3 (20 
mg, 0.018 mmol, 0.015 equiv),  (S)-t-BuPhox (16 mg, 0.042 mmol, 0.035 equiv), and 
toluene (12 mL, 0.003 M in Pd). The reaction vessel was immediately removed from the 
glovebox, placed under an argon atmosphere and introduced to a preheated 35 °C bath 
with stirring. After 20 minutes, a yellow-brown solution was observed. 
Chloroallylmesylate 253 (0.21 mL, 1.67 mmol, 1.40 equiv) was added quickly dropwise 
affording a blue-green solution. After 3 minutes, silyl enol ether 290 (340 mg, 1.19 
mmol, 1.00 equiv) was added quickly dropwise over 3 minutes. The resultant blue-green 
reaction mixture was allowed to stir for 20 h. The resultant yellow-brown reaction was 
then allowed to cool to ambient temperature, filtered through a pad of SiO2 using hexanes 
as the eluent to remove toluene, at which time separate fractions were collected, eluting 
with Et2O, to isolate the volatile reaction products. The filtrate was concentrated in vacuo 
to a bright yellow oil which was subsequently purified by flash chromatography 
(1%→3%→5% Et2O in pentane eluent) to afford volatile chloroallyl ketal 291 (2.95 g, 
82% yield) as a clear, colorless oil: Rf = 0.35 (19:1 pentane:Et2O eluent); 1H NMR (300 
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Hz, 1H), 4.21 (d, J = 18.2 Hz, 1H), 2.87 (dd, J = 14.5, 0.9 Hz, 1H), 2.76 (d, J = 14.5 Hz, 
1H), 1.81–1.63 (m, 4H), 1.46 (s, 3H), 0.92 (app td, J = 7.5, 5.9 Hz, 6H). 
 
 
Example Procedure for the Addition of Vinyl–MgBr to Ketodioxanones 
The following procedure was adapted from the literature.5 To a solution of 
chloroallylketone 258 (80 mg, 0.31 mmol, 1.00 equiv) in THF (1.0 mL) was added 
LaCl3•2LiCl (0.52 mL, 0.60 M in THF, 0.31 mmol). The reaction mixture was then 
cooled to 0 °C (ice/H2O bath). Vinyl magnesium bromide (0.50 mL, 0.68 M in THF, 1.10 
equiv) was then added slowly dropwise over 4 minutes. After 20 minutes, consumption 
of starting material was complete as determined by TLC (1:9 Et2O:Hexanes eluent). The 
reaction was immediately diluted with Et2O (50 mL) and poured onto a mixture of H2O 
(20 mL), brine (20 mL), and hexanes (30 mL). The organics were separated and the 
aqueous was extracted with Et2O (2 x 50 mL). The combined organics were dried over 
MgSO4, filtered, and concentrated in vacuo. The crude dark yellow oil was purified by 
silica gel column chromatography (20% Et2O in hexanes eluent) to yield syn-vinyl 
alcohol 302 (77 mg, 87% yield) and anti-vinyl alcohol 303 (12 mg, 13% yield), both as a 
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syn-Vinyl Chloroallylcyclohexyl Ketal 302: Rf = 0.37 (1:4 Et2O:Hexanes eluent); 1H 
NMR (300 MHz, CDCl3) δ 6.13 (ddd, J = 17.5, 11.0, 0.8 Hz, 1H), 5.50–5.22 (m, 4H), 
3.82–3.70 (m, 2H), 2.87–2.73 (m, 1H), 2.45–2.33 (m, 2H), 1.99–1.93 (m, 1H), 1.80–1.71 
(ddd, J = 19.4, 9.1, 4.4 Hz, 2H), 1.67–1.55 (m, 7H), 1.43 (s, 3H). 
 
 
anti-Vinyl Chloroallylcyclohexyl Ketal 303: Rf = 0.30 (1:4 Et2O:Hexanes eluent); 1H 
NMR (300 MHz, CDCl3) δ 5.68 (ddd, J = 17.2, 10.5, 1.5 Hz, 1H), 5.55 (dd, J = 17.2, 2.3 
Hz, 1H), 5.35–5.17 (m, 3H), 4.26 (dd, J = 11.9, 1.3 Hz, 1H), 3.33 (dd, J = 12.0, 1.5 Hz, 
1H), 3.17 (d, J = 1.5 Hz, 1H), 3.02–2.90 (m, 1H), 2.26 (dd, J = 14.9, 0.9 Hz, 1H), 2.10–
2.03 (m, 1H), 1.78–1.52 (m, 8H), 1.50 (s, 3H), 1.48–1.41 (m, 1H). 
 
 
syn-Vinyl Allylacetonide 296: Rf = 0.47 (1:4 Et2O:Hexanes eluent); 1H NMR (300 MHz, 
CDCl3) δ 5.99–5.73 (m, 2H), 5.51 (dd, J = 17.3, 1.8 Hz, 1H), 5.27 (dd, J = 11.0, 1.8 Hz, 
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1.2 Hz, 1H), 2.82–2.69 (m, 1H), 2.14 (ddt, J = 14.8, 8.2, 1.1 Hz, 1H), 1.52 (s, 3H), 1.45 
(s, 3H), 1.15 (s, 3H). 
 
 
anti-Vinyl Allylacetonide 297: Rf = 0.33 (1:4 Et2O:Hexanes eluent); 1H NMR (300 
MHz, CDCl3) δ 5.87 (dddd, J = 16.9, 10.4, 8.7, 5.8 Hz, 1H), 5.71 (ddd, J = 17.2, 10.7, 1.4 
Hz, 1H), 5.54 (dd, J = 17.2, 2.1 Hz, 1H), 5.33–5.21 (m, 1H), 5.11–4.92 (m, 2H), 4.18 (d, 
J = 11.9 Hz, 1H), 3.36 (d, J = 12.0 Hz, 1H), 3.08 (d, J = 1.4 Hz, 1H), 2.57 (ddtd, J = 14.2, 




syn-Vinyl Chloroallylacetonide 298: Rf = 0.31 (1:4 Et2O:Hexanes eluent); 1H NMR 
(300 MHz, CDCl3) δ 5.95 (ddd, J = 17.4, 11.0, 0.9 Hz, 1H), 5.53–5.43 (m, 2H), 5.38 (t, J 
= 1.2 Hz, 1H), 5.30 (dd, J = 11.0, 1.4 Hz, 1H), 3.97 (d, J = 11.8 Hz, 1H), 3.63 (d, J = 11.8 
Hz, 1H), 2.97–2.85 (m, 1H), 2.73 (d, J = 1.0 Hz, 1H), 2.41 (dd, J = 16.7, 1.0 Hz, 1H), 
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anti-Vinyl Chloroallylacetonide 299: Rf = 0.19 (1:4 Et2O:Hexanes eluent); 1H NMR 
(300 MHz, CDCl3) δ 5.68 (ddd, J = 17.2, 10.5, 1.5 Hz, 1H), 5.56 (dd, J = 17.2, 2.3 Hz, 
1H), 5.32–5.25 (m, 2H), 5.19 (t, J = 0.9 Hz, 1H), 4.22 (d, J = 12.0 Hz, 1H), 3.35 (d, J = 
12.0 Hz, 1H), 3.12 (d, J = 1.4 Hz, 1H), 2.93 (dd, J = 14.9, 1.4 Hz, 1H), 2.26 (dd, J = 14.9, 
0.9 Hz, 1H), 1.51–1.47 (m, 6H), 1.45–1.38 (m, 3H). 
 
 
Bicycle 305: To a stirred solution of syn-vinyl alcohol 296 (187 mg, 0.88 mmol, 1.00 
equiv) in benzene (9.0 mL) was added ruthenium carbene 304 (13 mg, 0.022 mmol, 
0.025 equiv). The reaction vessel was the introduced to a preheated 60 °C bath. After 2 h, 
consumption of starting material was complete as determined by TLC (1:4 Et2O:Hexanes 
eluent). The reaction mixture was then removed form the heating bath and allowed to 
cool to ambient temperature (ca. 23 °C). The crude reaction mixture was then directly 
purified by silica gel column chromatography (10%→20% Et2O in pentane eluent) to 
afford semi-volatile bicycle 305 (154 mg, 95% yield) as a clear, colorless oil: Rf = 0.25 
(3:7 Et2O:Hexanes eluent); 1H NMR (300 MHz, CDCl3) δ 5.89 (ddd, J = 6.0, 3.0, 1.8 Hz, 

















60 °C, 2 h
304
(2.5 mol%)
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Bicycle 306: To a stirred solution of syn-vinyl alcohol 298 (284 mg, 1.15 mmol, 1.00 
equiv) in benzene (12.0 mL) was added ruthenium carbene 304 (33 mg, 0.058 mmol, 
0.05 equiv). The reaction vessel was the introduced to a preheated 60 °C bath. After 1 h, 
consumption of starting material was complete as determined by TLC (1:4 Et2O:Hexanes 
eluent). The reaction mixture was then removed form the heating bath and allowed to 
cool to ambient temperature (ca. 23 °C). The crude reaction mixture was then directly 
purified by silica gel column chromatography (10%→20% Et2O in pentane eluent) to 
supply bicycle 306 (242 mg, 89% yield) as a clear, colorless oil: Rf = 0.20 (3:7 
Et2O:Hexanes eluent); 1H NMR (300 MHz, CDCl3) δ 5.59 (t, J = 1.9 Hz, 1H), 3.79 (d, J = 
12.0 Hz, 1H), 3.71 (d, J = 11.9 Hz, 1H), 2.86 (dd, J = 17.1, 1.8 Hz, 1H), 2.66 (dd, J = 


















60 °C, 1 h
304
(5.0 mol%)
Appendix 3 – Alternative Construction of Hydroxymethyl-1,3-cis-cyclopentenediol Framework 151 
 
Chloride 312: To a stirred solution of syn-vinyl alcohol 302 (35 mg, 0.12 mmol, 1.00 
equiv) in benzene (2.5 mL) was added ruthenium carbene 304 (3 mg, 0.006 mmol, 0.05 
equiv). The reaction vessel was the introduced to a preheated 60 °C bath. After 1.3 h, 
consumption of starting material was complete as determined by TLC (1:4 Et2O:Hexanes 
eluent). The reaction mixture was then removed form the heating bath and allowed to 
cool to ambient temperature (ca. 23 °C). The crude reaction mixture was then directly 
purified by silica gel column chromatography (10%→20% Et2O in pentane eluent) to 
furnish volatile chloride 312 (154 mg, 95% yield) as a clear, colorless oil: Rf = 0.14 (2:3 
Et2O:Hexanes eluent); 1H NMR (300 MHz, CDCl3) δ 5.59 (t, J = 1.9 Hz, 1H), 3.78 (d, J = 
11.8 Hz, 1H), 3.68 (d, J = 11.9 Hz, 1H), 2.85 (dd, J = 17.0, 1.8 Hz, 1H), 2.66 (dd, J = 
17.0, 1.9 Hz, 1H), 2.01 (s, 1H), 1.88–1.76 (m, 1H), 1.75–1.64 (m, 1H), 1.61–1.51 (m, 
5H), 1.54 (s, 3H), 1.45 (s, 3H). 
 
 
Acetonide 310: To a mixture of allylic alcohol 305 (35 mg, 0.19 mmol, 1.00 equiv) in 
CH2Cl2 (2.0 mL) was added PCC (123 mg, 0.57 mmol, 3.00 equiv) as a solid in a single 
portion. After 18 h, the consumption of starting material was complete as determined by 
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rinsing with Et2O. The combined organics were concentrated in vacuo to provide 
acetonide 310:16 Rf = 0.26 (1:1 Et2O:Hexanes eluent); 1H NMR (300 MHz, CDCl3) δ 5.76 
(dd, J = 6.2, 2.7 Hz, 1H), 5.56 (dd, J = 5.4, 2.6 Hz, 1H), 4.25–4.12 (m, 1H), 3.73–3.55 
(m, 1H), 3.35–3.21 (m, 1H), 2.43–2.30 (m, 1H), 2.27–2.12 (m, 1H), 1.25 (s, 3H), 1.22 (s, 
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Spectra Relevant to Appendix 3: 
Alternative Construction of Hydroxymethyl-cis- 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Progress Toward the Asymmetric Total Syntheses of the 
Furanobutenolide Norcembranoid Diterpene Natural Products 
 
 
3.1   Introduction 
Natural products produced by flora and fauna throughout the world have been 
successfully applied to the treatment of human ailments for centuries.1  Modern synthetic 
chemistry has enabled the isolation, identification, and manufacturing of many of the 
most promising biologically active natural products for therapeutic application against a 
breadth of diseases including cancer,1b,c, 2  malaria,1b, 3  infectious bacteria,1b,c, 4  and 
neurological diseases.1b,2a, 5  Despite these successes, the need for more effective 
therapeutics for a variety of intractable ailments remains constant.1c,6 Toward this end, the 
norcembranoid diterpenes remains a largely unexplored class of biologically active 
natural products.7  Included within this natural product family is the compact and highly 
oxygenated antileukemic and antitumor ineleganolide (9)8 as well as the closely related 
norcembranoid diterpenes horiolide (20),9 kavaranolide (21),10 sinulochmodin C (10),11 
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scabrolide B (23),12 scabrolide A (24),12 and yonarolide (25, Figure 3.1.1).13 The total 
synthesis of any member of these polycyclic furanobutenolide norcembranoids has not 
been accomplished to date, although the syntheses of select members have been 
investigated14 and the biomimetic semisynthesis of ineleganolide (9) and sinulochmodin 
C (10) has been disclosed.15  
Figure 3.1.1. Polycyclic Furanobutenolide Norcembranoid Diterpenes 
 
It has been proposed that ineleganolide (9) and sinulochmodin C (10) are the 
biosynthetic precursors to the other related polycyclic [6,7]- and [7,6]-fused 
norcembranoid diterpenes, respectively.7a,b,10 Ineleganolide is believed to undergo a retro-
oxa-Michael addition followed by a retroaldol cyclization to furnish intermediate 
triketone 39 (Scheme 3.1.1).  Although ketone 39 has not been isolated, it is the 
postulated biosynthetic precursor of horiolide (20), undergoing an intramolecular Michael 
addition with the vinylogous diketone moiety to construct the transannular C–C bond.  
Horiolide (20) would then undergo a β-acetoxy elimination from the methyl ketone 
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Scheme 3.1.1. Postulated Biosynthetic Conversion of Ineleganolide (9) to Kavaranolide (21) 
 
Sinulochmodin C (10), the constitutional isomer of ineleganolide (9), is the 
postulated biosynthetic precursor to each of the other related [7,6]-fused norcembranoid 
diterpenes furnishing scabrolide B (23) after undergoing a retro-oxa-Michael addition 
(Scheme 3.1.2).  Olefin isomerization of vinylogous diketone 23 would furnish the 
tetrasubstitued enone scabrolide A (24).  Finally, dehydration of tertiary alcohol 24 would 
afford bisenone yonarolide (25). 




We were drawn to the unique furanobutenolide scaffold of these norcembranoid 
diterpenes and the challenge of designing a convergent synthetic pathway toward 
complex late-stage polycyclic intermediates from which divergent access to each of these 
six closely related natural products could be achieved.  The synthesis would require 
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transformations, and intramolecular rearrangements to provide enantioselective synthetic 
access to these highly oxygenated, cycloheptanone-derived polycycles.  Successful 
development of such a synthetic route would enable the thorough exploration of the 
biological activity of these largely untested members of the known antitumor and 
antileukimia norcembranoid diterpene natural product family.  We targeted ineleganolide 
(9) and scabrolide A (24) as the intermediates through which we could access the 
remaining furanobutenolide norcembranoid diterpenes.   
3.2  Retrosynthetic Analysis 
Synthetic access to furanobutenolide norcembranoid diterpenes 20, 21, and 23–25 
could be achieved through either ineleganolide (9) or scabrolide A (24) in a divergent 
fashion from a common, late-stage synthetic intermediate 314 (Scheme 3.2.1).  
Retrosynthetically, completion of the asymmetric total synthesis of ineleganolide (9) 
would be achieved by the olefin isomerization of enone 313 followed by intramolecular 
oxa-Michael addition (Scheme 3.2.1.A).  Unsaturated diketone 313 could by synthesized 
after the selective dehydration of common intermediate diol 314.   
Scheme 3.2.1. Retrosynthetic Analysis of Ineleganolide (9) and Scabrolide A (24) 
 
The enantioselective construction of scabrolide A (24) would be achieved through a 
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furanobutenolide norcembranoids (9, 10, 20, 21, 23–25) from a common macrocyclic 
precursor through a sequential anionic cyclization cascade.7a,b,15  Scabrolide A (24) would 
be accessed by dehydration of diol 315 (Scheme 3.2.1.B).  Synthesis of [7,6,5,5]-
tetracyclic diol 315 would require a carbocyclic core isomerization from common 
intermediate diol 314.  We envision accomplishing this transformation directly from 
[6,7,5,5]-tetracyclic diol 314 by a biosynthesis-inspired tandem retroaldol-aldol 
cyclization.   
These divergent syntheses from [6,7,5,5]-tetracyclic diol 314 would be enabled by 
the concise, convergent enantioselective synthesis of the [6,7,5,5]-tetracyclic scaffold of 
ineleganolide (Scheme 3.2.2).  Access to diol 314 would be achieved by selective olefin 
hydration of α,β-unsaturated lactone 316.  Diketone 316 would be constructed by the 
isomerization of epoxide 317 via syn-facial 1,2-hydride shift.  Pentacycle 317 would be 
synthesized in a stereoselective fashion by hydroxyl-directed epoxidation of allylic 
alcohol 318.  Construction of the central cycloheptadiene within tetracycle 318 would be 
accomplished by the Cope rearrangement of divinylcyclopropane 319, which would be 
synthesized by the intramolecular cyclopropanation of α-diazoester 320.  Cyclization 
precursor 320 would be assembled in a convergent fashion by the coupling of carboxylic 
acid 321 and 1,3-cis-cyclopentenediol 322.  Acid 321 is rapidly constructed from (S)-(+)-
carvone.  Consequently, our initial synthetic efforts focused on the construction of 
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Scheme 3.2.2. Retrosynthetic Analysis of Divergent Tetracyclic Diol 314 
 
3.3  Enantioselective Construction of Cyclopentenediol Building Block 
Enantioselective synthesis of the targeted polycyclic norcembranoid diterpene 
natural products requires the enantioselective construction of the common 1,3-cis-
cyclopentenediol building block 322.  The isopropenyl stereocenter introduced from the 
chiral pool by the derivatization of the complimentary enantiomer of carvone to acid 321.  
However, the remaining chiral information within each natural product will be relayed 
from the two stereocenters in this highly oxygenated cyclopentene.  Thus, a highly 
enantioselective bond forming reaction is a compulsory feature of our route.   
Previously, our group had disclosed the development of the enantioselective 
synthesis of a functionalized hydroxymethyl-1,3-cis-cyclopentenediol synthetic building 
block.16  Selective formation of tetrasubstituted silyl enol ether 257 was accomplished in 
six steps from cyclohexanone dimethyl ketal (269) and amino alcohol hydrogen chloride 
salt 270 (Scheme 3.3.1).  Intermolecular asymmetric palladium-catalyzed allylic 
alkylation of bicyclic enol ether 257 using chloroallylmesylate 258 as the external 




























































Chapter 3 – Progress Toward the Furanobutenolide Norcembranoids 177 
chiral ligand, furnished (S)-chloroallylketone 258 in 82% yield and 92% ee.17  For the 
purposes of synthetic development, (S)-chloroallylketone 258 was used as an 
intermediate in the opposite enantiomeric series from the natural occurring 
norcembranoid diterpenes.  The synthesis of the enantiomerically matched 
norcembranoid diterpenes may be subsequently achieved using (R)-t-BuPhox18 as well as 
Phox ligands derived  (R)-valine, which have been shown to be comparably effective for 
the enantioselective formation of ketone 258.19 
Scheme 3.3.1. Synthesis of Hydroxymethyl-1,3-cis-cyclopentenediol Building Block 
 
Advancement of chloroallylketone 258 through oxidative α-bromoketone formation 
and subsequent intramolecular Wittig olefination provided cyclopentenone 260 in 94% 
yield over two steps.  Diastereoselective 1,2-reduction of enone 260 followed by 
benzoylation of the resultant secondary alcohol furnished allylic ester 275 in quantitative 
yield over two steps as a single diastereomer.  Cleavage of the cyclohexyl ketal revealed 










1. NaOBr,  AcOH
    acetone 
    0 °C, 1.5 h
2. (n-Bu)3P, Et3N
    toluene 
    110 °C, 16 h














    THF
    –78 °C → 0 °C, 1 h
2. Bz2O, DMAP, Et3N
    CH2Cl2
    0 °C, 13.5 h
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3.4  Synthesis of the Norcembranoid Diterpene Carbocyclic Core  
Hydroxymethylcyclopentene 262 could then be advanced toward the 
norcembranoid diterpenes natural products beginning with oxidation of the primary 
alcohol with Dess–Martin periodinane (DMP, Scheme 3.4.1.A).  Methylenation of the 
intermediate aldehyde and ultimate saponification of the benzoyl ester revealed the 
requisite diol fragment common to the norcembranoid diterpene natural product family 
(ent-322) in 85% yield over three steps. 
Scheme 3.4.1. Completion of Coupling Partners 
 
Synthesis of the complimentary coupling partner required for the synthesis of the 
enantiomeric norcembranoid diterpenes began with (R)-(–)-desmethylcarvone ((R)-217), 
which is available by a known procedure from (R)-(–) carvone.20  Cerium-mediated 1,2-
addition of the preformed lithium enolate of ethyl acetate into enone (R)-217 followed by 
a 1,3-oxidative allylic transposition21 provided ester 323 in 68% yield over two steps 
(Scheme 3.4.1.B).   
Saponification of ethyl ester 323 provided acid coupling partner ent-321 (Scheme 
3.4.2).  Coupling of crude acid ent-321 and diol ent-322 was accomplished using 
EDC•HCl with catalytic DMAP, requiring nearly a two-fold excess of acid ent-321 to 





    0 °C → 23 °C, 5 h
2. Ph3PMeBr, KOt-Bu, THF
    1.5 h
3. NaOH, MeOH, 14 h






1. CeCl3 , THF, –78 °C, 5 h
2. TEMPO•BF4 , CH3CN
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intermediate ester product using p-ABSA furnished α-diazoester ent-320 in 75% yield 
from diol ent-322. 
Scheme 3.4.2. Fragment Coupling and Synthesis of Cyclopropanation Precursor  
 
With α-diazoester ent-320 in hand, we began investigating the potential to 
accomplish a chemoselective intramolecular cyclopropanation.  Gratifyingly, exposure of 
diazo ent-320 to 1 mol % Rh2OAc4 in dichloromethane at ambient temperature enabled a 
tandem cyclopropanation-Cope rearrangement cascade, furnishing cycloheptadiene 324 
in 53% yield after in situ olefin isomerization from the unsaturated lactone ent-318 to the 
corresponding tetrasubstituted enone (Scheme 3.4.3).22  We were pleased to find diene 
324 was a crystalline solid and its relative configuration was unambiguously established 
by single crystal X-ray diffraction (Figure 3.4.1), confirming the stereocenters at C(11) 
and C(12) were set as required for the norcembranoid diterpenes natural products and 
revealing the creased conformation of the central heptacycle.   
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Figure 3.4.1. Three-Dimensional Structure of Diene 324 
 
The only other product observed from this transformation is extended enone 325, 
which was isolated in 35% yield.  Despite our efforts to optimize this transformation 
further, screening a variety of rhodium catalysts as well as reaction conditions, we were 
never able to improve the ratio between desired tetracycle 324 and cyclopentenone 
byproduct 325.23  We hypothesize that the nonproductive reaction pathway proceeds from 
the metal carbenoid of α-diazoester ent-320 through C–H insertion at or hydrogen 
abstraction from the allylic position of the cyclopentene fragment to furnish either 
intermediate β-lactone 326 or separated diradical 327, respectively.  Ultimately, retro-
ketene [2+2]-cycloaddition from heterocycle 326 or radical recombination by homolytic 
cleavage of the ester C–O single bond within diradical 327 would furnish cyclopentenone 
325. 
Enone byproduct 325 could be recycled through a diastereoselective 1,2-reduction 
with DIBAL at low temperature to provide cis-1,3-cyclopentenediol ent-322, albeit in 
low yield (Scheme 3.4.4).  The unsatisfactory yield of this transformation is likely due to 
coordination of the product to the byproduct aluminum salts, preventing extraction of diol 
ent-322 from the aqueous layer during purification. Other hydride sources like NaBH4 
and L-Selectride® failed to accomplish the reduction of enone 325 in a stereoselective 
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Scheme 3.4.4. Diastereoselective 1,2-Reduction of Enone Byproduct 325 
 
3.5  Synthetic Advancement Toward ent-Ineleganolide 
Nevertheless, we were please to have efficient and convergent synthetic access to 
the tetracyclic carbocyclic core of the norcembranoid diterpenes and began advancing 
toward the targeted natural products.  Hydroxyl-directed epoxidation of allylic alcohol 
324 was accomplished in 85% yield using catalytic VO(acac)2 (Scheme 3.5.1).  
Epoxytetracycle 328 was found to be a crystalline white solid and its configuration was 
unambiguously established by single crystal X-ray diffraction, confirming the success of 
the diastereoselective and chemoselective directed epoxidation.  Considering examples of 
successful epoxyketo rearrangements in the presence of free hydroxyl groups are 
extremely rare in the literature,24 conditions for the protection tertiary alcohol 328 were 
developed, affording silyl ether 329 in excellent yield at low temperature.   
Scheme 3.5.1. Advancement of Diene 324 and Formation of Isoineleganolide A (328) 
 
With two substrates in hand (328 and 329), we began screening reaction conditions 



































X-ray Crystal Structure of 328
Isoineleganolide A
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mediated by protic acid, aprotic base, and, most commonly, Lewis acids.24, 25   We 
hypothesized that epoxide 328 would undergo epoxyketo rearrangement to not only 
furnish the necessary 1,4-diketone pattern required for the norcembranoid diterpenes, but 
would result in an equilibrium mixture of enone ent-313 and vinylogous diketone 330 
(Scheme 3.5.2).  Intramolecular oxa-Michael addition of tertiary alcohol 330 into the 
vinylogous diketone system would then form the expected thermodynamically favored 
natural product ent-9, driving the equilibrium mixture toward vinylogous diketone and 
thus ent-ineleganolide.  Unfortunately, even under the most commonly employed 
conditions in the literature using magnesium(II)-, aluminum (III)-, and boron-based 
Lewis acids, both epoxytetracycle 328 and silyl ether derivative 329 proved largely 
unreactive or simply decomposed.26 
Scheme 3.5.2. Hypothesized Completion of Ineleganolide  
 
The only productive reactivity observed for either epoxytetracycle 328 or 329 was 
the isomerization of epoxyalcohol 328 to oxetane 331 using stoichiometric indium(III) 
triflate (Scheme 3.5.3).  Bridged ether 331 is another isomeric form of ent-ineleganolide 
(ent-9), although we did not envision isoineleganolide B (331) as immediately useful for 
completion of the asymmetric for either ent-ineleganolide or the remaining members of 
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Scheme 3.5.3. Isomerization of Isoineleganolide A (328) to Isoineleganolide B (331) 
 
3.6  Alternative Retrosynthetic Strategy 
In light of the difficulty encountered installing the transannular 1,4-dicarbonyl 
oxidation pattern that characterizes the norcembranoid diterpene natural product family 
from epoxytetracycle 328, we reevaluated our synthetic strategy.  Access to planned 
divergent intermediate 314 would be achieved by deprotection of enol ether 332 followed 
by olefin hydration of the unsaturated lactone moiety (Scheme 3.6.1).  Construction of 
tetracyclic core 332 would be accomplished through an analogous Cope rearrangement 
from cyclopropane 333 that would be formed in turn after the intramolecular 
cyclopropanation of α-diazoester 334.  Cyclization precursor 334 would be assembled by 
the coupling carboxylic acid 321 with methyl ketone 335. 
Scheme 3.6.1. Alternative Retrosynthetic Disconnection of Divergent Intermediate 314  
 
Having previously established synthetic access to acid ent-321, we turned our 
attention to the modification of the 1,3-cyclopentenediol synthetic route toward the 
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260, silylation of the intermediate alcohol using TBSOTf, and removal of the cyclohexyl 
ketal under fumaric acid-mediated transketalization conditions furnished silyl ether 336 
in 83% yield over three steps as a single diastereomer (Scheme 3.6.2).  Oxidation of 
primary alcohol 336 with DMP to the intermediate aldehyde followed by the 1,2-addition 
of a methyl substituent into the enal system provided secondary alcohol 337 as a 1 to 1 
mixture of diastereomers.  This mixture of diastereomers is inconsequential as the allylic 
oxidation of the diastereomeric mixture of alcohol 337 furnished methyl ketone 338 in 
89% yield.   
Scheme 3.6.2. Construction of Methyl Ketone 338 
 
We next needed to convert methyl ketone into the corresponding enol ether for use 
in the desired Cope rearrangement.  Unfortunately, all attempts to form a stable enol ether 
that would be orthogonal to the deprotection conditions needed for the requisite removal 
of the secondary TBS ether were unsuccessful (Scheme 3.6.3.A).27  Alternatively, we 
reasoned that the formation of the enol ether from the methyl ketone moiety could be 
accomplished at a later stage.  Thus, enone 339 was advanced by deprotection of the silyl 
ether using TBAF at ambient temperature for afford diol ent-335 in 98% yield (Scheme 






    0 °C → 23 °C, 3 h
2. MeLi, Et2O
    –15 °C → 23 °C, 3 h







   THF, –78 °C → 0 °C, 1 h
2. TBSOTf, Et3N
    CH2Cl2, 0 °C, 30 min
3. fumaric acid, HC(OMe)3
    MeOH, 0 °C → 35 °C, 9 h
  








1:1 Mixture of Diastereomers
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Scheme 3.6.3. Advancement of Silyl Ether 338  
 
Saponification of ethyl ester 323 again revealed coupling partner ent-321 (Scheme 
3.6.4).  Esterification of crude acid ent-321 with diol ent-335 was accomplished using 
catalytic DMAP in the presence of EDC•HCl, again requiring a 2-fold excess of acid ent-
321 to drive the reaction to completion relative to diol ent-335.  Diazo transfer onto the 
intermediate ester product using p-ABSA furnished α-diazoester 340 in 65% yield from 
diol ent-335.   
Scheme 3.6.4. Fragment Coupling with Methyl Ketone Diol ent-335 
 
With α-diazoester 340 in hand, we sought to form the enol ether from the methyl 
ketone moiety and subsequently accomplish a tandem cyclopropanation-Cope 
rearrangement.  Exposure of diazo 340 to a variety of base-mediated silyl enol ether 
forming conditions generated light sensitive, neon orange intermediates that quickly 
decomposed in the presence of silica or as neat crude oils.  Exposure of diazoester 340 to 
TBSOTf and Et3N at 0°C in the dark followed by immediate filtration through Florisil® 
and dilution of the crude oil with dichloromethane and the addition of catalytic 
Rh2(OAc)4 provided pyrazole 341 as the sole product in 38% yield over two steps 
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Scheme 3.6.5. Formation of Pyrazole 341 
 
Without success in accomplishing the tandem cyclopropanation-Cope 
rearrangement, we began exploring the potential to accomplish the synthesis of the 
central heptacycle in a stepwise fashion.  Intramolecular cyclopropanation of α-
diazoester 340 onto the olefin of the enone system to access cyclopropane 342 proved 
somewhat challenging (Scheme 3.6.6.).  While rhodium(II) dimers including Rh2(OAc)4 
and Rh2(CF3CO2)4 were ineffective catalysts for the desired intramolecular cyclization, 
we were pleased to find that Cu(tbs)2 (343) was able to catalyze the desired 
transformation, albeit in low yield over an extended reaction period.   
Scheme 3.6.6. Attempted Stepwise Formation of ent-316 from Diazoester 340 
 
With cyclopropane in hand, we next needed to induce the Cope rearrangement to 
access ent-316.  Unfortunately, formation of the silyl enol ether of methyl ketone 342 
was unsuccessful as the TMS, TES, or TBS enol ethers using reaction conditions 
mediated by either weak ((i-Pr)2NEt, Et3N) or strong (LDA, LHMDS) bases.  
Additionally, the anionic 2-oxa-Cope rearrangement failed to proceed after subjecting 
cyclopropane 342 to LDA or LHMDS at –78 °C and warming to ambient temperature, 
only resulting in decomposition of the cyclopropane starting material.28  Without a way to 
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employing substrates derived from methyl ketone analog diol ent-335, we returned to our 
initial route to explore alternative methods for the advancement of our previously isolated 
epoxytetracycle 328 toward the norcembranoid diterpenes natural products.   
3.7  Redox Advancement Toward ent-Ineleganolide 
Although all attempts to effect the epoxyketo rearrangement of isoineleganolide A 
(328) to provide ent-ineleganolide (ent-9) or any 1,4-diketone product had failed 
(Scheme 3.7.1), we sought to more thoroughly explore the reactivity of epoxide 328.  
Having encountered the productive rearrangement of epoxytetracycle 328 to oxetane 331 
(see Scheme 3.5.3), we set about characterizing the reactivity of epoxide 328 in the 
presence of indium(III) triflate on larger scale.  To our surprised, simply switching the 
solvent from unstabilized CDCl3 to CHCl3, stabilized with 0.75% EtOH, caused oxetane 
331 become a minor product (Scheme 3.7.2).  Instead, ether 344 became the major 
product and was isolated in 70% yield,29 with cycloheptatriene 345 as a third, minor 
product.  Given the apparent propensity of the epoxide moiety within isoineleganolide A 
(328) to undergo nucleophilic opening at the least hindered position, we began exploring 
the potential to exploit this reactivity for the synthesis of the norcembranoid diterpenes 
natural products.   
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Scheme 3.7.2. Reactivity of Isoineleganolide A (328) with In(OTF)3 in Stabilized CHCl3 
 
We quickly discovered that halogenated Lewis acids in nonpolar solvent systems 
containing a small amount to Lewis basic cosolvent could facilitate the opening of 
epoxide 328 with their halogen counterions.30  Under optimized conditions, in a 4 to 1 
mixture of toluene to THF, magnesium(II) bromide could accomplish the formation of 
furanopentacycle 346 in quantitative yield (Scheme 3.7.3.A).  Bromide 346 proved to be 
a crystalline white solid whose relative and absolute configuration was unambiguously 
established by single crystal X-ray diffraction, proving not only the stereochemical result 
of the expected Sn2 opening of the epoxide, but also the concomitant intramolecular oxa-
Michael addition and construction of the transannular ether bridge.   





































































X-ray Crystal Structure of 346
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Installation of the requisite 1,4-diketone oxidation pattern from bromide 346 would 
depend on the ability to oxidize the newly installed secondary halide.  The Kornblum 
oxidation is most routinely used for the oxidation of a halide to the ketone oxidation state, 
however this transformation is largely limited to the oxidation of primary or benzylic 
halides to the corresponding aldehydes or benzylic ketone.31  Fortunately, initial attempts 
to oxidize bromide 346 proved fruitful.32  Under optimized reaction conditions employing 
AgBF4 in DMSO at 120 °C for 9 hours provided diketone 347 in 96% yield; this high 
yield exemplifies the thermodynamic stability of the product, being formed under harsh, 
Lewis acidic conditions in the presence of a nucleophilic solvent (Scheme 3.7.3.B).  The 
stereochemical assignment of ketofuran 347 was unambiguously confirmed by single 
crystal X-ray diffraction.   
We hypothesize that the oxidation of secondary bromide 346 to ketone 347 is 
facilitated by the fused heterocyclic ring structure of the central furan.  The reaction 
proceeds initially by abstraction of the halide by the silver(I) salt to generate intermediate 
carbocation 348.  The ridged conformation of pentacycle 348 positions the furyl oxygen 
bridge appropriately to allow for the donation of electron density into the vacant p-orbital 
of the secondary carbocation.  The stabilization of cation 348 by distribution of the 
positive charge largely prevents nonproductive reaction pathways and decomposition, 
allowing the nucleophilic addition of DMSO to occur smoothly and, after the addition of 
Et3N, the formation of the desired product in excellent yield.  This hypothesis is 
supported by the failed Kornblum oxidation of the reduced substrate in which the vicinal 
hydroxyl group to the bromide cannot form the transannular ether bridge (vide infra).   
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With the assembly of the desired 1,4-diketone skeleton complete, the selective 
reductive opening of furan bridge at the α-alkoxyketone bond (C(7), Scheme 3.7.4) was 
needed.  The selective reduction of carbonyls oxidized at the α-position to the 
corresponding α-saturated carbonyl is routinely accomplished under single electron 
transfer conditions. We hypothesized that the rapid equilibration of the intermediate 
radical generated at C(7) under similar conditions would allow for the formation of the 
thermodynamically favorable cis-fused [7,5]-ring juncture. We were pleased to find that 
freshly formed SmI2 could accomplish the desired selective reduction to furnish diol 349 
in 85% yield.33  The stereochemical configuration of the newly formed methine was 
established by single crystal X-ray diffraction of the crystalline hemiketal isomer 350, 
confirming the formation of the desired epimer as required for the synthesis of the 
furanobutenolide norcembranoid natural products.  The use of LiCl as an additive was 
essential for the high yield of this transformation, as the use of either H2O or HMPA as 
an additive or the use of SmI2 without an additive furnished a complex mixture of diol 
349 and dehydrated forms of the desired product.   
Scheme 3.7.4. Reductive Furan Opening 
 
Fortuitously, diol 349 represents a form of the desired retron 316 in the 
enantiomeric series (see Scheme 3.2.1) for the planned retroaldol-aldol core 
isomerization to access the [7,6,5,5]-tetracyclic norcembranoid diterpenes (Scheme 





































Chapter 3 – Progress Toward the Furanobutenolide Norcembranoids 191 
solvent failed to induce any reactivity.  Alternatively, the use of hydroxide bases (e.g., 
NaOH, KOH) in H2O or H2O:MeOH blends resulted in the saponification of the lactone 
moiety.34  Although the use of stronger bases (NaH, LHMDS, KHMDS) in THF at low 
temperature failed to induce any productive reactivity, the exposure of diol 349 to excess 
LDA at –78 °C effected a retroaldol-aldol pathway, as determined by the isomerization of 
configuration at C(4) and C(13).35 Although we have not yet observed the formation of 
[7,6,5,5]-diol ent-315, we are optimistic that synthetic access to the [7,6,5,5]-
norcembranoid diterpenes may still be achieved by this retroaldol-aldol core 
isomerization pathway.   
Scheme 3.7.5. Core Isomerization of Divergent Intermediate Diol 349 
 
Complimentarily, diol 349 could be advanced toward ent-ineleganolide (ent-9).  
Selective dehydration of tertiary alcohol 349 was achieved in CH2Cl2 using the acidic 
resin Amberlyst 15 (Scheme 3.7.6).  Although the product of the desired dehydration 
(ent-313) is the first to form, the extended reaction period required to accomplish the 
complete consumption of the starting material results the formation of undesired enone 
isoineleganolide D (351) and bisenone 352 as minor products.  We were quite surprised 
to isolate isoineleganolide C (ent-313) from the reaction mixture as we had expected 
product ent-313 to spontaneously proceed to ent-ineleganolide (ent-9) (see Scheme 
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Scheme 3.7.6. Selective Dehydration of Diol 349 
 
We hypothesized that under olefin isomerization conditions, isoineleganolide C 
(ent-313) would proceed through vinylogous diketone 330 and then undergo a 
spontaneous intramolecular oxa-Michael addition to complete the total synthesis of ent-
ineleganolide (ent-9, Scheme 3.7.7).  Unfortunately, isoineleganolide C (ent-313) proved 
to be a somewhat unstable, intractable intermediate.  Exposure of enone ent-313 to protic 
acid-, protic base-, aprotic base-, and an assortment of transition metal-mediated as well 
as thermal olefin isomerization conditions failed to provide a single isolable product.36  
Scheme 3.7.7. Intended Completion of ent-Ineleganolide (ent-9) through Vinylogous Diketone 330 
 
Additionally, redox advancement of isoineleganolide C (ent-313) proved futile.  
Direct formation of the requisite ketofuran ring by C–H oxidation through α-
bromination37 or under Suárez conditions38 was complicated by the reactivity of the 
cyclohexanone system and the isopropenyl moiety under the reaction conditions and 
ultimately unsuccessful (Scheme 3.7.8).  Additionally, cyclohexanone ent-313 was 
unreactive to the conjugate reduction by the nucleophilic addition of hydride through 
transition metal catalysis and the 1,4-reduction could not be selectively accomplished 
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be facilitated by the 1,2-reduction of the cyclohexanone system as the selective reduction 
of the enone carbonyl could not be achieved in the presence of the cycloheptanone.39  
Scheme 3.7.8. Attempted Functionalization of Isoineleganolide C (ent-313) by C–H Oxidation 
 
3.8  Computational Studies of Conformational Limitations 
The empirical evidence surrounding isoineleganolide C (ent-313) and its obstinate 
nature suggests the barrier for isomerization of the enone system to the ketofuran ring is a 
more complex transformation than simply assessing the thermodynamic equilibrium 
between tetrasubstituted enone ent-313 and trisubstituted vinylogous diketone 330 (see 
Scheme 3.7.7).  In order to assess the conformation of isoineleganolide C (ent-313) in 
solution, we performed a series of two-dimensional 1H NOE studies. We found that 
isoineleganolide C (ent-313) in solution adopts a conformation that is highly related to 
the conformation of isoineleganolide A (328) in the solid state as determined by single 
crystal X-ray diffraction, wherein the central seven-membered ring is creased, bisecting 
the molecule (Schemes 3.8.1.A and 3.8.1.B).  By analogy to the conformation of 
isoineleganolide A (328), the cyclohexanone ring of isoineleganolide C (ent-313) is 
hypothesized to be in its most thermodynamically stable position when it has adopted a 
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Scheme 3.8.1. Consideration of Three-Dimensional Structures of Late-Stage Intermediates 
 
Considering the three-dimensional conformation of isoineleganolide C (ent-313) in 
comparison to the conformation of ent-ineleganolide (ent-9), observed by single crystal 
X-ray diffraction during the initial isolation,8 we need to not only effect the isomerization 
of the olefin from the enone system into vinylogous diketone, but also accomplish the 
conformational isomerization of the central cycloheptenone ring.  This conformational 
isomerization would induce the proximity between C(5) and the tertiary hydroxyl group 
required for intramolecular oxa-Michael addition.  Ultimate equilibration of the 
cyclohexanone ring into the chair conformation, placing the isopropenyl group in the 
axial position, would furnish ent-ineleganolide (ent-9) its observed, solid state 
conformation.   
In order to quantitatively assess the energy landscape of the intermediates along the 
proposed isomerization route toward ent-ineleganolide (ent-9) from isoineleganolide C 
(ent-313), we performed a series of DFT ground state energy computations in vacuo 
using the 6-311+G** basis set.40  All ground state energies were compared to the 
calculated ground state energy of ineleganolide in its preferred conformation (ent-9ax), as 
determined on its initial isolation by single crystal X-ray diffraction and confirmed herein 
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ent-9ax vs. ent-9equ, Figure 3.8.1).  The two conformers of isoineleganolide C in its 
isolated form, ent-313equ and ent-313ax, were calculated to be higher in energy than the 
natural product ent-9ax by 0.8 and 2.1 kcal, respectively.  This result implies that the most 
thermodynamically favorable conformation of isoineleganolide C (ent-313) is indeed 
closely related to the structure of isoineleganolide A (see Scheme 3.8.1.A vs. Scheme 
3.8.1.B).  This places the isopropenyl group of the cyclohexanone ring in the equatorial 
position in comparison to ent-ineleganolide (ent-9), which finds increased 
thermodynamic stability with the saturated cyclohexanone moiety in the chair 
conformation, although the isopropenyl substituent is forced into the axial position.   
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Conformational isomerization of the central heptacycle within ineleganolide C 
provides two enones, ent-313Aequ and ent-313Aax, that are both lower in energy than 
ineleganolide C in its isolated conformation.  In fact, ent-313Aequ was calculated to be the 
most thermodynamically stable compound within the set of isomers evaluated.  This 
conformational isomer closely resembles that of ineleganolide and would be correctly 
positioned for the construction of the ketofuran ring by oxa-Michael addition after olefin 
isomerization or directly by C–H oxidation.  Unfortunately, the lack of empirical 
evidence for the isolation of either ent-313Aequ or ent-313Aax throughout our synthetic 
explorations and propensity of the isolated ineleganolide C (ent-313) to undergo 
decomposition rather than productive isomerization or oxidation implies that the energy 
barrier to interconvert between the atropisomers of isoineleganolide C is greater than the 
energy required for the decomposition of the substrate.   
In order to convert isoineleganolide C to ent-ineleganolide (ent-9), we would need 
to accomplish an olefin isomerization, proceeding through vinylogous diketone 330.  
Computation of the ground state energies of the two conformational isomers of 
conjugated diketone 330equ and 330ax reveals that this intermediate is significantly higher 
in energy than either ineleganolide C or ineleganolide.  The energy gap between 
vinylogous diketone 330 and the highest energy conformation of ineleganolide C is still 
12.0 kcal/mol.  Considering the activation energy for this isomerization will make the 
energy cost even larger, decomposition of the substrate would likely occur before the 
direct conversion of isoineleganolide C (ent-313) to ent-ineleganolide (ent-9) by olefin 
isomerization through vinylogous diketone 330.  Armed with this knowledge, we began 
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exploring alternative synthetic pathways to complete the asymmetric total synthesis of 
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3.9  Experimental Methods and Analytical Data 
3.9.1   Materials and Methods 
Unless stated otherwise, reactions were performed at ambient temperature (23 °C) 
in flame-dried glassware under an argon atmosphere using dry, deoxygentated solvents 
(distilled or passed over a column of activated alumina)41 stirring with a Teflon®-coated 
magnetic stirring bar.  Commercially available reagents were used as received unless 
otherwise noted.  Et3N was distilled from calcium hydride immediately prior to use.  
MeOH was distilled from magnesium methoxide immediately prior to use.  Purified H2O 
was obtained using a Barnstead NANOpure Infinity UV/UF system.  4 Å molecular 
sieves were oven-dried at 120 °C for a minimum of 24 h and cooled in a desiccator to 
ambient temperature immediately prior to use.  (R)-Desmethylcarvone ((R)-217),20 
Cu(tbs)2 (343),42 and TEMPO•BF421 were prepared by known methods.  Reactions 
requiring external heat were modulated to the specified temperatures using an IKAmag 
temperature controller.  Thin-layer chromatography (TLC) was performed using E. 
Merck silica gel 60 F254 precoated plates (250 nm) and visualized by UV fluorescence 
quenching, potassium permanganate, or p-anisaldehyde staining.  Silicycle SiliaFlash P60 
Academic Silica gel (particle size 40-63 nm) was used for flash chromatography.  1H and 
13C NMR spectra were recorded on a Varian Inova 600 (600 MHz and 151 MHz, 
respectively), Varian Inova 500 (500 MHz and 126 MHz, respectively), Bruker AV III 
HD spectrometer equipped with a Prodigy liquid nitrogen temperature cryoprobe (400 
MHz and 101 MHz, respectively), or a Varian Mercury 300 spectrometer (300 MHz and 
76 MHz, respectively) and are reported in terms of chemical shift relative to residual 
CHCl3 (in CDCl3, δ 7.26 and δ 77.16, respectively).  Data for 1H NMR spectra are 
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reported as follows: chemical shift (δ ppm) (multiplicity, coupling constant (Hz), 
integration).  Infrared (IR) spectra were recorded on a Perkin Elmer Paragon 1000 
Spectrometer and are reported in frequency of absorption (cm-1). High resolution mass 
spectra (HRMS) were acquired using an Agilent 6200 Series TOF mass spectrometer 
with an Agilent G1978A Multimode source in atmospheric pressure chemical ionization 
(APCI) or mixed (MultiMode: ESI-APCI) ionization mode or were obtained from the 
Caltech Mass Spectral Facility using either a JEOL JMS-600H High Resolution Mass 
Spectrometer in fast atom bombardment (FAB+) or electron ionization (EI+) mode or an 
LCT Premier XE TOF mass spectrometer equipped with an electrospray ionization 
source (ES+). Optical rotations were measured on a Jasco P-2000 polarimeter using a 100 
mm path length cell at 589 nm. 
 
3.9.2  Experimental Procedures 
 
Diene 354: To a pale yellow solution of diol 262 (241 mg, 0.97 mmol, 1.00 equiv) in 
CH2Cl2 (49 mL) at 0 °C  (ice/H2O bath) was added Dess–Martin periodinane (DMP, 823 
mg, 1.94 mmol, 2.00 equiv) as a solid in one portion. After 3 h, the off-white 
heterogeneous reaction mixture was removed from the bath and allowed to warm to 
ambient temperature (ca. 23 °C). After an additional 2 h, the consumption of starting 
material was complete as determined by TLC (1:1 EtOAc:Hexanes eluent). The reaction 
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biphasic mixture was allowed to stir for 10 minutes and subsequently poured into 
saturated NaHCO3 (70 mL). The organics were separated and the aqueous layer was 
extracted with Et2O (3 x 70 mL). The combined organic layers were washed with brine 
(50 mL), dried quickly over MgSO4, filtered, and concentrated in vacuo to provide crude 
aldehyde 353, which was immediately used without further purification. 
 To a round-bottom flask in an N2-filled glovebox were charged Ph3PMeBr (1.040 
g, 2.91 mmol, 3.00 equiv) and KOt-Bu (294 mg, 2.62 mmol, 2.70 equiv) as solids 
followed by THF (97 mL). The bright yellow reaction mixture was then sealed with a 
rubber septum, removed from the glovebox, and placed under an argon atmosphere with 
stirring. After 2 h, a solution of crude aldehyde 353 in THF (3.00 mL) was added 
dropwise, causing the reaction mixture to become dark orange-brown. After 1.5 h, the 
consumption of starting material was complete as determined by TLC (3:7 
EtOAc:Hexanes eluent). The reaction was poured onto a mixture of H2O (90 mL) and 
Et2O (30 mL). The organics were separated and the aqueous layer was extracted with 
Et2O (3 x 30 mL). The combined organic layers were washed with brine (30 mL), dried 
over MgSO4, filtered, and concentrated in vacuo. The crude dark brown residue was 
purified by silica gel column chromatography (40% Et2O in hexanes eluent) to afford 
diene 354 (236 mg, >99% yield) as a pale yellow oil: Rf = 0.30 (2:3 Et2O:Hexanes 
eluent); 1H NMR (CDCl3, 500 MHz) δ 8.04–7.99 (m, 2H), 7.56–7.51 (m, 1H), 7.41 
(dddd, J = 7.6, 6.8, 1.5, 0.9 Hz, 2H), 6.35 (ddt, J = 17.8, 11.3, 0.7 Hz, 1H), 5.92 (d, J = 
2.3 Hz, 1H), 5.80 (ddt, J = 17.8, 1.5, 0.6 Hz, 1H), 5.75–5.70 (m, 1H), 5.31 (ddd, J = 11.4, 
1.6, 0.7 Hz, 1H), 2.73 (dd, J = 14.0, 7.3 Hz, 1H), 2.26 (dq, J = 6.6, 3.9, 3.0 Hz, 1H), 2.16 
(ddd, J = 14.0, 4.7, 0.7 Hz, 1H), 1.48 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 166.5, 
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151.2, 133.1, 130.3, 129.7, 129.1, 128.4, 127.0, 119.2, 81.1, 76.0, 49.3, 26.9; IR (Neat 
Film, NaCl) 3447, 2973, 1714, 1451, 1355, 1315, 1271, 1177, 1111, 1070, 1026, 954, 
858, 712 cm–1; HRMS (APCI) m/z calc’d for C15H15O2 [M–OH]+: 227.1067, found 
227.1064; [α]D25.0 +126.9° (c 3.850, CHCl3). 
 
 
Diol ent-322: To a pale yellow solution of diene 354 (2.04 g, 8.33 mmol, 1.00 equiv) in 
distilled MeOH (167 mL) was added NaOH (16.7 mmol, 2.00 equiv) as a 0.50 M solution 
in distilled MeOH quickly dropwise over 5 mintues. After 14 h, the consumption of 
starting material was complete as determined by TLC (2:3 Et2O:Hexanes eluent). The 
reaction was then concentrated to less than one-half of the original volume (ca. 70 mL) 
and then poured onto H2O (150 mL). This homogeneous aqueous mixture was then 
extracted with 1:1 CHCl3:i-PrOH (5 x 200 mL). The combined organic layers were dried 
over Na2SO4 for 1 h, filtered, and concentrated in vacuo. The crude off-white solid was 
then adsorbed onto Celite (6.0 g) and purified by silica gel column chromatography (75% 
EtOAc in hexanes eluent) to afford diol ent-322 (1.11 g, 85% yield) as an amorphous 
white solid: Rf = 0.13 (1:5 EtOAc:CH2Cl2); 1H NMR (300 MHz, CDCl3) δ 6.30 (dd, J = 
17.8, 11.3, 1H), 5.82 (d, J = 2.1, 1H), 5.73 (dd, J = 17.9, 1.7, 1H), 5.26 (dd, J = 11.2, 1.7, 
1H), 4.65 (dd, J = 11.5, 5.1, 1H), 2.54 (dd, J = 13.6, 6.8, 1H), 1.85 (app dd, J = 13.6, 4.8, 
2H), 1.68 (d, J = 6.6, 1H), 1.40 (s, 3H); 13C NMR (76 MHz, CDCl3) δ 149.5, 131.3, 
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1587, 1481, 1445, 1370, 1341, 1316, 1124, 1088, 1056, 1032, 987, 945, 926 cm–1; HRMS 




Ethyl Ester 323: To a flame-dried 250 mL round-bottom flask in an nitrogen-filled 
glovebox was charged anhydrous CeCl3 (3.60 g, 14.6 mmol, 2.00 equiv). The flask was 
seal with a rubber septum, removed from the glovebox, placed under vacuum, and heated 
in an oil bath to 140 °C with vigorous stirring.43  After 12 h the flask was removed from 
the oil bath, allowed to cool to ambient temperature (ca. 23 °C), placed under an 
atmosphere of argon, and charged with THF (49 mL). After 3.5 h, the reaction was 
cooled to –78 °C (i-PrOH/dry ice bath). (R)-Desmethylcarvone ((R)-217, 994 mg, 7.30 
mmol) was then added as a solution in THF (7.3 mL) and stirred for 1 h. Simultaneously, 
in a separate flask, to a solution of LDA (0.80 M in THF, 2.22 equiv) at –78 °C was 
added anhydrous EtOAc (1.47 mL, 15.0 mmol, 2.06 equiv) as a solution in THF (10.0 
mL) dropwise. After 40 m, to the solution of (R)-217 was added the EtOAc solution 
dropwise via cannula transfer with an overpressure of argon over 1 h. Exactly 3 h after 
the completion of addition, the reaction was quenched at temperature with saturated 
NH4Cl (24 mL) and warmed slowly to ambient temperature overnight. The reaction 
mixture was then filtered through a Celite plug, washing with 100% Et2O. To the 




1. CeCl3 , THF, –78 °C
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extracted with Et2O (2 x 120 mL). The combined organic layers were washed with brine 
(60 mL), dried over MgSO4, filtered, and concentrated in vacuo. The resultant crude 
orange-brown oil (1.64 g, >99% yield) was carried on without further purification.  
  To a solution of intermediate allylic alcohol (408 mg, 1.82 mmol) in CH3CN (18 
mL) was added TEMPO•BF4 (664 mg, 2.73 mmol, 1.5 equiv) as a solid in one portion 
with stirring. Consumption of starting material was complete after 12 h, as determined by 
TLC (3:2 Et2O:Hexanes eluent), and the reaction was diluted with Et2O (125 mL), 
washed with H2O (20 mL), brine (20 mL), dried over MgSO4, filtered, and concentrated 
in vacuo. The crude orange-red oil was purified by silica gel column chromatography 
(40% Et2O in hexanes eluent) to afford cyclohexenone ester 323 (275 mg, 68% yield) as 
an orange-tan oil: Rf = 0.26 (3:2 Et2O:Hexanes eluent); 1H NMR (500 MHz, CDCl3) δ 
5.93 (s, 1H), 4.79 (s, 1H), 4.75 (s, 1H), 4.14 (q, J = 7.1 Hz, 2H), 3.22 (s, 2H), 2.68 (ddd, J 
= 18.2, 9.5, 4.5 Hz, 1H), 2.49 (ddd, J = 16.3, 3.7, 1.1 Hz, 1H), 2.46–2.33 (m, 2H), 2.33–
2.24 (m, 1H), 1.73 (s, 3H), 1.24 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 199.1, 
169.2, 156.3, 146.0, 128.3, 110.8, 61.2, 43.2, 42.0, 41.7, 34.7, 20.4, 14.0; IR (Neat Film, 
NaCl) 2979, 1735, 1672, 1415, 1369, 1329, 1294, 1248, 1176, 1029, 891 cm-1; HRMS 
(MM: ESI-APCI) m/z calc’d for C13H19O3 [M+H]+: 223.1329, found 223.1326; [α]D25.0 
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Diazoester ent-320: To a stirred solution of ethyl ester 323 (2.07 g, 9.32 mmol, 1.00 
equiv) in MeOH (31 mL) and H2O (31 mL) was added K2CO3 (5.16 g, 37.3 mmol, 4.00 
equiv). After 7 h, the consumption of starting material was complete as determined by 
TLC (2:3 Et2O:Hexanes eluent). The reaction mixture was cooled to 0 °C (ice/H2O bath) 
and the pH was adjusted to between 1 and 2 by the careful addition of aqueous 1 N HCl 
(CAUTION: Vigorous gas evolution!). The reaction mixture was then poured onto a 
mixture of EtOAc (200 mL) and H2O (100 mL). The organics were separated and the 
aqueous layer was extracted with EtOAc (3 x 200 mL). The combined organics were 
dried over Na2SO4, filtered and concentrated in vacuo. The crude dark orange oil of 
carboxylic acid ent-321 (1.81 g, >99% yield) was carried on without further purification. 
To a stirred solution of diol ent-322 (119 mg, 0.85 mmol, 1.00 equiv) in CH2Cl2 (28 
mL) were added a portion of crude carboxylic acid ent-321 (330 mg, 1.70 mmol, 2.00 
equiv) and EDC•HCl (326 mg, 1.70 mmol, 2.00 equiv). The orange reaction mixture was 
cooled to 0 °C (ice/H2O bath) at which time DMAP (21 mg, 0.17 mmol, 0.20 equiv) was 
added in a single portion. After 30 minutes, the dark red-orange reaction mixture was 
removed from the cooling bath and allowed to warm to ambient temperature (ca. 23 °C). 
After 1 h, the consumption of starting material was complete as determined by TLC (3:1 
EtOAc:Hexanes eluent). The reaction was quenched by the addition of 0.50 N HCl (8.0 
mL) quickly dropwise with vigorous stirring. After 10 minutes, the heterogeneous 
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were separated and washed with 0.50 N HCl (20 mL) followed by 5 wt % K2CO3 (3 x 30 
mL), brine (30 mL), and saturated NH4Cl (30 mL). The organics were then dried over 
MgSO4, filtered, and concentrated in vacuo. The crude dark brown-orange oil of 
intermediate ester (269 mg, 0.85 mmol,  >99% yield) was carried on without further 
purification.  
Additionally, the combined K2CO3 washes were cooled to 0 °C (ice/H2O bath) and 
the pH was adjusted to between 1 and 2 by the careful addition of aqueous 1 N HCl 
(CAUTION: Vigorous gas evolution!). The aqueous mixture was extracted with EtOAc 
(4 x 50 mL). The combined organics were dried over Na2SO4, filtered and concentrated in 
vacuo providing a recovered portion (60 mg) of excess carboxylic acid ent-321. 
To a solution of crude ester (269 mg, 0.85 mmol, 1.00 equiv) in CH3CN (8.5 mL) in 
the dark was added p-acetamidobenzenesulfonyl azide (p-ABSA, 226 mg, 0.94 mmol, 
1.10 equiv) as a solid in one portion. The dark orange homogeneous reaction mixture was 
cooled to 0 °C (ice/H2O bath). Et3N (0.36 mL, 2.55 mmol, 3.00 equiv) was then added 
slowly dropwise. After 6 h, the consumption of starting material was complete as 
determined by TLC (1:4 EtOAc:CH2Cl2 eluent). The reaction was quenched by the 
addition of EtOAc (20 mL), removed from the cooling bath, and allowed warm to 
ambient temperature (ca. 23 °C). The reaction mixture was then concentrated in vacuo. 
The crude tan solid was the adsorbed onto Celite (2.0 g) and purified by silica gel column 
chromatography (20% EtOAc in CH2Cl2 eluent) to afford diazoester ent-320 (218 mg, 
75% yield from diol ent-322) as a dark yellow oil: Rf = 0.26 (1:4 EtOAc:CH2Cl2 eluent); 
1H NMR (CDCl3, 600 MHz) δ 6.39 (d, J = 2.0 Hz, 1H), 6.32 (dd, J = 17.8, 11.4 Hz, 1H), 
5.82 (s, 1H), 5.78 (s, 1H), 5.62 (ddd, J = 7.2, 4.8, 2.2 Hz, 1H), 5.34 (dd, J = 11.4, 1.6 Hz, 
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1H), 4.86 (t, J = 1.4 Hz, 1H), 4.80 (s, 1H), 2.78–2.71 (m, 1H), 2.70–2.64 (m, 2H), 2.53 
(ddd, J = 16.1, 3.7, 1.4 Hz, 1H), 2.43 (ddd, J = 17.4, 10.9, 2.2 Hz, 1H), 2.34 (dd, J = 16.3, 
13.0 Hz, 1H), 2.05 (dd, J = 14.0, 4.8 Hz, 1H), 1.78 (s, 3H), 1.45 (s, 3H); 13C NMR 
(CDCl3, 126 MHz) δ 197.2, 162.5, 151.7, 146.6, 145.9, 128.9, 126.0, 120.2, 119.6, 111.5, 
80.8, 76.9, 67.3, 49.2, 41.8, 41.6, 31.7, 27.1, 20.5; IR (Neat Film, NaCl) 3406, 2971, 
2102, 1708, 1645, 1579, 1377, 1328, 1250, 1222, 1140, 1061, 992, 952, 893, 744 cm–1; 
HRMS (FAB+) m/z calc’d for C19H23O4N2 [M+H]+: 343.1659, found 343.1634; [α]D25.0 
+233.5° (c 5.470, CHCl3). 
 
 
Diene 324 and Enone 325: To a stirred solution of diazoester ent-320 (630 mg, 1.84 
mmol, 1.00 equiv) in CH2Cl2 (184 mL) in an nitrogen-filled glovebox was added 
Rh2OAc4 (8 mg, 0.018 mmol, 0.01 equiv) at ambient temperature (ca. 30 °C). After 30 
minutes, the consumption of starting material was complete as determined by TLC (1:4 
EtOAc:CH2Cl2 eluent). The reaction mixture was then concentrated in vacuo and the 
yellow solid was purified by silica gel column chromatography (20% EtOAc in CH2Cl2 
eluent) to afford diene 324 (306 mg, 53% yield) as a crystalline pale yellow solid and 
cyclopentenone 325 (89 mg, 35% yield) as an amorphous bright yellow solid.  
Diene 324: Colorless, translucent X-ray quality crystals were obtained by slow diffusion 
of pentane into a solution of diene 324 in Et2O, mp: 150–153 °C: Rf = 0.38 (1:4 
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(dd, J = 4.5, 3.9 Hz, 1H), 4.76 (td, J = 1.4, 0.7 Hz, 1H), 4.67 (td, J = 1.3, 0.7 Hz, 1H), 
3.83–3.77 (m, 1H), 3.63–3.52 (m, 2H), 3.32–3.21 (m, 1H), 2.74–2.64 (m, 2H), 2.61 (ddd, 
J = 16.5, 4.0, 1.7 Hz, 1H), 2.44 (d, J = 15.5 Hz, 1H), 2.29 (dd, J = 16.5, 12.6 Hz, 1H), 
2.15–2.06 (m, 1H), 1.95 (dd, J = 15.4, 4.0 Hz, 1H), 1.71 (dt, J = 1.3, 0.6 Hz, 3H), 1.38 (s, 
3H); 13C NMR (CDCl3, 126 MHz) δ 198.2, 172.9, 149.2, 148.8, 146.3, 133.5, 128.1, 
110.5, 82.2, 78.1, 49.6, 47.0, 45.9, 42.7, 40.0, 36.4, 27.8, 22.6, 20.8; IR (Neat Film, 
NaCl) 3435, 2923, 2853, 1761, 1661, 1443, 1377, 1263, 1148, 1106 cm–1; HRMS 
(FAB+) m/z calc’d for C19H23O4 [M+H]+: 315.1596, found 315.1608; [α]D25.0 +39.6° (c 
0.680, CHCl3). 
Enone 325: Rf = 0.18 (1:4 EtOAc:CH2Cl2 eluent); 1H NMR (CDCl3, 600 MHz) δ 6.59 
(dd, J = 17.7, 11.2 Hz, 1H), 6.10 (d, J = 17.7 Hz, 1H), 6.03 (s, 1H), 5.73 (d, J = 11.1 Hz, 
1H), 2.62 (d, J = 2.3 Hz, 2H), 1.56 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 205.4, 174.7, 
128.5, 127.7, 126.2, 77.1, 53.2, 27.4; IR (Neat Film, NaCl) 3400, 2970, 2927, 1687, 
1599, 1408, 1373, 1261, 1233, 1195, 1064, 952, 864, 801 cm–1; HRMS (EI+) m/z calc’d 
for C8H10O2 [M•]+: 138.0681, found 138.0674; [α]D25.0 +71.4° (c 0.900, CHCl3). 
 
 
Diol ent-322: To a stirred solution of enone 325 (50 mg, 0.36 mmol, 1.00 equiv) in THF 
(5.0 mL) at –78 °C (i-PrOH/dry ice bath) was added DIBAL (540 µL, 1 M in THF, 1.50 
equiv) slowly dropwise. After 30 minutes, the consumption of starting material was 
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by the addition of Na2SO4•(H2O)n (made by stirring anhydrous Na2SO4 with H2O for 30 
minutes prior to use). The reaction vessel was immediately removed from the cooling 
bath and allowed to warm to ambient temperature (ca. 23 °C) with stirring. After 15 
minutes, the reaction was filtered, concentrated in vacuo, and the crude white solid was 
purified by silica gel column chromatography (75% EtOAc in hexanes eluent) to afford 
diol ent-322 (6 mg, 12% yield) as an amorphous white solid and as a single diastereomer: 
characterization data match those reported above.  
 
Isoineleganolide A (328): To a pale yellow stirred solution of diene 324 (100 mg, 0.32 
mmol, 1.00 equiv) in a vial open to air in benzene (10.7 mL) was added VO(acac)2 (0.9 
mg, 0.0032 mmol, 0.01 equiv). After 5 minutes, to this dark green solution was added t-
butyl hydroperoxide (TBHP, 72 µL, 0.036 mmol, 1.10 equiv) as a 5 M solution in decane 
dropwise causing the reaction to immediately become deep ruby red. After 45 minutes, 
the reaction had lost all red color and become pale yellow. The consumption of starting 
material was complete as determined by TLC (1:4 EtOAc:CH2Cl2 eluent). The reaction 
was concentrated in vacuo and the crude tan solid was purified by silica gel column 
chromatography (25% EtOAc in CH2Cl2 eluent) to afford epoxide 328 (89 mg, 89% 
yield) as a white crystalline solid. Colorless, translucent X-ray quality crystals were 
obtained by slow diffusion of 1% benzene in heptane into a solution of epoxide 328 in 
EtOAc, mp: 272–275 °C: Rf = 0.22 (1:4 EtOAc:CH2Cl2 eluent); 1H NMR (CDCl3, 600 
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1H), 3.42–3.35 (m, 2H), 3.26 (ddd, J = 17.3, 3.9, 2.0 Hz, 1H), 2.78 (ddt, J = 14.3, 10.7, 
3.9 Hz, 1H), 2.66 (ddd, J = 16.6, 3.9, 1.9 Hz, 1H), 2.48 (dt, J = 19.1, 2.0 Hz, 1H), 2.41 
(m, 1H), 2.36 (m, 1H), 2.27 (dd, J = 16.5, 13.4 Hz, 1H), 2.10 (ddd, J = 17.3, 11.0, 3.8 Hz, 
1H), 1.76 (d, J = 1.3 Hz, 3H), 1.35 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 198.8, 172.1, 
148.7, 146.4, 129.9, 110.6, 79.9, 75.0, 70.2, 54.4, 50.2, 45.8, 43.6, 42.6, 39.8, 37.3, 26.7, 
22.4, 20.9; IR (Neat Film, NaCl) 3479, 2965, 1767, 1647, 1625, 1369, 1233, 1154, 1102, 
992, 975, 907 cm–1; HRMS (FAB+) m/z calc’d for C19H23O5 [M+H]+: 331.1545, found 
331.1540; [α]D25.0 +161.3° (c 0.900, CHCl3). 
 
 
Silyl ether 329: To a stirred solution of isoineleganolide A (328, 3 mg, 0.009 mmol, 1.00 
equiv) in CH2Cl2 (0.25 mL) at –78 °C (i-PrOH/dry ice bath) was added Et3N (50 µL, 0.36 
mmol, 40.0 equiv) dropwise. After 5 minutes, TMSOTf (8 µL, 0.045 mmol, 5.00 equiv) 
was added slowly dropwise. After 15 minutes, the consumption of starting material was 
complete as determined by TLC (1:4 EtOAc:CH2Cl2 eluent). The reaction was quenched 
by the addition of saturated NaHCO3 (50 µL), removed from the cooling bath and 
allowed to warm to ambient temperature (ca. 23 °C). The reaction mixture was then 
filtered through a pad of SiO2 (100% EtOAc eluent). The combined organics were then 
concentrated in vacuo to afford silyl ether 329 (3 mg, >99% yield) was as amorphous 
white solid: Rf = 0.50 (EtOAc eluent); 1H NMR (CDCl3, 600 MHz) δ 4.83 (qd, J = 4.0, 
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1H), 3.43–3.35 (m, 2H), 3.27 (ddd, J = 17.5, 3.9, 1.9 Hz, 1H), 2.79 (td, J = 14.4, 3.9 Hz, 
1H), 2.67 (ddd, J = 16.6, 3.9, 1.9 Hz, 1H), 2.56–2.33 (m, 3H), 2.28 (dd, J = 16.6, 13.3 
Hz, 1H), 2.14–2.05 (m, 1H), 1.77 (s, 3H), 1.36 (s, 3H), 0.07 (s, 9H); 13C NMR (CDCl3, 
126 MHz) δ 198.8, 172.1, 148.7, 146.4, 129.9, 110.6, 79.9, 75.0, 70.2, 54.5, 50.2, 45.8, 
43.7, 42.6, 39.8, 37.3, 26.8, 22.4, 20.9, 1.2; IR (Neat Film, NaCl) 2962, 1770, 1665, 
1380, 1262, 1101, 1024, 799 cm–1; HRMS (FAB+) m/z calc’d for C22H29O5Si [(M+H)–H-
2]+: 401.1784, found 401.1798; [α]D25.0 +1.4° (c 0.150, CHCl3). 
 
 
Isoineleganolide B (331):44 To a stirred solution of isoineleganolide A (328, 5 mg, 0.015 
mmol, 1.00 equiv) in CDCl3 (0.60 mL) at ambient temperature (ca. 23 °C) was added 
In(OTf)3 (20 mg, 0.036 mmol, 2.40 equiv) as a solid in one portion. The white suspension 
was stirred for 5 minutes and then introduced to a preheated 50 °C bath. After 12 h, the 
consumption of starting material was complete as determined by TLC (1:4 
EtOAc:CH2Cl2 eluent). The reaction was directly purified by silica gel column 
chromatography (10% EtOAc in CH2Cl2 eluent) to provide isoineleganolide B (331, 4 
mg, 80% yield) as an amorphous white solid: Rf = 0.78 (1:4 EtOAc:CH2Cl2 eluent); 1H 
NMR (CDCl3, 400 MHz) δ 5.31 (dd, J = 10.1, 6.0 Hz, 1H), 4.92–4.84 (m, 2H), 4.83–4.80 
(s, 1H), 3.58 (t, J = 9.2 Hz, 1H), 3.25 (d, J = 9.2 Hz, 1H), 3.19–3.08 (m, 1H), 2.73 (d, J = 
5.9 Hz, 1H), 2.69–2.56 (m, 2H), 2.45–2.12 (m, 4H), 2.02 (ddd, J = 14.8, 4.2, 2.1 Hz, 1H), 
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NMR (CDCl3, 101 MHz) δ 204.8, 174.6, 145.6, 111.6, 94.0, 89.6, 79.0, 77.4, 77.1, 54.9, 
54.6, 48.1, 46.4, 45.4, 41.3, 36.3, 26.3, 24.3, 20.3; IR (Neat Film, NaCl) 3485, 2963, 
1767, 1721, 1410, 1260, 1243, 1209, 1142, 1034, 926, 798 cm–1; HRMS (EI+) m/z calc’d 
for C19H22O5 [M•]+: 330.1467, found 330.1491; [α]D25.0 +10.4° (c 0.100, CHCl3).	  
 
 
Diol 336: To a pale yellow solution of cyclopentenone 260 (918 mg, 4.13 mmol, 1.00 
equiv) in THF (41 mL) at –78 °C (i-PrOH/dry ice bath) was added a solution of DIBAL 
(1.47 mL, 8.26 mmol, 2.00 equiv) in THF (8.3 mL) slowly dropwise over 15 minutes. 
After 30 minutes, the golden reaction mixture was removed from the bath and allowed to 
warm slowly. After an additional 30 minutes, the consumption of starting material was 
complete as determined by TLC (1:4 EtOAc:Hexanes eluent) and the reaction mixture 
was cooled to 0 °C (ice/H2O bath). The reaction was subsequently quenched with a 1:1 
solution of saturated aqueous NH4Cl and saturated aqueous Rochelle’s salt (40 mL) 
dropwise, vigorously evolving gas on the first drops. The mixture was then diluted with 
CH2Cl2 (250 mL) and H2O (30 mL). The aqueous layer was then extracted with CH2Cl2 
(3 x 75 mL). The combined organic layers were dried over Na2SO4, filtered, and 
concentrated in vacuo to provide crude allylic alcohol 355 (0.848 g, >99% yield), which 
was used without further purification.  
To a stirred solution of crude allylic alcohol 355 (880 mg, 3.92 mmol, 1.00 equiv) 
in CH2Cl2 (39 mL) at 0 °C (ice/H2O bath) was added Et3N (1.09 mL, 7.84 mmol, 2.00 
DIBAL
THF


















0 °C → 35 °C
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equiv). After 15 minutes, TBSOTf (0.99 mL, 4.31 mmol, 1.10 equiv) was added 
dropwise. After 30 minutes, the consumption of starting material was complete as 
determined by TLC (2:3 Et2O:Hexanes eluent). The reaction mixture was diluted with 
CH2Cl2 (150 mL) and washed with H2O (50 mL). The aqueous was extracted with CH2Cl2 
(2 x 70 mL). The combined organic layers were dried over Na2SO4, filtered, and 
concentrated in vacuo to afford intermediate silyl ether alcohol 356 (1.33 g, >99% yield), 
which was used without further purification. 
To a flask containing silyl ether 356 (1.33 g, 3.92 mmol, 1.00 equiv) were added 
MeOH (79 mL) and HC(OMe)3 (3.86 mL, 35.3 mmol, 9.00 equiv). The reaction mixture 
was cooled to 0 °C (ice/H2O bath) with stirring, at which time the addition of fumaric 
acid (1.14 g, 9.80 mmol, 2.50 equiv) was accomplished in one portion. After 10 minutes, 
the reaction was removed from the cold bath and immediately introduced to a preheated 
35 °C oil bath. After 9 hours, the consumption of starting material was complete as 
determined by TLC (2:3 Et2O:Hexanes eluent) and the reaction was removed from the 
heating bath and allowed to cool to ambient temperature (ca. 23 °C). The reaction 
mixture was diluted with EtOAc (150 mL) and poured onto saturated NaHCO3 (125 mL). 
The organics were separated and the aqueous was extracted with EtOAc (2 x 125 mL). 
The combined organic layers were washed with brine (100 mL), dried over MgSO4 for 2 
minutes, filtered, and concentrated in vacuo to generate a yellow oil. The crude residue 
was then purified by silica gel column chromatography (50% EtOAc in hexanes eluent) 
to afford diol 336 (841 mg, 83% yield) as a pale yellow oil: Rf = 0.27 (1:1 
EtOAc:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 5.60 (q, J = 1.7 Hz, 1H), 4.59 
(ddt, J = 6.7, 4.7, 1.9 Hz, 1H), 4.30 (dt, J = 14.6, 1.7 Hz, 1H), 4.19 (dt, J = 15.0, 1.6 Hz, 
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1H), 3.67 (s, 2H), 2.38 (dd, J = 13.4, 6.9 Hz, 1H), 1.86 (dd, J = 13.4, 4.6 Hz, 1H), 1.26 (s, 
3H), 0.86 (s, 9H), 0.05 (app d, J = 2.1 Hz, 6H); 13C NMR (CDCl3, 126 MHz) δ 150.5, 
129.2, 80.9, 73.6, 58.4, 52.4, 26.3, 26.0, 18.3, –4.6, –4.6; IR (Neat Film, NaCl) 3367, 
2929, 2857, 1472, 1362, 1256, 1089, 1017, 939, 901, 835, 776 cm–1; HRMS (FAB+) m/z 




Allylic alcohol 337: To a stirred solution of diol 336 (187 mg, 0.72 mmol, 1.00 equiv) in 
CH2Cl2 (36 mL) at 0 °C (ice/H2O bath) was added DMP (611 mg, 1.44 mmol, 2.00 equiv) 
as a solid in a single portion. After 30 minutes, the reaction vessel was removed from the 
cooling bath and allowed to warm to ambient temperature (ca. 23 °C). After an additional 
2.5 h, the consumption of starting material was complete as determined by TLC (1:1 
EtOAc:Hexanes eluent). The reaction was quenched by the addition of saturated aqueous 
Na2S2O3 (50 mL) with vigorous stirring. After 10 minutes, the reaction was diluted with 
CH2Cl2 (50 mL) and poured onto saturated aqueous NaHCO3 (75 mL). The organics were 
separated and the aqueous was extracted with CH2Cl2 (2 x 80 mL). The combined 
organics were dried quickly over MgSO4 (< 2 minutes), filtered, and concentrated in 
vacuo to afford crude aldehyde 357 (187 mg >99% yield), which was carried on without 
further purification.  
DMP, CH2Cl2












1:1 Mixture of Diastereomers
Chapter 3 – Progress Toward the Furanobutenolide Norcembranoids 214 
To a stirred solution of crude aldehyde 357 (187 mg, 0.72 mmol, 1.00 equiv) in 
Et2O (4.9 mL) at –15 °C (ice/MeOH bath) was added MeLi (1.92 mL, 1.5 M in Et2O, 
4.00 equiv) quickly dropwise. After 1.5 h, an additional portion of MeLi (0.96 mL, 1.5 M 
in Et2O, 2.00 equiv) was added quickly dropwise and the reaction vessel was removed 
from the cooling bath and allowed to warm to ambient temperature (ca. 23 °C). After an 
additional 1.5 h, the consumption of starting material was complete as determined by 
TLC (1:1 EtOAc:Hexanes eluent). The reaction was quenched by the careful addition of 
saturated aqueous NH4Cl (15 mL, CAUTION: Vigorous gas evolution!) with vigorous 
stirring. The biphasic reaction mixture was diluted with Et2O (60 mL) and poured onto 
H2O (30 mL). The organics were separated and the aqueous was extracted with Et2O (2 x 
60 mL). The combined organics were washed with brine (20 mL), dried over Na2SO4, 
filtered, and concentrated in vacuo. The crude golden oil was purified by silica gel 
column chromatography (60% Et2O in hexanes eluent) to afford diol 337 (152 mg, 76% 
yield) as a pale yellow oil. For the purpose of characterization, a portion of each 
diastereomer was collected during purification. 
Diol 337, Diastereomer A: Rf = 0.43 (3:1 Et2O:Hexanes eluent); 1H NMR (CDCl3, 500 
MHz) δ 5.59 (dd, J = 2.1, 1.4 Hz, 1H), 4.58 (ddt, J = 6.6, 4.5, 1.9 Hz, 1H), 4.48 (qt, J = 
6.4, 1.7 Hz, 1H), 3.64 (s, 1H), 3.55 (s, 1H), 2.38 (dd, J = 13.4, 6.8 Hz, 1H), 1.89 (dd, J = 
13.4, 4.5 Hz, 1H), 1.36 (d, J = 6.4 Hz, 3H), 1.34 (s, 3H), 0.87 (s, 9H), 0.06 (app d, J = 1.9 
Hz, 6H); 13C NMR (CDCl3, 126 MHz) δ 152.6, 129.0, 81.9, 73.1, 63.7, 52.2, 26.5, 26.0, 
21.8, 18.3, –4.5, –4.5; IR (Neat Film, NaCl) 3364, 2929, 2856, 1463, 1362, 1256, 1204, 
1080, 1001, 940, 905, 835, 775 cm–1; HRMS (FAB+) m/z calc’d for C14H27O3Si [(M+H)–
H2]+: 271.1730, found 271.1728; [α]D25.0 +54.9° (c 3.500, CHCl3).	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Diol 337, Diastereomer B: Rf = 0.35 (3:1 Et2O:Hexanes eluent); 1H NMR (CDCl3, 500 
MHz) δ 5.63 (dd, J = 2.1, 1.2 Hz, 1H), 4.59 (dddd, J = 6.6, 4.3, 2.2, 1.2 Hz, 2H), 2.94–
2.76 (m, 1H), 2.68 (s, 1H), 2.33 (dd, J = 13.2, 6.5 Hz, 1H), 1.86 (dd, J = 13.2, 4.1 Hz, 
1H), 1.41 (d, J = 6.6 Hz, 3H), 1.39 (s, 3H), 0.87 (s, 9H), 0.06 (s, 6H); 13C NMR (CDCl3, 
126 MHz) δ 154.3, 129.0, 81.5, 73.2, 65.4, 52.9, 26.7, 26.0, 24.1, 16.3, –4.6; IR (Neat 
Film, NaCl) 3370, 2929, 2857, 1472, 1362, 1257, 1206, 1085, 1004, 939, 905, 836, 775 
cm–1; HRMS (FAB+) m/z calc’d for C14H27O3Si [(M+H)–H2]+: 271.1730, found 271.1735; 
[α]D25.0 +61.4° (c 3.100 CHCl3). 
	  
 
Methyl ketone 338: To a stirred solution of diol 337 (152 mg, 0.56 mmol, 1.00 equiv) as 
a 1:1 mixture of diastereomers in CH2Cl2 (3.8 mL) at ambient temperature (ca. 23 °C) 
was added MnO2 (1.45 g, 16.7 mmol, 30.0 equiv) as a solid in a single portion. After 16 
h, the consumption of starting material was complete as determined by TLC (1:1 
EtOAc:Hexanes eluent). The reaction mixture was then filtered through a Celite plug, 
washing with CH2Cl2. The combined organics were concentrated in vacuo to provide 
methyl ketone 338 (134 mg, 89% yield) as a spectroscopically pure dark yellow oil: Rf = 
0.24 (1:9 EtOAc:Hexanes eluent); 1H NMR (CDCl3, 400 MHz) δ 6.53 (d, J = 1.9 Hz, 
1H), 4.76 (td, J = 7.1, 1.9 Hz, 1H), 2.41 (dd, J = 12.6, 7.0 Hz, 1H), 2.34 (s, 3H), 2.05–
1.96 (m, 1H), 1.41 (d, J = 1.0 Hz, 3H), 0.90 (s, 9H), 0.11 (s, 3H), 0.09 (s, 3H); 13C NMR 
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4.6; IR (Neat Film, NaCl) 3534, 2929, 2857, 1667, 1472, 1362, 1275, 1259, 1094, 939, 
914, 884, 836, 777 cm–1; HRMS (FAB+) m/z calc’d for C14H25O3Si [(M+H)–H2]+: 
269.1573, found 269.1584; [α]D25.0 +114.7° (c 0.750, CHCl3).	  
 
 
Methyl Ketone Diol ent-335: To a golden yellow stirred solution of methyl ketone 338 
(200 mg, 0.78 mmol, 1.00 equiv) in THF (3.8 mL) at ambient temperature (ca. 23 °C) 
was added TBAF (0.92 mL, 1 M in THF, 1.20 equiv) dropwise. After 20 minutes, the 
consumption of starting material was complete as determined by TLC (3:7 
EtOAc:Hexanes eluent). The orange-brown reaction mixture was then concentrated in 
vacuo and immediately purified by silica gel column chromatography (80% EtOAc in 
hexanes eluent) to furnish cis-1,3-cyclopentenediol ent-335 (120 mg, 98% yield) as an 
amorphous white solid: Rf = 0.18 (3:1 EtOAc:Hexanes eluent); 1H NMR (CDCl3, 400 
MHz) δ 6.63 (d, J = 2.0 Hz, 1H), 4.75 (ddd, J = 7.2, 6.1, 2.1 Hz, 1H), 2.49 (dd, J = 13.4, 
7.2 Hz, 1H), 2.35 (s, 3H), 1.96 (dd, J = 13.4, 6.1 Hz, 1H), 1.43 (s, 3H); 13C NMR (CDCl3, 
101 MHz) δ 199.0, 148.1, 145.0, 80.6, 72.9, 50.4, 27.9, 27.6; IR (Neat Film, NaCl) 3386, 
2968, 1667, 1372, 1316, 1275, 1231, 1107, 1071, 958 cm–1; HRMS (ES+) m/z calc’d for 
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Methyl Ketone Diazoester 340: To a stirred solution of ethyl ester 323 (2.07 g, 9.32 
mmol, 1.00 equiv) in MeOH (31 mL) and H2O (31 mL) was added K2CO3 (5.16 g, 37.3 
mmol, 4.00 equiv). After 7 h, the consumption of starting material was complete as 
determined by TLC (2:3 Et2O:Hexanes eluent). The reaction mixture was cooled to 0 °C 
(ice/H2O bath) and the pH was adjusted to between 1 and 2 by the careful addition of 
aqueous 1 N HCl (CAUTION: Vigorous gas evolution!). The reaction mixture was then 
poured onto a mixture of EtOAc (200 mL) and H2O (100 mL). The organics were 
separated and the aqueous layer was extracted with EtOAc (3 x 200 mL). The combined 
organics were dried over Na2SO4, filtered and concentrated in vacuo. The crude dark 
orange oil of carboxylic acid ent-321 (1.81 g, >99% yield) was carried on without further 
purification. 
To a stirred solution of diol ent-335 (76 mg, 0.49 mmol, 1.00 equiv) in CH2Cl2 (16 
mL) were added a portion of crude carboxylic acid ent-321 (190 mg, 0.98 mmol, 2.00 
equiv) and EDC•HCl (188 mg, 0.98 mmol, 2.00 equiv). The orange reaction mixture was 
cooled to 0 °C (ice/H2O bath) at which time DMAP (12 mg, 0.010 mmol, 0.20 equiv) was 
added in a single portion. After 30 minutes, the dark red-orange reaction mixture was 
removed from the cooling bath and allowed to warm to ambient temperature (ca. 23 °C). 
After 2.5 h, additional DMAP (12 mg, 0.010 mmol, 0.20 equiv) was added in a single 
portion. After an additional 2 h, the consumption of starting material was nearly complete 
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concentrated in vacuo to approximately 25% of the original reaction volume and directly 
purified by silica gel column chromatography (50%→70%→90% EtOAc in hexanes 
eluent) to furnish a recovered portion of diol ent-335 (11 mg, 14% yield) and the 
intermediate ester (125 mg, 77% yield), which was directly carried on to the next 
reaction.  
To a portion of intermediate ester (57 mg, 0.17 mmol, 1.00 equiv) in CH3CN (1.7 
mL) in the dark was added p-acetamidobenzenesulfonyl azide (p-ABSA, 46 mg, 0.19 
mmol, 1.10 equiv) as a solid in one portion. The dark orange homogeneous reaction 
mixture was cooled to 0 °C (ice/H2O bath). Et3N (71 µL, 0.51 mmol, 3.00 equiv) was 
then added slowly dropwise. After 5 h, the consumption of starting material was 
complete as determined by TLC (1:4 EtOAc:CH2Cl2 eluent). The reaction was quenched 
by the addition of EtOAc (20 mL), removed from the cooling bath, and allowed warm to 
ambient temperature (ca. 23 °C). The reaction mixture was then concentrated in vacuo. 
The crude tan solid was then adsorbed onto Celite (1.0 g) and purified by silica gel 
column chromatography (20% EtOAc in CH2Cl2 eluent) to afford diazoester 340 (51 mg, 
65% yield from diol ent-335) as a dark yellow oil: Rf = 0.17 (1:4 EtOAc:CH2Cl2 eluent); 
1H NMR (CDCl3, 400 MHz) δ 6.63 (d, J = 2.0 Hz, 1H), 6.45 (d, J = 2.0 Hz, 1H), 5.80 
(ddd, J = 7.6, 6.6, 2.0 Hz, 1H), 4.89 (p, J = 1.5 Hz, 1H), 4.85–4.81 (m, 1H), 3.50 (s, 1H), 
2.78 (tt, J = 11.1, 4.2 Hz, 1H), 2.69 (ddd, J = 17.4, 4.2, 1.4 Hz, 1H), 2.62 (dd, J = 13.5, 
7.5 Hz, 1H), 2.59–2.53 (m, 1H), 2.47 (ddd, J = 17.3, 10.9, 2.2 Hz, 1H), 2.46–2.36 (m, 
4H), 2.17 (dd, J = 13.5, 6.6 Hz, 1H), 1.80 (s, 3H), 1.51 (s, 3H); 13C NMR (CDCl3, 101 
MHz) δ 198.2, 197.1, 162.3, 150.1, 146.0, 145.9, 139.5, 120.6, 111.6, 80.2, 75.6, 67.2, 
46.7, 41.9, 41.6, 31.7, 28.3, 27.7, 20.6; IR (Neat Film, NaCl) 3454, 2967, 2104, 1709, 
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1652, 1580, 1377, 1274, 1223, 1136, 1048, 893, 741 cm–1; HRMS (FAB+) m/z calc’d for 
C19H23O5N2 [M+H]+: 359.1607, found 359.1598; [α]D25.0 +164.2° (c 0.500, CHCl3).	  
 
 
Pyrazole 341: In the dark, to a stirred solution of diazoester 340 (20 mg, 0.056 mmol, 
1.00 equiv) in CH2Cl2 (0.56 mL) at 0 °C (ice/H2O bath) was added Et3N (78 µL, 0.56 
mmol, 10.0 equiv) dropwise. After 5 minutes, TBSOTf (64 µL, 0.28 mmol, 5.00 equiv) 
was added dropwise. After an additional 15 minutes, the consumption of starting material 
was complete as determined by TLC (1:4 EtOAc:CH2Cl2 eluent). The deep red reaction 
mixture was filtered through a Florisil plug, washing with 100% EtOAc. The combined 
organics were concentrated in vacuo to afford a bright red oil that was immediately 
carried on to the next reaction. 
In the dark, to a solution of the red oil in CH2Cl2 (5.6 mL) was added Rh2OAc4 (0.3 
mg, 0.0006 mmol, 0.01 equiv) as a solid in one portion. After an additional 15 minutes, 
the consumption of starting material was complete as determined by IR spectroscopy 
(complete disappearance of diazo absorbance at ca. 2100 cm-1). The reaction mixture was 
then poured onto H2O (10 mL). The organics were separated and the aqueous was 
extracted with CH2Cl2 (3 x 25 mL). The combined organics were washed with brine (10 
mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude golden solid was 
purified by silica gel column chromatography (30%→50% EtOAc in CH2Cl2 eluent) to 
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EtOAc:CH2Cl2 eluent); 1H NMR (CDCl3, 600 MHz) δ 6.59 (d, J = 2.0 Hz, 1H), 5.79 
(ddd, J = 7.4, 6.6, 2.0 Hz, 1H), 4.89 (t, J = 1.4 Hz, 1H), 4.86 (q, J = 1.0 Hz, 1H), 3.32 
(ddd, J = 16.3, 3.7, 1.3 Hz, 1H), 2.97–2.83 (m, 2H), 2.78–2.69 (m, 2H), 2.68–2.58 (m, 
1H), 2.36 (s, 3H), 2.25 (dd, J = 13.0, 6.6 Hz, 1H), 1.82 (t, J = 1.1 Hz, 3H), 1.59 (s, 3H), 
0.83 (s, 9H), 0.12 (s, 3H), 0.09 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 196.1, 189.2, 
161.0, 152.4, 145.6, 136.6, 111.8, 81.8, 75.3, 49.9, 44.0, 43.5, 28.8, 28.5, 26.5, 25.7, 20.7, 
18.0, –2.4, –2.5; IR (Neat Film, NaCl) 3207, 2928, 2856, 1688, 1464, 1367, 1259, 1167, 
1101, 1006, 837, 776 cm–1; HRMS (FAB+) m/z calc’d for C25H36O5N2NaSi [M+Na]+: 
495.2286, found 495.2291; [α]D25.0 +55.1° (c 0.135, CHCl3).45	  
 
 
Cyclopropane 342: To a stirred solution of diazoester 340 (14 mg, 0.039 mmol, 1.00 
equiv) in CH2Cl2 (3.9 mL) in a nitrogen-filled glovebox at ambient temperature (ca. 30 
°C) was added Cu(tbs)2 (1.6 mg, 0.004 mmol, 0.10 equiv) as a solid in one portion. After 
4 days, although the starting material was not fully consumed as determined by TLC (1:4 
EtOAc:CH2Cl2 eluent), the reaction was removed from the glovebox and concentrated in 
vacuo to approximately 25% of the original reaction volume. The crude reaction solution 
was directly purified by silica gel column chromatography (50% EtOAc in CH2Cl2 
eluent) to afford cyclopropane 342 (4 mg, 29% yield, Rf = 0.21 (1:1 EtOAc:CH2Cl2 
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Isoineleganolide B (331), Ethyl Ether 344, and Cycloheptatriene 345: To a colorless 
stirred solution of isoineleganolide A (328, 10 mg, 0.30 mmol, 1.00 equiv) in CHCl3 
(stabilized with 0.75% EtOH, 1.0 mL) at ambient temperature (ca. 23 °C) was added 
In(OTf)3 (40 mg, 0.71 mmol, 2.37 equiv). The white suspension was stirred for 5 minutes 
and then introduced to a preheated 50 °C bath. After 13 h, the consumption of starting 
material was complete as determined by TLC (1:4 EtOAc:CH2Cl2 eluent). The reaction 
was directly purified by silica gel column chromatography (10%→20% EtOAc in CH2Cl2 
eluent) to provide isoineleganolide B (331, 2 mg, 20% yield) as an amorphous white 
solid, ethyl ether 344 (7 mg, 70% yield) as an amorphous white solid, and 
cycloheptatriene 345 (1 mg, 10% yield) as an amorphous white solid. 
Isoineleganolide B (331): Characterization data match those reported above. 
Ethyl ether 344: Rf = 0.39 (1:4 EtOAc:CH2Cl2 eluent); 1H NMR (CDCl3, 400 MHz) δ 
4.88–4.76 (m, 3H), 3.79–3.65 (m, 2H), 3.59–3.44 (m, 2H), 3.15 (d, J = 9.2 Hz, 1H), 2.91 
(ddt, J = 13.3, 5.6, 1.1 Hz, 1H), 2.65 (tt, J = 13.2, 3.7 Hz, 1H), 2.60–2.49 (m, 2H), 2.36–
2.18 (m, 4H), 2.17–2.09 (m, 1H), 1.98 (ddd, J = 14.5, 3.7, 2.1 Hz, 1H), 1.79–1.73 (m, 
3H), 1.30 (d, J = 1.2 Hz, 3H), 1.17 (t, J = 7.0 Hz, 3H); 13C NMR (CDCl3, 101 MHz) δ 
206.7, 176.1, 146.2, 111.1, 95.5, 89.0, 79.6, 78.1, 69.3, 64.4, 55.4, 54.0, 48.5, 46.3, 45.7, 
41.2, 36.8, 25.6, 24.7, 20.4, 15.7; IR (Neat Film, NaCl) 3490, 2965, 1767, 1717, 1447, 
1357, 1262, 1178, 1107, 1025, 967, 895, 799, 758 cm–1; HRMS (FAB+) m/z calc’d for 
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Cycloheptatriene 345: Rf = 0.94 (1:4 EtOAc:CH2Cl2 eluent); 1H NMR (CDCl3, 500 
MHz) δ 7.86 (d, J = 6.7 Hz, 1H), 6.46 (ddd, J = 6.7, 1.8, 0.6 Hz, 1H), 6.36 (t, J = 1.8 Hz, 
1H), 5.48 (ddd, J = 7.2, 2.3, 1.1 Hz, 1H), 4.84 (t, J = 1.4 Hz, 1H), 4.76 (q, J = 1.0 Hz, 
1H), 3.33 (dq, J = 6.8, 2.3 Hz, 2H), 2.93 (dd, J = 7.5, 1.9 Hz, 1H), 2.76–2.69 (m, 1H), 
2.67–2.58 (m, 2H), 2.01 (t, J = 1.3 Hz, 3H), 1.81 (dd, J = 1.5, 0.8 Hz, 3H); 13C NMR 
(CDCl3, 126 MHz) δ 200.1, 166.1, 149.1, 146.2, 145.9, 143.5, 140.2, 138.1, 137.5, 117.4, 
114.8, 111.3, 81.1, 44.8, 44.1, 38.7, 32.2, 21.1, 12.7; IR (Neat Film, NaCl) 2924, 2854, 
1738, 1684, 1611, 1495, 1451, 1262, 1234, 1086, 1006, 827 cm–1; HRMS (EI+) m/z 
calc’d for C19H18O3 [M•]+: 294.1256, found 294.1260; [α]D25.0 –84.6° (c 0.100, CHCl3). 
 
 
Bromide 346: To a stirred colorless solution of isoineleganolide A (328, 133 mg, 0.40 
mmol, 1.00 equiv) in a mixture of toluene (27 mL) and THF (7 mL) in a nitrogen-filled 
glovebox was added MgBr2 (370 mg, 2.01 mmol, 5.00 equiv) in a single portion. The 
reaction mixture was then sealed and heated to 70 °C. After 6 h, the consumption of 
starting material was complete as determined by TLC (1:4 EtOAc:CH2Cl2 eluent). The 
golden yellow solution was removed from the glovebox and concentrated in vacuo to 
approximately 25% of the original reaction volume. The reaction was then filtered 
through a silica gel plug, eluting the product with 20% EtOAc in CH2Cl2 to afford 
spectroscopically pure bromide 346 (166 mg, >99% yield) as a white crystalline solid. 
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benzene in heptane into a solution of bromide 346 in EtOAc, mp: 150–153 °C: Rf = 0.26 
(1:19 EtOAc:CH2Cl2 eluent); 1H NMR (CDCl3, 600 MHz) δ 4.89 (dt, J = 9.1, 7.6 Hz, 
1H), 4.84 (t, J = 1.5 Hz, 1H), 4.81 (s, 1H), 4.39 (dd, J = 11.3, 5.5 Hz, 1H), 3.74 (t, J = 9.2 
Hz, 1H), 3.25 (d, J = 9.0 Hz, 1H), 3.08 (ddd, J = 14.1, 5.6, 1.4 Hz, 1H), 2.66 (tt, J = 13.2, 
3.9 Hz, 1H), 2.56 (ddd, J = 13.2, 3.7, 2.0 Hz, 1H), 2.52 (d, J = 5.8 Hz, 1H), 2.36–2.27 (m, 
2H), 2.22 (dd, J = 14.6, 12.9 Hz, 1H), 2.15 (m, 1H), 1.94 (m, 2H), 1.76 (d, J = 1.0 Hz, 
3H), 1.49 (d, J = 1.2 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 205.7, 175.2, 145.7, 111.2, 
96.3, 88.9, 80.8, 77.5, 55.5, 55.4, 48.4, 46.2, 45.4, 41.5, 41.1, 36.7, 32.3, 26.6, 20.2; IR 
(Neat Film, NaCl) 3508, 2970, 1767, 1716, 1443, 1354, 1271, 1203, 1173, 1073, 1016, 
755 cm–1; HRMS (FAB+) m/z calc’d for C19H24O579Br [M+H]+: 411.0807, found 
411.0800; [α]D25.0 +26.7° (c 1.150, CHCl3). 
 
 
Diketonefuranopentacycle 347: A reaction vessel in a nitrogen-filled glove box was 
charged with AgBF4 (43 mg, 0.22 mmol, 3.00 equiv) followed by bromide 346 (30 mg, 
0.073 mmol, 1.00 equiv) as a solution in DMSO (1.5 mL) with stirring. The reaction 
vessel was sealed and after 5 minutes the white suspension had become a completely 
homogenous, pale yellow solution. The reaction vessel was removed from the glovebox, 
and introduced to an argon atmosphere and a preheated 120 °C bath. After 9 h, the 
consumption of starting material was complete as determined by TLC (1:19 
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heating bath and allowed to cool to ambient temperature (ca. 23 °C). Once the 
temperature had equilibrated, Et3N (0.30 mL, 2.15 mmol, 29.5 equiv) was added quickly 
dropwise with vigorous stirring. After 2 h, the reaction was filtered through a Celite plug, 
washing with EtOAc. The combined organics were diluted with EtOAc (30 mL) and 
washed with H2O (4 x 20 mL). The combined aqueous layers were then extracted with 
EtOAc (3 x 20 mL). The combined organics were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude brown solid was purified by silica gel column 
chromatography (40% EtOAc in CH2Cl2 eluent) to furnish diketone 347 (24 mg, 96% 
yield) as a crystalline white solid. Colorless, translucent X-ray quality crystals were 
obtained by slow diffusion of 1% benzene in heptane into a solution of diketone 347 in 
ethyl acetate, mp: 270–273 °C: Rf = 0.40 (1:3 EtOAc:CH2Cl2 eluent); 1H NMR (CDCl3, 
500 MHz) δ 4.89–4.84 (m, 2H), 4.83 (dd, J = 2.3, 1.2 Hz, 1H), 3.56 (t, J = 9.0 Hz, 1H), 
3.44 (d, J = 9.1 Hz, 1H), 3.20 (d, J = 15.6 Hz, 1H), 3.07 (dt, J = 7.4, 1.0 Hz, 1H), 2.76 (tt, 
J = 13.2, 3.6 Hz, 1H), 2.61 (ddd, J = 13.0, 3.6, 2.1 Hz, 1H), 2.43–2.28 (m, 5H), 2.13 
(ddd, J = 14.7, 3.6, 2.1 Hz, 1H), 1.77 (t, J = 1.0 Hz, 3H), 1.50 (d, J = 1.1 Hz, 3H); 13C 
NMR (CDCl3, 126 MHz) δ 204.9, 199.1, 174.6, 145.8, 111.4, 95.2, 90.8, 78.1, 77.5, 57.4, 
54.4, 51.2, 46.1, 45.5, 41.0, 36.6, 34.9, 24.6, 20.4; IR (Neat Film, NaCl) 3484, 2965, 
2923, 1766, 1732, 1204, 1172, 1071, 1032, 947, 754 cm–1; HRMS (EI+) m/z calc’d for 
C19H22O6 [M•]+: 346.1416, found 346.1403; [α]D25.0 –30.8° (c 0.800, CHCl3). 
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Diol tetracycle 349: 
Preparation of a 0.07 M Stock Solution SmI2 
Into a Schlenk tube was added freshly filed samarium metal (150 mg, 1.00 mmol, 
1.41 equiv). The reaction vessel was then thoroughly flame-dried, backfilled with argon, 
and allowed to cool to ambient temperature (ca. 23 °C). To the reaction vessel was then 
added THF (10.0 mL) that had previously been sparged with argon for 60 minutes and 
cooled to 0 °C (ice/H2O bath) with stirring. EtI2 (200 mg, 0.71 mmol, 1.00 equiv) was 
then added in separate 100 mg portions 30 minutes apart. After the addition of the second 
portion, the Schlenk tube was removed from the cooling bath, allowed to warm to 
ambient temperature, and the pale yellow solution was stirred overnight (ca. 14 h) 
causing the reaction to become deep blue, indicating the formation of SmI2. 
Reduction of Vinlyogous Diketone 347 
A reaction vessel in a nitrogen-filled glovebox was charged with LiCl (49 mg, 1.15 
mmol, 19.8 equiv), sealed, removed from the glovebox, and introduced to an argon 
atmosphere. To the reaction vessel was added a solution of diketone 347 (20 mg, 0.058 
mmol, 1.00 equiv) in THF (26 mL) followed by t-BuOH (15 µL, 0.16 mmol, 1.23 equiv). 
The white suspension was then sparged with argon for 1 h, reducing the reaction volume 
to 20 mL. The reaction solution was then cooled to –78 °C (i-PrOH/dry ice bath) at which 
time SmI2 (2.00 mL, 0.07 M in THF, 1.08 equiv) was added slowly dropwise over 5 
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minutes, the consumption of starting material was complete as determined by TLC (1:3 
EtOAc:CH2Cl2 eluent). The reaction was quenched by the addition of saturated aqueous 
NH4Cl (100 µL), immediately removed from the cooling bath, and allowed to warm to 
ambient temperature (23 °C). The yellow reaction mixture was filtered through a silica 
gel plug, eluting the product with 100% EtOAc. The organics were concentrated in vacuo 
and the crude pale yellow solid was purified by silica gel column chromatography 
(75%→85% EtOAc in CH2Cl2 eluent) to provide diol 349 (17 mg, 85% yield) as a 
crystalline white solid. Diol 349 was characterized as an inseparable, equilibrium mixture 
of free diol 349 and hemiketal 350. Colorless, translucent X-ray quality crystals of 
hemiketal 350 were obtained by slow diffusion of 1% benzene in heptane into a solution 
of diol 349 in EtOAc, mp: 225–228 °C: Rf = 0.32 (3:1 EtOAc:CH2Cl2 eluent); 1H NMR 
(CDCl3, 500 MHz) δ 4.92 (dd, J = 7.0, 5.1 Hz, 1.00 H), 4.84 (dt, J = 2.8, 1.4 Hz, 2.28 H), 
4.82–4.76 (m, 3.44 H), 3.63 (s, 0.95 H), 3.38 (tdd, J = 10.4, 7.0, 0.7 Hz, 0.99 H), 3.30 (d, 
J = 13.6 Hz, 1.23 H), 3.24 (d, J = 8.2 Hz,  1.23 H), 3.22–3.09 (m, 3.39 H), 3.02–2.95 (m, 
2.16 H), 2.86–2.80 (m, 2.43 H), 2.76–2.55 (m, 8.89 H), 2.46 (dd, J = 14.0, 10.1 Hz, 1.00 
H), 2.39–2.22 (m, 6.90 H), 2.19 (d, J = 10.3 Hz, 0.98 H), 2.15–2.09 (m, 1.16 H), 1.90 
(dd, J = 15.3, 12.4 Hz, 1.03 H), 1.82–1.75 (m, 6.90 H), 1.72 (dd, J = 14.3, 12.1 Hz, 1.13 
H), 1.53 (s, 2.90 H), 1.35 (d, J = 1.0 Hz, 3.61 H); 13C NMR (CDCl3, 126 MHz) δ 209.9, 
209.1, 206.1, 174.8, 173.2, 146.5, 146.2, 111.0, 110.9, 105.6, 83.9, 81.2, 80.5, 79.3, 78.9, 
75.0, 58.0, 54.4, 54.3, 52.2, 51.9, 47.6, 47.4, 46.4, 46.0, 45.6, 44.5, 42.7, 41.7, 41.1, 40.3, 
38.2, 37.5, 36.1, 28.8, 24.8, 20.8, 20.7; IR (Neat Film, NaCl) 3358, 2921, 1752, 1711, 
1689, 1358, 1261, 1182, 1098, 1026, 936, 896, 799, 756 cm–1; HRMS (MM: ESI-APCI) 
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Isoineleganolide C (ent-313), Isoineleganolide D (351), and Dienone 352: To a 
heterogeneous mixture of diol 349 (30 mg, 0.086 mmol, 1.00 equiv) in CH2Cl2 (6.0 mL) 
was added Amberlyst® 15 (75 mg, 2.5 equiv by wt. to diol 349) as a solid in one portion. 
After 24 h, the consumption of starting material was complete as determined by TLC (3:1 
EtOAc:CH2Cl2 eluent). The heterogeneous, light yellow reaction mixture was filtered and 
the organics were concentrated in vacuo. The crude yellow solid was purified by silica 
gel column chromatography (30% EtOAc in CH2Cl2 eluent) to provide isoineleganolide C 
(ent-313, 19 mg, 63% yield) as an amorphous yellow solid, isoineleganolide D (351, 5 
mg, 17% yield) as an amorphous white solid, and dienone 352 (3 mg, 10% yield) as an 
amorphous white solid. 
Isoineleganolide C (ent-313): Rf = 0.27 (2:3 EtOAc:CH2Cl2 eluent); 1H NMR (CDCl3, 
600 MHz) δ 4.86 (dd, J = 2.3, 1.2 Hz, 1H), 4.80 (ddd, J = 7.0, 5.7, 2.6 Hz, 1H), 4.71–
4.68 (m, 1H), 4.21 (d, J = 15.3 Hz, 1H), 3.91 (ddt, J = 7.4, 2.6, 1.3 Hz, 1H), 3.71 (dtd, J = 
17.9, 2.8, 1.3 Hz, 1H), 3.31 (ddd, J = 13.2, 7.4, 5.8 Hz, 1H), 3.08 (dq, J = 15.3, 2.8 Hz, 
1H), 2.91–2.83 (m, 1H), 2.78 (dp, J = 9.1, 4.5 Hz, 1H), 2.71 (ddd, J = 16.5, 4.5, 1.2 Hz, 
1H), 2.53 (m, 1H), 2.48–2.41 (m, 1H), 2.41–2.35 (m, 1H), 2.26–2.22 (m, 1H), 1.79–1.78 










































Isoineleganolide C Isoineleganolide D
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128.2, 111.3, 79.5, 78.2, 59.8, 51.0, 46.2, 43.0, 42.4, 39.7, 39.5, 33.8, 25.2, 21.3; IR (Neat 
Film, NaCl) 3458, 2960, 2923, 2854, 1767, 1709, 1662, 1438, 1377, 1262, 1139, 1038 
cm–1; HRMS (FAB+) m/z calc’d for C19H23O5 [M+H]+: 331.1545, found 331.1548; [α]D25.0 
–66.3° (c 0.275, CHCl3). 
Isoineleganolide D (351): Rf = 0.73 (3:1 EtOAc:CH2Cl2 eluent); 1H NMR (CDCl3, 500 
MHz) δ 4.99 (t, J = 5.1 Hz, 1H), 4.83 (q, J = 1.5 Hz, 1H), 4.77 (s, 1H), 4.01 (bt, J = 7.0 
Hz, 1H), 3.53 (dd, J = 14.3, 2.7 Hz, 1H), 3.22 (d, J = 8.6 Hz, 1H), 3.19 (t, J = 2.9 Hz, 
1H), 2.95–2.77 (m, 3H), 2.77–2.64 (m, 2H), 2.54 (dd, J = 14.3, 10.9 Hz, 1H), 2.25 (t, J = 
13.3 Hz, 1H), 2.19 (s, 3H) 1.77 (s, 3H), 1.69 (app t, J = 13.9 Hz, 1H); 13C NMR (CDCl3, 
126 MHz) δ 205.1, 195.1, 175.0, 151.2, 146.5, 131.3, 110.7, 79.0, 76.3, 53.5, 53.2, 49.2, 
46.2, 45.7, 42.8, 38.7, 37.9, 20.9, 16.3; IR (Neat Film, NaCl) 3355, 2922, 1750, 1712, 
1679, 1626, 1372, 1260, 1184, 1017, 801 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for 
C19H23O5 [M+H]+: 331.1540, found 331.1539; [α]D25.0 +10.5 ° (c 0.200, CHCl3). 
Dienone 352: Rf = 0.61 (2:3 EtOAc:CH2Cl2 eluent); 1H NMR (CDCl3, 500 MHz) δ 4.98 
(td, J = 4.5, 1.1 Hz, 1H), 4.84 (td, J = 1.4, 0.7 Hz, 1H), 4.72 (q, J = 1.0 Hz, 1H), 4.16–
4.08 (m, 2H), 3.76 (ddt, J = 7.4, 2.5, 1.2 Hz, 1H), 3.62 (dd, J = 18.1, 3.5 Hz, 1H), 3.14 
(ddt, J = 13.6, 3.3, 2.4 Hz, 1H), 2.92–2.88 (m, 2H), 2.79–2.68 (m, 2H), 2.49–2.41 (m, 
1H), 2.28–2.20 (m, 4H), 1.78 (dt, J = 1.2, 0.5 Hz, 3H); 13C NMR (CDCl3, 126 MHz) δ 
196.4, 193.8, 172.1, 156.9, 149.0, 145.9, 131.4, 128.2, 110.8, 78.5, 50.4, 49.0, 45.7, 42.5, 
39.8, 38.7, 34.3, 21.0, 16.7; IR (Neat Film, NaCl) 2924, 1767. 1674, 1622, 1435, 1377, 
1259, 1158, 893, 754 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C19H21O4 [M+H]+: 
313.1434, found 313.1437; [α]D25.0 +41.1° (c 0.250, CHCl3). 
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Gaulon-Nourry, C.; Gosselin, P. Org. Biomol. Chem. 2012, 10, 502–505. (b) Li, 
S.; Parish, E. J.; Webb, T.; Brodie, A. M. Bioorg. Med. Chem. Lett. 1997, 7, 403–
408. 
25. (a) Procopio, A.; Dalpozzo, R.; De Nino, A.; Nardi, M.; Sindona, G.; Tagarelli, A. 
Synlett 2004, 2633–2635. (b) Karamé, I.; Tommasino, M. L.; Lemaire, M. 
Tetrahedron Lett. 2003, 44, 7687–7689. (c) Maruoka, K.; Murase, N.; Bureau, R.; 
Ooi, T.; Yamamoto, H. Tetrahedron 2001, 50, 3663–3672. (d) Ranu, B. C.; Jana, 
U. J. Org. Chem. 1998, 63, 8212–8216. (e) Marson, C. M.; Harper, S.; Walker, A. 
J.; Pickering, J.; Campbell, J.; Wrigglesworth, R.; Edge, S. J. Tetrahedron 1993, 
49, 10339–10354. (f) Smith, J. G. Synthesis 1984, 629–656. (g) Lee, K. H.; Ibuka, 
T.; Kim, S. H.; Vestal, B. R.; Hall, I. H.; Huang, E. S. J. Med. Chem. 1975, 18, 
812–817. 
26. A characteristic list of the conditions attempted to induce the desired epoxide 
isomerization: H2SO4/CHCl3,  SiO2/CHCl3, DBU/CHCl3, KOt-Bu/THF, 
Pd(CH3CN)2Cl2/benzene, BF3•Et2O/CHCl3, In(OTf)3/CHCl3, Al(Oi-Pr)3/CHCl3, 
Ti(Oi-Pr)4/THF, Zn(OTf)2/toluene, Mg(OTf)2/toluene, MgCl2/toluene, 
MgBr2/toluene. 
27. Conditions attempted to make enol ether of methyl ketone 338: PMBCl/EtN(i-
Pr)2/CH2Cl2, PMBCl/TBAI/EtN(i-Pr)2/CH2Cl2, PMBCl/LDA/CH2Cl2, MOMCl/ 
EtN(i-Pr)2/CH2Cl2, methyl chloroformate/EtN(i-Pr)2/CH2Cl2, pyrrolidine/MgSO4/ 
toluene. 
28. To our knowledge, there is no example of an anionic 2-oxy-Cope rearrangement 
in the literature, although the comparable 2-siloxy-Cope rearrangements have 
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been accomplished, see: (a) Vedejs, E.; Duncan, S. M. J. Org. Chem. 2000, 65, 
6073–6081. (b) Hsu, D.-S.; Hsu, P.-Y.; Lee, Y.-C.; Liao, C.-C. J. Org. Chem. 
2008, 73, 2554–2563. 
29. The stereochemical assignment of ethyl ether 344 was accomplished by 
comparison to the unambiguous assignment of bromide 346 by single crystal X-
ray analysis (vide infra).	  	  
30. The Lewis acids that accomplished the opening of epoxide 328 with their 
counterion include BF3•Et2O, YbCl3, MgCl2, MgBr2, and MgI2. 
31. (a) Ly, T. W.; Liao, J.-H.; Shia, K.-S.; Liu, H.-J. Synthesis 2004, 271–275. (b) 
Paisdor, B.; Kuck, D. J. Org. Chem. 1991, 56, 4753–4759. (c) Paritosh, D.; Byun, 
H.-S.; Engel, R. Synth. Commun. 1986, 16, 1343–1346. (d) Mancuso, A. J.; 
Swern, D. Synthesis 1981, 165–185. (e) Kornblum, N.; Jones, W. J.; Anderson, G. 
J. J. Am. Chem. Soc. 1959, 81, 4113–4114. 
32. The chloride analog of bromide 346 failed to undergo oxidation, resulting in the 
quantitative recovery of starting material. Alternatively, the iodide analog 
underwent oxidation, but provided diketone 347 in reduced yield. For further 
details and discussion, see appendix 8. 
33. (a) Szostak, M.; Spain, M.; Procter, D. J. J. Org. Chem. 2014, 79, 2522–2537. (b) 
Egger, J.; Bretscher, P.; Freigang, S.; Kopf, M.; Carreira, E. M. Angew. Chem., 
Int. Ed. 2013, 52, 5382–5385. (c) Shoji, M.; Uno, T.; Kakeya, H.; Onose, R.; 
Shiina, I.; Osada, H.; Hayashi, Y. J. Org. Chem. 2005, 70, 9905–9915. (d) 
Yamaguchi, J.; Kakeya, H.; Uno, T.; Shoji, M.; Osada, H.; Hayashi, Y. Angew. 
Chem., Int. Ed. 2005, 44, 3110–3115. (e) Ready, J. M.; Reisman, S. E.; Hirata, 
Chapter 3 – Progress Toward the Furanobutenolide Norcembranoids 235 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
M.; Weiss, M. M.; Tamaki, K.; Ovaska, T. V.; Wood, J. L. Angew. Chem. Int. Ed. 
2004, 43, 1270–1272. (f) Fuchs, J. R.; Mitchell, M. L.; Shabangi, M.; Flowers, R. 
A. Tetrahedron Lett. 1997, 38, 8157–8158. (g) Molander, G. A.; Hahn, G. J. Org. 
Chem. 1986, 51, 1135–1138. (h) Molander, G. A.; Hahn, G. J. Org. Chem. 1986, 
51, 2596–2599. 
34. Product formation assessed by 1H NMR evaluation of the crude reaction product. 
35. Exposure of diol 349 to LDA at low temperature induced an equilibrium between 
diol 349 and diastereomer I as determined by extensive 1H NMR studies. 
          
36. A characteristic list of the conditions attempted to induce the desired epoxide 
isomerization: DBU/CH2Cl2, PdCl2(CH3CN)2/CH2Cl2, Grubbs Gen. II/MeOH, 
RhCl3•H2O/EtOH, LiHMDS/THF. 
37. White, D. E.; Stewart, I. C.; Grubbs, R. H.; Stoltz, B. M. J. Am. Chem. Soc. 2008, 
130, 810–811. 
38. (a) Betancor, C.; Freire, R.; Pérez-Martín, I.; Prangé, T.; Suárez, E. Tetrahedron 
2005, 61, 2803–2814. (b) Cornella, I.; Sestelo, J. P.; Mouriño, A.; Sarandeses, L. 
A. J. Org. Chem. 2002, 67, 4707–4714. (c) Paquette, L. A.; Sun, L.-Q.; Friedrich, 
D.; Savage, P. B. J. Am. Chem. Soc. 1997, 119, 8438–8450. (d) Dorta, R. L.; 
Francisco, C. G.; Hernández, R.; Salazar, J. A.; Suárez, E. J. Chem. Res. (S) 1990, 
240–241. (e) Concepción, J. I.; Francisco, C. G.; Hernández, R.; Salazar, J. A.; 
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39. The ketone moieties within enone could be reduced with hydride sources (e.g., 
NaBH4, Li(Ot-Bu)3AlH), but the reaction could not be performed chemo- or 
diastereoselectively.  
40. Calculations were performed with Spartan ’10 (Wavefunction, Inc., Irvine, CA).  
The in vacuo equilibrium geometry for each structure was calculated by a series 
of sequential calculations as follows: Hartree–Fock computation (equilibrium 
geometry, 3-21G basis set), DFT (equilibrium geometry, B3LYP/6-31G basis 
set), DFT (energy, B3LYP/6-311+G** basis set), DFT (equilibrium geometry, 
B3LYP/6-311+G** basis set). The error from these calculations is ±0.23 
kcal/mol, thus all energy differences larger than 0.46 kcal/mol were considered 
significant. Except for molecular mechanics and semi-empirical models, the 
calculation methods used in Spartan have been documented in: Shao, Y.; Molnar, 
L. F.; Jung, Y.; Kussmann, J.; Ochsenfeld, C.; Brown, S. T.; Gilbert, A. T. B.; 
Slipchenko, L. V.; Levchenko, S. V.; O’Neill, D. P.; DiStasio, Jr., R. A.; Lochan, 
R. C.; Wang, T.; Beran, G. J. O.; Besley, N. A.; Herbert, J. M.; Lin, C. Y.; Van 
Voorhis, T.; Chien, S. H.; Sodt, A.; Steele, R. P.; Rassolov, V. A.; Maslen, P. E.; 
Korambath, P. P.; Adamson, R. D.; Austin, B.; Baker, J.; Byrd, E. F. C.; Dachsel, 
H.; Doerksen, R. J.; Dreuw, A.; Dunietz, B. D.; Dutoi, A. D.; Furlani, T. R.; 
Gwaltney, S. R.; Heyden, A.; Hirata, S.; Hsu, C-P.; Kedziora, G.; Khalliulin, R. 
Z.; Klunzinger, P. Lee, A. M.; Lee, M. S.; Liang, W. Z.; Lotan, I.; Nair, N.; 
Peters, B.; Proynov, E. I.; Pieniazek, P. A.; Rhee, Y. M.; Ritchie, J.; Rosta, E; 
Sherrill, C. D.; Simmonett, A. C.; Subotnik, J. E.; Woodcock, III, H. L.; Zhang, 
W.; Bell, A. T.; Chakraborty, A. K.; Chipman, D. M.; Keil, F. J.; Warshel, A.; 
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Hehre, W. J.; Schaefer, H. F.; Kong, J.; Krylov, A. I.; Gill, P. M. W.; Head-
Gordon M. Phys. Chem. Chem. Phys. 2006, 8, 3172–3191. 
41. Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. 
Organometallics 1996, 15, 1518–1520. 
42. Voss, H.; Wannowius, K. J.; Elias, H. J. Inorg. Nucl. Chem. 1974, 36, 1402–
1404. 
43. Although we began with anhydrous CeCl3, the drying procedure greatly increased 
the yield. It is likely increased surface area of the CeCl3 after grinding due to 
stirring during the drying procedure that facilitated this yield increase.  
44. The assignment of the structure of isoineleganolide B due to the fact that, while 
all of the predictive NMR experiments and empirical two-dimensional NMR data 
and mass spectral data indicate the oxetane structure is correct, some doubt still 
remains from the apparent O–H absorbance in the IR spectrum and the indication 
of an exchangeable proton on the molecule itself as deduced by two-dimensional 
NOE and DOSY experiments. Unfortunately, isoineleganolide B was not 
crystalline. 
45. Only 20 lines appear in the 13C spectrum of pyrazole 341.  Two are lost due to the 
symmetry of the TBS group. The remaining three carbons belong to the pyrazole 
ring and are broadened by the adjacent nitrogen atoms. Two of these three 
carbons, however, can be identified by two-dimensional 1H–13C gradient HMBC 
experiments and their approximate shifts are as follows: 146 ppm and 140 ppm. 
46. For discussion of these failed reactions, see secton 3.6. 
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Scheme A5.1. Construction of cis-1,3-Cyclopentenediol ent-322 
 
 














    0 °C → 23 °C, 5 h
2. Ph3PMeBr
    KOt-Bu, THF, 1.5 h













1. CeCl3 , THF, –78 °C, 5 h
2. TEMPO•BF4 , CH3CN
     12 h


















































































































70 °C, 6 h
(>99% yield)
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    0 °C → 23 °C, 3 h
2. MeLi, Et2O
    –15 °C → 23 °C, 3 h








   THF, –78 °C → 0 °C, 1 h
2. TBSOTf, Et3N
    CH2Cl2, 0 °C, 30 min
3. fumaric acid, HC(OMe)3
    MeOH, 0 °C → 35 °C, 9 h
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 Figure A6.2. Infrared spectrum (Thin Film, NaCl) of compound 354. 
 
 Figure A6.3. 13C NMR (126 MHz, CDCl3) of compound 354. 
 










































































































Figure A6.5. Infrared spectrum (Thin Film, NaCl) of compound ent-322. 
Figure A6.6. 13C NMR (76 MHz, CDCl3) of compound ent-322. 










































































































Figure A6.8. Infrared spectrum (Thin Film, NaCl) of compound 323. 
Figure A6.9. 13C NMR (126 MHz, CDCl3) of compound 323. 
















































































































Figure A6.11. Infrared spectrum (Thin Film, NaCl) of compound ent-320. 
Figure A6.12. 13C NMR (126 MHz, CDCl3) of compound ent-320. 













































































































Figure A6.14. Infrared spectrum (Thin Film, NaCl) of compound 324. 
Figure A6.15. 13C NMR (126 MHz, CDCl3) of compound 324. 







































































































Figure A6.17. Infrared spectrum (Thin Film, NaCl) of compound 325. 
Figure A6.18. 13C NMR (126 MHz, CDCl3) of compound 325. 





















































































































Figure A6.20. Infrared spectrum (Thin Film, NaCl) of compound 328. 
Figure A6.21. 13C NMR (126 MHz, CDCl3) of compound 328. 














































































































Figure A6.23. Infrared spectrum (Thin Film, NaCl) of compound 329. 
Figure A6.24. 13C NMR (126 MHz, CDCl3) of compound 329. 






















































































































Figure A6.26. Infrared spectrum (Thin Film, NaCl) of compound 331. 
Figure A6.27. 13C NMR (101 MHz, CDCl3) of compound 331. 











































































































Figure A6.29. Infrared spectrum (Thin Film, NaCl) of compound 336. 
Figure A6.30. 13C NMR (126 MHz, CDCl3) of compound 336. 






















































































































Figure A6.32. Infrared spectrum (Thin Film, NaCl) of compound 337-A. 
Figure A6.33. 13C NMR (126 MHz, CDCl3) of compound 337-A. 



















































































































Figure A6.35. Infrared spectrum (Thin Film, NaCl) of compound 337-B. 
Figure A6.36. 13C NMR (126 MHz, CDCl3) of compound 337-B. 









































































































Figure A6.38. Infrared spectrum (Thin Film, NaCl) of compound 338. 
Figure A6.39. 13C NMR (101 MHz, CDCl3) of compound 338. 











































































































Figure A6.41. Infrared spectrum (Thin Film, NaCl) of compound ent-335. 
Figure A6.42. 13C NMR (101 MHz, CDCl3) of compound ent-335. 











































































































Figure A6.44. Infrared spectrum (Thin Film, NaCl) of compound 340. 
Figure A6.45. 13C NMR (101 MHz, CDCl3) of compound 340. 












































































































Figure A6.47. Infrared spectrum (Thin Film, NaCl) of compound 341. 
Figure A6.48. 13C NMR (126 MHz, CDCl3) of compound 341. 













































































































Figure A6.50. Infrared spectrum (Thin Film, NaCl) of compound 344. 
Figure A6.51. 13C NMR (101 MHz, CDCl3) of compound 344. 







































































































Figure A6.53. Infrared spectrum (Thin Film, NaCl) of compound 345. 
Figure A6.54. 13C NMR (126 MHz, CDCl3) of compound 345. 













































































































Figure A6.56. Infrared spectrum (Thin Film, NaCl) of compound 346. 
Figure A6.57. 13C NMR (126 MHz, CDCl3) of compound 346. 













































































































Figure A6.59. Infrared spectrum (Thin Film, NaCl) of compound 347. 
Figure A6.60. 13C NMR (126 MHz, CDCl3) of compound 347. 





























































































































Figure A6.62. Infrared spectrum (Thin Film, NaCl) of compound 349/350. 
Figure A6.63. 13C NMR (126 MHz, CDCl3) of compound 349/350. 























































































































Figure A6.65. Infrared spectrum (Thin Film, NaCl) of compound ent-313. 
Figure A6.66. 13C NMR (126 MHz, CDCl3) of compound ent-313. 




















































































































Figure A6.68. Infrared spectrum (Thin Film, NaCl) of compound 351. 
Figure A6.69. 13C NMR (126 MHz, CDCl3) of compound 351. 








































































































Figure A6.71. Infrared spectrum (Thin Film, NaCl) of compound 352. 
Figure A6.72. 13C NMR (126 MHz, CDCl3) of compound 352. 
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A7.1   X-Ray Crystal Structure Analysis of Diene 324 
 
Contents 
Table A7.1.1. Experimental Details 
Table A7.1.2. Crystal Data 
Table A7.1.3. Atomic Coordinates  
Table A7.1.4. Full Bond Distances and Angles 
Table A7.1.5. Anisotropic Displacement Parameters 
Table A7.1.6. Hydrogen Atomic Coordinates 
Table A7.1.7. Torsion Angles 
Table A7.1.8. Hydrogen Bond Distances and Angle 
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Table A7.1.1. Experimental Details for X-Ray Structure Determination of Diene 324. 
Low-temperature diffraction data (φ-and ω-scans) were collected on a Bruker AXS 
KAPPA APEX II diffractometer coupled to a APEX II CCD detector with graphite 
monochromated Mo Kα radiation (λ = 0.71073 Å) for the structure of diene 324. The 
structure was solved by direct methods using SHELXS1 and refined against F2 on all data 
by full-matrix least squares with SHELXL-20142 using established refinement 
techniques.3 All non-hydrogen atoms were refined anisotropically. All hydrogen atoms 
were included into the model at geometrically calculated positions and refined using a 
riding model. The isotropic displacement parameters of all hydrogen atoms were fixed to 
1.2 times the U value of the atoms they are linked to (1.5 times for methyl groups).  
Diene 324 crystallizes in the monoclinic space group P21 with one molecule in the 
asymmetric unit. The coordinates for the hydrogen atom bound to O4 was located in the 
difference Fourier synthesis and refined semi-freely with the help of a restraint on the O-
H distance (0.84(4) Å). The crystal diffracted to 0.93 Å leading to low pond precision. 
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Table A7.1.2. Crystal Data and Structure Refinement for Diene 324. 
Caltech Identification code  rac01 
CCDC Deposition Number 1061010 
Empirical formula  C19 H22 O4 
Formula weight  314.36 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 11.7563(19) Å α= 90°. 
 b = 5.3917(8) Å β= 104.529(8)°. 
 c = 12.861(2) Å γ = 90°. 
Volume 789.2(2) Å3 
Z 2 
Density (calculated) 1.323 Mg/m3 
Absorption coefficient 0.092 mm-1 
F(000) 336 
Crystal size 0.500 x 0.100 x 0.050 mm3 
Theta range for data collection 1.636 to 22.464°. 
Index ranges –12 ≤ h ≤ 11, –5 ≤ k ≤ 5, –13 ≤ l ≤ 13 
Reflections collected 8970 
Independent reflections 2037 [R(int) = 0.0848] 
Completeness to theta = 22.464° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2037 / 2 / 213 
Goodness-of-fit on F2 1.016 
Final R indices [I>2sigma(I)] R1 = 0.0505, wR2 = 0.1037 
R indices (all data) R1 = 0.0898, wR2 = 0.1180 
Absolute structure parameter 0.4(10) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.181 and -0.210 e.Å-3 
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Table A7.1.3.       Atomic coordinates (x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for Diene 324.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 3461(4) 5365(8) 3878(3) 40(1) 
C(1) 4556(7) 4881(12) 3816(5) 36(2) 
O(2) 5025(4) 2972(8) 4167(3) 49(1) 
C(2) 5051(5) 7063(10) 3307(5) 29(2) 
C(3) 6016(6) 6448(10) 2746(5) 29(2) 
C(4) 7038(6) 5073(14) 3464(5) 46(2) 
C(5) 7733(5) 3556(10) 2834(5) 28(2) 
C(16) 8739(6) 2141(10) 3541(5) 32(2) 
C(17) 8632(7) 1281(13) 4544(6) 56(2) 
C(18) 9737(6) 1587(14) 3197(6) 62(2) 
C(6) 8111(6) 5325(13) 2068(6) 44(2) 
C(7) 7114(6) 6803(11) 1381(5) 32(2) 
O(3) 7222(4) 7704(8) 541(4) 44(1) 
C(8) 6042(5) 7252(10) 1764(5) 27(2) 
C(9) 5096(5) 8726(11) 995(5) 32(2) 
C(10) 3886(5) 7674(10) 819(5) 31(2) 
C(11) 3363(5) 7471(10) 1604(5) 26(2) 
C(12) 2148(6) 6428(10) 1542(5) 32(2) 
O(4) 2230(4) 3726(8) 1651(3) 36(1) 
C(19) 1219(5) 7101(11) 538(5) 40(2) 
C(13) 1888(6) 7406(13) 2568(5) 41(2) 
C(14) 3051(6) 7757(11) 3367(5) 35(2) 
C(15) 3927(5) 8399(10) 2713(5) 27(2) 
________________________________________________________________________________ 
Appendix 7 – X-Ray Crystallography Reports Relevant to Chapter 3 295 
 
Table A7.1.4.      Bond lengths [Å] and angles [°] for Diene 324. 
_____________________________________________________  
O(1)-C(1)  1.336(8) 
O(1)-C(14)  1.473(7) 
C(1)-O(2)  1.201(8) 
C(1)-C(2)  1.530(8) 
C(2)-C(3)  1.526(8) 
C(2)-C(15)  1.531(8) 
C(2)-H(2)  1.0000 
C(3)-C(8)  1.342(8) 
C(3)-C(4)  1.513(9) 
C(4)-C(5)  1.525(8) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-C(16)  1.506(8) 
C(5)-C(6)  1.516(8) 
C(5)-H(5)  1.0000 
C(16)-C(18)  1.387(8) 
C(16)-C(17)  1.406(8) 
C(17)-H(17A)  0.9800 
C(17)-H(17B)  0.9800 
C(17)-H(17C)  0.9800 
C(18)-H(18A)  0.9500 
C(18)-H(18B)  0.9500 
C(6)-C(7)  1.506(9) 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(7)-O(3)  1.221(7) 
C(7)-C(8)  1.484(8) 
C(8)-C(9)  1.515(8) 
C(9)-C(10)  1.495(8) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(10)-C(11)  1.311(7) 
C(10)-H(10)  0.9500 
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Table A7.1.4. (cont’d) 
C(11)-C(15)  1.499(8) 
C(11)-C(12)  1.519(8) 
C(12)-O(4)  1.465(7) 
C(12)-C(19)  1.512(8) 
C(12)-C(13)  1.522(8) 
O(4)-H(4O)  0.83(3) 
C(19)-H(19A)  0.9800 
C(19)-H(19B)  0.9800 
C(19)-H(19C)  0.9800 
C(13)-C(14)  1.502(8) 
C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 
C(14)-C(15)  1.524(8) 
C(14)-H(14)  1.0000 
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Symmetry transformations used to generate equivalent atoms:  
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Table A7.1.5.  Anisotropic displacement parameters  (Å2x103) for Diene 324.  The anisotropic 
displacement factor exponent takes the form: -2π2[ h2a*2U11  + ... + 2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 53(4)  37(3) 32(3)  -5(2) 14(3)  -10(3) 
C(1) 74(6)  13(4) 16(4)  -6(3) 5(4)  -11(4) 
O(2) 91(4)  20(2) 29(3)  -2(2) 3(3)  -6(3) 
C(2) 43(4)  23(3) 20(3)  -3(3) 5(3)  -1(3) 
C(3) 38(5)  22(3) 29(4)  0(3) 12(4)  3(3) 
C(4) 54(5)  54(4) 32(4)  3(4) 10(4)  22(4) 
C(5) 40(4)  11(3) 34(4)  -6(3) 9(4)  -4(3) 
C(16) 43(5)  22(3) 30(4)  -2(3) 10(4)  -6(3) 
C(17) 61(6)  46(4) 55(5)  -1(4) 5(4)  12(4) 
C(18) 53(5)  70(5) 69(6)  30(5) 26(5)  32(5) 
C(6) 40(5)  47(4) 48(4)  23(4) 14(4)  12(4) 
C(7) 44(5)  17(3) 32(4)  -4(3) 7(4)  -6(3) 
O(3) 50(3)  37(2) 48(3)  18(2) 20(3)  4(2) 
C(8) 35(4)  16(3) 28(4)  -3(3) 5(3)  -1(3) 
C(9) 42(5)  22(3) 30(4)  3(3) 9(4)  -3(3) 
C(10) 37(4)  21(3) 33(4)  -6(3) 7(3)  -2(3) 
C(11) 30(4)  17(3) 30(4)  3(3) 6(3)  2(3) 
C(12) 42(5)  23(3) 32(4)  -4(3) 9(4)  -1(3) 
O(4) 48(3)  23(2) 39(3)  -6(2) 14(3)  -6(2) 
C(19) 40(4)  29(4) 48(5)  -3(3) 8(4)  -2(3) 
C(13) 53(5)  35(4) 39(4)  -10(3) 18(4)  -4(4) 
C(14) 49(5)  24(3) 35(4)  -7(3) 16(4)  2(3) 
C(15) 33(4)  20(3) 25(4)  -6(3) 0(3)  -1(3) 
______________________________________________________________________________ 
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Table A7.1.6.      Hydrogen coordinates (x104) and isotropic  displacement parameters (Å2x103)  
for Diene 324. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 5428 8178 3918 35 
H(4A) 6736 3951 3943 56 
H(4B) 7570 6285 3921 56 
H(5) 7183 2320 2392 34 
H(17A) 9335 334 4894 84 
H(17B) 7938 212 4441 84 
H(17C) 8547 2697 4996 84 
H(18A) 10348 627 3639 74 
H(18B) 9810 2168 2519 74 
H(6A) 8703 6486 2489 53 
H(6B) 8493 4362 1594 53 
H(9A) 5094 10436 1275 38 
H(9B) 5297 8828 294 38 
H(10) 3484 7139 119 37 
H(4O) 2450(60) 3220(130) 1120(40) 54 
H(19A) 1426 6385 -90 60 
H(19B) 1170 8910 465 60 
H(19C) 457 6445 589 60 
H(13A) 1460 9002 2429 49 
H(13B) 1398 6206 2846 49 
H(14) 3016 9069 3907 42 
H(15) 4056 10232 2706 33 
________________________________________________________________________________ 
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Symmetry transformations used to generate equivalent atoms:  
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Table A7.1.8.      Hydrogen bonds for Diene 324  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 C(2)-H(2)...O(2)#1 1.00 2.65 3.309(7) 123.5 
 O(4)-H(4O)...O(3)#2 0.83(3) 2.28(3) 3.094(6) 165(7) 
 C(15)-H(15)...O(2)#3 1.00 2.44 3.167(7) 129.5 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,y+1/2,-z+1    #2 -x+1,y-1/2,-z    #3 x,y+1,z       
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 A7.2   X-Ray Crystal Structure Analysis of Isoineleganolide A (328) 
 
Contents 
Table A7.2.1. Experimental Details 
Table A7.2.2. Crystal Data 
Table A7.2.3. Atomic Coordinates  
Table A7.2.4. Full Bond Distances and Angles 
Table A7.2.5. Anisotropic Displacement Parameters 
Table A7.2.6. Hydrogen Atomic Coordinates 
Table A7.2.7. Torsion Angles 
Table A7.2.8. Hydrogen Bond Distances and Angles 
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Table A7.2.1. Experimental Details for X-Ray Structure Determination of Isoineleganolide A (328). 
Low-temperature diffraction data (φ-and ω-scans) were collected on a Bruker AXS 
KAPPA APEX II diffractometer coupled to a APEX II CCD detector with graphite 
monochromated Mo Kα radiation (λ = 0.71073 Å) for the structure of isoineleganolide A 
(328). The structure was solved by direct methods using SHELXS1 and refined against F2 
on all data by full-matrix least squares with SHELXL-20142 using established refinement 
techniques.3 All non-hydrogen atoms were refined anisotropically. Unless otherwise 
noted, all hydrogen atoms were included into the model at geometrically calculated 
positions and refined using a riding model. The isotropic displacement parameters of all 
hydrogen atoms were fixed to 1.2 times the U value of the atoms they are linked to (1.5 
times for methyl groups).  
Isoineleganolide A (328) crystallizes in the monoclinic space group P21 with one 
molecule in the asymmetric unit. The coordinates for the hydrogen atom bound to O4 
was located in the difference Fourier synthesis and refined semi-freely with the help of a 
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Table A7.2.2. Crystal Data and Structure Refinement for Isoineleganolide A (328). 
Caltech Identification code  rac03 
CCDC Deposition Number 853379 / 1061011 
Empirical formula  C19 H22 O5 
Formula weight  330.36 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 6.9222(2) Å α= 90°. 
 b = 11.1470(4) Å β= 94.070(2)°. 
 c = 10.4409(4) Å γ = 90°. 
Volume 803.61(5) Å3 
Z 2 
Density (calculated) 1.365 Mg/m3 
Absorption coefficient 0.098 mm-1 
F(000) 352 
Crystal size 0.500 x 0.450 x 0.200 mm3 
Theta range for data collection 1.955 to 36.317°. 
Index ranges –11 ≤ h ≤ 11, –18 ≤ k ≤ 18, –17 ≤ l ≤ 17 
Reflections collected 30117 
Independent reflections 7796 [R(int) = 0.0404] 
Completeness to theta = 25.242° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7475 and 0.6239 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7796 / 2 / 222 
Goodness-of-fit on F2 1.067 
Final R indices [I>2sigma(I)] R1 = 0.0445, wR2 = 0.1109 
R indices (all data) R1 = 0.0538, wR2 = 0.1198 
Absolute structure parameter -0.5(3) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.732 and -0.318 e.Å-3 
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Table A7.2.3.       Atomic coordinates (x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for Isoineleganolide A (328).  U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor.  
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 6780(2) 3526(1) 2529(1) 17(1) 
C(1) 6361(2) 3631(1) 3770(1) 13(1) 
O(2) 6200(2) 2761(1) 4432(1) 18(1) 
C(2) 6086(2) 4958(1) 4084(1) 11(1) 
C(3) 6324(2) 5269(1) 5490(1) 11(1) 
C(4) 4753(2) 4700(1) 6220(1) 14(1) 
C(5) 5248(2) 4650(1) 7666(1) 12(1) 
C(16) 3659(2) 4140(1) 8421(1) 15(1) 
C(17) 1649(2) 4643(2) 8156(2) 23(1) 
C(18) 4057(3) 3309(2) 9322(2) 21(1) 
C(6) 5752(2) 5923(1) 8097(1) 14(1) 
C(7) 7361(2) 6450(1) 7385(1) 14(1) 
O(3) 8395(2) 7238(1) 7898(1) 22(1) 
C(8) 7629(2) 6048(1) 6053(1) 12(1) 
C(9) 9282(2) 6681(1) 5467(2) 16(1) 
C(10) 10375(2) 6022(1) 4484(1) 13(1) 
O(5) 10127(1) 4727(1) 4366(1) 13(1) 
C(11) 9411(2) 5510(1) 3334(1) 11(1) 
C(12) 10337(2) 5381(1) 2046(1) 13(1) 
O(4) 12121(2) 4754(1) 2164(1) 18(1) 
C(19) 10782(3) 6615(2) 1521(2) 25(1) 
C(13) 8747(2) 4724(2) 1184(1) 18(1) 
C(14) 6917(2) 4701(2) 1921(1) 14(1) 
C(15) 7241(2) 5555(1) 3068(1) 12(1) 
________________________________________________________________________________ 
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Table A7.2.4.      Bond lengths [Å] and angles [°] for Isoineleganolide A (328). 
_____________________________________________________  
O(1)-C(1)  1.3531(18) 
O(1)-C(14)  1.462(2) 
C(1)-O(2)  1.2007(19) 
C(1)-C(2)  1.5291(19) 
C(2)-C(3)  1.5070(18) 
C(2)-C(15)  1.5255(19) 
C(2)-H(2)  1.0000 
C(3)-C(8)  1.3565(18) 
C(3)-C(4)  1.5109(19) 
C(4)-C(5)  1.5248(19) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-C(16)  1.509(2) 
C(5)-C(6)  1.522(2) 
C(5)-H(5)  1.0000 
C(16)-C(18)  1.335(2) 
C(16)-C(17)  1.508(2) 
C(17)-H(17A)  0.9800 
C(17)-H(17B)  0.9800 
C(17)-H(17C)  0.9800 
C(18)-H(18A)  0.9500 
C(18)-H(18B)  0.9500 
C(6)-C(7)  1.502(2) 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(7)-O(3)  1.2318(18) 
C(7)-C(8)  1.485(2) 
C(8)-C(9)  1.511(2) 
C(9)-C(10)  1.508(2) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(10)-C(11)  1.4490(19) 
C(10)-O(5)  1.4582(18) 
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Table A7.2.4. (cont’d) 
C(10)-H(10)  1.0000 
O(5)-C(11)  1.4458(17) 
C(11)-C(15)  1.5093(19) 
C(11)-C(12)  1.5377(19) 
C(12)-O(4)  1.4163(18) 
C(12)-C(19)  1.521(2) 
C(12)-C(13)  1.555(2) 
O(4)-H(4O)  0.83(2) 
C(19)-H(19A)  0.9800 
C(19)-H(19B)  0.9800 
C(19)-H(19C)  0.9800 
C(13)-C(14)  1.528(2) 
C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 
C(14)-C(15)  1.534(2) 
C(14)-H(14)  1.0000 
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Symmetry transformations used to generate equivalent atoms:  
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Table A7.2.5.  Anisotropic displacement parameters  (Å2x103) for Isoineleganolide A (328).  The 
anisotropic displacement factor exponent takes the form: -2π2[ h2a*2U11  + ... + 2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 17(1)  16(1) 18(1)  -5(1) 3(1)  -2(1) 
C(1) 8(1)  13(1) 17(1)  -3(1) 0(1)  -2(1) 
O(2) 16(1)  11(1) 26(1)  0(1) 2(1)  -1(1) 
C(2) 7(1)  12(1) 13(1)  -1(1) 0(1)  0(1) 
C(3) 9(1)  10(1) 13(1)  -1(1) 0(1)  1(1) 
C(4) 12(1)  16(1) 14(1)  -1(1) 1(1)  -4(1) 
C(5) 12(1)  10(1) 14(1)  0(1) 1(1)  1(1) 
C(16) 16(1)  13(1) 16(1)  0(1) 3(1)  0(1) 
C(17) 15(1)  23(1) 31(1)  4(1) 8(1)  3(1) 
C(18) 24(1)  18(1) 20(1)  4(1) 3(1)  -2(1) 
C(6) 16(1)  11(1) 15(1)  -1(1) 1(1)  1(1) 
C(7) 13(1)  12(1) 17(1)  -3(1) -1(1)  0(1) 
O(3) 22(1)  19(1) 24(1)  -9(1) 3(1)  -7(1) 
C(8) 11(1)  9(1) 15(1)  -1(1) 1(1)  0(1) 
C(9) 15(1)  12(1) 20(1)  -3(1) 4(1)  -5(1) 
C(10) 9(1)  11(1) 20(1)  -1(1) 0(1)  -1(1) 
O(5) 11(1)  10(1) 18(1)  1(1) -2(1)  1(1) 
C(11) 8(1)  10(1) 16(1)  1(1) 0(1)  0(1) 
C(12) 9(1)  14(1) 17(1)  1(1) 2(1)  1(1) 
O(4) 8(1)  19(1) 25(1)  -3(1) 1(1)  2(1) 
C(19) 30(1)  17(1) 29(1)  5(1) 10(1)  -1(1) 
C(13) 10(1)  28(1) 15(1)  -2(1) 1(1)  1(1) 
C(14) 9(1)  20(1) 14(1)  -1(1) 0(1)  0(1) 
C(15) 8(1)  13(1) 14(1)  1(1) 0(1)  2(1) 
______________________________________________________________________________ 
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Table A7.2.6.      Hydrogen coordinates (x104) and isotropic  displacement parameters (Å2x103)  
for Isoineleganolide A (328). 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 4698 5133 3818 13 
H(4A) 4519 3874 5897 17 
H(4B) 3539 5160 6051 17 
H(5) 6428 4140 7829 15 
H(17A) 792 4315 8777 34 
H(17B) 1155 4422 7285 34 
H(17C) 1692 5519 8233 34 
H(18A) 3058 3018 9819 25 
H(18B) 5338 3009 9467 25 
H(6A) 4587 6435 7960 17 
H(6B) 6141 5920 9028 17 
H(9A) 8762 7428 5061 19 
H(9B) 10228 6922 6176 19 
H(10) 11720 6319 4387 16 
H(4O) 11890(40) 4050(20) 2350(30) 26 
H(19A) 11784 7003 2089 37 
H(19B) 9605 7106 1475 37 
H(19C) 11245 6532 660 37 
H(13A) 8498 5155 360 21 
H(13B) 9165 3896 999 21 
H(14) 5727 4906 1364 17 
H(15) 6769 6385 2859 14 
________________________________________________________________________________ 
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Symmetry transformations used to generate equivalent atoms:  
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Table A7.2.8.      Hydrogen bonds for Isoineleganolide A (328)  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 C(2)-H(2)...O(4)#1 1.00 2.43 3.2893(17) 143.6 
 C(6)-H(6A)...O(1)#2 0.99 2.55 3.4282(18) 147.3 
 C(10)-H(10)...O(2)#3 1.00 2.43 3.2055(18) 133.5 
 O(4)-H(4O)...O(3)#4 0.83(2) 2.04(2) 2.8276(19) 158(3) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 x-1,y,z    #2 -x+1,y+1/2,-z+1    #3 -x+2,y+1/2,-z+1       
#4 -x+2,y-1/2,-z+1       
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 A7.3   X-Ray Crystal Structure Analysis of Bromide 346 
 
Contents 
Table A7.3.1. Experimental Details 
Table A7.3.2. Crystal Data 
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Table A7.3.4. Full Bond Distances and Angles 
Table A7.3.5. Anisotropic Displacement Parameters 
Table A7.3.6. Hydrogen Atomic Coordinates 
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Table A7.3.1. Experimental Details for X-Ray Structure Determination of Bromide 346. 
Low-temperature diffraction data (φ-and ω-scans) were collected on a Bruker AXS 
KAPPA APEX II diffractometer coupled to a APEX II CCD detector with graphite 
monochromated Mo Kα radiation (λ = 0.71073 Å) for the structure of bromide 346. The 
structure was solved by direct methods using SHELXS1 and refined against F2 on all data 
by full-matrix least squares with SHELXL-20142 using established refinement 
techniques.3 All non-hydrogen atoms were refined anisotropically. Unless otherwise 
noted, all hydrogen atoms were included into the model at geometrically calculated 
positions and refined using a riding model. The isotropic displacement parameters of all 
hydrogen atoms were fixed to 1.2 times the U value of the atoms they are linked to (1.5 
times for methyl groups).  
Bromide 346 crystallizes in the orthorhombic space group P212121 with one 
molecule in the asymmetric unit. The coordinates for the hydrogen atom bound to O4 
was located in the difference Fourier synthesis and refined semi-freely with the help of a 
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Table A7.3.2. Crystal Data and Structure Refinement for Bromide 346. 
Caltech Identification code  rac10 
CCDC Deposition Number 1061013 
Empirical formula  C19 H23 Br O5 
Formula weight  411.28 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 7.6137(4) Å α= 90°. 
 b = 9.3584(5) Å β= 90°. 
 c = 24.1592(13) Å γ = 90°. 
Volume 1721.39(16) Å3 
Z 4 
Density (calculated) 1.587 Mg/m3 
Absorption coefficient 2.416 mm-1 
F(000) 848 
Crystal size 0.500 x 0.450 x 0.100 mm3 
Theta range for data collection 2.334 to 36.318°. 
Index ranges –12 ≤ h ≤ 12, –15 ≤ k ≤ 14, –39 ≤ l ≤ 40 
Reflections collected 51998 
Independent reflections 8272 [R(int) = 0.0380] 
Completeness to theta = 25.242° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7478 and 0.5973 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8272 / 1 / 231 
Goodness-of-fit on F2 1.035 
Final R indices [I>2sigma(I)] R1 = 0.0251, wR2 = 0.0613 
R indices (all data) R1 = 0.0297, wR2 = 0.0625 
Absolute structure parameter 0.014(2) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.746 and -0.367 e.Å-3 
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Table A7.3.3.       Atomic coordinates (x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for Bromide 346.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor.  
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 6345(1) 6209(1) 7159(1) 14(1) 
C(1) 4823(2) 6108(2) 6871(1) 11(1) 
O(2) 3840(2) 7103(1) 6827(1) 16(1) 
C(2) 4583(2) 4619(1) 6642(1) 10(1) 
C(3) 5114(2) 4473(2) 6017(1) 8(1) 
O(5) 6928(1) 4038(1) 6041(1) 8(1) 
C(4) 5024(2) 5837(2) 5681(1) 10(1) 
C(5) 5590(2) 5618(2) 5077(1) 11(1) 
C(6) 4489(2) 4411(2) 4820(1) 13(1) 
C(7) 4584(2) 3064(2) 5155(1) 12(1) 
O(3) 5000(2) 1919(1) 4955(1) 19(1) 
C(8) 4104(2) 3212(2) 5760(1) 10(1) 
C(9) 4411(2) 1846(2) 6093(1) 12(1) 
C(10) 6347(2) 1653(1) 6251(1) 11(1) 
Br(1) 6456(1) -42(1) 6729(1) 19(1) 
C(11) 7078(2) 3035(1) 6497(1) 8(1) 
C(12) 9005(2) 3218(2) 6685(1) 11(1) 
O(4) 10208(1) 3067(1) 6239(1) 14(1) 
C(13) 8951(2) 4740(2) 6926(1) 14(1) 
C(14) 7176(2) 4824(2) 7226(1) 12(1) 
C(15) 5948(2) 3720(2) 6947(1) 10(1) 
C(16) 5502(2) 6970(2) 4728(1) 15(1) 
C(17) 5870(2) 6771(2) 4117(1) 22(1) 
C(18) 5173(2) 8249(2) 4935(1) 20(1) 
C(19) 9621(2) 2179(2) 7128(1) 18(1) 
________________________________________________________________________________ 
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Table A7.3.4.      Bond lengths [Å] and angles [°] for Bromide 346. 
_____________________________________________________  
O(1)-C(1)  1.3544(17) 
O(1)-C(14)  1.4514(18) 
C(1)-O(2)  1.1989(18) 
C(1)-C(2)  1.5115(19) 
C(2)-C(15)  1.5264(19) 
C(2)-C(3)  1.5679(18) 
C(2)-H(2)  1.0000 
C(3)-O(5)  1.4409(14) 
C(3)-C(4)  1.515(2) 
C(3)-C(8)  1.5388(18) 
O(5)-C(11)  1.4519(16) 
C(4)-C(5)  1.5342(18) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-C(16)  1.522(2) 
C(5)-C(6)  1.538(2) 
C(5)-H(5)  1.0000 
C(6)-C(7)  1.500(2) 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(7)-O(3)  1.2170(17) 
C(7)-C(8)  1.5142(19) 
C(8)-C(9)  1.527(2) 
C(8)-H(8)  1.0000 
C(9)-C(10)  1.5334(19) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(10)-C(11)  1.5275(19) 
C(10)-Br(1)  1.9635(13) 
C(10)-H(10)  1.0000 
C(11)-C(15)  1.5273(18) 
C(11)-C(12)  1.5456(17) 
C(12)-O(4)  1.4205(16) 
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Table A7.3.4. (cont’d) 
C(12)-C(19)  1.520(2) 
C(12)-C(13)  1.539(2) 
O(4)-H(4O)  0.893(18) 
C(13)-C(14)  1.5356(18) 
C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 
C(14)-C(15)  1.5484(19) 
C(14)-H(14)  1.0000 
C(15)-H(15)  1.0000 
C(16)-C(18)  1.322(2) 
C(16)-C(17)  1.512(2) 
C(17)-H(17A)  0.9800 
C(17)-H(17B)  0.9800 
C(17)-H(17C)  0.9800 
C(18)-H(18A)  0.9500 
C(18)-H(18B)  0.9500 
C(19)-H(19A)  0.9800 
C(19)-H(19B)  0.9800 
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Symmetry transformations used to generate equivalent atoms:  
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Table A7.3.5.  Anisotropic displacement parameters  (Å2x103) for Bromide 346.  The anisotropic 
displacement factor exponent takes the form: -2π2[ h2a*2U11  + ... + 2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 15(1)  12(1) 13(1)  -4(1) -2(1)  0(1) 
C(1) 14(1)  12(1) 8(1)  -1(1) 3(1)  -1(1) 
O(2) 21(1)  14(1) 13(1)  -2(1) 1(1)  5(1) 
C(2) 10(1)  10(1) 9(1)  -1(1) 2(1)  0(1) 
C(3) 7(1)  9(1) 9(1)  -2(1) 1(1)  0(1) 
O(5) 7(1)  9(1) 8(1)  2(1) 1(1)  0(1) 
C(4) 12(1)  10(1) 10(1)  -1(1) -2(1)  0(1) 
C(5) 11(1)  12(1) 9(1)  1(1) -1(1)  0(1) 
C(6) 15(1)  15(1) 10(1)  -1(1) -2(1)  -1(1) 
C(7) 11(1)  13(1) 11(1)  -3(1) 0(1)  -2(1) 
O(3) 28(1)  15(1) 14(1)  -5(1) 2(1)  1(1) 
C(8) 9(1)  12(1) 11(1)  -2(1) 1(1)  -2(1) 
C(9) 13(1)  9(1) 14(1)  -2(1) 3(1)  -4(1) 
C(10) 14(1)  9(1) 11(1)  0(1) 5(1)  -1(1) 
Br(1) 27(1)  9(1) 22(1)  5(1) 8(1)  2(1) 
C(11) 10(1)  8(1) 8(1)  1(1) 2(1)  1(1) 
C(12) 10(1)  15(1) 8(1)  2(1) 1(1)  2(1) 
O(4) 9(1)  23(1) 10(1)  1(1) 2(1)  2(1) 
C(13) 11(1)  16(1) 13(1)  -3(1) 0(1)  -2(1) 
C(14) 13(1)  13(1) 10(1)  -2(1) 0(1)  1(1) 
C(15) 11(1)  10(1) 8(1)  0(1) 2(1)  0(1) 
C(16) 12(1)  16(1) 15(1)  5(1) -2(1)  -1(1) 
C(17) 28(1)  25(1) 13(1)  6(1) -1(1)  -5(1) 
C(18) 21(1)  16(1) 24(1)  7(1) 3(1)  3(1) 
C(19) 17(1)  23(1) 14(1)  6(1) -1(1)  6(1) 
______________________________________________________________________________ 
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Table A7.3.6.      Hydrogen coordinates (x104) and isotropic  displacement parameters (Å2x103)  
for Bromide 346. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 3367 4256 6709 12 
H(4A) 5792 6564 5854 13 
H(4B) 3806 6206 5688 13 
H(5) 6841 5293 5081 13 
H(6A) 3250 4723 4792 16 
H(6B) 4919 4217 4440 16 
H(8) 2823 3441 5781 13 
H(9A) 4023 1014 5872 15 
H(9B) 3691 1877 6434 15 
H(10) 7020 1439 5905 14 
H(4O) 9730(30) 3450(20) 5936(8) 21 
H(13A) 9934 4894 7188 16 
H(13B) 9022 5464 6628 16 
H(14) 7323 4596 7628 14 
H(15) 5427 3016 7211 11 
H(17A) 4884 6268 3944 33 
H(17B) 6946 6209 4071 33 
H(17C) 6019 7708 3942 33 
H(18A) 5165 9063 4700 24 
H(18B) 4944 8356 5320 24 
H(19A) 9719 1219 6968 27 
H(19B) 8772 2164 7432 27 
H(19C) 10770 2482 7268 27 
________________________________________________________________________________ 
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Symmetry transformations used to generate equivalent atoms:  
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Table A7.3.8.      Hydrogen bonds for Bromide 346  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 C(8)-H(8)...O(4)#1 1.00 2.31 3.1874(15) 146.5 
 O(4)-H(4O)...O(5) 0.893(18) 2.22(2) 2.7004(14) 113.4(17) 
 O(4)-H(4O)...O(3)#2 0.893(18) 2.19(2) 2.8908(16) 135.0(19) 
 C(15)-H(15)...O(1)#3 1.00 2.65 3.6389(17) 172.5 
 C(15)-H(15)...O(2)#3 1.00 2.54 3.3305(17) 136.0 
 C(19)-H(19A)...Br(1) 0.98 2.81 3.3248(17) 113.5 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 x-1,y,z    #2 x+1/2,-y+1/2,-z+1    #3 -x+1,y-1/2,-z+3/2       
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 A7.4   X-Ray Crystal Structure Analysis of Diketone 347 
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Table A7.4.1. Experimental Details for X-Ray Structure Determination of Diketone 347. 
Low-temperature diffraction data (φ-and ω-scans) were collected on a Bruker AXS 
KAPPA APEX II diffractometer coupled to a APEX II CCD detector with graphite 
monochromated Mo Kα radiation (λ = 0.71073 Å) for the structure of diketone 347. The 
structure was solved by direct methods using SHELXS1 and refined against F2 on all data 
by full-matrix least squares with SHELXL-20142 using established refinement 
techniques.3 All non-hydrogen atoms were refined anisotropically. Unless otherwise 
noted, all hydrogen atoms were included into the model at geometrically calculated 
positions and refined using a riding model. The isotropic displacement parameters of all 
hydrogen atoms were fixed to 1.2 times the U value of the atoms they are linked to (1.5 
times for methyl groups).  
Diketone 347 crystallizes in the orthorhombic space group P212121 with one 
molecule in the asymmetric unit. The coordinates for the hydrogen atom bound to O4 
was located in the difference Fourier synthesis and refined semi-freely with the help of a 
restraint on the O-H distance (0.84(4) Å). The chirality of the molecule cannot be reliably 
determined from the diffraction data. The molecule could be the wrong enantiomer or a 
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Table A7.4.2. Crystal Data and Structure Refinement for Diketone 347. 
Caltech Identification code  rac06 
CCDC Deposition Number 1061012 
Empirical formula  C19 H22 O6 
Formula weight  346.36 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 8.2576(3) Å α= 90°. 
 b = 10.4049(4) Å β= 90°. 
 c = 19.0995(8) Å γ = 90°. 
Volume 1641.02(11) Å3 
Z 4 
Density (calculated) 1.402 Mg/m3 
Absorption coefficient 0.104 mm-1 
F(000) 736 
Crystal size 0.450 x 0.350 x 0.100 mm3 
Theta range for data collection 2.133 to 43.738°. 
Index ranges –16 ≤ h ≤ 14, –20 ≤ k ≤ 18, –37 ≤ l ≤ 37 
Reflections collected 85501 
Independent reflections 12633 [R(int) = 0.0489] 
Completeness to theta = 25.242° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7487 and 0.7039 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 12633 / 1 / 231 
Goodness-of-fit on F2 1.060 
Final R indices [I>2sigma(I)] R1 = 0.0442, wR2 = 0.1107 
R indices (all data) R1 = 0.0613, wR2 = 0.1176 
Absolute structure parameter 0.35(16) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.468 and -0.291 e.Å-3 
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Table A7.4.3.       Atomic coordinates (x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for Diketone 347.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor.  
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 10548(1) 6025(1) 1279(1) 16(1) 
C(1) 9704(1) 5326(1) 1747(1) 13(1) 
O(2) 10382(1) 4599(1) 2142(1) 18(1) 
C(2) 7892(1) 5564(1) 1681(1) 11(1) 
C(3) 7159(1) 6320(1) 2311(1) 10(1) 
O(5) 7376(1) 7644(1) 2113(1) 10(1) 
C(4) 8008(1) 6121(1) 3008(1) 12(1) 
C(5) 7310(1) 6968(1) 3590(1) 13(1) 
C(16) 8277(1) 6778(1) 4253(1) 14(1) 
C(17) 9841(2) 7514(1) 4288(1) 22(1) 
C(18) 7820(2) 6000(1) 4772(1) 19(1) 
C(6) 5484(1) 6699(1) 3661(1) 16(1) 
C(7) 4701(1) 6954(1) 2966(1) 14(1) 
O(3) 3728(1) 7814(1) 2870(1) 22(1) 
C(8) 5303(1) 6116(1) 2362(1) 12(1) 
C(9) 4451(1) 6481(1) 1677(1) 14(1) 
C(10) 5157(1) 7655(1) 1315(1) 12(1) 
O(6) 4336(1) 8392(1) 971(1) 20(1) 
C(11) 6996(1) 7729(1) 1379(1) 10(1) 
C(12) 8007(1) 8868(1) 1102(1) 12(1) 
O(4) 7848(1) 9969(1) 1533(1) 15(1) 
C(19) 7572(2) 9275(1) 359(1) 17(1) 
C(13) 9732(1) 8287(1) 1121(1) 14(1) 
C(14) 9514(1) 6892(1) 888(1) 13(1) 
C(15) 7753(1) 6507(1) 1067(1) 10(1) 
________________________________________________________________________________ 
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Table A7.4.4.      Bond lengths [Å] and angles [°] for Diketone 347. 
_____________________________________________________  
O(1)-C(1)  1.3464(14) 
O(1)-C(14)  1.4494(13) 
C(1)-O(2)  1.2070(13) 
C(1)-C(2)  1.5217(14) 
C(2)-C(15)  1.5328(13) 
C(2)-C(3)  1.5593(13) 
C(2)-H(2)  1.0000 
C(3)-O(5)  1.4396(12) 
C(3)-C(4)  1.5185(13) 
C(3)-C(8)  1.5501(13) 
O(5)-C(11)  1.4381(11) 
C(4)-C(5)  1.5318(13) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-C(16)  1.5101(15) 
C(5)-C(6)  1.5397(15) 
C(5)-H(5)  1.0000 
C(16)-C(18)  1.3338(15) 
C(16)-C(17)  1.5029(17) 
C(17)-H(17A)  0.9800 
C(17)-H(17B)  0.9800 
C(17)-H(17C)  0.9800 
C(18)-H(18A)  0.9500 
C(18)-H(18B)  0.9500 
C(6)-C(7)  1.5010(16) 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(7)-O(3)  1.2165(14) 
C(7)-C(8)  1.5292(14) 
C(8)-C(9)  1.5326(15) 
C(8)-H(8)  1.0000 
C(9)-C(10)  1.5204(15) 
C(9)-H(9A)  0.9900 
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Table A7.4.4. (cont’d) 
C(9)-H(9B)  0.9900 
C(10)-O(6)  1.2150(13) 
C(10)-C(11)  1.5255(13) 
C(11)-C(15)  1.5379(13) 
C(11)-C(12)  1.5436(13) 
C(12)-O(4)  1.4169(13) 
C(12)-C(19)  1.5238(14) 
C(12)-C(13)  1.5477(14) 
O(4)-H(4O)  0.797(17) 
C(19)-H(19A)  0.9800 
C(19)-H(19B)  0.9800 
C(19)-H(19C)  0.9800 
C(13)-C(14)  1.5296(15) 
C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 
C(14)-C(15)  1.5462(14) 
C(14)-H(14)  1.0000 
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Symmetry transformations used to generate equivalent atoms:  
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Table A7.4.5.  Anisotropic displacement parameters  (Å2x103) for Diketone 347.  The anisotropic 
displacement factor exponent takes the form: -2π2[ h2a*2U11  + ... + 2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 10(1)  18(1) 19(1)  1(1) 0(1)  3(1) 
C(1) 12(1)  13(1) 12(1)  -3(1) -1(1)  3(1) 
O(2) 19(1)  20(1) 16(1)  0(1) -3(1)  9(1) 
C(2) 11(1)  10(1) 11(1)  -2(1) -1(1)  1(1) 
C(3) 10(1)  9(1) 10(1)  -1(1) 0(1)  0(1) 
O(5) 11(1)  9(1) 10(1)  0(1) -1(1)  -1(1) 
C(4) 13(1)  13(1) 10(1)  -1(1) -1(1)  2(1) 
C(5) 15(1)  12(1) 11(1)  -1(1) 1(1)  0(1) 
C(16) 20(1)  12(1) 10(1)  -1(1) 1(1)  0(1) 
C(17) 28(1)  23(1) 15(1)  0(1) -5(1)  -8(1) 
C(18) 26(1)  18(1) 14(1)  3(1) 1(1)  -1(1) 
C(6) 17(1)  16(1) 14(1)  -1(1) 4(1)  1(1) 
C(7) 12(1)  12(1) 18(1)  0(1) 4(1)  0(1) 
O(3) 21(1)  18(1) 27(1)  0(1) 3(1)  9(1) 
C(8) 10(1)  11(1) 15(1)  0(1) 1(1)  -1(1) 
C(9) 9(1)  16(1) 18(1)  1(1) -3(1)  -3(1) 
C(10) 10(1)  13(1) 14(1)  0(1) -2(1)  1(1) 
O(6) 14(1)  21(1) 26(1)  6(1) -4(1)  2(1) 
C(11) 9(1)  10(1) 10(1)  0(1) -2(1)  -1(1) 
C(12) 12(1)  11(1) 12(1)  0(1) -1(1)  -2(1) 
O(4) 18(1)  11(1) 15(1)  -1(1) -2(1)  -2(1) 
C(19) 19(1)  18(1) 13(1)  4(1) -2(1)  -2(1) 
C(13) 10(1)  16(1) 16(1)  1(1) 0(1)  -2(1) 
C(14) 11(1)  16(1) 12(1)  0(1) 1(1)  1(1) 
C(15) 10(1)  11(1) 10(1)  -2(1) -2(1)  0(1) 
______________________________________________________________________________ 
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Table A7.4.6.      Hydrogen coordinates (x104) and isotropic  displacement parameters (Å2x103)  
for Diketone 347. 
 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 7285 4750 1588 13 
H(4A) 9174 6316 2952 14 
H(4B) 7909 5208 3147 14 
H(5) 7440 7884 3443 15 
H(17A) 10447 7253 4705 33 
H(17B) 9609 8436 4311 33 
H(17C) 10487 7331 3869 33 
H(18A) 8487 5902 5174 23 
H(18B) 6826 5543 4740 23 
H(6A) 5304 5794 3801 19 
H(6B) 5007 7264 4024 19 
H(8) 5077 5194 2471 14 
H(9A) 4510 5741 1352 17 
H(9B) 3293 6644 1777 17 
H(4O) 8170(20) 9790(20) 1914(10) 22 
H(19A) 6468 9622 352 25 
H(19B) 7635 8529 47 25 
H(19C) 8332 9937 199 25 
H(13A) 10463 8753 798 16 
H(13B) 10188 8329 1600 16 
H(14) 9716 6805 374 15 
H(15) 7139 6154 659 12 
________________________________________________________________________________ 
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Symmetry transformations used to generate equivalent atoms:  
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Table A7.4.8.      Hydrogen bonds for Diketone 347  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 C(2)-H(2)...O(3)#1 1.00 2.41 3.2731(13) 143.6 
 C(6)-H(6A)...O(6)#1 0.99 2.55 3.5149(15) 163.6 
 C(9)-H(9B)...O(1)#2 0.99 2.54 3.3451(13) 138.2 
 O(4)-H(4O)...O(2)#3 0.797(17) 2.171(17) 2.9477(12) 164.6(19) 
 C(19)-H(19A)...O(6) 0.98 2.48 3.0578(15) 117.7 
 C(14)-H(14)...O(6)#4 1.00 2.60 3.5664(14) 163.4 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,y-1/2,-z+1/2    #2 x-1,y,z    #3 -x+2,y+1/2,-z+1/2       
#4 x+1/2,-y+3/2,-z       
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 A7.5   X-Ray Crystal Structure Analysis of Hemiketal 350 
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Table A7.5.1. Experimental Details for X-Ray Structure Determination of Hemiketal 350. 
Low-temperature diffraction data (φ-and ω-scans) were collected on a Bruker AXS 
KAPPA APEX II diffractometer coupled to a APEX II CCD detector with graphite 
monochromated Mo Kα radiation (λ = 0.71073 Å) for the structure of hemiketal 350 and 
on a Bruker AXS D8 VENTURE KAPPA diffractometer coupled to a PHOTON 100 
CMOS detector with Cu Kα radiation (λ = 1.54178 Å) from an IµS micro-source for the 
structure of compound P15149 and P15156. The structure was solved by direct methods 
using SHELXS1 and refined against F2 on all data by full-matrix least squares with 
SHELXL-20142 using established refinement techniques.3 All non-hydrogen atoms were 
refined anisotropically. Unless otherwise noted, all hydrogen atoms were included into 
the model at geometrically calculated positions and refined using a riding model. The 
isotropic displacement parameters of all hydrogen atoms were fixed to 1.2 times the U 
value of the atoms they are linked to (1.5 times for methyl groups).  
Hemiketal 350 crystallizes in the orthorhombic space group P212121 with one 
molecule in the asymmetric unit. The coordinates for all hydrogen atoms were located in 
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Table A7.5.2. Crystal Data and Structure Refinement for Hemiketal 350. 
Caltech Identification code  p15156cu 
CCDC Deposition Number 1061009 
Empirical formula  C19 H24 O6 
Formula weight  348.38 
Temperature  100 K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 8.2463(2) Å α= 90° 
 b = 10.3683(3) Å β= 90° 
 c = 19.3151(5) Å γ = 90° 
Volume 1651.44(8) Å3 
Z 4 
Density (calculated) 1.401 Mg/m3 
Absorption coefficient 0.859 mm-1 
F(000) 744 
Crystal size 0.16 x 0.09 x 0.08 mm3 
Theta range for data collection 4.578 to 79.097°. 
Index ranges –10 ≤ h ≤ 10, –13 ≤ k ≤ 13, –24 ≤ l ≤ 24 
Reflections collected 40519 
Independent reflections 3557 [R(int) = 0.0399] 
Completeness to theta = 67.000° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.0000 and 0.8788 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3557 / 0 / 322 
Goodness-of-fit on F2 1.070 
Final R indices [I>2sigma(I)] R1 = 0.0252, wR2 = 0.0607 
R indices (all data) R1 = 0.0268, wR2 = 0.0619 
Absolute structure parameter 0.03(4) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.170 and -0.183 e.Å-3 
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Table A7.5.3.       Atomic coordinates (x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for Hemiketal 350.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor.  
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 23254(14) 24829(11) 25005(6) 192(2) 
O(2) 33537(15) 14564(11) 34069(6) 209(3) 
O(3) 100576(16) 50516(12) 31547(7) 248(3) 
O(4) 42360(16) 11573(11) 13350(6) 193(2) 
O(5) 67107(13) 18290(10) 24612(5) 128(2) 
O(6) 75229(14) 16546(12) 13315(6) 180(2) 
C(1) 34786(19) 23022(15) 29832(8) 161(3) 
C(2) 48069(19) 33135(15) 29051(8) 144(3) 
C(3) 65329(19) 27942(14) 29950(7) 133(3) 
C(4) 68360(20) 21649(15) 36942(8) 158(3) 
C(5) 86350(20) 19583(16) 38463(8) 165(3) 
C(6) 94700(20) 32790(17) 38913(9) 202(3) 
C(7) 91720(20) 41371(16) 32757(8) 168(3) 
C(8) 77580(20) 38877(15) 27971(8) 148(3) 
C(9) 83759(19) 34565(16) 20787(8) 164(3) 
C(10) 70447(19) 25448(15) 18354(7) 139(3) 
C(11) 55282(19) 32674(15) 15786(8) 140(3) 
C(12) 43210(20) 24883(15) 11226(8) 161(3) 
C(13) 26650(20) 30857(16) 12851(9) 194(3) 
C(14) 27380(20) 35427(16) 20304(9) 181(3) 
C(15) 45172(19) 38751(14) 21820(8) 146(3) 
C(16) 89610(20) 11948(16) 45052(8) 190(3) 
C(17) 106770(30) 7743(19) 46225(10) 250(4) 
C(18) 77930(30) 8900(20) 49571(9) 270(4) 
C(19) 47170(20) 25661(18) 3518(9) 218(3) 
________________________________________________________________________________ 
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Table A7.5.4.      Bond lengths [Å] and angles [°] for Hemiketal 350. 
_____________________________________________________  
O(1)-C(1)  1.345(2) 
O(1)-C(14)  1.466(2) 
O(2)-C(1)  1.204(2) 
O(3)-C(7)  1.220(2) 
O(4)-H(4)  0.86(3) 
O(4)-C(12)  1.4414(18) 
O(5)-C(3)  1.4443(17) 
O(5)-C(10)  1.4448(18) 
O(6)-H(6)  0.88(3) 
O(6)-C(10)  1.3982(18) 
C(1)-C(2)  1.524(2) 
C(2)-H(2)  0.97(2) 
C(2)-C(3)  1.532(2) 
C(2)-C(15)  1.532(2) 
C(3)-C(4)  1.520(2) 
C(3)-C(8)  1.566(2) 
C(4)-H(4A)  0.98(2) 
C(4)-H(4B)  0.97(2) 
C(4)-C(5)  1.528(2) 
C(5)-H(5)  1.00(2) 
C(5)-C(6)  1.535(2) 
C(5)-C(16)  1.523(2) 
C(6)-H(6A)  0.99(3) 
C(6)-H(6B)  0.96(3) 
C(6)-C(7)  1.505(2) 
C(7)-C(8)  1.510(2) 
C(8)-H(8)  1.01(2) 
C(8)-C(9)  1.544(2) 
C(9)-H(9A)  0.94(2) 
C(9)-H(9B)  0.96(2) 
C(9)-C(10)  1.523(2) 
C(10)-C(11)  1.540(2) 
C(11)-H(11)  0.97(2) 
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Table A7.5.4. (cont’d) 
C(11)-C(12)  1.556(2) 
C(11)-C(15)  1.565(2) 
C(12)-C(13)  1.531(2) 
C(12)-C(19)  1.526(2) 
C(13)-H(13A)  1.00(2) 
C(13)-H(13B)  1.01(3) 
C(13)-C(14)  1.517(2) 
C(14)-H(14)  0.99(2) 
C(14)-C(15)  1.535(2) 
C(15)-H(15)  0.98(2) 
C(16)-C(17)  1.497(3) 
C(16)-C(18)  1.338(3) 
C(17)-H(17A)  0.98(3) 
C(17)-H(17B)  1.00(3) 
C(17)-H(17C)  0.99(3) 
C(18)-H(18A)  0.97(3) 
C(18)-H(18B)  0.99(3) 
C(19)-H(19A)  1.00(3) 
C(19)-H(19B)  0.97(2) 
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Symmetry transformations used to generate equivalent atoms:  
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Table A7.5.5.  Anisotropic displacement parameters  (Å2x103) for Hemiketal 350.  The anisotropic 
displacement factor exponent takes the form: -2π2[ h2a*2U11  + ... + 2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 128(5)  177(5) 271(6)  6(5) 5(4)  -21(4) 
O(2) 179(6)  197(6) 252(6)  19(5) 52(5)  -36(5) 
O(3) 222(6)  220(6) 303(6)  33(5) -55(5)  -112(5) 
O(4) 199(6)  118(5) 262(6)  16(4) -21(5)  1(5) 
O(5) 152(5)  113(5) 118(4)  -14(4) 9(4)  2(4) 
O(6) 166(5)  232(6) 140(5)  -24(4) 2(4)  80(5) 
C(1) 127(7)  149(7) 207(7)  -50(6) 50(6)  -1(6) 
C(2) 135(7)  116(7) 181(7)  -30(6) 35(6)  -11(6) 
C(3) 136(7)  125(6) 138(6)  -33(5) 18(5)  -20(6) 
C(4) 172(7)  169(7) 134(6)  -10(6) 17(6)  -33(6) 
C(5) 190(7)  183(7) 123(6)  -9(6) 4(6)  -19(6) 
C(6) 199(8)  226(8) 183(7)  -1(6) -43(6)  -58(7) 
C(7) 146(7)  161(7) 197(7)  -35(6) 14(6)  -22(6) 
C(8) 130(7)  136(7) 177(7)  -3(6) 0(6)  -30(6) 
C(9) 122(7)  212(8) 159(7)  38(6) 13(6)  -24(7) 
C(10) 134(7)  158(7) 124(6)  9(6) 15(5)  29(6) 
C(11) 125(7)  121(7) 174(7)  17(6) 1(6)  15(6) 
C(12) 156(7)  126(7) 201(7)  19(6) -31(6)  15(6) 
C(13) 138(7)  177(7) 266(8)  15(7) -45(6)  10(6) 
C(14) 122(7)  144(7) 277(8)  21(6) 9(6)  23(6) 
C(15) 109(7)  100(6) 230(7)  -7(6) 7(6)  20(6) 
C(16) 256(9)  179(7) 134(7)  -28(6) -16(6)  0(7) 
C(17) 276(9)  280(9) 193(8)  38(7) 11(7)  41(8) 
C(18) 308(10)  323(10) 178(8)  56(7) 30(7)  22(8) 
C(19) 241(9)  227(8) 186(7)  18(7) -40(7)  21(7) 
______________________________________________________________________________ 
Appendix 7 – X-Ray Crystallography Reports Relevant to Chapter 3 360 
 
Table A7.5.6.      Hydrogen coordinates (x104) and isotropic  displacement parameters (Å2x103)  
for Hemiketal 350. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(4) 5230(40) 900(30) 1322(13) 38(7) 
H(6) 8360(30) 1210(20) 1486(12) 34(6) 
H(2) 4580(30) 3950(20) 3257(11) 19(5) 
H(4A) 6250(30) 1350(20) 3715(11) 24(5) 
H(4B) 6350(30) 2710(20) 4045(11) 21(5) 
H(5) 9160(30) 1480(20) 3459(10) 19(5) 
H(6A) 9050(30) 3760(20) 4292(13) 36(6) 
H(6B) 10620(30) 3210(20) 3943(12) 28(6) 
H(8) 7220(30) 4750(20) 2755(11) 19(5) 
H(9A) 8530(30) 4150(20) 1771(11) 21(5) 
H(9B) 9350(30) 2960(19) 2130(10) 14(4) 
H(11) 5910(30) 3980(20) 1292(10) 17(5) 
H(13A) 2480(30) 3840(20) 972(11) 18(5) 
H(13B) 1740(30) 2460(20) 1210(12) 33(6) 
H(14) 1970(30) 4250(20) 2137(10) 16(5) 
H(15) 4670(30) 4810(20) 2186(11) 22(5) 
H(17A) 11020(30) 170(30) 4263(14) 43(7) 
H(17B) 10810(30) 340(20) 5083(13) 37(7) 
H(17C) 11460(40) 1500(30) 4620(14) 48(8) 
H(18A) 8080(30) 390(30) 5363(14) 39(7) 
H(18B) 6650(30) 1110(30) 4869(13) 37(7) 
H(19A) 5790(30) 2140(20) 258(12) 32(6) 
H(19B) 4800(30) 3450(20) 190(12) 27(6) 
H(19C) 3830(30) 2130(20) 88(12) 29(6) 
________________________________________________________________________________ 
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Symmetry transformations used to generate equivalent atoms:  
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Table A7.5.8.      Hydrogen bonds for Hemiketal 350  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(4)-H(4)...O(6) 0.86(3) 2.04(3) 2.7591(18) 140(2) 
 O(6)-H(6)...O(3)#1 0.88(3) 1.90(3) 2.7799(17) 172(2) 
 C(2)-H(2)...O(4)#2 0.97(2) 2.61(2) 3.3870(19) 138.0(16) 
 C(4)-H(4A)...O(2) 0.98(2) 2.46(2) 3.015(2) 115.7(16) 
 C(8)-H(8)...O(4)#2 1.01(2) 2.58(2) 3.324(2) 130.9(15) 
 C(9)-H(9B)...O(1)#3 0.96(2) 2.60(2) 3.506(2) 156.9(16) 
 C(15)-H(15)...O(2)#2 0.98(2) 2.62(2) 3.397(2) 136.0(17) 
 C(15)-H(15)...O(5)#2 0.98(2) 2.48(2) 3.2986(18) 141.5(17) 
 C(19)-H(19A)...O(6) 1.00(3) 2.57(2) 3.135(2) 115.5(16) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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Alternative Synthetic Strategies  
Toward Ineleganolide  
 
 
A8.1   Alternative Synthesis of Acid Coupling Partner 
Coupling partner ent-321 was available after three synthetic transformations from 
literature known (R)-(–)-desmethylcarvone ((R)-217).1  In an effort to improve the overall 
transformation of enone (R)-217 to acid ent-321, we sought to improve the synthesis of 
intermediate ester 358.    
Scheme A8.1.1. Synthesis of Acid ent-321 Using Isopropyl Acetate 
 
The ethyl analog of ester 358 could be accessed in 68% yield over two steps form 
enone (R)-217.2  We hypothesized that the introduction of additional steric bulk at the 
ester position would impart greater stability to the substrate and thus improve the 










1. CeCl3 , THF, –78 °C
2. TEMPO•BF4 , CH3CN
   (63% yield, 2 steps)
K2CO3
1:1 MeOH:H2O
(96% yield)(R)-217 358 ent-321
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isolated yield of the intermediate ester 358.   Introduction of increased steric bulk was 
accomplished directly by the 1,2-addition of the lithium enolate of isopropyl acetate into 
(R)-(–)-desmethylcarvone ((R)-(217), Scheme A8.1.1).   Oxidative 1,3-allylic 
transposition of the intermediate tertiary alcohol provided isopropyl ester in 63% yield 
over two steps.   Although the yield was not improved compared to the analogous ethyl 
ester series (see Chapter 3)2 and we ultimately chose not to pursue the syntheses of 
isopropyl ester 358 for the large scale advancement of material, ester 358 could be 
efficiently saponified to provide acid coupling ent-321 partner in 96% yield.   With acid 
coupling partner ent-321 in hand, we were able to advance through the synthetic route 
and explore the reactivity of the tetracyclic core of the norcembranoid diterpenes natural 
products.    
A8.2   Olefin Isomerization of [6,7,5,5]-Tetracyclic Diene 
Advancement toward the norcembranoid diterpene natural products began with an 
evaluation of the reactivity profile of tetracyclic diene 324, the first intermediate 
developed with complete core of the norcembranoid diterpenes.   We wanted to explore 
the potential to isomerize 1,4-diene 324 into the extended conjugated system within 1,3-
diene 359.  This would accomplish the transposition the oxidation state onto C(5) as 
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Table A8.2.1. Attempted Olefin Isomerization 
 
Unfortunately, standard conditions for olefin isomerization failed to produce any 
desired reactivity (Table A8.2.1).  Diene 324 was largely unstable to the reaction 
conditions tested, save the sole addition of thermal energy in toluene (Entry 5).   Under 
these conditions, diene 324 was completely unreactive.  We did find, however, that in the 
presence of palladium dichloride bis(acetonitrile) in benzene at 60 °C, diene 324 
underwent an unexpected isomerization (Scheme A8.2.1).  Rather than isomerizing the 
enone olefin into conjugation, palladium(II) facilitated the transposition of the tertiary 
allylic alcohol into a 1:1 mixture of the secondary alcohol diastereomers 360 and 361, 
forming cycloheptatriene 345 as a byproduct.  The structural assignment of diastereomers 
360 and 361 was accomplished by extensive two-dimensional 1H and 13C NMR studies. 
To our knowledge, this is the first example of the 1,3-transposition of an allylic alcohol 
by palladium(II).  Unfortunately, the unoptimized transformation was low yielding and 
was not pursued further for advancement toward ent-ineleganolide (ent-9) and the 





















Entry Conditions Result a
1 KOt-Bu, THF Decomposition
2 DBU, CHCl3 Decomposition
3 RhCl3•H2O, K2CO3, EtOH, 60 °C Decomposition
4 HCl, Et2O Decomposition
5 toluene, 80 °C No reaction
a: All results assessed by crude 1H NMR
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Scheme A8.2.1. 1,3-Allylic Transposition of Alcohol 324 
 
A8.3   Redox Advancement of [6,7,5,5]-Tetracyclic Diene 
We briefly explored the potential to advance diene core 324 by redox manipulation.   
Conjugate reduction of enone 324 using dimethylphenylsilane in the presence of 
Wilkinson’s catalyst failed to produce any isolable product, resulting in complete 
decomposition of the staring material (Scheme A8.3.1).   Attempted oxidative 
advancement of diene 324 was met with similar results (Scheme A8.3.2).   Although the 
double allylic C–H bonds appear poised for facile C–H oxidation, the use of typically 
efficient palladium-catalyzed C–H acetoxylation conditions caused decomposition of the 
substrate.3  
Scheme A8.3.1. Attempted 1,4-Reduction of Enone 324 with Wilkinson’s Catalyst 
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A8.4   Olefin Isomerization of Isoineleganolide A (328) 
Without successfully developing any productive alternative advancement 
procedures from diene 324 toward the norcembranoid diterpenes, we turned our attention 
to the exploration of the reactivity of isoineleganolide A (328, Scheme A8.4.1).   We 
began by applying the isomerization conditions that had proven productive for diene 324 
to see if they would induce the desired isomerization of enone 328 in the absence of the 
allylic alcohol moiety.   Unfortunately, epoxide 328 underwent a slow decomposition 
under the reaction conditions, failing to provide any isolable products. 
Scheme A8.4.1. Attempted Olefin Isomerization of Enone 328 
 
 
A8.5   Nucleophilic Epoxide Opening of Isoineleganolide A (328) 
We envisioned advancing isoineleganolide A (328) instead by the nucleophilic 
opening of the epoxide moiety.   While the opening of the strained heterocycle with a 
sulfur nucleophile failed (Scheme A8.5.1),4 the opening of epoxide 328 with an oxygen 
nucleophile was indeed successful, furnishing furan 366 on small scale.5  Unfortunately, 
the efficacy of the reaction could not be maintained as scale increased, thus we sought 
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Scheme A8.5.1. Nucleophilic Opening of Epoxide 328 
 
During our exploration of the potential of isoineleganolide A (328) to undergo an 
epoxyketo rearrangement, we discovered that halogenated Lewis acids would regularly 
accomplish the nucleophilic opening of the epoxide moiety with their halogen 
counterion.6  While we used the product of nucleophilic opening by bromide for our 
optimize synthetic route, we found that epoxide 328 could smoothly be opened by Lewis 
acids with other halogen counterions.   Both MgCl2 and YbCl3 under the same reaction 
conditions furnished chloride 367 (Scheme A8.5.2.A).   This reactivity could be 
duplicated using TMSCl in the presence of zinc metal to furnish the identical product 
(367, Scheme A8.5.2.B).7  The structural assignment of chloride 367 was unambiguously 
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Scheme A8.5.2. Nucleophilic Opening of Epoxide 328 with Halogen Ions 
 
The opening of epoxide 328 could also be accomplished with MgI2 in a mixed 
toluene and THF solvent system, providing iodide 368 in 45% yield (Scheme A8.5.2.C).   
Surprisingly, the formation of the analogous fluoride 369 was achieved by the exposure 
of epoxide 328 to superstoichiometric BF3•Et2O in THF at cold temperatures (Scheme 
A8.5.2.D).   We were able to unambiguously establish the structural assignment of 
unexpected fluoride 369 by single crystal X-ray diffraction.   Although the nucleophilic 
transfer of a fluoride anion from BF3•Et2O is rare, it has been shown previously to occur 
in the presence of a Lewis basic solvent to accomplish epoxide opening.8 
We next explored the potential to advance the halogenated furanopentacycles by 
Kornblum oxidation.9  Exposure of chloride 367 to excess AgBF4 in DMSO at elevated 






























































































X-ray Crystal Structure of 367
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quantitative recovery of staring material (Scheme   A8.5.3.A).  Contrastingly, iodide 368 
underwent the desired oxidation to provide 1,4-diketone 347,10 albeit in a reduced 60% 
yield in comparison to the bromide analog employed in our optimized synthetic route 
(Scheme   A8.5.3.B).6  
Scheme A8.5.3. Kornblum Oxidation of Halogenated Furanopentacycles 
 
Although the exploration of the reactivity profile of diene 324 and epoxide 328 was 
largely unfruitful, the information gleaned form these studies contributed to the 
development of an optimized route for progression toward the norcembranoid diterpene 
























































DMSO, 100 °C, 20 h
then Et3N
(60% yield)
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A8.6  Experimental Methods and Analytical Data 
A8.6.1  Materials and Methods 
Unless stated otherwise, reactions were performed at ambient temperature (23 °C) 
in flame-dried glassware under an argon atmosphere using dry, deoxygentated solvents 
(distilled or passed over a column of activated alumina) 11  using a Teflon®-coated 
magnetic stirring bar.  Commercially available reagents were used as received unless 
otherwise noted. Reactions requiring external heat were modulated to the specified 
temperatures using an IKAmag temperature controller.  Thin-layer chromatography 
(TLC) was performed using E. Merck silica gel 60 F254 precoated plates (250 nm) and 
visualized by UV fluorescence quenching, potassium permanganate, or p-anisaldehyde 
staining.  Silicycle SiliaFlash P60 Academic Silica gel (particle size 40-63 nm) was used 
for flash chromatography.  1H and 13C NMR spectra were recorded on a Varian Inova 500 
(500 MHz and 126 MHz, respectively) and are reported in terms of chemical shift 
relative to residual CHCl3 (in CDCl3, δ 7.26 and δ 77.16, respectively).  Data for 1H NMR 
spectra are reported as follows: chemical shift (δ ppm) (multiplicity, coupling constant 
(Hz), integration).  Infrared (IR) spectra were recorded on a Perkin Elmer Paragon 1000 
Spectrometer and are reported in frequency of absorption (cm-1). High resolution mass 
spectra (HRMS) were obtained from the Caltech Mass Spectral Facility using a JEOL 
JMS-600H High Resolution Mass Spectrometer in fast atom bombardment (FAB+) 
ionization mode.  Optical rotations were measured on a Jasco P-2000 polarimeter using a 
100 mm path length cell at 589 nm. 
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A8.6.2  Experimental Procedures 
 
Allylic Alcohol 360, Allylic Alcohol 361, and Cycloheptatriene 345: To a stirred 
solution diene 324 (15 mg, 0.070 mmol, 1.00 equiv) in a mixture of benzene (5.0 mL) 
and CH3CN (5.0 µL) was added PdCl2(CH3CN)2 (0.6 mg, 0.0024 mmol, 0.05 equiv) as a 
solid in a single portion. After 2 minutes, the homogeneous golden solution was 
introduced to a preheated 50 °C bath. After 18 h, the consumption of starting material 
was complete as determined by TLC (1:4 EtOAc:CH2Cl2 eluent). The brown reaction 
mixture was then removed from the heating bath and allowed to cool to ambient 
temperature (ca. 23 °C). The reaction mixture was then filtered through a short silica gel 
plug, rinsing with 50% EtOAc in CH2Cl2 eluent. The combined organics were then 
concentrated in vacuo and the crude brown residue was dissolved in CH3CN and purified 
by reverse phase HPLC to provide allylic alcohol 360 (1.5 mg, 10% yield), allylic alcohol 
361 (1.5 mg, 10% yield), and cycloheptatriene 345 (1.5 mg, 10% yield): 
Allylic Alcohol 360: Rf = 0.23 (1:9 EtOAc:CH2Cl2 eluent). 
Allylic Alcohol 361: Rf = 0.23 (1:9 EtOAc:CH2Cl2 eluent). 
Cycloheptatriene 345: Rf = 0.94 (1:4 EtOAc:CH2Cl2 eluent); Characterization data 
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A8.7  X-Ray Crystallography Reports  
A8.7.1  X-Ray Crystal Structure Analysis of Chloride 367	  
	  
Contents 
Table A8.7.1.1. Experimental Details 
Table A8.7.1.2. Crystal Data 
Table A8.7.1.3. Atomic Coordinates  
Table A8.7.1.4. Full Bond Distances and Angles 
Table A8.7.1.5. Anisotropic Displacement Parameters 
Table A8.7.1.6. Hydrogen Atomic Coordinates 
Table A8.7.1.7. Torsion Angles 
Table A8.7.1.8. Hydrogen Bond Distances and Angles 
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Table A8.7.1.1. Experimental Details for X-Ray Structure Determination of Chloride 367. 
Low-temperature diffraction data (φ-and ω-scans) were collected on a Bruker AXS 
KAPPA APEX II diffractometer coupled to a APEX II CCD detector with graphite 
monochromated Mo Kα radiation (λ = 0.71073 Å) for the structure of chloride 367. The 
structure was solved by direct methods using SHELXS12 and refined against F2 on all 
data by full-matrix least squares with SHELXL-201413 using established refinement 
techniques.14 All non-hydrogen atoms were refined anisotropically. Unless otherwise 
noted, all hydrogen atoms were included into the model at geometrically calculated 
positions and refined using a riding model. The isotropic displacement parameters of all 
hydrogen atoms were fixed to 1.2 times the U value of the atoms they are linked to (1.5 
times for methyl groups).  
Chloride 367 crystallizes in the orthorhombic space group P212121 with one 
molecule in the asymmetric unit. The coordinates for the hydrogen atom bound to O4 
was located in the difference Fourier synthesis and refined semi-freely with the help of a 
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Table A8.7.1.2. Crystal Data and Structure Refinement for Chloride 367. 
Identification code  rac04 
CCDC Deposition Number 1061354 
Empirical formula  C19 H23 Cl O5 
Formula weight  366.82 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 7.6863(4) Å α= 90°. 
 b = 9.2978(4) Å β= 90°. 
 c = 23.9062(11) Å γ = 90°. 
Volume 1708.47(14) Å3 
Z 4 
Density (calculated) 1.426 Mg/m3 
Absorption coefficient 0.251 mm-1 
F(000) 776 
Crystal size 0.300 x 0.150 x 0.100 mm3 
Theta range for data collection 1.704 to 33.726°. 
Index ranges –11 ≤ h ≤ 12, –14 ≤ k ≤ 14, –37 ≤ l ≤ 37 
Reflections collected 47183 
Independent reflections 6809 [R(int) = 0.0598] 
Completeness to theta = 25.242° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7473 and 0.6980 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6809 / 1 / 231 
Goodness-of-fit on F2 1.042 
Final R indices [I>2sigma(I)] R1 = 0.0379, wR2 = 0.0894 
R indices (all data) R1 = 0.0472, wR2 = 0.0933 
Absolute structure parameter -0.01(2) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.430 and -0.191 e.Å-3 
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Table A8.7.1.3.       Atomic coordinates (x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for Chloride 367.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor.  
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 6332(2) 6433(1) 7135(1) 16(1) 
C(1) 4809(2) 6305(2) 6854(1) 14(1) 
O(2) 3852(2) 7312(1) 6792(1) 19(1) 
C(2) 4536(2) 4776(2) 6654(1) 11(1) 
C(3) 4993(2) 4542(2) 6022(1) 10(1) 
O(5) 6795(1) 4114(1) 6035(1) 9(1) 
C(4) 4860(2) 5871(2) 5655(1) 12(1) 
C(5) 5379(2) 5568(2) 5049(1) 13(1) 
C(16) 5277(2) 6872(2) 4667(1) 16(1) 
C(17) 5698(3) 6601(2) 4060(1) 24(1) 
C(18) 4888(3) 8182(2) 4847(1) 23(1) 
C(6) 4264(2) 4325(2) 4820(1) 16(1) 
C(7) 4394(2) 3009(2) 5185(1) 15(1) 
O(3) 4772(2) 1830(2) 4999(1) 23(1) 
C(8) 3976(2) 3238(2) 5797(1) 13(1) 
C(9) 4323(2) 1903(2) 6157(1) 16(1) 
C(10) 6252(2) 1729(2) 6304(1) 14(1) 
Cl(1) 6423(1) 268(1) 6794(1) 23(1) 
C(11) 6990(2) 3162(2) 6512(1) 10(1) 
C(12) 8912(2) 3358(2) 6682(1) 13(1) 
O(4) 10060(2) 3165(2) 6221(1) 16(1) 
C(19) 9565(3) 2355(2) 7138(1) 21(1) 
C(13) 8880(2) 4921(2) 6901(1) 16(1) 
C(14) 7160(2) 5045(2) 7218(1) 14(1) 
C(15) 5913(2) 3905(2) 6965(1) 12(1) 
________________________________________________________________________________ 
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Table A8.7.1.4.      Bond lengths [Å] and angles [°] for Chloride 367. 
_____________________________________________________  
O(1)-C(1)  1.356(2) 
O(1)-C(14)  1.453(2) 
C(1)-O(2)  1.200(2) 
C(1)-C(2)  1.515(2) 
C(2)-C(15)  1.526(2) 
C(2)-C(3)  1.566(2) 
C(2)-H(2)  1.0000 
C(3)-O(5)  1.4411(18) 
C(3)-C(4)  1.518(2) 
C(3)-C(8)  1.539(2) 
O(5)-C(11)  1.4509(18) 
C(4)-C(5)  1.529(2) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-C(16)  1.520(2) 
C(5)-C(6)  1.540(2) 
C(5)-H(5)  1.0000 
C(16)-C(18)  1.326(3) 
C(16)-C(17)  1.508(3) 
C(17)-H(17A)  0.9800 
C(17)-H(17B)  0.9800 
C(17)-H(17C)  0.9800 
C(18)-H(18A)  0.9500 
C(18)-H(18B)  0.9500 
C(6)-C(7)  1.506(2) 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(7)-O(3)  1.218(2) 
C(7)-C(8)  1.515(2) 
C(8)-C(9)  1.533(2) 
C(8)-H(8)  1.0000 
C(9)-C(10)  1.532(3) 
C(9)-H(9A)  0.9900 
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Table A8.7.1.4. (cont’d) 
C(9)-H(9B)  0.9900 
C(10)-C(11)  1.532(2) 
C(10)-Cl(1)  1.8003(16) 
C(10)-H(10)  1.0000 
C(11)-C(15)  1.528(2) 
C(11)-C(12)  1.543(2) 
C(12)-O(4)  1.4234(19) 
C(12)-C(19)  1.519(2) 
C(12)-C(13)  1.545(2) 
O(4)-H(4O)  0.854(19) 
C(19)-H(19A)  0.9800 
C(19)-H(19B)  0.9800 
C(19)-H(19C)  0.9800 
C(13)-C(14)  1.528(2) 
C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 
C(14)-C(15)  1.552(2) 
C(14)-H(14)  1.0000 
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Symmetry transformations used to generate equivalent atoms:  
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Table A8.7.1.5.  Anisotropic displacement parameters  (Å2x103) for Chloride 367.  The anisotropic 
displacement factor exponent takes the form: -2π2[ h2a*2U11  + ... + 2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 18(1)  14(1) 16(1)  -4(1) -1(1)  1(1) 
C(1) 17(1)  14(1) 10(1)  -1(1) 3(1)  1(1) 
O(2) 25(1)  16(1) 16(1)  -3(1) 0(1)  6(1) 
C(2) 12(1)  12(1) 10(1)  -2(1) 3(1)  0(1) 
C(3) 8(1)  12(1) 10(1)  -1(1) 1(1)  0(1) 
O(5) 8(1)  11(1) 9(1)  1(1) 1(1)  0(1) 
C(4) 14(1)  12(1) 11(1)  -1(1) -1(1)  0(1) 
C(5) 14(1)  14(1) 11(1)  1(1) 0(1)  1(1) 
C(16) 14(1)  19(1) 14(1)  3(1) -1(1)  1(1) 
C(17) 32(1)  26(1) 14(1)  5(1) 2(1)  1(1) 
C(18) 28(1)  18(1) 23(1)  6(1) 3(1)  6(1) 
C(6) 19(1)  17(1) 12(1)  -2(1) -3(1)  -1(1) 
C(7) 13(1)  17(1) 14(1)  -4(1) -1(1)  -4(1) 
O(3) 33(1)  17(1) 18(1)  -6(1) 1(1)  -1(1) 
C(8) 12(1)  14(1) 13(1)  -3(1) 2(1)  -3(1) 
C(9) 18(1)  12(1) 18(1)  -1(1) 6(1)  -4(1) 
C(10) 18(1)  9(1) 14(1)  2(1) 5(1)  -1(1) 
Cl(1) 31(1)  12(1) 26(1)  7(1) 9(1)  2(1) 
C(11) 12(1)  10(1) 9(1)  2(1) 3(1)  1(1) 
C(12) 12(1)  18(1) 10(1)  1(1) 1(1)  1(1) 
O(4) 11(1)  24(1) 12(1)  1(1) 3(1)  3(1) 
C(19) 20(1)  27(1) 15(1)  6(1) -1(1)  8(1) 
C(13) 14(1)  20(1) 14(1)  -3(1) -1(1)  -2(1) 
C(14) 16(1)  16(1) 11(1)  -2(1) -1(1)  2(1) 
C(15) 13(1)  12(1) 10(1)  0(1) 3(1)  1(1) 
______________________________________________________________________________ 
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Table A8.7.1.6.      Hydrogen coordinates (x104) and isotropic  displacement parameters (Å2x103)  
for Chloride 367. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 3336 4427 6742 14 
H(4A) 5623 6632 5809 15 
H(4B) 3649 6232 5664 15 
H(5) 6616 5236 5052 15 
H(17A) 4724 6098 3882 36 
H(17B) 6749 6009 4033 36 
H(17C) 5894 7521 3870 36 
H(18A) 4872 8966 4592 28 
H(18B) 4626 8337 5230 28 
H(6A) 3033 4636 4798 19 
H(6B) 4655 4083 4437 19 
H(8) 2708 3467 5826 15 
H(9A) 3639 1974 6507 19 
H(9B) 3923 1038 5952 19 
H(10) 6891 1453 5955 17 
H(4O) 9640(30) 3520(30) 5920(9) 24 
H(19A) 9645 1374 6990 31 
H(19B) 8753 2372 7454 31 
H(19C) 10716 2672 7264 31 
H(13A) 9878 5104 7153 19 
H(13B) 8922 5615 6587 19 
H(14) 7343 4858 7626 17 
H(15) 5419 3227 7248 14 
________________________________________________________________________________ 
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Symmetry transformations used to generate equivalent atoms:  
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 Table A8.7.1.8.      Hydrogen bonds for Chloride 367  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 C(6)-H(6B)...O(4)#1 0.99 2.63 3.453(2) 140.2 
 C(8)-H(8)...O(4)#2 1.00 2.26 3.177(2) 151.6 
 O(4)-H(4O)...O(3)#3 0.854(19) 2.22(2) 2.9252(18) 139(2) 
 C(19)-H(19A)...Cl(1) 0.98 2.72 3.205(2) 110.9 
 C(15)-H(15)...O(1)#4 1.00 2.60 3.5895(19) 169.8 
 C(15)-H(15)...O(2)#4 1.00 2.51 3.325(2) 138.4 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 x-1/2,-y+1/2,-z+1    #2 x-1,y,z    #3 x+1/2,-y+1/2,-z+1       
#4 -x+1,y-1/2,-z+3/2       
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A8.7.2  X-Ray Crystal Structure Analysis of Fluoride 369	  
	  
Contents 
Table A8.7.2.1. Experimental Details 
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Table A8.7.2.4. Full Bond Distances and Angles 
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Table A8.7.2.6. Hydrogen Atomic Coordinates 
Table A8.7.2.7. Torsion Angles 
Table A8.7.2.8. Hydrogen Bond Distances and Angles 
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Table A8.7.2.1. Experimental Details for X-Ray Structure Determination of Fluoride 369. 
Low-temperature diffraction data (φ-and ω-scans) were collected on a Bruker AXS 
D8 VENTURE KAPPA diffractometer coupled to a PHOTON 100 CMOS detector with 
Cu Kα radiation (λ = 1.54178 Å) from an IμS micro-source for the structure of fluoride 
369. The structure was solved by direct methods using SHELXS12 and refined against F2 
on all data by full-matrix least squares with SHELXL-201413 using established 
refinement techniques.14 All non-hydrogen atoms were refined anisotropically. Unless 
otherwise noted, all hydrogen atoms were included into the model at geometrically 
calculated positions and refined using a riding model. The isotropic displacement 
parameters of all hydrogen atoms were fixed to 1.2 times the U value of the atoms they 
are linked to (1.5 times for methyl groups).  
Fluoride 369 crystallizes in the orthorhombic space group P212121 with one 
molecule in the asymmetric unit. The coordinates for the hydrogen atom bound to O4 
were located in the difference Fourier synthesis and refined semi-freely with the help of a 
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Table A8.7.2.2. Crystal Data and Structure Refinement for Fluoride 369. 
Identification code  P15151 
CCDC Deposition Number 1061353 
Empirical formula  C19 H23 F O5 
Formula weight  350.37 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 8.1325(2) Å α= 90°. 
 b = 10.5090(3) Å β= 90°. 
 c = 19.6596(5) Å γ = 90°. 
Volume 1680.20(8) Å3 
Z 4 
Density (calculated) 1.385 Mg/m3 
Absorption coefficient 0.891 mm-1 
F(000) 744 
Crystal size 0.400 x 0.300 x 0.250 mm3 
Theta range for data collection 4.498 to 74.493°. 
Index ranges –9 ≤ h ≤ 10, –12 ≤ k ≤ 12, –24 ≤ l ≤ 24 
Reflections collected 16744 
Independent reflections 3389 [R(int) = 0.0435] 
Completeness to theta = 67.679° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7542 and 0.6923 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3389 / 1 / 231 
Goodness-of-fit on F2 1.055 
Final R indices [I>2sigma(I)] R1 = 0.0322, wR2 = 0.0713 
R indices (all data) R1 = 0.0389, wR2 = 0.0745 
Absolute structure parameter 0.06(8) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.161 and -0.205 e.Å-3 
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Table A8.7.2.3.       Atomic coordinates (x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for Fluoride 369.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor.  
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) -520(2) 4008(2) 1300(1) 22(1) 
C(1) 323(3) 4685(2) 1766(1) 18(1) 
O(2) -378(2) 5405(2) 2146(1) 25(1) 
C(2) 2157(3) 4430(2) 1720(1) 16(1) 
C(3) 2851(3) 3668(2) 2336(1) 15(1) 
O(5) 2600(2) 2363(1) 2136(1) 15(1) 
C(4) 1963(3) 3869(2) 3008(1) 18(1) 
C(5) 2652(3) 3039(2) 3584(1) 19(1) 
C(16) 1667(3) 3245(2) 4229(1) 22(1) 
C(17) 76(3) 2526(2) 4262(1) 31(1) 
C(18) 2131(4) 4013(2) 4728(1) 29(1) 
C(6) 4502(3) 3301(2) 3661(1) 22(1) 
C(7) 5333(3) 3042(2) 2992(1) 21(1) 
O(3) 6358(2) 2210(2) 2920(1) 29(1) 
C(8) 4734(3) 3845(2) 2395(1) 18(1) 
C(9) 5598(3) 3481(2) 1730(1) 20(1) 
C(10) 4912(3) 2261(2) 1424(1) 19(1) 
F(1) 5530(2) 2168(1) 751(1) 27(1) 
C(11) 3049(3) 2285(2) 1425(1) 15(1) 
C(12) 2014(3) 1174(2) 1144(1) 18(1) 
O(4) 2148(2) 80(1) 1566(1) 21(1) 
C(19) 2510(3) 751(2) 432(1) 22(1) 
C(13) 281(3) 1763(2) 1138(1) 20(1) 
C(14) 545(3) 3147(2) 925(1) 19(1) 
C(15) 2320(3) 3502(2) 1120(1) 15(1) 
________________________________________________________________________________ 
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Table A8.7.2.4.      Bond lengths [Å] and angles [°] for Fluoride 369. 
_____________________________________________________  
O(1)-C(1)  1.348(3) 
O(1)-C(14)  1.453(3) 
C(1)-O(2)  1.206(3) 
C(1)-C(2)  1.518(3) 
C(2)-C(15)  1.535(3) 
C(2)-C(3)  1.558(3) 
C(2)-H(2)  1.0000 
C(3)-O(5)  1.441(2) 
C(3)-C(4)  1.520(3) 
C(3)-C(8)  1.547(3) 
O(5)-C(11)  1.446(2) 
C(4)-C(5)  1.536(3) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-C(16)  1.515(3) 
C(5)-C(6)  1.537(3) 
C(5)-H(5)  1.0000 
C(16)-C(18)  1.324(3) 
C(16)-C(17)  1.499(4) 
C(17)-H(17A)  0.9800 
C(17)-H(17B)  0.9800 
C(17)-H(17C)  0.9800 
C(18)-H(18A)  0.9500 
C(18)-H(18B)  0.9500 
C(6)-C(7)  1.504(3) 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(7)-O(3)  1.216(3) 
C(7)-C(8)  1.525(3) 
C(8)-C(9)  1.534(3) 
C(8)-H(8)  1.0000 
C(9)-C(10)  1.522(3) 
C(9)-H(9A)  0.9900 
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Table A8.7.2.4. (cont’d) 
C(9)-H(9B)  0.9900 
C(10)-F(1)  1.420(2) 
C(10)-C(11)  1.516(3) 
C(10)-H(10)  1.0000 
C(11)-C(15)  1.531(3) 
C(11)-C(12)  1.541(3) 
C(12)-O(4)  1.422(3) 
C(12)-C(19)  1.524(3) 
C(12)-C(13)  1.540(3) 
O(4)-H(4O)  0.85(2) 
C(19)-H(19A)  0.9800 
C(19)-H(19B)  0.9800 
C(19)-H(19C)  0.9800 
C(13)-C(14)  1.529(3) 
C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 
C(14)-C(15)  1.540(3) 
C(14)-H(14)  1.0000 
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Symmetry transformations used to generate equivalent atoms:  
  
Appendix 8 – Alternative Synthetic Strategies Toward Ineleganolide 400 
Table A8.7.2.5.  Anisotropic displacement parameters  (Å2x103) for Fluoride 369.  The anisotropic 
displacement factor exponent takes the form: -2π2[ h2a*2U11  + ... + 2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 16(1)  25(1) 23(1)  -1(1) -2(1)  4(1) 
C(1) 19(1)  19(1) 17(1)  5(1) 1(1)  2(1) 
O(2) 28(1)  25(1) 21(1)  0(1) 4(1)  10(1) 
C(2) 17(1)  15(1) 16(1)  1(1) 1(1)  1(1) 
C(3) 16(1)  13(1) 17(1)  0(1) 1(1)  0(1) 
O(5) 17(1)  15(1) 13(1)  0(1) 2(1)  -2(1) 
C(4) 19(1)  19(1) 14(1)  0(1) 0(1)  2(1) 
C(5) 24(1)  18(1) 16(1)  1(1) -1(1)  0(1) 
C(16) 30(1)  21(1) 16(1)  4(1) -1(1)  3(1) 
C(17) 40(2)  32(1) 21(1)  0(1) 9(1)  -5(1) 
C(18) 36(2)  30(1) 20(1)  -3(1) -1(1)  2(1) 
C(6) 25(1)  22(1) 20(1)  3(1) -7(1)  -1(1) 
C(7) 17(1)  18(1) 28(1)  0(1) -6(1)  -4(1) 
O(3) 28(1)  25(1) 35(1)  1(1) -7(1)  7(1) 
C(8) 17(1)  16(1) 20(1)  -1(1) -1(1)  -1(1) 
C(9) 13(1)  22(1) 26(1)  2(1) 2(1)  -2(1) 
C(10) 17(1)  24(1) 15(1)  1(1) 5(1)  1(1) 
F(1) 26(1)  36(1) 19(1)  -4(1) 8(1)  -2(1) 
C(11) 16(1)  18(1) 12(1)  1(1) 1(1)  1(1) 
C(12) 19(1)  18(1) 16(1)  1(1) 1(1)  -1(1) 
O(4) 27(1)  17(1) 19(1)  1(1) 1(1)  -2(1) 
C(19) 25(1)  23(1) 19(1)  -2(1) 2(1)  0(1) 
C(13) 17(1)  22(1) 20(1)  -2(1) 0(1)  -5(1) 
C(14) 19(1)  22(1) 16(1)  0(1) 1(1)  5(1) 
C(15) 14(1)  18(1) 13(1)  2(1) 2(1)  0(1) 
______________________________________________________________________________ 
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Table A8.7.2.6.      Hydrogen coordinates (x104) and isotropic  displacement parameters (Å2x103)  
for Fluoride 369. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 2792 5230 1639 19 
H(4A) 782 3672 2946 21 
H(4B) 2054 4775 3140 21 
H(5) 2518 2129 3447 23 
H(17A) -533 2782 4670 46 
H(17B) 303 1611 4281 46 
H(17C) -581 2716 3857 46 
H(18A) 1451 4117 5117 35 
H(18B) 3144 4459 4696 35 
H(6A) 4681 4198 3796 27 
H(6B) 4971 2745 4019 27 
H(8) 4970 4760 2495 21 
H(9A) 5468 4182 1398 24 
H(9B) 6788 3371 1818 24 
H(10) 5305 1516 1696 23 
H(4O) 1790(30) 290(30) 1956(11) 31 
H(19A) 3638 424 441 34 
H(19B) 2448 1478 120 34 
H(19C) 1763 80 276 34 
H(13A) -438 1316 810 24 
H(13B) -227 1717 1596 24 
H(14) 374 3247 424 23 
H(15) 2976 3851 733 18 
________________________________________________________________________________ 
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Symmetry transformations used to generate equivalent atoms:  
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Table A8.7.2.8.      Hydrogen bonds for Fluoride 369  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 C(2)-H(2)...O(3)#1 1.00 2.36 3.239(3) 146.7 
 C(9)-H(9B)...O(1)#2 0.99 2.51 3.315(3) 138.8 
 C(10)-H(10)...O(3) 1.00 2.66 3.168(3) 111.9 
 O(4)-H(4O)...O(2)#3 0.85(2) 2.11(2) 2.933(2) 163(3) 
 C(14)-H(14)...F(1)#4 1.00 2.35 3.310(2) 159.9 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,y+1/2,-z+1/2    #2 x+1,y,z    #3 -x,y-1/2,-z+1/2       
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Revised Plan for the Synthesis of Ineleganolide: 
Alternative Advancement Toward the Asymmetric Total Synthesis  
of Ineleganolide by Late-Stage Oxidation State Manipulation 
 
 
4.1   Revised Retrosynthetic Analysis – Conjugate Reduction 
Having completed an effective synthesis of the carbocyclic core of ineleganolide, 
yet unable to advance the olefin migration strategy further, we envisioned an alternative 
completion of the asymmetric total synthesis of ent-ineleganolide (ent-9). Our new plan 
could proceed through the identical late-stage vinylogous diketone 330, furnishing the 
natural product following an intramolecular oxa-Michael addition (Scheme 4.1.1).  
Rather than by olefin isomerization, we envisioned synthesizing endione 330 by the 
oxidation of saturated 1,4-diketone 370, which would be formed by a syn-facial 1,2-
hydride shift from epoxide 371.  Ketone 371 would be synthesized by the sequential 
conjugate reduction and hydroxyl-directed epoxidation from diene 324. 
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Scheme 4.1.1. Adapted Retrosynthetic Analysis of ent-Ineleganolide with Late-Stage Oxidation 
 
4.2  Exploration of Conjugate Reduction Pathway 
The conjugate reduction of the tetrasubstituted enone moiety within tetracyclic 
triene 324 proved nontrivial.  All attempts to reduce the conjugated system using metal 
hydride sources failed, likely due to the steric environment surrounding the fully-
substituted β-position. Alternatively, we were pleased to discover the use of samarium 
diiodide was a suitable reductant to enable the formation of ketoalcohol 372 (Scheme 
4.2.1).  The use of water as an additive proved crucial for this transformation.  While the 
absence of an additive or the addition of MeOH, t-BuOH, LiCl, or fewer equivalents of 
H2O prevented the complete consumption of starting material, the addition of HMPA or 
the use of additional equivalents of H2O resulted in diminished yield of tetracycle 372. 
Scheme 4.2.1. Conjugate Reduction of Diene 324 
 
The hydroxyl-directed epoxidation of cycloheptene 372 was then accomplished 
under vanadium-catalyzed conditions to provide epoxide 371 in 94% yield.  Tetracycle 
























































































(94% yield) X-ray Crystal Structure of 371
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configuration by single-crystal X-ray diffraction.  This crystal structure confirmed the 
assignment of both the epoxide, being correctly directed to the β-face of the molecule, 
and also the configuration of the trans-fusion at the A,B-ring junction, matching that 
found in ent-ineleganolide (ent-9).   
Similar to our experiences with related epoxide 328 (see Chapter 3, Scheme 3.5.2), 
advancement of epoxide 371 to diketone 373 through an epoxide rearrangement proved 
unfruitful under a variety of Lewis acidic conditions (Scheme 4.2.2). Thus, we sought 
alternative access to diketone 373 employing the method used successfully in the 
synthesis of isoineleganolide C (ent-313, see Chapter 3, Section 3.7).  Epoxide 371 was 
first opened with magnesium(II) bromide to provide bromohydrin 374 in 80% yield 
(Scheme 4.2.3).  Unfortunately, Kornblum oxidation conditions failed to install the 
desired ketone at C(6).1,2  This result reenforces our hypothesis that the furan bridge in 
pentacycle 347 is critical for the efficacy of the Kornblum oxidation of secondary 
bromide 346 en route to isoineleganolide C (ent-313, see Scheme 3.7.3). 
Scheme 4.2.2. Unsuccessful Epoxide Rearrangement of Epoxide 371 
 
Scheme 4.2.3. Attempted Kornblum Oxidation of Epoxide 371 
 
In place of a bromohydrin strategy to access diketone 373, we began to pursue a 
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generated in situ from CpTiCl2 and a reductant.3  Initial exploration of this reductive 
epoxide opening proved immediately successful (Scheme 4.2.4).  The use of H2O as an 
additive results in the formation of the Cp2TiCl aquo complex and thereby provides a 
sacrificial hydrogen atom donor.3a,4  Subsequent oxidation under optimized conditions 
using DMP in DCE at elevated temperature provided 2H-ineleganolide (373) in 33% 
yield over two steps with the translactonized ketone 375 isolated in equivalent amounts. 
The structures of both 2H-ineleganolide (373) and lactone 375 were unambiguously 
determined by single crystal X-ray diffraction, confirming the relative configuration at 
C(7) by reductive epoxide. 
Scheme 4.2.4. Sequential Reductive Epoxide Opening and Carbinol Oxidation 
 
In order to explore the conformational constraints of 2H-ineleganolide (373), we 
explored the in vacuo ground state energy (DFT/B3LYP/6-311+G**) of four different 
conformational isomers: 373ax and 373equ and 373Aax and 373Aequ  (Figure 4.2.1).5 The 
two conformations in which the cyclohexanone ring adopts a chair conformation, placing 
the isopropenyl substituent in the axial position (373ax and 373Aax) are calculated to be 
energetically equivalent in the ground state, within the error of the calculation method 
(±0.23 kcal/mol), and have the lowest ground state energies of the calculated isomers, 
mirroring the preferred conformation of ent-ineleganolide (ent-9ax, see Figure 3.8.1).  The 
difference in energy between 373ax and 373Aax and the corresponding equatorial 









1) Cp2TiCl2 , Zn0
    H2O, THF
    –78 °C → 23 °C, 22 h
2) DMP
    ClCH2CH2Cl

































Chapter 4 – Alternative Advancement Toward Ineleganolide 412 
kcal/mol.  Complimentarily, the X-ray crystal structure of the isolated 2H-ineleganlolide 
generated through our synthetic pathway shows 373ax is the preferred conformation.  We 
were optimistic, however, that given the small ground state energy differences among 
these conformational isomers, we could induce an equilibrium between the isolated 373ax 
and one of the conformational isomers 373Aax or 373Aequ en route the completion of the 
asymmetric total synthesis of ent-ineleganolide (ent-9).   
Figure 4.2.1. Computational Evaluation of Conformational Isomers of 2H-Ineleganolide 
 
Toward this end, completion of the total synthesis would require the oxidation of 
2H-ineleganolide (373) in order to install the final requisite C–O bond and construct the 
characteristic furan bridge of ent-ineleganolide (ent-9).  We envisioned accomplishing 
this transformation directly by C–H oxidation at C(5) (Scheme 4.2.5).  We focused on the 
application of C–H oxidation methods that were known to accomplish the direct 
intramolecular formation a C–O bond from a free hydroxyl group.  We tested methods 
based on the Suárez oxidation including the standard reaction conditions (PhI(OAc)2, I2, 
hν) and a series of modified Suarez oxidation conditions, which used mixed cyclohexane 
and dichloromethane solvent systems and exclude light.6  Additionally, we attempted the 
oxidation of C(5) using lead(IV) acetate and light as well as with functionalized 
hypervalent iodine reagents such as PhI(OH)(OTs). 7   Unfortunately, all reaction 
























































373ax : 0.1 kcal/mol
373equ : 1.1 kcal/mol
373Aax : 0.0 kcal/mol
373Aequ : 0.7 kcal/mol
373ax Conformation
X-ray Crystal Structure of 373
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Scheme 4.2.5. Attempted C(5) Oxidation by C–H Activation 
 
We also explored the potential to access ineleganolide through the oxidation of 2H-
ineleganolide (373), proceeding through vinylogous diketone 330, which we hypothesize 
would undergo a spontaneous intramolecular oxa-Michael addition to furnish ent-
ineleganlide (ent-9, Scheme 4.2.6). Oxidative desaturation could be accomplished 
through either selective kinetic deprotonation relative to the cycloheptanone carbonyl at 
C(5) or by “thermodynamic” enolization relative to the cycloheptanone carbonyl at C(4).  
Complicated by potential enolization at C(2) and C(7), all attempts to accomplish this 
transformation by direct oxidation using palladium(II) salts (e.g.,  Pd(OAc)2, Pd(TFA)2),8 
hypervalent iodine reagents (e.g.,  IBX),9 or various selenides (e.g., (PhSeO)2O, PhSeCl 
then H2O2) failed to yield any trace of intermediate 330 or ent-ineleganolide (ent-9), 
typically resulting in selective functionalization at C(2). 10   Similar nonproductive 
reactivity was observed when attempting the C(4)–C(5) oxidation by a Saegusa–Ito 
oxidation.11  In order to avoid the undesired functionalization of the cyclohexanone ring, 
we explored the selective reduction of the C(3) carbonyl.  While the selective reduction 
of the C(3) ketone in the presence of the C(6) carbonyl of 2H-ineleganolide (373) could 





























PhI(OAc)2 , I2 , CH2Cl2 , hυ
OR
Pb(OAc)4 , pyridine, benzene, 0 °C, hυ
OR
PhI(OH)(OTs), CH2Cl2 , reflux
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Scheme 4.2.6. Representative Reaction Conditions for Attempted C(4)–C(5) Oxidation   
 
Stereoselective reduction of ketone 372 at C(3) was accomplished using L-
selectride at low temperature (Scheme 4.2.7).12  Subsequent silylation of the intermediate 
secondary alcohol provided tetracycle 376 in 79% yield over two steps.  Epoxidation 
could then be smoothly accomplished to furnish epoxyalcohol 377 in 80% yield.  
Reductive epoxide opening of pentacycle 377 under optimized conditions using in situ 
generated titanium(III) resulted in concomitant translactonization, affording alcohol 378 
in 66% yield as the sole product. Unable to manipulate lactone 379 further toward 
ineleganolide we again revised our retrosynthetic strategy.   
Scheme 4.2.7. Advancement of Tetracycle 372 by Diastereoselective C(3) Reduction 
 
4.3  Revised Retrosynthetic Analysis – 1,2-Reduction 
Armed with knowledge that selective late-stage functionalization of the tetracyclic 
core is complicated by the presence of the ketone functionality at C(3), we revised of our 
retrosynthetic strategy again.  We envisioned accessing ent-ineleganolide (ent-9) after 
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(Scheme 4.3.1).  We anticipated enone 380 would be accessible by the isomerization of 
olefin 381 into conjugation with the isolated ketone at C(6) followed by deprotection of 
the masked secondary C(3) hydroxyl group.  Ketone 381 would be synthesized after the 
stereoselective epoxide rearrangement or sequential reductive epoxide opening-oxidation 
from epoxide 382, which would be accessible from isoineleganolide A (328) after 
selective 1,2-reduction of the conjugated system and subsequent protection.   
Scheme 4.3.1. Retrosynthetic Analysis of ent-Ineleganolide Employing a 1,2-Reduction 
 
4.4  Exploration of 1,2-Reduction Pathway 
Exploration of the revised synthetic route began with the development of conditions 
that could accomplish the chemoselective 1,2-reduction of cyclohexenone 328.  We were 
gratified to find that we could accomplish this transformation chemoselectively and 
diastereoselectively using sodium borohydride in a mixed CH2Cl2 and MeOH solvent 
system at low temperature to provide allylic alcohol 383 in quantitative yield as the sole 
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Scheme 4.4.1. 1,2-Reduction of Enone 328 
 
With alcohol 383 in hand, we sought to evaluate the potential to accomplish an 
epoxide rearrangement on this reduced system.  To thoroughly evaluate this desired 
reactivity, selective protection of the hydroxyl groups on substrate 383 was 
accomplished, allowing for the isolation of monoprotected allylic alcohol 384 and disilyl 
ether 385.  Unfortunately, as with all other epoxides containing the [6,7,5,5]-core related 
to ent-ineleganolide, diol 383, allylic alcohol 384, and secondary silyl ether 385 all failed 
to undergo the desired 1,2-hydride shift (Scheme 4.4.2).  
Scheme 4.4.2. Attempted Epoxide Rearrangement  
 
During this investigation, we sought to assess the reactivity of an analog of diol 383 
that was functionalized with a silyl ether at solely the allylic secondary alcohol.  Under 
standard imidazole-mediated silylation conditions employing a bulky silyl chloride, we 
were indeed able to synthesize silyl ether 389 in 26% yield (Scheme 4.4.3).  We were 































































383 (R1  = H, R2 = H)
384 (R1  = H, R2 = TMS)
385 (R1  = TES, R2 = TMS)
386 (R1  = H, R2 = H)
387 (R1  = H, R2 = TMS)
388 (R1  = TES, R2 = TMS)
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portion of diol 383 had been converted to α,β-unstaured lactone 390 to provide 
unexpected epoxytetracycle 390 as the major product.  Under optimized conditions, 
conjugated lactone 390 was produced in 74% yield.14  
Scheme 4.4.3. Silyl Ether Formation with Unexpected Olefin Isomerization 
 
Intrigued by olefin isomerization product 390, we tested configurational stability of 
the conjugated lactone.  Deprotection of silyl ester 390 using TBAF provided secondary 
alcohol 391 in quantitative yield (Scheme 4.4.1).  Unfortunately, oxidation of secondary 
alcohol 391 with DMP was accompanied by concomitant olefin migration back into 
conjugation at the [6,7] ring fusion providing isoineleganolide A (328) in 66% yield.  No 
trace of the desired α,β-unsaturated lactone 392 was detected.  Although this oxidative 
route proved unfruitful, simply returning the original enone starting material 328 after 4 
synthetic transformations, we continued to investigate the utility of silyl ether isomers 
389 and 390 in our synthetic efforts. 
Scheme 4.4.4. Assessment of Configurational Stability of Unsaturated Lactone Moiety 
 
In order to advance allylic ether 389 or unsaturated lactone 390 toward 
ineleganolide, the epoxide moiety needed to be converted into the requisite C(6) ketone.  
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substrate for titanium(III)-mediated reductive epoxide opening (Scheme 4.4.5.A),15 both 
isomers 389 and 390 proved to be competent substrates for this transformation (Scheme 
4.4.5).16  Epoxide opening of allylic silyl ether 389 provided translactonized alcohol 393 
as the sole product in 60% yield (Scheme 4.4.5.B).  Subsequent oxidation failed to induce 
the desired retrotranslactontization, furnishing ketone 394 as the sole product that would 
not be useful for continued advancement toward ent-ineleganolide (ent-9), without any 
trace of desired cycloheptanone 395.   
Scheme 4.4.5. Reductive Epoxide Opening of Isomeric Silyl Ethers 
 
Alternatively, exposure of α,β-unsaturated lactone 390 to identical titanium(III) 
reductive conditions accomplished the desired epoxide opening while avoiding any 
translactontization, affording 1,3-diol 396 in 42% yield (Scheme 4.4.5.C).16  Interestingly, 
under these reducing and Lewis acidic conditions, the reduction of the conjugated system 
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the secondary alcohol with DMP smoothly provided ketone 397 in 23% yield as the sole 
product. 
With ketone 397 in hand, we sought to accomplish the installation of the 
unsaturation required between C(4) and C(5) for the vinylogous diketone system and 
ultimate oxa-Michael addition to build the desired ketofuran bridge.  Using TESOTf and 
Et3N, we could indeed access desired enol ether 399, albeit with undesired concomitant 
hydration of the α,β-unsaturated lactone (Scheme 4.4.6).  Unfortunately, we were unable 
to advance further toward ineleganolide at this stage as the oxidation of this enol ether 
399 could not be accomplished.17  
Scheme 4.4.6. Silyl Enol Ether Formation from Ketone 397 
 
To test if the steric bulk of the disilylated enol ether 399 was preventing the 
oxidation, we performed the silyl ether formation stepwise.  Tertiary alcohol 397 was 
first protected as TMS ether 401 (Scheme 4.4.7).   Surprisingly, when ketone 401 was 
subjected to silyl enol ether formation conditions, although the starting material was fully 
consumed, no trace of either desired enol ether 402 or its hydrated analog were detected 
in the product mixture.10  
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Unfortunately, alternative advancement of ketone 397 or its diol precursor (396) by 
selective conjugate reduction of the unsaturated lactone could not be accomplished. 
Although the α,β-unsaturated lactone moiety within these compounds had enabled the 
synthesis of ketone 397, the inability to advance further toward ent-ineleganolide (ent-9) 
forced another reevaluation of our synthetic strategy. 
As such, we began to develop an alternative pathway to avoid the problematic 
translactontization regularly observed using our titanium(III) epoxide openings.  To 
prevent this undesired isomerization, we investigated the potential to mask the lactone as 
a lactol by reducing earlier synthetic intermediates.  Beginning with either diene 
tetracycle 324 (Scheme 4.4.8.A) or epoxide 328 (Scheme 4.4.8.B), we could accomplish 
a completely diastereoselective double reduction in the presence of excess DIBAL at low 
temperature to afford either allylic alcohol 403 or epoxyalcohol 404, respectively. The 
relative stereochemistry of reduction products 403 and 404 was not rigorously assigned. 
Although the selective reduction of the lactol was desired, reduction of the isolated 
ketone was the requisite precursor (Scheme 4.4.8.C).  Since a late-stage oxidation would 
be required in this route to regenerate the lactone moiety, the advancement of the 
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Scheme 4.4.8. Lactol Formation 
 
Exploiting the higher yielding reduction of diene 324 compared to epoxide 328, we 
chose to advance employing lactol 403.  Disilyl ether formation using TBSCl under 
standard conditions provided lactol ether 406 in 89% yield (Scheme 4.4.9).  Epoxidation 
of allyl alcohol 406 was then efficiently accomplished in 90% yield to furnish epoxide 
407.  Titanium(III)-mediated epoxide opening accomplished the regioselective epoxide 
opening, smoothly furnishing a single product.  Unfortuately, the product observed had 
undergone an intramolecular tranketalization, furnishing acetal 408 in 89% yield.12 Yet 
again, we had produced an intermediate that was not useful for the progression toward 
ent-ineleganolide (ent-9) as opening of the acetal under oxidative conditions could not be 
achieved.  Attempted reactions using SO3•pyridine in DMSO, DMP in wet CH2Cl2, other 
hypervalent iodine oxidants in wet solvents, and chromium oxidants all proved 
ineffective, routinely quantitatively returning the starting material after reaction times up 
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Scheme 4.4.9. Advancement of Lactol 403 
 
Unable to advance acetal 408 further, we had again encountered an unsuccessful 
synthetic strategy pairing early-stage reduction with a late-stage oxidation.  Thus, we 
began to design alternative retrosynthetic strategies employing an early-stage oxidation, 
requiring a late-stage reduction to complete ent-ineleganolide. 
4.5  Retrosynthetic Analysis — Late-Stage Reduction 
We envisioned alternative completion of the asymmetric total synthesis of 
ineleganolide after dehydration of ketofuran 409 and ultimate conjugate reduction 
(Scheme 4.5.1).  Synthesis of α-alkoxyketone 409 would be accomplished by an 
intramolecular oxa-Michael addition from vinylogous diketone 410.  Access to enedione 
410 was envisioned through the selective reductive opening of furanopentacycle 411.  
Access to conjugated dione 411 would be achieved after the oxidation of saturated 1,4-
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Scheme 4.5.1. Retrosynthetic Analysis of ent-Ineleganolide Employing Late-Stage Reduction 
 
4.6  Exploration of Enedione Synthesis 
Evaluation of this synthetic route began with the previously synthesized 
intermediate furanopentacycle 347 (Scheme 4.6.1).  Formation of the thermodynamic 
trimethylsilyl enol ether at C(3) enabled the subsequent Saegusa-Ito oxidation, smoothly 
furnishing vinylogous diketone 412 in 56% yield as the major product.  Unfortunately, 
even under optimized conditions, the production of dienone 413 could not be avoided, 
which can be isolated in 44% yield.18  
Scheme 4.6.1. Oxidation of 1,4-Diketone 347 
 
With vinylogous diketone 412 in hand, we began investigating reductive α-
alkoxyketone cleavage procedures.  These studies focused on the use of samarium 
diiodide considering that this reagent is known to accomplish related transformations19 
and has been used previously for the α-alkoxyketone cleavage of saturated 1,4-diketone 
347.  The use of SmI2 in the absence of an additive or with H2O, LiCl, LiBr, HMPA, or t-
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conditions selectively reduced the conjugated system.  For example, exposure of enone 
412 to SmI2 at low temperature followed sequentially by TBAF-mediated tertiary silyl 
ether cleavage produced saturated diketone 347 in 75% yield.   
Scheme 4.6.2. Reduction of Vinylogous Diketone 412 
 
Unable to advance further toward ent-ineleganolide (ent-9) using enedione 412, we 
regressed further in the synthetic route to find other substrates that could be oxidized in a 
productive fashion.  We were pleased to find that isoineleganolide A (328) could be 
selectively enolized at the γ-position of the conjugated system when DMAP was used as 
the base (Scheme 4.6.3).  Formation of both disilylenol ether 416 (Scheme 4.6.3.A) and 
dienol acetate 416 (Scheme 4.6.3.B) could be achieved using TESCl and acetic 
anhydride, respectively.  Although TES enol ether 415 could be isolated and purified on 
small scale, attempts to increase the scale of its production routinely resulted in 
hydrolysis during purification and reformation of starting material 328.  Although the 
formation of the analogous TIPS dienol ether could not be accomplished under similar 
conditions, the TBS analog could be formed using TBSCl in place of TESCl, furnishing a 
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Scheme 4.6.3. Dienol Ether Formation 
 
In order to advance the dienol ether substrates toward ent-ineleganolide (ent-9), we 
sought to apply our previously employed titanium(III)-mediated reductive epoxide 
opening conditions.  Isoineleganolide A (328) was first converted into the TBS dienol 
ether 417A and was subsequently exposed to titanium(III) reductive conditions (Scheme 
4.6.4).  Not only did we observe hydrolysis of the dienol ether under the reaction 
conditions, but we observed solely the recovery of starting material 328 without the 
detection of desired product 417 or epoxide-opened starting material 418. 
Scheme 4.6.4. Attempted Reductive Epoxide Opening of Disilyl Enol Ether of Enone 328 
 
Comparably, dienol acetate 416 proved an incompetent substrate for reductive 
epoxide opening under the same conditions (Scheme 4.6.5).  Rather than producing 
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Scheme 4.6.5. Attempted Reductive Epoxide Opening of Dienol Ether 416 
 
Leaving the epoxide opening for a later stage, we began to investigate the oxidative 
advancement of these dienol ether intermediates.  In an attempt to functionalize 
isoineleganolide A (328) at C(4), we first formed the TBS dienol ether (Scheme 4.6.6).  
Exposure of this intermediate to NBS in dichloromethane at room temperature afforded 
solely α-bromolactone 420 rather than α-bromoketone 421.20  We did not believe γ-
bromide 420 was immediately useful for progression toward ent-ineleganolide (ent-9), so 
we sought alternative oxidative procedures. 
Scheme 4.6.6. Construction of α-Bromolactone 420 
 
During that investigation, we were gratified to find C(4)–C(5) oxidation of 
isoineleganolide A (328) could indeed be accomplished (Scheme 4.6.7).  Beginning again 
with the formation of the TBS dienol ether from epoxide 328, oxidation using 
stoichiometric palladium(II) acetate in DMSO provided dehydroineleganolide (422) in 
60% yield.  Unfortunately, this transformation was plagued by routinely low yields, but 
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Scheme 4.6.7. Oxidation of Isoineleganolide A (328) to Cycloheptadiene 422 
 
Dehydroineleganolide (422) was characterized by unique spectroscopic features, 
including an unexpected 13C NMR spectrum.  For example, consider epoxide 328 and the 
13C NMR shifts of C6 and C7 at 54.5 ppm and 70.2 ppm, respectively (Table 4.6.1). 
These shifts were characteristic with the remaining epoxytetracycles synthesized 
throughout this study (e.g., 371, 377, 383).  In contrast, while the carbon shift of the 
secondary epoxide carbon C6 of dehydroineleganolide (422) is within the expected range 
at 52.1 ppm, the tertiary epoxide carbon C7 is found at 94.9 ppm.  We hoped that the 
spectral data associated with enone 422 was indicative of a reactivity profile that we 
could exploit. 
Table 4.6.1. Comparison of 13C NMR Shifts of Enone 328 and Diene 422 
 
Any further advancement toward ent-ineleganolide (ent-9) would now require the 
opening of the epoxide moiety.  Unfortunately, dehydroineleganolide (422) was 
extremely reactive under titanium(III)-mediated reductive epoxide opening conditions, 
largely decomposing upon initiation of the reaction and routinely furnishing a complex 
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1,2-hyride shift and generation of the vinylogous diketone 422 were unfruitful. In fact, 
the only productive reactivity observed during this screen was the production of 
cycloheptatrienone 423 in 75% yield in the presence of Yb(OTf)3 (Scheme 4.6.8).   
Scheme 4.6.8. Formation of Cycloheptatrienone 423 
 
4.7  New Approach toward Ineleganolide 
After thorough exploration of the reactivity of a range of [6,7,5,5]-tetracyclic 
intermediates, without accomplishing the completion of the total synthesis of ent-
ineleganolide, we revisited and completely redesigned our retrosynthetic strategy. We 
envisioned completion of ent-ineleganolide (ent-9) by an intramolecular cascade from 
α,β-unsaturated ester 425 (Scheme 4.7.1). Macrocycle 425 would be formed by the 
intramolecular cyclization of ester 426. Ketofuran 426 would be constructed by the 
coupling of ketone 427 and bicycle 428. Ketone 427 could be formed from known 
derivatives of (R)-(–)-carvone by Z-selective olefination. Ketofuran 428 would be 
accessible after the intramolecular cyclization of previously synthesized methyl ketone 
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Scheme 4.7.1. Redesigned Retrosynthetic Strategy Toward ent-Ineleganolide (ent-9) 
 
This redesigned strategy was inspired by the biomimetic semisynthesis of 
ineleganolide21 as well as the empirical evidence that the late-stage construction of the 
characteristic ketofuran furan moiety is not feasible. Currently, the investigation of this 
synthetic strategy toward ent-ineleganolide and the related polycyclic furanobutenolide 
norcembranoid natural products is ongoing in the Stoltz lab. 
4.8.  Conclusion 
We have disclosed a research program dedicated to developing synthetic access to 
the core structures of the furanobutenolide norcembranoid diterpene natural products.  
The synthetic strategy was designed to convergently build the [6,7,5,5]-core tetracycle of 
ineleganolide (9) and then accomplish divergent access to the isomerized carbon 
skeletons of horiolide (20), kavaranolide (21), sinulochmodin C (10), scabrolide A (23), 
scabrolide B (24), and yonarolide (25).  The convergent assembly of the [6,7,5,5]-core 
tetracyclic scaffold was accomplished using two independent fragments.  The western 
carboxylic acid fragment was derived from (R)-(–)-carvone and contained the requisite 
enantioenriched remote stereocenter possessing the isopropenyl group that 
characteristically decorates the norcembranoid diterpenes.  The complimentary eastern 
diol what constructed using a palladium-catalyzed asymmetric allylic alkylation to 
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then used to relay chiral information to all remaining stereocenters with the [6,7,5,5]-core 
through a diastereoselective reduction followed by a key cyclopropanation-Cope 
rearrangement cascade (Scheme 4.8.1). 




Although the synthesis of the furanobutenolide norcembranoid diterpene natural 
products themselves has not yet been accomplished, these investigations have provided 
synthetic access to a large variety of natural product-like “ineleganoloids” (Figure 4.8.1).  
We are currently in the process of evaluating the biological activity of this class of 
synthetic, natural product-like compounds in collaboration with Eli Lilly and the City of 
Hope, as efforts continue toward the completion of the asymmetric total syntheses of the 
norcembranoid diterpenes natural products.  Throughout the course of this research 
program, we have thoroughly explored the limits of chemical transformation on highly 
oxygenation cyclopentanediols and complex, constrained fused cycloheptane polycycles.  
The understanding of this chemistry will not only benefit the derivatization and biological 
evaluation of the norcembranoid diterpenes, but will be broadly applicable to other total 
synthetic and semi-synthetic efforts toward the general class of terpenoid natural 
products.  Perhaps then, the greater value in total synthesis is truly derived from the 
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4.9  Experimental Methods and Analytical Data 
4.9.1   Materials and Methods 
Unless stated otherwise, reactions were performed at ambient temperature (23 °C) 
in flame-dried glassware under an argon atmosphere using dry, deoxygentated solvents 
(distilled or passed over a column of activated alumina)22 stirring with a Teflon®-coated 
magnetic stirring bar. Commercially available reagents were used as received unless 
otherwise noted.  Et3N was distilled from calcium hydride immediately prior to use.  
MeOH was distilled from magnesium methoxide immediately prior to use.  Reagent 
grade acetone was obtained from Sigma-Aldrich and used as received.  Purified water 
was obtained using a Barnstead NANOpure Infinity UV/UF system. Reactions requiring 
external heat were modulated to the specified temperatures using an IKAmag temperature 
controller.  Thin-layer chromatography (TLC) was performed using E. Merck silica gel 
60 F254 precoated plates (250 nm) and visualized by UV fluorescence quenching, 
potassium permanganate, or p-anisaldehyde staining.  Silicycle SiliaFlash P60 Academic 
Silica gel (particle size 40-63 nm) was used for flash chromatography.  1H and 13C NMR 
spectra were recorded on a Varian Inova 600 (600 MHz and 151 MHz, respectively), 
Varian Inova 500 (500 MHz and 126 MHz, respectively), Bruker AV III HD 
spectrometer equipped with a Prodigy liquid nitrogen temperature cryoprobe (400 MHz 
and 101 MHz, respectively), or a Varian Mercury 300 spectrometer (300 MHz and 76 
MHz, respectively) and are reported in terms of chemical shift relative to residual CHCl3 
(in CDCl3, δ 7.26 and δ 77.16, respectively) or C6D5H (in C6D6, δ 7.16 and δ 128.06, 
respectively).  Data for 1H NMR spectra are reported as follows: chemical shift (δ ppm) 
(multiplicity, coupling constant (Hz), integration).  Infrared (IR) spectra were recorded on 
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a Perkin Elmer Paragon 1000 Spectrometer and are reported in frequency of absorption 
(cm-1). High resolution mass spectra (HRMS) were obtained from the Caltech Mass 
Spectral Facility using either a JEOL JMS-600H High Resolution Mass Spectrometer in 
fast atom bombardment (FAB+) or electron ionization (EI+) mode or an LCT Premier 
XE TOF mass spectrometer equipped with an electrospray ionization source (ES+) or 
were acquired using an Agilent 6200 Series TOF mass spectrometer with an Agilent 
G1978A Multimode source in atmospheric pressure chemical ionization (APCI) or mixed 
(MultiMode: ESI-APCI) ionization mode. Optical rotations were measured on a Jasco P-
2000 polarimeter using a 100 mm path length cell at 589 nm. 
 
4.9.2   Experimental Procedures 
 
Allylic alcohol 372: Into each of two Schlenk tubes was added freshly filed samarium 
metal (150 mg, 1.00 mmol, 6.25 equiv). The reaction vessel was then thoroughly flame-
dried, backfilled with argon, and allowed to cool to ambient temperature (ca. 23 °C). To 
each reaction vessel was added THF (10.0 mL) that had previously been sparged with 
argon for 60 minutes and cooled to 0 °C (ice/H2O bath) with stirring. EtI2 (200 mg, 0.71 
mmol, 4.44 equiv) was then added to each Schlenk tube in separate 100 mg portions 30 
minutes apart. After the addition of the second portion, the Schlenk tubes were removed 

















–78 °C → 23 °C
H
H
Chapter 4 – Alternative Advancement Toward Ineleganolide 434 
solution was stirred overnight (ca. 14 h) causing the reaction to become deep blue, 
indicating formation of SmI2. 
Each Schlenk tube was cooled to –78 °C (i-PrOH/dry ice bath) followed by the 
addition of H2O (75 µL, 4.16 mmol, 26.0 equiv). After stirring for 5 minutes, the addition 
of diene 324 (50 mg, 0.16 mmol, 1.00 equiv) as solution in thoroughly sparged THF 
(1.60 mL) was accomplished quickly dropwise over 4 minutes. After 2 h, the reaction 
vessel was warmed to 0 °C (ice/H2O bath). After an additional 2 h, the Schlenk tube was 
removed from the cooling bath and allowed to warm. After 20 minutes, before warming 
all the way to ambient temperature, the consumption of starting material was complete as 
determined by TLC (1:4 EtOAc:CH2Cl2 eluent). The dark blue reaction mixture was 
quenched by the addition of hexanes (10.0 mL) and H2O (0.10 mL). After stirring for 5 
minutes, both reaction mixtures were combined, filtered through a pad of silica gel (50% 
acetone in hexanes eluent), and concentrated in vacuo. The crude tan solid was purified 
by silica gel column chromatography (20% acetone in hexanes eluent) to afford allylic 
alcohol 372 (56 mg, 56% yield) as an amorphous white solid: Rf = 0.21 (1:4 
Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 6.32–6.24 (m, 1H), 4.93–4.86 
(m, 1H), 4.74–4.70 (m, 1H), 4.63 (dt, J = 1.8, 0.9 Hz, 1H), 3.37 (dq, J = 6.0, 2.9 Hz, 1H), 
3.12 (ddd, J = 15.9, 9.7, 1.7 Hz, 1H), 2.99–2.89 (m, 2H), 2.84 (dq, J = 7.8, 4.4 Hz, 1H), 
2.68 (ddd, J = 15.1, 3.2, 2.3 Hz, 1H), 2.62 (ddd, J = 15.2, 6.0, 0.9 Hz, 1H), 2.40–2.29 (m, 
2H), 2.19 (tt, J = 11.4, 3.8 Hz, 1H), 2.08 (dd, J = 15.7, 4.3 Hz, 1H), 2.02 (s, 1H), 1.83 
(dtd, J = 14.1, 3.8, 2.0 Hz, 1H), 1.74 (dt, J = 1.5, 0.7 Hz, 3H), 1.73–1.65 (m, 1H), 1.35 (s, 
3H); 13C NMR (CDCl3, 126 MHz) δ 210.3, 174.8, 149.9, 146.2, 128.2, 113.0, 83.1, 79.4, 
49.7, 49.4, 48.4, 45.8, 44.5, 40.0, 39.8, 32.4, 30.0, 26.9, 22.5; IR (Neat Film, NaCl) 3479, 
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2965, 1760, 1699, 1444, 1372, 1224, 1138, 992, 900, 754 cm–1; HRMS (FAB+) m/z 
calc’d for C19H25O4 [M+H]+: 315.1596, found 315.1600; [α]D25.0 –17.7° (c 0.400, CHCl3). 
 
 
Epoxytetracycle 371: To a pale yellow stirred solution of allylic alcohol 372 (50 mg, 
0.16 mmol, 1.00 equiv) in a vial open to air in benzene (5.3 mL) was added VO(acac)2 
(0.5 mg, 0.0016 mmol, 0.01 equiv). After 5 minutes, to this dark green solution was 
added t-butyl hydroperoxide (TBHP, 36 µL, 0.018 mmol, 1.10 equiv) as a 5 M solution 
in decane dropwise causing the reaction to immediately became deep ruby red. After 1 h, 
the reaction had lost all red color and become pale yellow and the consumption of 
starting material was complete as determined by TLC (1:4 Acetone:Hexanes eluent). The 
reaction was concentrated in vacuo and the crude tan solid was purified by silica gel 
column chromatography (25% acetone in hexanes eluent) to afford epoxide 371 (47 mg, 
94% yield) as a white crystalline solid. Colorless, translucent X-ray quality crystals were 
obtained by slow diffusion of 1% benzene in heptane into a solution of epoxide 371 in 
EtOAc, mp: 183–185 °C: Rf = 0.15 (1:4 Acetone:Hexanes eluent); 1H NMR (CDCl3, 600 
MHz) δ 4.87 (s, 1H), 4.79–4.73 (m, 1H), 4.63–4.57 (m, 1H), 3.34 (d, J = 7.1 Hz, 1H), 
3.24 (ddd, J = 15.9, 7.2, 1.8 Hz, 1H), 3.05 (dd, J = 6.0, 4.4 Hz, 1H), 2.97 (ddd, J = 13.5, 
11.8, 4.5 Hz, 1H), 2.84 (dd, J = 6.5, 3.4 Hz, 1H), 2.76 (dd, J = 6.0, 3.5 Hz, 1H), 2.67 (m, 
2H), 2.63 (dd, J = 15.3, 6.0 Hz, 1H), 2.48 (bs, 1H), 2.38 (dd, J = 15.8, 6.7 Hz, 1H), 2.18 
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1.31 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 210.3, 173.8, 146.2, 113.0, 79.2, 75.3, 71.4, 
54.4, 46.8, 46.2, 45.3, 44.3, 44.2, 39.7, 38.0, 31.8, 26.3, 25.6, 22.4; IR (Neat Film, NaCl) 
3518, 2963, 2931, 1766, 1703, 1442, 1370, 1259, 1131, 985, 893, 758 cm–1; HRMS 




Bromohydrin 374: To a stirred colorless solution of epoxide 371 (8 mg, 0.024 mmol, 
1.00 equiv) in a mixture of toluene (1.6 mL) and THF (0.4 mL) in a nitrogen-filled 
glovebox was added MgBr2 (22 mg, 0.12 mmol, 5.00 equiv) in a single portion. The 
reaction mixture was then sealed and heated to 70 °C. After 15 h, the consumption of 
starting material was complete as determined by TLC (3:7 Acetone:Hexanes eluent). The 
golden yellow solution was removed from the glovebox. The reaction mixture was 
concentrated in vacuo and the crude tan solid was purified by silica gel column 
chromatography (20% acetone in hexanes eluent) to afford bromide 374 (8 mg, 80% 
yield) as an amorphous white solid: Rf = 0.38 (3:7 Acetone:Hexanes eluent); 1H NMR 
(CDCl3, 600 MHz) δ 4.96 (ddd, J = 9.6, 4.1, 2.9 Hz, 1H), 4.89 (dd, J = 2.2, 1.1 Hz, 1H), 
4.80–4.74 (m, 1H), 4.65 (dt, J = 1.7, 0.8 Hz, 1H), 3.17 (d, J = 2.6 Hz, 1H), 2.88–2.70 (m, 
5H), 2.51 (ddd, J = 14.6, 6.5, 1.0 Hz, 1H), 2.39–2.31 (m, 2H), 2.26 (dd, J = 12.0, 10.8 
Hz, 1H), 2.20 (d, J = 9.6 Hz, 1H), 2.15–2.09 (m, 2H), 1.98 (s, 3H), 1.88 (tt, J = 12.5, 3.1 
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126 MHz) δ 209.0, 176.1, 146.1, 113.3, 98.1, 72.5, 69.5, 68.4, 51.0, 49.9, 46.9, 46.8, 
44.2, 43.2, 40.4, 33.7, 33.0, 26.1, 22.6; IR (Neat Film, NaCl) 3437, 2926, 1766, 1708, 
1444, 1262, 1109, 1014, 799 cm–1; HRMS (FAB+) m/z calc’d for C19H26O579Br [M+H]+: 
413.0964, found 413.0965; [α]D25.0 –8.1° (c 0.150, CHCl3). 
 
 
2H-Ineleganolide (373) and Lactone 375: 
Preparation of a 0.50 M Stock Solution of Titanocene Monchloride (Cp2TiCl) 
Into a thoroughly flame-dried Schlenk tube under an overpressure of argon was 
charged with zinc(0) dust (647 mg, 9.90 mmol, 3.00 equiv) and titanocene dichloride 
(Cp2TiCl2, 822 mg, 3.30 mmol, 1.00 equiv). The flask was then evacuated and back filled 
with argon (3 x 5 minute cycles). To the reaction vessel was then added THF (6.6 mL) 
that had previously been sparged with argon for 60 minutes and stirring commenced. 
After 1.5 h, the bright red reaction mixture had become dark green and stirring was 
halted. After 30 minutes, the supernatant was used as a 0.50 M stock solution of Cp2TiCl. 
Epoxide Opening with Cp2TiCl 
A stirred solution of epoxide 371 (26 mg, 0.078 mmol, 1.00 equiv) in THF (2.5 mL) 
was sparged with argon for 1 h, resulting in a reaction volume of 1.5 mL. The 
homogeneous, off-white reaction mixture was then cooled to –78 °C (i-PrOH/dry ice 
bath) followed by the addition of H2O (108 µL, 6.00 mmol, 76.9 equiv). After stirring for 
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minutes. After 2 h, the reaction vessel was warmed to 0 °C (ice/H2O bath). After an 
additional 1.5 h, the Schlenk tube was removed from the cooling bath and allowed to 
warm to ambient temperature (ca. 23 °C). After an additional 18.5 h, the consumption of 
starting material was complete as determined by TLC (3:7 Acetone:Hexanes eluent). The 
reaction was quenched by the addition of saturated NaH2PO4 (1.0 mL) and brine (1.0 
mL), sparged with compressed air for 5 minutes, and allowed to stir for an additional 15 
minutes. The reaction mixture was then filtered through a Celite® plug, washing with 
50% acetone in hexanes eluent. The combined organics were concentrated in vacuo and 
immediately purified by silica gel column chromatography (50% EtOAc in CH2Cl2 
eluent), furnishing a mixture of diol products (21 mg, 81% yield) that was directly carried 
on without further purification. 
Oxidation of Intermediate Diol Products 
To a portion of the diol products (8 mg, 0.024 mmol, 1.00 equiv) in wet DCE (3.0 
mL) was added DMP (60 mg, 0.14 mmol, 5.82 equiv) at ambient temperature with 
stirring. The reaction vessel was then sealed and heated to 65 °C. After 18 h, the 
consumption of starting material was complete as determined by TLC (1:1 
EtOAc:CH2Cl2 eluent). The reaction vessel was removed from the heating bath and 
allowed to cool to ambient temperature. The reaction mixture was then quenched by the 
addition of saturated NaS2O3 (3.0 mL) and saturated NaHCO3 (3.0 mL). After stirring to 
10 minutes, the reaction mixture was diluted with H2O (10 mL) and extracted with 
CH2Cl2 (3 x 10 mL). The combined organics were then dried over MgSO4, filtered, and 
concentrated in vacuo. The crude brown solid was purified by silica gel column 
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chromatography (25% acetone in hexanes eluent) to furnish 2H-ineleganolide (373, 4 mg, 
50% yield) and lactone 375 (4 mg, 50% yield), both as crystalline white solids. 
2H-Ineleganolide (373): Colorless, translucent X-ray quality crystals were obtained by 
slow diffusion of 1% benzene in heptane into a solution of ketone 373 in EtOAc, mp: 
218–220 °C: Rf = 0.23 (3:7 Acetone:Hexanes eluent); 1H NMR (CDCl3, 500 MHz) δ 
4.96–4.92 (m, 1H), 4.80 (ddd, J = 7.2, 6.2, 3.8 Hz, 1H), 4.68 (dt, J = 1.7, 0.8 Hz, 1H), 
3.62 (q, J = 1.3 Hz, 1H), 3.21 (td, J = 9.3, 6.2 Hz, 1H), 3.08 (d, J = 9.6 Hz, 1H), 3.03 (dd, 
J = 9.0, 1.7 Hz, 1H), 2.96 (dd, J = 11.6, 3.8 Hz, 1H), 2.89–2.78 (m, 3H), 2.73 (dt, J = 
14.7, 2.3 Hz, 1H), 2.67 (ddd, J = 14.7, 6.1, 1.0 Hz, 1H), 2.51–2.37 (m, 3H), 2.24–2.15 
(m, 1H), 1.91 (ddd, J = 10.9, 6.0, 2.6 Hz, 1H), 1.78–1.74 (m, 3H), 1.28 (t, J = 1.0 Hz, 
3H).; 13C NMR (CDCl3, 126 MHz) δ 213.8, 208.2, 174.1, 145.7, 113.7, 80.9, 80.4, 61.8, 
48.0, 46.4, 46.3, 46.1, 44.0, 43.2, 40.3, 37.0, 34.0, 28.7, 22.6; IR (Neat Film, NaCl) 3501, 
2965, 2925, 1761, 1698, 1440, 1368, 1318, 1262, 1160, 1081, 1030, 1003, 800, 758 cm–1; 
HRMS (FAB+) m/z calc’d for C19H25O5 [M+H]+: 333.1702, found 333.1714; [α]D25.0 –
32.6° (c 0.150, CHCl3). 
Lactone 375: Colorless, translucent X-ray quality crystals were obtained by slow 
diffusion of 1% benzene in heptane into a solution of ketone 375 in EtOAc, mp: 230–232 
°C: Rf = 0.14 (3:7 Acetone:Hexanes eluent); 1H NMR (CDCl3, 600 MHz) 5.28 (d, J = 9.2 
Hz, 1H), 4.90 (d, J = 1.8 Hz, 1H), 4.66 (s, 1H), 3.02 (d, J = 1.8 Hz, 1H), 2.87 (d, J = 10.8 
Hz, 1H), 2.84 (d, J = 5.6 Hz, 1H), 2.72–2.62 (m, 2H), 2.58–2.49 (m, 2H), 2.45 (d, J = 
16.9 Hz, 1H), 2.41 (d, J = 10.8 Hz, 1H), 2.27 (td, J = 12.5, 5.4 Hz, 1H), 2.13–2.07 (m, 
2H), 1.90 (s, 1H), 1.82–1.70 (m, 4H), 1.71 (dd, J = 15.0, 12.1 Hz, 1H), 1.49 (s, 3H); 13C 
NMR (CDCl3, 126 MHz) δ 211.5, 208.9, 170.4, 146.3, 113.4, 75.0, 73.6, 53.1, 51.2, 50.1, 
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49.8, 47.5, 44.1, 41.7, 40.8, 34.4, 31.8, 28.7, 22.7; IR (Neat Film, NaCl) 3449, 2943, 
1742, 1661, 1451, 1378, 1260, 1103, 1041, 801 cm–1; HRMS (EI+) m/z calc’d for 
C19H24O5 [M•]+: 332.1624, found 332.1620; [α]D25.0 +7.8° (c 0.100, CHCl3).	  
 
 
Silyl Ether 376: To a stirred colorless solution of ketone 372 (10 mg, 0.032 mmol, 1.00 
equiv) in THF (2.50 mL) at –78 °C (i-PrOH/dry ice bath) was added L-Selectride® (100 
µL, 1.0 M in THF, 3.00 equiv) slowly dropwise over 2 minutes. After 15 minutes, the 
consumption of starting material was complete as determined by TLC (3:7 
Acetone:Hexanes eluent). The light yellow reaction mixture was quenched by the 
addition of saturated NH4Cl (2.00 mL), removed from the cooling bath, and allowed to 
warm to ambient temperature (ca. 23 °C). The reaction mixture was then diluted with 
H2O (10 mL) and extracted with EtOAc (3 x 8 mL). The combined organics were then 
dried over MgSO4, filtered, and concentrated in vacuo to afford an amorphous white solid 
that was carried on without further purification, assuming quantitative yield.  
To a solution of the crude white solid in CH2Cl2 (0.65 mL) were added imidazole 
(22 mg, 0.32 mmol, 10.0 equiv) and DMAP (0.7 mg, 0.006 mmol, 0.20 equiv) at ambient 
temperature (ca. 23 °C). The pale yellow reaction mixture was the cooled to 0 °C 
(ice/H2O bath) at which time TBSCl (15 mg, 0.096 mmol, 3.00 equiv) was added as a 
solution in CH2Cl2 (0.25 mL) quickly dropwise. After 15 minutes, the reaction was 
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After 18 h, additional imidazole (50 mg, 0.74 mmol, 23.1 equiv), DMAP (10 mg, 0.082, 
2.56 equiv), and TBSCl (30 mg, 0.20 mmol, 6.35 equiv) were added sequentially as 
solids, each in a single portion. After 6 h, the consumption of starting material was 
complete as determined by TLC (3:7 Acetone:Hexanes eluent). The reaction mixture was 
concentrated in vacuo and the resultant crude white solid was purified by silica gel 
column chromatography (15% acetone in hexanes eluent) to provide silyl ether 376 (79% 
yield, 2 steps) as an amorphous white solid: Rf = 0.19 (3:17 Acetone:Hexanes eluent); 1H 
NMR (CDCl3, 400 MHz) δ 6.30 (ddd, J = 8.8, 5.0, 2.9 Hz, 1H), 4.77–4.64 (m, 3H), 3.86 
(dt, J = 4.9, 2.6 Hz, 1H), 3.36 (tt, J = 5.9, 2.6 Hz, 1H), 2.97 (dd, J = 5.7, 3.9 Hz, 1H), 
2.77–2.66 (m, 1H), 2.45–2.32 (m, 2H), 2.14–2.00 (m, 4H), 1.99–1.82 (m, 3H), 1.74 (dt, J 
= 1.2, 0.6 Hz, 3H), 1.73–1.66 (m, 1H), 1.61 (tt, J = 11.0, 3.1 Hz, 1H), 1.37 (s, 3H), 0.88 
(s, 9H), 0.07 (s, 3H), 0.03 (s, 3H); 13C NMR (CDCl3, 101 MHz) δ 175.4, 149.7, 149.0, 
129.9, 108.3, 83.0, 79.4, 73.1, 50.3, 50.2, 45.9, 39.7, 36.6, 36.5, 35.2, 33.4, 32.8, 29.7, 
26.1, 21.9, 18.2, –3.9, –4.5; IR (Neat Film, NaCl) 3501, 2927, 2855, 1767, 1444, 1360, 
1256, 1151, 1069, 1003, 959, 836, 807, 773 cm–1; HRMS (FAB+) m/z calc’d for 
C25H39O4Si [(M+H)–H2]+: 431.2618, found 431.2611; [α]D25.0 –8.1° (c 0.250, CHCl3). 
 
 
Epoxide 377: To a pale yellow stirred solution of allylic alcohol 376 (5 mg, 0.012 mmol, 
1.00 equiv) in a vial open to air in benzene (2.0 mL) was added VO(acac)2 (0.6 mg, 
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hydroperoxide (TBHP, 3 µL, 0.014 mmol, 1.10 equiv) as a 5 M solution in decane 
dropwise causing the reaction to immediately become deep ruby red. After 1.5 h, the 
reaction had lost all red color and become pale yellow and the consumption of starting 
material was complete as determined by TLC (3:17 Acetone:Hexanes eluent). The 
reaction was concentrated in vacuo and the crude tan solid was purified by silica gel 
column chromatography (15% acetone in hexanes eluent) to afford epoxide 377 (4 mg, 
80% yield) as an amorphous white solid: Rf = 0.19 (3:17 Acetone:Hexanes eluent); 1H 
NMR (CDCl3, 400 MHz) δ 4.74 (ddd, J = 6.6, 4.5, 1.3 Hz, 1H), 4.68 (qt, J = 1.9, 0.9 Hz, 
2H), 3.87 (dt, J = 5.0, 1.7 Hz, 1H), 3.28 (d, J = 6.8 Hz, 1H), 3.04 (dd, J = 6.0, 4.5 Hz, 
1H), 2.79 (dd, J = 6.2, 2.7 Hz, 2H), 2.53 (d, J = 1.2 Hz, 1H), 2.37 (dd, J = 15.7, 6.6 Hz, 
1H), 2.17 (d, J = 15.7 Hz, 1H), 2.11 (dd, J = 13.5, 6.9 Hz, 1H), 2.03–1.83 (m, 6H), 1.76–
1.69 (m, 3H), 1.64 (ddd, J = 14.3, 7.8, 2.1 Hz, 1H), 1.35–1.30 (m, 3H), 0.88 (s, 9H), 0.07 
(s, 3H), 0.04 (s, 3H); 13C NMR (CDCl3, 101 MHz) δ 174.3, 149.7, 108.3, 79.0, 77.4, 
75.4, 73.6, 71.5, 55.4, 48.4, 45.5, 44.8, 36.6, 36.4, 35.4, 33.5, 32.7, 32.3, 26.1, 25.6, 21.7, 
18.1, –3.9, –4.5; IR (Neat Film, NaCl) 3521, 2928, 2856, 1771, 1645, 1463, 1361, 1257, 
1163, 1069, 986, 963, 878, 836, 774 cm–1; HRMS (FAB+) m/z calc’d for C25H39O5Si 
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Diol 378: 
Preparation of a 0.50 M Stock Solution of Titanocene Monchloride (Cp2TiCl) 
Into a thoroughly flame-dried Schlenk tube under an overpressure of argon was 
charged with zinc(0) dust (647 mg, 9.90 mmol, 3.00 equiv) and titanocene dichloride 
(Cp2TiCl2, 822 mg, 3.30 mmol, 1.00 equiv). The flask was then evacuated and back filled 
with argon (3 x 5 minute cycles). To the reaction vessel was then added THF (6.6 mL) 
that had previously been sparged with argon for 60 minutes and stirring commenced. 
After 1.5 h, the bright red reaction mixture had become dark green and stirring was 
halted. After 30 minutes, the supernatant was used as a 0.50 M stock solution of Cp2TiCl. 
Epoxide Opening with Cp2TiCl 
A stirred solution of epoxide 377 (5 mg, 0.013 mmol, 1.00 equiv) in THF (1.5 mL) 
was sparged with argon for 1 h, resulting in a reaction volume of 0.5 mL. The 
homogeneous, off-white reaction mixture was then cooled to –78 °C (i-PrOH/dry ice 
bath) followed by the addition of H2O (18 µL, 1.00 mmol, 76.9 equiv). After stirring for 
5 minutes, Cp2TiCl (0.25 mmol, 0.50 M in THF, 19.2 equiv) was added dropwise over 3 
minutes. After 2 h, the reaction vessel was warmed to 0 °C (ice/H2O bath). After an 
additional 2.5 h, the Schlenk tube was removed from the cooling bath and allowed to 
warm to ambient temperature. After an additional 12 h, the consumption of starting 
material was complete as determined by TLC (3:17 Acetone:Hexanes eluent). The 
reaction was quenched by the addition of saturated NaH2PO4 (0.25 mL) and brine (0.25 
378
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mL), sparged with compressed air for 5 minutes, and allowed to stir for an additional 15 
minutes. The reaction mixture was then filtered through a Celite® plug, washing with 
50% acetone in hexanes eluent. The combined organics were concentrated in vacuo and 
immediately purified by silica gel column chromatography (40% EtOAc in CH2Cl2 
eluent) to furnish diol 378 (4 mg, 66% yield) as an amorphous white solid: Rf = 0.42 (1:1 
EtOAc:CH2Cl2 eluent); 1H NMR (CDCl3, 400 MHz) δ 4.92 (d, J = 8.7 Hz, 1H), 4.69 (t, J 
= 1.8 Hz, 1H), 4.67 (q, J = 1.6 Hz, 1H), 4.33 (q, J = 4.3 Hz, 1H), 3.72 (q, J = 2.8 Hz, 1H), 
3.20 (s, 1H), 2.67–2.58 (m, 2H), 2.50 (d, J = 5.1 Hz, 1H), 2.28–2.20 (m, 1H), 2.19–2.05 
(m, 2H), 2.05–1.91 (m, 4H), 1.75–1.66 (m, 5H), 1.64–1.52 (m, 2H), 1.34 (dddd, J = 12.1, 
9.0, 6.0, 2.9 Hz, 1H), 1.28 (s, 3H), 0.80 (s, 9H), 0.00 (d, J = 3.0 Hz, 3H), –0.06 (s, 3H); 
13C NMR (CDCl3, 101 MHz) 174.76, 148.41, 108.35, 81.39, 76.21, 74.16, 70.00, 52.77, 
50.22, 48.81, 48.35, 42.47, 37.26, 36.95, 35.81, 34.91, 34.69, 27.47, 25.95, 23.23, 18.18, 
–3.84, –4.81.; IR (Neat Film, NaCl) 3391, 2927, 2855, 1726, 1444, 1386, 1252, 1173, 
1081, 1056, 881 838, 774 cm–1; HRMS (FAB+) m/z calc’d for C25H43O5Si [M+H]+: 
451.2880, found 451.2890; [α]D25.0 –2.9° (c 0.200, CHCl3). 
 
 
Allylic alcohol 383: To a stirred solution of enone 328 (11 mg, 0.033 mmol, 1.00 equiv) 
in MeOH (0.3 mL) and CH2Cl2 (0.3 mL) at –78 °C (i-PrOH/dry ice bath) was added 
NaBH4 (4 mg, 0.10 mmol, 3.00 equiv) as a solid in single portion. After 1 h, the 
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additional 1 h, the consumption of starting material was complete as determined by TLC 
(1:4 EtOAc:CH2Cl2 eluent). The reaction was quenched by the addition of saturated 
aqueous NaHCO3 (80 µL), removed from the cooling bath, and allowed to warm to 
ambient temperature (ca. 23 °C). The reaction mixture was then filtered through a silica 
gel plug, eluting with EtOAc. The combined organics were concentrated in vacuo. The 
crude white solid was purified by silica gel column chromatography (95% EtOAc in 
hexanes eluent) to provide allylic alcohol 383 (11 mg, >99% yield) as an amorphous 
white solid: Rf = 0.17 (19:1 EtOAc:Hexanes eluent); 1H NMR (CDCl3, 600 MHz) δ 4.79–
4.68 (m, 3H), 4.21 (t, J = 8.3 Hz, 1H), 3.35 (dd, J = 6.1, 4.5 Hz, 1H), 3.32 (d, J = 5.2 Hz, 
1H), 3.21 (d, J = 6.1 Hz, 1H), 3.01–2.93 (m, 1H), 2.92–2.84 (m, 2H), 2.42–2.32 (m, 2H), 
2.29 (d, J = 16.0 Hz, 1H), 2.22–2.15 (m, 1H), 1.79–1.70 (m, 4H), 1.42 (td, J = 12.3, 9.7 
Hz, 1H), 1.33 (s, 3H); 13C NMR (CDCl3, 126 MHz) δ 173.8, 148.4, 129.7, 126.8, 109.4, 
79.6, 75.2, 73.8, 70.4, 55.5, 48.8, 45.7, 44.1, 38.5, 38.1, 37.2, 28.0, 26.5, 21.0; IR (Neat 
Film, NaCl) 3441, 2930, 1771, 1645, 1436, 1373, 1234, 1140, 986, 890, 757 cm–1; 
HRMS (FAB+) m/z calc’d for C19H25O5 [M+H]+: 333.1702, found 333.1695; [α]D25.0 +0.5 
° (c 0.550, CHCl3). 
 
 
Silyl Ether 384: To a stirred solution of allylic alcohol 383 (11 mg, 0.033 mmol, 1.00 
equiv) in CH2Cl2 (0.7 mL) at –78 °C (i-PrOH/dry ice bath) was added Et3N (92 µl, 0.66 
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was added slowly dropwise. After an additional 10 minutes, the consumption of starting 
material was complete as determined by TLC (19:1 EtOAc:Hexanes eluent). The reaction 
was quenched by the addition of saturated aqueous NaHCO3 (80 µL), removed from the 
cooling bath, and allowed to warm to ambient temperature (ca. 23 °C). The reaction 
mixture was then filtered through a silica gel plug, eluting with 100% EtOAc. The 
combined organics were concentrated in vacuo. The crude white solid was purified by 
silica gel column chromatography (40% EtOAc in hexanes eluent) to furnish silyl ether 
384 (10 mg, 77% yield) as an amorphous white solid: Rf = 0.36 (1:1 EtOAc:Hexanes 
eluent); 1H NMR (CDCl3, 600 MHz) δ 4.83–4.67 (m, 3H), 4.33–4.22 (m, 1H), 3.35–3.30 
(m, 2H), 3.17 (d, J = 6.2 Hz, 1H), 3.00–2.90 (m, 1H), 2.83 (ddt, J = 16.6, 4.0, 2.1 Hz, 
1H), 2.68 (dd, J = 19.7, 5.5 Hz, 1H), 2.55 (bs, 1H), 2.44–2.25 (m, 3H), 2.13–2.04 (m, 
1H), 1.83–1.69 (m, 4H), 1.48–1.38 (m, 1H), 1.33 (s, 3H), 0.18 (s, 9H); 13C NMR (CDCl3, 
126 MHz) δ 173.8, 148.4, 129.8, 127.0, 109.4, 79.6 (d, J = 4.1 Hz), 75.2, 74.8, 70.4, 
55.6, 48.8, 45.7, 44.2, 38.6, 38.4, 37.3, 28.5, 26.5, 20.8, 0.6; IR (Neat Film, NaCl) 3429, 
2959, 1764, 1371, 1250, 1142, 1056, 887, 841 cm–1; HRMS (FAB+) m/z calc’d for 
C22H33O5Si [M+H]+: 405.2097, found 405.2088; [α]D25.0 +60.4° (c 0.250, CHCl3). 
 
 
 Silyl Ether 385: To a stirred solution of allylic alcohol 384 (5 mg, 0.012 mmol, 1.00 
equiv) in CH2Cl2 (0.3 mL) at –78 °C (i-PrOH/dry ice bath) was added Et3N (35 µl, 0.25 
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was added slowly dropwise. After an additional 20 minutes, the consumption of starting 
material was complete as determined by TLC (1:1 EtOAc:Hexanes eluent). The reaction 
was quenched by the addition of saturated aqueous NaHCO3 (80 µL), removed from the 
cooling bath, and allowed to warm to ambient temperature (ca. 23 °C). The reaction 
mixture was then filtered through a silica gel plug, eluting with EtOAc. The combined 
organics were concentrated in vacuo. The crude white solid was purified by silica gel 
column chromatography (10% EtOAc in hexanes eluent) to afford silyl ether 385 (4 mg, 
66% yield) as an amorphous white solid: Rf = 0.14 (1:9 EtOAc:Hexanes eluent); 1H NMR 
(CDCl3, 600 MHz) δ 4.84–4.72 (m, 2H), 4.70 (s, 1H), 4.33–4.21 (m, 1H), 3.25 (dd, J = 
6.4, 4.7 Hz, 1H), 3.20 (d, J = 5.4 Hz, 1H), 3.10 (d, J = 6.4 Hz, 1H), 2.93–2.84 (m, 2H), 
2.65 (dd, J = 19.5, 5.5 Hz, 1H), 2.41–2.32 (m, 2H), 2.28 (dd, J = 15.0, 6.5 Hz, 1H), 2.10–
2.03 (m, 1H), 1.76–1.70 (m, 4H), 1.41 (td, J = 12.7, 10.0 Hz, 1H), 1.31 (s, 3H), 0.93 (t, J 
= 7.9 Hz, 9H), 0.68–0.54 (m, 6H), 0.18 (s, 9H); 13C NMR (CDCl3, 126 MHz) δ 173.7, 
148.6, 130.0, 127.0, 109.3, 79.3, 77.0, 74.9, 69.6, 53.8, 48.6, 44.5, 43.4, 38.6, 38.5, 37.2, 
29.7, 28.7, 20.8, 7.2, 6.5, 0.6; IR (Neat Film, NaCl) 3464, 2956, 1766, 1665, 1451, 1376, 
1249, 1143, 1047, 890, 841, 795, 744 cm–1; HRMS (FAB+) m/z calc’d for C28H47O5Si2 
[M+H]+: 519.2962, found 519.2959; [α]D25.0 +53.6° (c 0.100, CHCl3). 
 
 
Allylic Silyl Ether 389 and Unsaturated Lactone 390: To a stirred solution of allylic 
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(2.72 g, 40.0 mmol, 200.0 equiv) and DMAP (98 mg, 0.80 mmol, 4.00 equiv) as solids 
sequential, each in a single portion. After 5 minutes, to the resulting homogenous, pale 
yellow solution was added TBSCl (3.01 g, 20.0 mmol, 100.0 equiv) as a solution in 
CH2Cl2 (7.5 mL) quickly dropwise over 5 minutes. After 17 h, the consumption of 
starting material was complete as determined by TLC (19:1 EtOAc:Hexanes eluent). The 
reaction mixture was then filtered through a Celite® plug, washing with CH2Cl2 eluent. 
The combined organics were concentrated in vacuo and purified by silica gel column 
chromatography (15% acetone in hexanes eluent) to furnish diol allylic silyl ether 389 
(23 mg, 26% yield) as an amorphous white solid and unsaturated lactone 390 (66 mg, 
74% yield) as an amorphous white solid. 
Allylic Silyl Ether 389: Rf = 0.20 (3:17 Acetone:Hexanes eluent); 1H NMR (CDCl3, 400 
MHz) δ 4.78–4.67 (m, 3H), 4.26 (bt, J = 8.0 Hz, 1H), 3.35 (dd, J = 6.1, 4.5 Hz, 1H), 3.31 
(d, J = 5.4 Hz, 1H), 3.17 (dd, J = 5.8, 1.9 Hz, 1H), 2.97–2.78 (m, 2H), 2.78–2.67 (m, 1H), 
2.55 (bs, 1H), 2.42–2.24 (m, 3H), 2.06 (ddt, J = 12.2, 6.3, 2.3 Hz, 1H), 1.79–1.69 (m, 
4H), 1.40 (ddd, J = 13.5, 12.4, 10.3 Hz, 1H), 1.34 (s, 3H), 0.92 (s, 9H), 0.13 (s, 3H), 0.11 
(s, 3H); 13C NMR (CDCl3, 101 MHz) δ 173.9, 148.6, 130.5, 126.5, 109.4, 79.7, 75.3, 
75.0, 70.5, 55.8, 48.9, 45.8, 44.3, 38.7, 38.5, 37.4, 28.6, 26.6, 26.2, 20.9, 18.4, –3.5, –4.6; 
IR (Neat Film, NaCl) 3465, 2930, 2857, 1771, 1463, 1370, 1256, 1140, 1102, 1056, 988, 
972, 883, 836, 774 cm–1; HRMS (FAB+) m/z calc’d for C25H39O5Si [M+H]+:447.2567, 
found 447.2552; [α]D25.0 +87.5 ° (c 0.400, CHCl3). 
Unsaturated Lactone 390: Rf = 0.29 (3:17 Acetone:Hexanes eluent); 1H NMR (CDCl3, 
400 MHz) δ 4.80 (ddd, J = 9.3, 7.8, 7.2 Hz, 1H), 4.75 (dt, J = 1.8, 0.9 Hz, 1H), 4.73 (s, 
1H), 4.16–4.07 (m, 1H), 3.88 (ddd, J = 10.1, 9.0, 4.3 Hz, 1H), 3.81 (dt, J = 9.3, 2.5 Hz, 
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1H), 3.37 (ddd, J = 5.4, 2.0, 0.7 Hz, 1H), 2.61–2.51 (m, 2H), 2.41 (dtd, J = 9.3, 4.7, 2.4 
Hz, 1H), 2.38–2.32 (m, 1H), 2.14 (tt, J = 11.7, 4.1 Hz, 1H), 2.08–1.97 (m, 2H), 1.97–1.90 
(m, 1H), 1.86 (ddd, J = 13.7, 11.1, 2.5 Hz, 1H), 1.74 (dd, J = 1.5, 0.8 Hz, 3H), 1.43 (td, J 
= 12.5, 10.2 Hz, 1H), 1.32 (d, J = 0.9 Hz, 3H), 0.93 (s, 9H), 0.13 (s, 3H), 0.12 (s, 3H); 13C 
NMR (CDCl3, 101 MHz) δ 169.7, 158.8, 148.2, 116.1, 109.6, 74.5, 73.5, 73.3, 70.9, 54.3, 
51.6, 48.1, 41.5, 41.0, 40.4, 32.6, 26.0, 23.5, 22.7, 20.6, 18.2, –3.9, –4.7; IR (Neat Film, 
NaCl) 3494, 2929, 2857, 1742, 1645, 1455, 1360, 1259, 1176, 1121, 1078, 1053, 957, 
918, 898, 837, 775 cm–1; HRMS (FAB+) m/z calc’d for C25H39O5Si [M+H]+: 447.2567, 
found 447.2577; [α]D25.0 +56.1° (c 0.600, CHCl3). 
 
 
Epoxyalcohol 391: To a stirred solution of silyl ether 390 (4 mg, 0.009 mmol, 1.00 
equiv) in THF (0.6 mL) at –78 °C (i-PrOH/dry ice bath) was added TBAF (11 mL, 1 M 
in THF, 1.22 equiv) slowly dropwise. After 3 h, the reaction was introduced to a 0 °C 
bath (ice/H2O). After a further 4 h, the consumption of starting material was complete as 
determined by TLC (1:4 Acetone:Hexanes eluent). The reaction was removed from the 
cooling bath and immediately concentrated in vacuo. The crude dark brown oil was 
purified by silica gel column chromatography (EtOAc eluent) to provide diol 391 (3 mg, 
>99% yield) as an amorphous white solid: Rf = 0.31 (EtOAc eluent); 1H NMR (CDCl3, 
400 MHz) δ 4.83 (dt, J = 9.2, 7.4 Hz, 1H), 4.77 (dt, J = 1.7, 0.9 Hz, 1H), 4.75 (q, J = 1.5 
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1H), 3.43 (dd, J = 4.8, 2.2 Hz, 1H), 2.63–2.52 (m, 2H), 2.42 (dddd, J = 8.3, 6.2, 4.3, 2.2 
Hz, 1H), 2.32 (bs, 1H), 2.26–2.03 (m, 4H), 1.93 (dd, J = 13.3, 7.3 Hz, 1H), 1.75 (t, J = 
1.1 Hz, 3H), 1.44 (ddd, J = 12.4, 11.7, 10.5 Hz, 1H), 1.33 (t, J = 0.8 Hz, 3H); 13C NMR 
(CDCl3, 101 MHz) δ 169.6, 158.0, 148.0, 116.9, 109.8, 74.6, 73.5, 72.7, 70.4, 54.3, 50.8, 
48.0, 41.6, 40.8, 40.1, 31.9, 23.5, 23.0, 20.8; IR (Neat Film, NaCl) 3418, 2964, 2925, 
2855, 1732, 1644, 1446, 1372, 1260, 1177, 1103, 1048, 1029, 911, 802, 732 cm–1; HRMS 




Enone 328: To a stirred solution of unsaturated lactone 391 (3 mg, 0.009 mmol, 1.00 
equiv) in wet CH2Cl2 (1.3 mL) at 0 °C (ice/H2O bath) was added Dess–Martin 
periodinane (DMP, 8 mg, 0.018 mmol, 2.00 equiv) as a solid in a single portion. After 2.5 
h, the consumption of starting material was complete as determined by TLC (EtOAc 
eluent). The reaction was quenched by the addition of saturated aqueous Na2S2O3 (2 mL) 
with vigorous stirring. After 15 minutes, the reaction was diluted with CH2Cl2 (5 mL) and 
poured onto saturated aqueous NaHCO3 (2 mL). The organics were separated and the 
aqueous was extracted with CH2Cl2 (3 x 2 mL). The combined organics were 
concentrated in vacuo. The crude golden solid was purified by silica gel column 






















Chapter 4 – Alternative Advancement Toward Ineleganolide 451 




Diol 393:  
Preparation of a 0.50 M Stock Solution of Titanocene Monchloride (Cp2TiCl) 
Into a thoroughly flame-dried Schlenk tube under an overpressure of argon was 
charged with zinc(0) dust (647 mg, 9.90 mmol, 3.00 equiv) and titanocene dichloride 
(Cp2TiCl2, 822 mg, 3.30 mmol, 1.00 equiv). The flask was then evacuated and back filled 
with argon (3 x 5 minute cycles). To the reaction vessel was then added THF (6.6 mL) 
that had previously been sparged with argon for 60 minutes and stirring commenced. 
After 1.5 h, the bright red reaction mixture had become dark green and stirring was 
halted. After 30 minutes, the supernatant was used as a 0.50 M stock solution of Cp2TiCl. 
Epoxide Opening with Cp2TiCl 
A stirred solution of epoxide 389 (8 mg, 0.018 mmol, 1.00 equiv) in THF (2.0 mL) 
was sparged with argon for 1 h, resulting in a reaction volume of 0.8 mL. The 
homogeneous, off-white reaction mixture was then cooled to –78 °C (i-PrOH/dry ice 
bath) followed by the addition of H2O (27 µL, 1.50 mmol, 55.6 equiv). After stirring for 
5 minutes, Cp2TiCl (0.38 mmol, 0.50 M in THF, 14.1 equiv) was added dropwise over 3 
minutes. After 2 h, the reaction vessel was warmed to 0 °C (ice/H2O bath). After an 
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warm to ambient temperature. After an additional 12.5 h, the consumption of starting 
material was complete as determined by TLC (3:17 Acetone:Hexanes eluent). The 
reaction was quenched by the addition of saturated NaH2PO4 (0.25 mL) and brine (0.25 
mL), sparged with compressed air for 5 minutes, and allowed to stir for an additional 15 
minutes. The reaction mixture was then filtered through a Celite® plug, washing with 
50% acetone in hexanes eluent. The combined organics were concentrated in vacuo and 
purified twice by silica gel column chromatography (first column: 45% EtOAc in CH2Cl2 
eluent, second column: 40% EtOAc in CH2Cl2 eluent) to furnish diol 393 (2 mg, 25% 
yield) as an amorphous white solid: Rf = 0.40 (1:1 EtOAc:CH2Cl2 eluent); 1H NMR 
(CDCl3, 400 MHz) δ 5.00 (dd, J = 4.5, 2.6 Hz, 1H), 4.74 (p, J = 1.7 Hz, 1H), 4.71 (dd, J 
= 1.9, 0.9 Hz, 1H), 4.33 (tt, J = 4.9, 2.1 Hz, 1H), 4.14 (td, J = 6.3, 3.0 Hz, 1H), 3.55 (s, 
1H), 3.16 (d, J = 5.3 Hz, 1H), 3.06 (d, J = 1.6 Hz, 1H), 2.98 (ddd, J = 12.3, 5.0, 1.6 Hz, 
1H), 2.84–2.71 (m, 1H), 2.60–2.47 (m, 1H), 2.35–2.15 (m, 3H), 2.06–1.91 (m, 2H), 1.74–
1.70 (m, 3H), 1.67 (dd, J = 14.0, 3.7 Hz, 1H), 1.44 (td, J = 13.3, 12.8, 10.2 Hz, 1H), 1.34 
(s, 3H), 0.90 (s, 9H), 0.09 (s, 3H), 0.08 (s, 3H); 13C NMR (CDCl3, 101 MHz) δ 173.3, 
148.2, 132.7, 129.4, 109.7, 81.4, 76.0, 74.0, 71.6, 51.5, 49.6, 48.4, 47.7, 39.7, 38.1, 37.6, 
36.8, 27.4, 26.1, 20.6, 18.3, -4.0, -4.7; IR (Neat Film, NaCl) 3365, 2927, 2855, 1733, 
1454, 1386, 1259, 1081, 1060, 876, 836, 775 cm–1; HRMS (FAB+) m/z calc’d for 
C25H41O5Si [M+H]+: 449.2723, found 449.2735; [α]D25.0 +31.3° (c 0.100, CHCl3). 
 
 
Chapter 4 – Alternative Advancement Toward Ineleganolide 453 
 
Diol 396:  
Preparation of a 0.50 M Stock Solution of Titanocene Monchloride (Cp2TiCl) 
Into a thoroughly flame-dried Schlenk tube under an overpressure of argon was 
charged with zinc(0) dust (647 mg, 9.90 mmol, 3.00 equiv) and titanocene dichloride 
(Cp2TiCl2, 822 mg, 3.30 mmol, 1.00 equiv). The flask was then evacuated and back filled 
with argon (3 x 5 minute cycles). To the reaction vessel was then added THF (6.6 mL) 
that had previously been sparged with argon for 60 minutes and stirring commenced. 
After 1.5 h, the bright red reaction mixture had become dark green and stirring was 
halted. After 30 minutes, the supernatant was used as a 0.50 M stock solution of Cp2TiCl. 
Epoxide Opening with Cp2TiCl  
A stirred solution of epoxide 390 (12 mg, 0.027 mmol, 1.00 equiv) in THF (2.0 mL) 
was sparged with argon for 1 h, resulting in a reaction volume of 0.8 mL. The 
homogeneous, off-white reaction mixture was then cooled to –78 °C (i-PrOH/dry ice 
bath) followed by the addition of H2O (27 µL, 1.50 mmol, 55.6 equiv). After stirring for 
5 minutes, Cp2TiCl (0.38 mmol, 0.50 M in THF, 14.1 equiv) was added dropwise over 3 
minutes. After 2 h, the reaction vessel was warmed to 0 °C (ice/H2O bath). After an 
additional 2.5 h, the Schlenk tube was removed from the cooling bath and allowed to 
warm to ambient temperature. After an additional 12.5 h, the consumption of starting 
material was complete as determined by TLC (3:17 Acetone:Hexanes eluent). The 
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mL), sparged with compressed air for 5 minutes, and allowed to stir for an additional 15 
minutes. The reaction mixture was then filtered through a Celite® plug, washing with 
50% acetone in hexanes eluent. The combined organics were concentrated in vacuo and 
purified twice by silica gel column chromatography (25% EtOAc in CH2Cl2 eluent) to 
furnish diol 396 (5 mg, 42% yield) as an amorphous white solid: Rf = 0.19 (1:4 
EtOAc:CH2Cl2 eluent); 1H NMR (CDCl3, 400 MHz) δ 4.89 (ddd, J = 8.3, 6.3, 2.2 Hz, 
1H), 4.77–4.73 (m, 1H), 4.69 (q, J = 1.5 Hz, 1H), 4.53 (q, J = 4.2 Hz, 1H), 3.89 (ddd, J = 
9.4, 7.6, 4.2 Hz, 1H), 3.86–3.80 (m, 1H), 3.79–3.69 (m, 1H), 3.44–3.34 (m, 1H), 2.76 
(ddt, J = 19.1, 10.6, 5.3 Hz, 2H), 2.60 (dt, J = 8.7, 7.0 Hz, 1H), 2.42 (ddt, J = 14.7, 11.9, 
4.4 Hz, 1H), 2.20 (dd, J = 14.6, 2.1 Hz, 1H), 2.17–1.92 (m, 5H), 1.71 (dd, J = 1.4, 0.7 Hz, 
3H), 1.43 (s, 3H), 1.37 (ddd, J = 13.2, 11.2, 9.2 Hz, 1H), 0.90 (s, 9H), 0.09 (app d, J = 0.9 
Hz, 6H); 13C NMR (CDCl3, 101 MHz) δ 169.8, 158.2, 148.9, 122.7, 109.7, 81.7, 78.6, 
74.6, 68.3, 52.8, 48.4, 47.4, 44.3, 38.8, 37.7, 34.2, 29.6, 26.9, 26.0, 20.1, 18.1, –3.9, –4.5; 
IR (Neat Film, NaCl) 3359, 2928, 2856, 1727, 1661, 1463, 1360, 1311, 1257, 1230, 
1110, 1073, 1034, 887, 836, 775 cm–1; HRMS (FAB+) m/z calc’d for C25H41O5Si [M+H]+: 
449.2723, found 449.2721; [α]D25.0 +46.4° (c 0.250, CHCl3). 
 
 
Ketone 394: To a stirred solution of diol 393 (10 mg, 0.022 mmol, 1.00 equiv) in wet 
CH2Cl2 (2.0 mL) at 0 °C (ice/H2O bath) was added Dess–Martin periodinane (DMP, 30 
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suspension was removed from the cooling bath and allowed to warm to ambient 
temperature (ca. 23 °C). After an additional 10 h, the consumption of starting material 
was complete as determined by TLC (1:1 EtOAc:CH2Cl2 eluent). The reaction was 
quenched by the addition of saturated aqueous Na2S2O3 (3 mL) with vigorous stirring. 
After 15 minutes, the reaction was diluted with CH2Cl2 (10 mL) and poured onto 
saturated aqueous NaHCO3 (3 mL). The organics were separated and the aqueous was 
extracted with CH2Cl2 (4 x 2 mL). The combined organics were concentrated in vacuo. 
The crude golden solid was purified by silica gel column chromatography (15% EtOAc 
in hexanes eluent) to provide ketone 394 (6 mg, 60% yield) as an amorphous white solid: 
Rf = 0.27 (3:17 EtOAc:CH2Cl2 eluent); 1H NMR (CDCl3, 400 MHz) δ 5.25 (ddd, J = 5.0, 
2.3, 0.8 Hz, 1H), 4.75 (p, J = 1.5 Hz, 1H), 4.72 (dd, J = 1.7, 0.9 Hz, 1H), 4.19–4.11 (m, 
1H), 3.26 (d, J = 2.0 Hz, 1H), 3.22 (ddt, J = 10.8, 2.0, 0.9 Hz, 1H), 2.86 (dd, J = 18.5, 2.6 
Hz, 1H), 2.69–2.38 (m, 4H), 2.33–2.16 (m, 3H), 2.04–1.95 (m, 1H), 1.72 (dd, J = 1.5, 0.8 
Hz, 3H), 1.48 (s, 3H), 1.47–1.38 (m, 1H), 0.92 (s, 9H), 0.10 (s, 3H), 0.10 (s, 3H); 13C 
NMR (CDCl3, 101 MHz) δ 212.0, 169.9, 147.8, 133.3, 129.3, 109.9, 75.1, 74.0, 71.6, 
53.3, 52.9, 47.8, 47.4, 39.6, 37.5, 37.5, 36.7, 29.1, 26.1, 20.5, 18.3, –3.9, –4.7; IR (Neat 
Film, NaCl) 3447, 2927, 2856, 1750, 1378, 1257, 1185, 1063, 872, 836, 777 cm–1; 
HRMS (FAB+) m/z calc’d for C25H39O5Si [M+H]+: 447.2567, found 447.2551; [α]D25.0 
+35.4° (c 0.300, CHCl3). 
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Ketone 397: To a stirred solution of diol 396 (49 mg, 0.11 mmol, 1.00 equiv) in wet 
CH2Cl2 (2.2 mL) at 0 °C (ice/H2O bath) was added Dess–Martin periodinane (DMP, 140 
mg, 0.33 mmol, 3.00 equiv) was a solid in a single portion. After 30 minutes, the white 
suspension was removed from the cooling bath and allowed to warm to ambient 
temperature (ca. 23 °C). After 2 h, additional DMP (140 mg, 0.33 mmol, 3.00 equiv) was 
added in a single portion. After an additional 10.5 h, the consumption of starting material 
was complete as determined by TLC (1:4 EtOAc:CH2Cl2 eluent). The reaction was 
quenched by the addition of saturated aqueous Na2S2O3 (4 mL) with vigorous stirring. 
After 15 minutes, the reaction was diluted with CH2Cl2 (10 mL) and poured onto 
saturated aqueous NaHCO3 (4 mL). The organics were separated and the aqueous was 
extracted with CH2Cl2 (4 x 2 mL). The combined organics were concentrated in vacuo. 
The crude golden brown solid was purified by silica gel column chromatography (8% 
EtOAc in hexanes eluent) to provide ketone 397 (10 mg, 23% yield) as an amorphous 
white solid: Rf = 0.27 (1:19 EtOAc:CH2Cl2 eluent); 1H NMR (CDCl3, 400 MHz) δ 4.94 
(ddd, J = 8.2, 7.4, 0.9 Hz, 1H), 4.76–4.70 (m, 2H), 4.37 (ddd, J = 14.4, 3.9, 2.0 Hz, 1H), 
4.17 (tt, J = 8.5, 2.8 Hz, 1H), 3.73 (ddd, J = 10.6, 9.2, 4.5 Hz, 1H), 3.13 (dd, J = 12.2, 6.8 
Hz, 1H), 3.08 (d, J = 8.9 Hz, 1H), 2.82 (dd, J = 12.2, 3.8 Hz, 1H), 2.68 (ddt, J = 9.9, 6.6, 
3.2 Hz, 1H), 2.58 (d, J = 2.4 Hz, 1H), 2.28 (d, J = 15.2 Hz, 1H), 2.11–1.95 (m, 2H), 1.87 
(ddd, J = 15.2, 7.4, 2.5 Hz, 1H), 1.81–1.70 (m, 4H), 1.51–1.40 (m, 4H), 0.91 (s, 9H), 0.18 
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109.6, 78.5, 73.1, 67.6, 50.5, 47.3, 43.8, 40.5, 40.4, 40.0, 32.3, 29.9, 27.2, 26.1, 20.8, 
18.2, –3.9, –4.5; IR (Neat Film, NaCl) 3542, 2929, 2857, 1733, 1634, 1456, 1362, 1256, 
1182, 1147, 1090, 1033, 891, 838, 777 cm–1; HRMS (FAB+) m/z calc’d for C25H39O5Si 
[M+H]+: 447.2567, found 447.2553; [α]D25.0 +94.3° (c 0.750, CHCl3). 
 
 
Silyl Enol Ether 399: To a stirred solution of ketone 397 (13 mg, 0.029 mmol, 1.00 
equiv) in CH2Cl2 (1.0 mL) at 0 °C (ice/H2O bath) was added Et3N (0.20 mL, 1.45 mmol, 
50.0 equiv) dropwise. After 5 minutes, TESOTf (66 µL, 0.29 mmol, 10.0 equiv) was 
added slowly dropwise. After an additional 20 minutes, the consumption of starting 
material was complete as determined by TLC (1:19 EtOAc:CH2Cl2 eluent). The reaction 
was quenched by the addition of saturated aqueous NaHCO3 (50 µL) and immediately 
removed from the cooling bath and allowed to warm to ambient temperature (ca. 23 °C). 
The reaction mixture was then filtered through a silica gel plug, eluting with 10% EtOAc 
in hexanes. The combined organics were concentrated in vacuo. The crude tan solid was 
purified by silica gel column chromatography (5% EtOAc in hexanes eluent) to provide 
enol ether 399 (11 mg, 55% yield) as an amorphous white solid: Rf = 0.50 (1:9 
EtOAc:Hexanes eluent); 1H NMR (CDCl3, 400 MHz) δ  5.48 (t, J = 2.5 Hz, 1H), 4.91 (td, 
J = 8.3, 6.0 Hz, 1H), 4.72 (q, J = 1.2 Hz, 2H), 3.61 (ddd, J = 11.6, 8.3, 3.4 Hz, 1H), 3.13–
3.04 (m, 1H), 2.68–2.53 (m, 3H), 2.45–2.33 (m, 2H), 2.26 (ddd, J = 13.1, 8.1, 1.3 Hz, 
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3H), 0.95 (td, J = 8.0, 5.4 Hz, 18H), 0.92 (s, 9H), 0.68–0.57 (m, 12H), 0.10 (s, 6H); 13C 
NMR (CDCl3, 101 MHz) δ 174.7, 147.8, 138.3, 124.2, 110.7, 88.6, 82.3, 80.2, 74.9, 59.6, 
56.4, 48.1, 47.4, 47.0, 45.0, 44.2, 38.1, 29.9, 25.9, 20.2, 18.2, 7.4, 7.2, 6.9, 6.8, –4.0, –
4.5; IR (Neat Film, NaCl) 2954, 2876, 1767, 1463, 1373, 1353, 1332, 1251, 1157, 1116, 
1090, 1028, 871, 836, 775, 743 cm–1; HRMS (ES+) m/z calc’d for C37H69O6 Si3 [M+H]+: 
693.4402, found 693.4422; [α]D25.0 +34.9° (c 0.250, CHCl3). 
 
 
Silyl ether 401: To a stirred solution of ketone 397 (4 mg, 0.009 mmol, 1.00 equiv) in 
CH2Cl2 (1.0 mL) at 0 °C (ice/H2O bath) was added Et3N (126 µl, 0.90 mmol, 100.0 equiv) 
dropwise. After 5 minutes, TMSOTf (20 µL, 0.11 mmol, 12.2 equiv) was added slowly 
dropwise. After an additional 5 minutes, the consumption of starting material was 
complete as determined by TLC (1:19 EtOAc:CH2Cl2 eluent). The reaction was quenched 
by the addition of saturated aqueous NaHCO3 (1.5 mL) and immediately removed from 
the cooling bath and allowed to warm to ambient temperature (ca. 23 °C). The reaction 
was diluted with Et2O (2 mL) and poured onto H2O (3 mL). The organics were separated 
and the aqueous was extracted with Et2O (3 x 2 mL). The combined organics were dried 
over MgSO4, filtered, and concentrated in vacuo. The crude white solid was purified by 
silica gel column chromatography (18% EtOAc in hexanes eluent) to provide enol ether 
401 (4 mg, >99% yield) as an amorphous white solid: Rf = 0.28 (1:4 EtOAc:Hexanes 
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4.84 (p, J = 1.5 Hz, 1H), 4.18 (t, J = 7.8 Hz, 1H), 3.73 (ddd, J = 10.7, 9.6, 4.4 Hz, 1H), 
3.13 (tt, J = 8.1, 2.9 Hz, 1H), 2.86 (dd, J = 11.5, 3.6 Hz, 1H), 2.62 (dd, J = 11.5, 5.4 Hz, 
1H), 2.41 (ddt, J = 9.0, 6.0, 3.3 Hz, 1H), 2.28–2.16 (m, 2H), 1.90 (d, J = 14.9 Hz, 1H), 
1.83 (dd, J = 1.5, 0.8 Hz, 3H), 1.70 (d, J = 8.0 Hz, 1H), 1.68–1.49 (m, 2H), 1.39 (s, 3H), 
1.08 (s, 9H), 1.03 (dd, J = 14.9, 7.6 Hz, 1H), 0.40 (s, 3H), 0.20 (s, 3H), 0.15 (s, 9H) ; 13C 
NMR (C6D6, 101 MHz) δ 204.9, 169.9, 150.1, 148.5, 124.5, 109.5, 81.3, 76.5, 73.3, 68.3, 
50.9, 48.5, 43.6, 41.2, 41.2, 40.3, 33.3, 26.4, 26.0, 21.1, 18.5, 2.4, –4.1, –4.3; IR (Neat 
Film, NaCl) 2928, 2856, 1738, 1716, 1635, 1455, 1362, 1251, 1184, 1149, 1093, 1017, 
886, 837, 778 cm–1; HRMS (FAB+) m/z calc’d for C28H47O5Si2 [M+H]+: 519.2962, found 
519.2954; [α]D25.0 +61.8° (c 0.200, benzene). 
 
 
Lactol 403:23 To a stirred solution of enone 324 (5 mg, 0.016 mmol, 1.00 equiv) in 
CH2Cl2 (0.70 mL) at –78 °C (i-PrOH/dry ice bath) was added DIBAL (48 µL, 1.00 M in 
CH2Cl2, 3.00 equiv) slowly dropwise. After 5.5 h, the consumption of starting material 
was complete as determined by TLC (1:4 EtOAc:CH2Cl2 eluent). The reaction was 
quenched by the addition of saturated aqueous NH4Cl (0.5 mL) and saturated aqueous 
Rochelle salt (0.5 mL) and immediately removed from the cooling bath and allowed to 
warm to ambient temperature (ca. 23 °C). After stirring for 1 h, the reaction was diluted 
with CH2Cl2 (2.0 mL) and poured onto H2O (3.0 mL). The organics were separated and 
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over MgSO4, filtered, and concentrated in vacuo. The crude off-white solid was purified 
by silica gel column chromatography (50% EtOAc in hexanes eluent) to provide lactol 
403 (11 mg, 55% yield) as an amorphous white solid: Rf = 0.21 (1:1 EtOAc:CH2Cl2 
eluent); 1H NMR (CDCl3, 400 MHz) δ 6.19 (ddd, J = 8.6, 4.5, 3.0 Hz, 1H), 5.55 (d, J = 
5.2 Hz, 1H), 4.77 (p, J = 1.7 Hz, 1H), 4.73 (dt, J = 2.0, 1.0 Hz, 1H), 4.61 (t, J = 4.7 Hz, 
1H), 4.28–4.17 (m, 1H), 3.66–3.58 (m, 1H), 3.06 (d, J = 17.5 Hz, 1H), 3.01–2.93 (m, 
1H), 2.83 (dd, J = 17.2, 8.6 Hz, 1H), 2.40 (d, J = 15.1 Hz, 1H), 2.37–2.20 (m, 2H), 2.16 
(dddd, J = 12.6, 6.1, 2.9, 1.8 Hz, 1H), 2.02–1.92 (m, 2H), 1.76 (t, J = 1.1 Hz, 3H), 1.65–
1.59 (m, 1H), 1.41 (s, 3H); 13C NMR (CDCl3, 101 MHz) δ 151.6, 149.0, 134.05, 129.7, 
126.9, 109.8, 100.7, 85.1, 79.0, 72.9, 52.1, 48.8, 47.7, 38.8, 37.9, 36.2, 27.9, 27.3, 21.0; 
IR (Neat Film, NaCl) 3316, 2923, 1658, 1442, 1373, 1260, 1107, 1023, 925, 888, 806, 
754 cm–1; HRMS (ES+) m/z calc’d for C19H26O4 [M•]+: 318.1831, found 318.1780; [α]D25.0 
+27.1° (c 0.200, CHCl3). 
 
 
Lactol 404:24 To a stirred solution of enone 328 (5 mg, 0.015 mmol, 1.00 equiv) in 
toluene (0.70 mL) at –78 °C (i-PrOH/dry ice bath) was added DIBAL (45 µL, 1.00 M in 
toluene, 3.00 equiv) slowly dropwise. After 1.5 h, the consumption of starting material 
was complete as determined by TLC (1:4 EtOAc:CH2Cl2 eluent). The reaction was 
quenched by the addition of saturated aqueous NH4Cl (0.5 mL) and saturated aqueous 
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warm to ambient temperature (ca. 23 °C). After stirring for 1 h, the reaction was diluted 
with CH2Cl2 (2.0 mL) and poured onto H2O (3.0 mL). The organics were separated and 
the aqueous was extracted with CH2Cl2 (4 x 1.5 mL). The combined organics were dried 
over MgSO4, filtered, and concentrated in vacuo. The crude off-white solid was purified 
by silica gel column chromatography (EtOAc eluent) to provide lactol 404 (2 mg, 40% 
yield) as an amorphous white solid: Rf = 0.23 (EtOAc eluent); 1H NMR (CDCl3, 400 
MHz) δ 5.47 (dd, J = 12.1, 5.6 Hz, 1H), 5.39 (d, J = 12.1 Hz, 1H), 4.82–4.77 (m, 1H), 
4.72 (dt, J = 1.8, 0.9 Hz, 1H), 4.58–4.51 (m, 1H), 4.22–4.13 (m, 1H), 3.55 (dd, J = 5.5, 
1.1 Hz, 1H), 3.19 (ddd, J = 7.7, 6.2, 3.8 Hz, 1H), 3.14–3.05 (m, 1H), 3.01–2.92 (m, 2H), 
2.47 (dd, J = 14.6, 6.8 Hz, 1H), 2.37 (s, 1H), 2.36–2.23 (m, 2H), 2.21–2.13 (m, 2H), 1.91 
(ddt, J = 14.1, 10.3, 5.1 Hz, 1H), 1.78 (s, 3H), 1.55–1.43 (m, 1H), 1.35 (s, 3H); 13C NMR 
(CDCl3, 101 MHz) δ 148.7, 129.7, 128.1, 109.9, 99.4, 80.3, 76.0, 73.9, 71.4, 57.6, 53.2, 
48.9, 43.4, 38.5, 38.0, 36.6, 27.8, 25.7, 21.0; IR (Neat Film, NaCl) 3388, 2925, 1660, 
1445, 1260, 1098, 1027, 888, 800, 759 cm–1; HRMS (ES+) m/z calc’d for C19H26O5 [M•]+: 
334.1780, found 334.2023; [α]D25.0 +36.2° (c 0.250, CHCl3). 
 
 
Allylic Alcohol 405: To a stirred solution of enone 324 (35 mg, 0.11 mmol, 1.00 equiv) 
in CH2Cl2 (4.5 mL) at –78 °C (i-PrOH/dry ice bath) was added DIBAL (121 µL, 1.00 M 
in toluene, 1.10 equiv) slowly dropwise. After 2 h, the reaction was quenched before the 
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eluent), by the addition of saturated aqueous NH4Cl (6.0 mL) and saturated aqueous 
Rochelle salt (6.0 mL) and immediately removed from the cooling bath and allowed to 
warm to ambient temperature (ca. 23 °C). After stirring for 1 h, the reaction was diluted 
with CH2Cl2 (10 mL) and poured onto H2O (30 mL). The organics were separated and the 
aqueous was extracted with CH2Cl2 (4 x 20 mL). The combined organics were dried over 
MgSO4, filtered, and concentrated in vacuo. The crude off-white solid was purified by 
silica gel column chromatography (60% EtOAc in hexanes eluent) to provide allylic 
alcohol 405 (4 mg, 11% yield) as an amorphous white solid: Rf = 0.28 (1:1 
EtOAc:CH2Cl2 eluent); 1H NMR (CDCl3, 400 MHz) δ 6.22 (dt, J = 8.2, 3.3 Hz, 1H), 
4.83–4.69 (m, 3H), 4.20 (q, J = 7.0, 6.5 Hz, 1H), 3.73 (dq, J = 6.0, 2.9 Hz, 1H), 3.36 (dd, 
J = 6.9, 3.0 Hz, 1H), 3.27–3.14 (m, 1H), 2.95–2.78 (m, 2H), 2.43 (d, J = 15.4 Hz, 1H), 
2.40–2.31 (m, 1H), 2.25–2.14 (m, 1H), 2.02 (dd, J = 15.5, 4.1 Hz, 1H), 1.97 (s, 1H), 1.87 
(ddt, J = 14.2, 10.6, 3.2 Hz, 1H), 1.77 (s, 3H), 1.53 (dd, J = 12.2, 9.4 Hz, 1H), 1.41 (s, 
3H); 13C NMR (CDCl3, 101 MHz) δ 174.7, 148.7, 148.3, 133.2, 128.0, 127.1, 109.6, 
82.3, 78.6, 73.0, 49.1, 47.8, 46.0, 38.7, 38.1, 37.0, 28.9, 28.4, 21.1; IR (Neat Film, NaCl) 
3379, 2925, 2855, 1761, 1442, 1373, 1283, 1225, 1151, 1102, 1048, 987, 963, 890, 849, 
805, 756 cm–1; HRMS (ES+) m/z calc’d for C19H25O4 [M+H]+: 317.1753, found 317.1759; 
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Silyl Ether 406: To a stirred solution of diol 403 (11 mg, 0.035 mmol, 1.00 equiv) in 
CH2Cl2 (2.0 mL) were added imidazole (181 mg, 2.66 mmol, 76.0 equiv) and DMAP (26 
mg, 0.21 mmol, 6.00 equiv) sequentially, each as a solid in a single portion. After 2 
minutes, to the colorless homogeneous solution was added TBSCl (80 mg, 0.53 mmol, 
15.1 equiv) as a solid in one portion. After 16 h, the consumption of starting material was 
complete as determined by TLC (1:1 EtOAc:CH2Cl2 eluent). The reaction mixture was 
diluted with hexanes (6.0 mL) and the white suspension was filtered over Celite®, 
washing with 30% EtOAc in hexanes eluent. The combined organics were concentrated 
in vacuo. The crude white solid was purified by silica gel column chromatography (5% 
EtOAc in hexanes eluent) to afford silyl ether 406 (17 mg, 89% yield) as an amorphous 
white solid: Rf = 0.43 (1:19 EtOAc:Hexanes eluent); 1H NMR (CDCl3, 400 MHz) δ 6.13 
(dt, J = 8.5, 3.4 Hz, 1H), 5.27 (d, J = 5.4 Hz, 1H), 4.71 (q, J = 1.7 Hz, 1H), 4.69 (d, J = 
1.7 Hz, 1H), 4.66 (t, J = 3.2 Hz, 1H), 4.27 (d, J = 8.8 Hz, 1H), 3.47–3.34 (m, 2H), 3.05–
2.92 (m, 1H), 2.80 (t, J = 6.1 Hz, 1H), 2.66 (dd, J = 18.5, 8.5 Hz, 1H), 2.28 (d, J = 17.6 
Hz, 1H), 2.22–2.11 (m, 2H), 2.03 (ddt, J = 11.3, 6.4, 2.4 Hz, 1H), 1.89–1.76 (m, 2H), 
1.74–1.66 (m, 3H), 1.52–1.39 (m, 1H), 1.35 (s, 3H), 0.92 (s, 9H), 0.87 (s, 9H), 0.13 (s, 
3H), 0.10 (s, 3H), 0.09 (s, 3H), 0.06 (s, 3H); 13C NMR (CDCl3, 101 MHz) δ 150.8, 148.8, 
132.5, 129.7, 126.7, 109.3, 104.0, 83.7, 78.6, 74.2, 55.8, 50.5, 46.3, 39.6, 38.7, 36.3, 28.2, 
26.2, 25.9, 25.8, 20.5, 18.4, 17.9, –3.4, –3.6, –4.7, –4.9; IR (Neat Film, NaCl) 2928, 
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Epoxide 407: To a colorless stirred solution of allylic alcohol 406 (20 mg, 0.036 mmol, 
1.00 equiv) in a vial open to air in benzene (2.0 mL) was added VO(acac)2 (1.0 mg, 
0.0036 mmol, 0.01 equiv). After 5 minutes, to this dark green solution was added t-butyl 
hydroperoxide (TBHP, 20 µL, 0.10 mmol, 2.78 equiv) as a 5 M solution in decane 
dropwise causing the reaction to immediately become deep ruby red. After 1 h, the 
reaction had lost all red color and become pale yellow and the consumption of starting 
material was complete as determined by TLC (1:19 EtOAc:Hexanes eluent). The reaction 
was concentrated in vacuo and the crude tan solid was purified by silica gel column 
chromatography (10% EtOAc in hexanes eluent) to afford epoxide 407 (18 mg, 90% 
yield) as an amorphous white solid: Rf = 0.17 (1:19 EtOAc:Hexanes eluent); 1H NMR 
(CDCl3, 400 MHz) δ  5.27 (d, J = 5.0 Hz, 1H), 4.71 (t, J = 1.6 Hz, 1H), 4.68 (dt, J = 1.9, 
0.9 Hz, 1H), 4.53 (td, J = 4.0, 2.0 Hz, 1H), 4.23 (t, J = 8.0 Hz, 1H), 3.22–3.17 (m, 1H), 
2.96 (dd, J = 6.0, 3.6 Hz, 1H), 2.82–2.65 (m, 3H), 2.62 (s, 1H), 2.43 (d, J = 17.0 Hz, 1H), 
2.25–2.09 (m, 3H), 2.02 (ddt, J = 11.3, 6.4, 2.2 Hz, 1H), 1.79–1.71 (m, 1H), 1.70 (t, J = 
1.1 Hz, 3H), 1.39 (ddd, J = 13.1, 12.1, 10.0 Hz, 1H), 1.28 (s, 3H), 0.92 (s, 9H), 0.87 (s, 
9H), 0.13 (s, 3H), 0.11 (s, 3H), 0.10 (s, 3H), 0.08 (s, 3H); 13C NMR (CDCl3, 101 MHz) δ 
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36.5, 28.2, 27.2, 26.2, 25.9, 20.5, 18.4, 17.9, –3.5, –3.6, –4.7, –4.9.; IR (Neat Film, NaCl) 
3441, 2955, 2928, 2856, 1471, 1257, 1093, 1066, 1018, 957, 878, 833, 776 cm–1; HRMS 
(FAB+) m/z calc’d for C31H53O5Si2 [(M+H)–H2]+: 561.3432, found 561.3441; [α]D25.0 




Preparation of a 0.50 M Stock Solution of Titanocene Monchloride (Cp2TiCl) 
Into a thoroughly flame-dried Schlenk tube under an overpressure of argon was 
charged with manganese(0) dust (543 mg, 9.90 mmol, 3.00 equiv) and titanocene 
dichloride (Cp2TiCl2, 822 mg, 3.30 mmol, 1.00 equiv). The flask was then evacuated and 
back filled with argon (3 x 5 minute cycles). To the reaction vessel was then added THF 
(6.6 mL) that had previously been sparged with argon for 60 minutes and stirring 
commenced. After 1.5 h, the bright red reaction mixture had become yellow-green and 
stirring was halted. After 30 minutes, the supernatant was used as a 0.50 M stock solution 
of Cp2TiCl. 
Epoxide Opening with Cp2TiCl 
A stirred solution of epoxide 407 (18 mg, 0.042 mmol, 1.00 equiv) in THF (3.0 mL) 
was sparged with argon for 1 h, resulting in a reaction volume of 2.0 mL. The 
homogeneous, off-white reaction mixture was then cooled to –78 °C (i-PrOH/dry ice 
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5 minutes, Cp2TiCl (0.88 mmol, 0.50 M in THF, 21.0 equiv) was added dropwise over 3 
minutes. After 2.5 h, the reaction vessel was warmed to 0 °C (ice/H2O bath). After an 
additional 5.5 h, the Schlenk tube was removed from the cooling bath and allowed to 
warm to ambient temperature. After an additional 42 h, the consumption of starting 
material was complete as determined by TLC (3:17 Acetone:Hexanes eluent). The 
reaction was quenched by the addition of saturated NaH2PO4 (0.25 mL) and brine (0.25 
mL), sparged with compressed air for 5 minutes, and allowed to stir for an additional 15 
minutes. The reaction mixture was then filtered through a Celite® plug, washing with 
50% acetone in hexanes eluent. The combined organics were concentrated in vacuo and 
immediately purified by silica gel column chromatography (8% acetone in hexanes 
eluent) to furnish ketal 408 (16 mg, 89% yield) as an amorphous white solid: Rf = 0.22 
(3:17 Acetone:Hexanes eluent); 1H NMR (CDCl3, 400 MHz) δ 5.46 (dd, J = 3.7, 1.0 Hz, 
1H), 4.80–4.69 (m, 2H), 4.44 (ddd, J = 6.0, 1.9, 0.8 Hz, 1H), 4.27–4.15 (m, 2H), 3.27 (d, 
J = 1.3 Hz, 1H), 3.14 (dt, J = 9.9, 3.3 Hz, 1H), 2.65–2.56 (m, 1H), 2.50–2.41 (m, 1H), 
2.39 (d, J = 9.9 Hz, 1H), 2.35–2.27 (m, 2H), 2.24 (dd, J = 14.9, 1.1 Hz, 1H), 2.17 (dddd, 
J = 16.1, 11.3, 5.5, 2.3 Hz, 1H), 1.98 (dddt, J = 13.4, 7.5, 4.7, 2.3 Hz, 2H), 1.87 (ddd, J = 
14.5, 3.2, 1.1 Hz, 1H), 1.73 (t, J = 1.1 Hz, 3H), 1.48 (ddd, J = 13.1, 12.3, 10.2 Hz, 1H), 
1.33 (d, J = 1.1 Hz, 3H), 0.91 (s, 9H), 0.09 (app s, 6H); 13C NMR (CDCl3, 101 MHz) δ 
148.7, 133.6, 126.9, 109.5, 103.6, 84.9, 82.1, 72.4, 65.8, 54.3, 51.0, 50.0, 48.3, 40.2, 39.8, 
39.5, 37.8, 29.9, 26.1, 20.5, 18.4, –3.9, –4.6; IR (Neat Film, NaCl) 3440, 2928, 2856, 
1463, 1367, 1258, 1211, 1068, 1046, 958, 869, 836, 776 cm–1; HRMS (FAB+) m/z calc’d 
for C25H39O4Si [(M+H)–H2]+: 431.2618, found 431.2622; [α]D25.0 +44.3° (c 0.150, 
CHCl3). 
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Vinylogous Diketone 412 and Dienone 413: To a stirred solution of diketone 347 (15 
mg, 0.043 mmol, 1.00 equiv) in CH2Cl2 (0.4 mL) at 0 °C (ice/H2O bath) was added Et3N 
(0.12 mL, 0.87 mmol, 20.0 equiv) dropwise. After 2 minutes, TMSOTf (24 µL, 0.13 
mmol, 3.00 equiv) was added slowly dropwise. After 1.5 h, TMSOTf (24 µL, 0.13 mmol, 
3.00 equiv) was added slowly dropwise. After an additional 1.5 h, the consumption of 
starting material was complete as determined by TLC (1:1 EtOAc:CH2Cl2 eluent). The 
reaction was quenched by the addition of saturated aqueous NaHCO3 (1.5 mL) and the 
biphasic mixture was immediately removed from the cooling bath and allowed to warm 
to ambient temperature (ca. 23 °C). The reaction mixture was diluted with Et2O (2 mL) 
and poured onto H2O (3 mL). The organics were separated and the aqueous was extracted 
with Et2O (5 x 2 mL). The combined organics were dried over MgSO4, filtered, and 
concentrated in vacuo. The crude amorphous white solid was carried on without further 
purification.  
To a stirred solution of the crude white solid in DMSO (1.5 mL) was added 
Pd(OAc)2 (30 mg, 0.13 mmol, 3.11 equiv) as a solid in single portion. After 7 h, the 
consumption of starting material was complete as determined by TLC (3:3 
EtOAc:Hexanes eluent). The dark brown reaction mixture was diluted with H2O (8 mL) 
and the aqueous was extracted with CH2Cl2 (5 x 10 mL) followed by EtOAc (2 x 5 mL). 
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crude brown solid was purified by semi-preparative HPLC (Agilent ZORBAX RX-SIL 
silica gel column, 5 µm mesh, 9.4 mm x 250 mm, mobile phase: 20% EtOAc in hexanes, 
flow rate: 7.00 mL/min) to provide vinylogous diketone 412 (retention time 9.9 minutes, 
10 mg, 56% yield) as an amorphous white solid and dienone 413 (retention time 11.4 
minutes, 8 mg, 44% yield) as an amorphous white solid. 
Vinylogous Diketone 412: Rf = 0.37 (3:7 EtOAc:Hexanes eluent); 1H NMR (CDCl3, 600 
MHz) δ 6.26 (q, J = 0.7 Hz, 1H), 4.93 (dddd, J = 9.4, 8.3, 6.8, 1.5 Hz, 1H), 4.89 (s, 1H), 
4.84–4.82 (m, 1H), 3.35 (td, J = 8.8, 1.5 Hz, 1H), 3.15 (dd, J = 8.8, 1.5 Hz, 1H), 2.77–
2.61 (m, 3H), 2.49–2.38 (m, 2H), 2.31 (ddd, J = 12.6, 7.7, 1.4 Hz, 1H), 2.19 (dtd, J = 
15.1, 2.6, 1.6 Hz, 1H), 1.81 (m, 3H), 1.66 (s, 3H), 0.11 (s, 9H); 13C NMR (CDCl3, 126 
MHz) δ 199.8, 194.3, 173.4, 156.2, 145.2, 127.7, 111.6, 96.7, 86.1, 81.2, 77.8, 54.0, 49.9, 
47.1, 44.9, 37.8, 35.3, 27.1, 20.9, 2.4; IR (Neat Film, NaCl) 2960, 2928, 1765, 1702, 
1252, 1193, 1069, 1046, 869, 841 cm–1; HRMS (FAB+) m/z calc’d for C22H29O6Si 
[M+H]+: 417.1733, found 417.1741; [α]D25.0 –16.9 ° (c 0.100, CHCl3).	  
Dienone 413: Rf = 0.37 (3:7 EtOAc:Hexanes); 1H NMR (CDCl3, 400 MHz) δ 6.64 (d, J = 
0.7 Hz, 1H), 6.44 (d, J = 2.5 Hz, 1H), 5.75 (s, 1H), 5.57 (dd, J = 1.9, 1.0 Hz, 1H), 4.93 
(tdd, J = 9.5, 8.6, 7.7, 3.4 Hz, 1H), 3.45–3.36 (m, 2H), 3.26 (dd, J = 8.8, 0.6 Hz, 1H), 
3.01 (dd, J = 17.0, 2.6 Hz, 1H), 2.48–2.38 (m, 1H), 2.37–2.30 (m, 1H), 2.08 (d, J = 1.3 
Hz, 3H), 1.68 (d, J = 1.2 Hz, 3H), 0.16–0.08 (m, 9H); 13C NMR (CDCl3, 101 MHz) δ 
193.8, 185.0, 173.2, 157.2, 151.4, 141.1, 127.0, 124.9, 122.9, 95.6, 86.5, 80.8, 78.0, 52.8, 
50.2, 47.2, 30.3, 26.8, 20.6, 2.4; IR (Neat Film, NaCl) 2959, 1770, 1702, 1660, 1611, 
1378, 1252, 1179, 1066, 1036, 870, 842, 759 cm–1; HRMS (FAB+) m/z calc’d for 
C22H27O6Si [M+H]+: 415.1577, found 415.1588; [α]D25.0 +70.9° (c 0.100, CHCl3).	  
Chapter 4 – Alternative Advancement Toward Ineleganolide 469 
 
Diketone 347:  
Preparation of a 0.07 M Stock Solution SmI2 
Into a Schlenk tube was added freshly filed samarium metal (150 mg, 1.00 mmol, 
1.41 equiv). The reaction vessel was then thoroughly flame-dried, backfilled with argon, 
and allowed to cool to ambient temperature (ca. 23 °C). To the reaction vessel was then 
added THF (10.0 mL) that had previously been sparged with argon for 60 minutes and 
cooled to 0 °C (ice/H2O bath) with stirring. EtI2 (200 mg, 0.71 mmol, 1.00 equiv) was 
then added in separate 100 mg portions 30 minutes apart. After the addition of the second 
portion, the Schlenk tube was removed from the cooling bath, allowed to warm to 
ambient temperature, and the pale yellow solution was stirred overnight (ca. 14 h) 
causing the reaction to become deep blue, indicating to formation of SmI2. 
Reduction of Vinlyogous Diketone 412 
A stirred solution of vinylogous diketone 412 (4 mg, 0.0010 mmol, 1.00 equiv) in 
THF (1.5 mL) was sparged to 1.5 h, leaving a reaction volume of 0.25 mL. The resultant 
colorless reaction mixture was then cool to –78 °C (i-PrOH/dry ice bath) at which time 
SmI2 (0.010 mmol, 0.07 M in THF, 10.0 equiv) was added dropwise. After 20 minutes, 
the consumption of starting material was complete as determined by TLC (1:4 
EtOAc:CH2Cl2 eluent). To the reaction mixture was then added TBAF (0.01 mmol, 1.0 M 
in THF, 10.0 equiv). After 10 minutes, the reaction was quenched by addition of H2O (50 
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dark yellow reaction mixture was then filtered through a pad of silica gel (50% EtOAc in 
CH2Cl2 eluent), and concentrated in vacuo. The crude dark gold solid was purified by 
silica gel column chromatography (20% EtOAc in CH2Cl2 eluent) to afford saturated 
diketone 347 (3 mg, 75% yield) as a crystalline white solid: characterization data match 
those reported above (see chapter 3, Section 3.9.2). 
 
 
Dienol ether 415: To a stirred solution of enone 328 (5 mg, 0.015 mmol, 1.00 equiv) in 
CH2Cl2 (0.5 mL) was added DMAP (7 mg, 0.057 mmol, 3.83 equiv) as a solid in one 
portion. After 2 minutes, the reaction mixture had become a completely homogenous pale 
yellow solution, and TESCl (25 µL, 0.15 mmol, 10.0 equiv) was added quickly dropwise. 
After 4 h, the consumption of starting material was complete as determined by TLC (1:4 
EtOAc:CH2Cl2 eluent). The reaction was quenched by the addition of saturated aqueous 
NaHCO3 (50 µL). After 5 minutes, the white suspension was filtered through a pad of 
silica gel (20% EtOAc in CH2Cl2 eluent). The combined organics were concentrated in 
vacuo and the resultant crude white solid was purified by silica gel column 
chromatography (30% EtOAc in hexanes eluent) to provide intermediate enol ether 415 
(1.5 mg, 50% yield) as an amorphous white solid: Rf = 0.24 (3:7 EtOAc:Hexanes eluent); 
1H NMR (CDCl3, 400 MHz) δ 4.82–4.70 (m, 3H), 4.04–3.95 (m, 1H), 3.91–3.85 (m, 1H), 
3.68 (dd, J = 16.0, 6.6 Hz, 1H), 3.49 (dd, J = 6.5, 0.7 Hz, 1H), 2.57 (dd, J = 12.9, 7.0 Hz, 
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1.31 (d, J = 1.0 Hz, 3H), 1.02 (t, J = 7.9 Hz, 6H), 0.75 (qd, J = 7.9, 0.8 Hz, 9H); 13C 
NMR (CDCl3, 101 MHz) δ 171.0, 160.7, 154.7, 147.2, 114.7, 110.5, 110.2, 73.8, 72.9, 
71.5, 53.9, 48.8, 42.4, 39.9, 36.8, 30.7, 23.6, 23.0, 21.2, 6.8, 5.9; IR (Neat Film, NaCl) 
3478, 2960, 1728, 1586, 1449, 1345, 1192, 1112, 1046, 961, 937, 889, 790, 764 cm–1; 
HRMS (FAB+) m/z calc’d for C25H37O5Si [M+H]+: 445.2410, found 445.2419; [α]D25.0 
+229.2° (c 0.100, CHCl3). 
 
 
Enol Acetate 416: To a stirred solution of enone 328 (10 mg, 0.030 mmol, 1.00 equiv) in 
CH2Cl2 (1.0 mL) was added DMAP (14 mg, 0.11 mmol, 3.67 equiv) as a solid in one 
portion. After 2 minutes, the reaction mixture had become a completely homogenous pale 
yellow solution, and Ac2O (30 µL, 0.32 mmol, 10.7 equiv) was added quickly dropwise. 
After 2 h, the consumption of starting material was complete as determined by TLC (1:4 
EtOAc:CH2Cl2 eluent). The reaction was diluted with CH2Cl2 (3 mL) and poured onto 
saturated aqueous NaHCO3 (3 mL). The organics were separated and the aqueous was 
extracted with CH2Cl2 (2 x 5 mL). The combined organics were dried over MgSO4, 
filtered, and concentrated in vacuo. The crude golden solid was purified by silica gel 
column chromatography (50% EtOAc with 0.5% Et3N in hexanes eluent) to provide enol 
acetate 416 (11 mg, 85% yield) as an amorphous white solid: Rf = 0.42 (1:1 
EtOAc:Hexanes eluent); 1H NMR (CDCl3, 400 MHz) δ 4.84 (ddd, J = 9.4, 7.9, 7.2 Hz, 
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6.5, 0.7 Hz, 1H), 3.24 (dd, J = 16.1, 6.5 Hz, 1H), 3.01 (dd, J = 13.2, 7.2 Hz, 1H), 2.57–
2.24 (m, 6H), 2.23 (s, 3H), 1.98 (s, 3H), 1.77–1.72 (m, 3H), 1.61 (d, J = 1.0 Hz, 3H); 13C 
NMR (CDCl3, 101 MHz) δ 170.2, 170.0, 168.1, 156.0, 152.4, 146.7, 122.2, 115.1, 110.6, 
80.9, 73.1, 69.7, 53.2, 46.3, 42.8, 39.7, 34.2, 30.5, 23.6, 21.9, 21.7, 21.1, 21.0; IR (Neat 
Film, NaCl) 2925, 1740, 1615, 1440, 1372, 1241, 1204, 1153, 1118, 1043, 968, 934, 899, 
792, 754 cm–1; HRMS (FAB+) m/z calc’d for C23H27O7 [M+H]+: 415.1757, found 
415.1737; [α]D25.0 +241.6° (c 0.100, CHCl3). 
 
 
Bromide 420: To a stirred solution of enone 328 (15 mg, 0.047 mmol, 1.00 equiv) in 
CH2Cl2 (3.0 mL) was added DMAP (25 mg, 0.20 mmol, 4.36 equiv) as a solid in one 
portion. After 2 minutes, the reaction mixture had become a completely homogenous pale 
yellow solution, and TBSCl (70 mg, 0.46 mmol, 9.79 equiv) was added as a solution in 
CH2Cl2 (0.7 mL) quickly dropwise over 2 minutes. After 2 h, the consumption of starting 
material was complete as determined by TLC (1:4 EtOAc:CH2Cl2 eluent). The reaction 
was quenched by the addition of Et3N (0.30 mL, 2.15 mmol, 45.7 equiv) in hexanes (3.0 
mL) with stirring. After 5 minutes, the white suspension was loaded directly onto a silica 
gel column and purified by silica gel column chromatography (30% EtOAc with 0.5% 
Et3N in hexanes eluent, silica gel deactivated by wet loading with eluent prior to 
purification) to provide intermediate enol ether 429 (20 mg, >99% yield), which was 
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To a clear, colorless stirred solution of a portion of enol ether 429 (5 mg, 0.011 
mmol, 1.00 equiv) in CH2Cl2 (0.6 mL) at –78 °C (i-PrOH/dry ice bath) was added N-
bromosuccinimide (NBS, 3.4 mg, 0.019 mmol, 1.73 equiv) as a solid in a single portion 
to provide a homogenous, colorless reaction mixture. After 2 h, the consumption of 
starting material was complete as determined by TLC (1:1 EtOAc:Hexanes eluent). The 
reaction was quenched by the addition of saturated aqueous Na2S2O3 (0.5 mL) and the 
reaction vessel was immediately removed from the cooling bath and allowed to warm to 
ambient temperature (ca. 23 °C). The biphasic solution was then diluted with CH2Cl2 (4.0 
mL) and poured onto saturated aqueous NaHCO3 (3.0 mL). The organics were separated 
and the aqueous was extracted with CH2Cl2 (3 x 2 mL). The combined organics were 
dried over MgSO4, filtered, and concentrated in vacuo. The crude white solid was 
purified by silica gel column chromatography (50% EtOAc in hexanes eluent) to afford 
bromide 420 (4 mg, 80% yield) as an amorphous white solid: Rf = 0.32 (1:1 
EtOAc:Hexanes eluent); 1H NMR (CDCl3, 400 MHz) δ 5.18 (ddd, J = 5.1, 4.2, 2.2 Hz, 
1H), 4.88–4.83 (m, 1H), 4.77 (q, J = 1.0 Hz, 1H), 3.96 (dd, J = 17.3, 6.7 Hz, 1H), 3.68 
(ddt, J = 16.8, 3.5, 1.9 Hz, 1H), 3.62 (d, J = 4.2 Hz, 1H), 3.36 (d, J = 6.6 Hz, 1H), 2.80–
2.65 (m, 2H), 2.62–2.49 (m, 1H), 2.49–2.42 (m, 2H), 2.39 (dd, J = 3.5, 1.3 Hz, 2H), 
2.37–2.32 (m, 1H), 1.82 (s, 3H), 1.35 (s, 3H); 13C NMR (CDCl3, 101 MHz) δ 198.8, 
169.3, 150.2, 146.4, 129.0, 110.8, 80.7, 75.1, 69.8, 62.1, 54.3, 52.4, 45.1, 43.1, 40.6, 35.6, 
27.4, 21.1, 20.8; IR (Neat Film, NaCl) 3508, 2965, 1774, 1668, 1443, 1367, 1260, 1168, 
1100, 973, 894, 789, 759 cm–1; HRMS (FAB+) m/z calc’d for C19H22O581Br [M+H]+: 
411.0630, found 411.0634; [α]D25.0 +141.1° (c 0.200, CHCl3). 
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Diene 422: To a stirred solution of enone 328 (46 mg, 0.14 mmol, 1.00 equiv) in CH2Cl2 
(6.0 mL) was added DMAP (85 mg, 0.70 mmol, 5.00 equiv) as a solid in one portion. 
After 2 minutes, the reaction mixture had become a completely homogenous pale yellow 
solution, and TBSCl (210 mg, 1.39 mmol, 10.0 equiv) was added as a solution in CH2Cl2 
(2.1 mL) quickly dropwise over 2 minutes. After 2 h, the consumption of starting 
material was complete as determined by TLC (1:4 EtOAc:CH2Cl2 eluent). The reaction 
was quenched by the addition of Et3N (0.97 mL, 7.0 mmol, 50.0 equiv) in hexanes (6.0 
mL) with stirring. After 5 minutes, the white suspension was loaded directly onto a silica 
gel column and purified by silica gel column chromatography (30% EtOAc with 0.5% 
Et3N in hexanes eluent, silica gel deactivated by wet loading with eluent prior to 
purification) to provide intermediate enol ether 429 (62 mg, >99% yield), which was 
immediately carried on to the next transformation.  
To a clear, colorless stirred solution to enol ether 429 (62 mg, 0.14 mmol, 1.00 
equiv) in DMSO (3.0 mL) was added Pd(OAc)2 (35 mg, 0.016 mmol, 1.14 equiv) as a 
solid in a single portion. After 2 h, the golden yellow homogeneous reaction mixture had 
become dark brown and the consumption of starting material was complete as determined 
by TLC (3:7 EtOAc:Hexanes eluent). The reaction was then diluted with EtOAc (10 mL) 
and poured onto H2O (30 mL).  The organics were separated and the aqueous was 
extracted with EtOAc (3 x 20 mL). The combined organics were washed with H2O (30 




























Chapter 4 – Alternative Advancement Toward Ineleganolide 475 
concentrated in vacuo.  The crude brown solid was purified by silica gel column 
chromatography (55% EtOAc in hexanes eluent) to afford diene 422 (27 mg, 60% yield) 
as an amorphous white solid: Rf = 0.25 (1:1 EtOAc:Hexanes eluent); 1H NMR (CDCl3, 
400 MHz) δ 7.19 (d, J = 4.6 Hz, 1H), 4.98 (ddd, J = 8.4, 7.5, 6.8 Hz, 1H), 4.83 (h, J = 1.5 
Hz, 1H), 4.72–4.65 (m, 1H), 3.72 (d, J = 4.6 Hz, 1H), 3.59–3.47 (m, 2H), 3.18–3.05 (m, 
1H), 2.73–2.60 (m, 3H), 2.56–2.46 (m, 1H), 2.15 (d, J = 1.0 Hz, 1H), 1.87 (ddd, J = 13.7, 
7.0, 1.2 Hz, 1H), 1.79 (dt, J = 1.2, 0.6 Hz, 3H), 1.41 (t, J = 1.0 Hz, 3H); 13C NMR 
(CDCl3, 101 MHz) δ 197.5, 169.5, 146.3, 145.9, 140.5, 137.7, 119.6, 111.5, 94.9, 74.6, 
74.5, 52.1, 47.1, 44.0, 43.7, 37.9, 31.7, 23.8, 21.3; IR (Neat Film, NaCl) 3459, 2923, 
2852, 1742, 1706, 1634, 1449, 1377, 1259, 1173, 1090, 1026, 798 cm–1; HRMS (FAB+) 




Cycloheptatrienone 423: To a reaction vessel in a nitrogen-filled glovebox was charged 
Yb(OTf)3 (8 mg, 0.013 mmol, 1.08 equiv). The reaction vessel was sealed, removed from 
the glovebox, and introduced to an argon atmosphere. To the white solid was added diene 
422 (4 mg, 0.012 mmol, 1.00 equiv) as a solution in toluene (1.0 mL) with stirring. The 
white suspension was then introduced to a preheated 50 °C bath. After 7 h, the reaction 
was further heated to 80 °C. After an additional 17 h, the reaction was heated to 100 °C. 
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EtOAc:Hexanes eluent). The golden yellow heterogeneous reaction mixture was removed 
from the heating bath and allowed to cool to ambient temperature (ca. 23 °C). The 
reaction was then concentrated in vacuo. The crude golden brown solid was purified by 
silica gel column chromatography (40% EtOAc in hexanes eluent) to provide 
cycloheptatrienone 423 (3 mg, 75% yield) as an amorphous white solid: Rf = 0.09 (3:7 
EtOAc:Hexanes eluent); 1H NMR (CDCl3, 400 MHz) δ 8.85 (s, 1H), 5.54 (dd, J = 12.8, 
5.5 Hz, 1H), 4.94–4.91 (m, 1H), 4.86 (dd, J = 1.8, 0.9 Hz, 1H), 3.95 (ddd, J = 18.4, 4.0, 
2.0 Hz, 1H), 3.57 (s, 1H), 3.18 (dd, J = 18.5, 10.2 Hz, 1H), 2.99–2.80 (m, 3H), 2.72 (dd, 
J = 16.0, 11.7 Hz, 1H), 2.20 (t, J = 12.3 Hz, 1H), 1.89–1.79 (m, 3H), 1.59 (s, 3H); 13C 
NMR (CDCl3, 101 MHz) δ 197.4, 195.4, 168.1, 158.5, 151.0, 145.3, 135.9, 131.7, 124.6, 
123.8, 112.2, 75.2, 73.8, 43.8, 42.6, 41.0, 30.4, 25.7, 20.8; IR (Neat Film, NaCl) 3366, 
2923, 2853, 1775, 1692, 1603, 1441, 1332, 1261, 1202, 1090, 1046, 988, 891, 801 cm–1; 
HRMS (ES+) m/z calc’d for C19H19O5 [M+H]+: 327.1232, found 327.1236; [α]D25.0 +22.7° 
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13. The C(3) configuration of allylic alcohol 383 was determined by two-dimensional 
1H NOE studies and the positive NOE correlation between the methine protons at 
C(1) and C(3). 
14. Reexposure of isolated silyl ethers 389 and 390 to the reaction conditions did not 
result in any detectable interconversion between the two products. 
15. Under titanium(III)-mediated reductive epoxide opening conditions as employed 
in Scheme 4.4.5, diol 383 failed to furnish any expected product.  Rather, 
dehydration of the secondary alcohol at C(3) was routinely observed under the 
acidic reaction conditions, as determined by crude 1H NMR.	  
16. The relative stereochemistry of products 394 and 397 was assigned by analogy to 
ketones 373 and 375, whose configurations were established unambiguously by 
single crystal X-ray diffraction. 
17. Attempts to oxidize enol ether 399 focused on reaction conditions employing 
stoichiometric palladium(II) (e.g., Pd(OAc)2/DMSO) and halogenation reagents 
(e.g., NBS/CH2Cl2). 
18. In solution, the s-trans conformation of extended enone 413 is preferred and was 
determined by two-dimensional 1H NOE studies and the positive NOE correlation 

























1:1 mixture of diastereomers
3 3
Chapter 4 – Alternative Advancement Toward Ineleganolide 481 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
19. (a) Szostak, M.; Spain, M.; Procter, D. J. J. Org. Chem. 2014, 79, 2522–2537. (b) 
Egger, J.; Bretscher, P.; Freigang, S.; Kopf, M.; Carreira, E. M. Angew. Chem., 
Int. Ed. 2013, 52, 5382–5385. (c) Shoji, M.; Uno, T.; Kakeya, H.; Onose, R.; 
Shiina, I.; Osada, H.; Hayashi, Y. J. Org. Chem. 2005, 70, 9905–9915. (d) 
Yamaguchi, J.; Kakeya, H.; Uno, T.; Shoji, M.; Osada, H.; Hayashi, Y. Angew. 
Chem., Int. Ed. 2005, 44, 3110–3115. (e) Ready, J. M.; Reisman, S. E.; Hirata, 
M.; Weiss, M. M.; Tamaki, K.; Ovaska, T. V.; Wood, J. L. Angew. Chem. Int. Ed. 
2004, 43, 1270–1272. (f) Fuchs, J. R.; Mitchell, M. L.; Shabangi, M.; Flowers, R. 
A. Tetrahedron Lett. 1997, 38, 8157–8158. (g) Molander, G. A.; Hahn, G. J. Org. 
Chem. 1986, 51, 1135–1138. (h) Molander, G. A.; Hahn, G. J. Org. Chem. 1986, 
51, 2596–2599.  
20. The relative stereochemistry of bromide 420 was assigned by analogy to the 
unambiguous assignment of the relative stereochemistry of diene 324 by single 
crystal X-ray diffraction (see Chapter 3 and Figure 3.4.1).  
21. (a) Li, Y.; Pattenden, G. Nat. Prod. Rep. 2011, 28, 1269–1310. (b) Li, Y.; 
Pattenden, G. Nat. Prod. Rep. 2011, 28, 429–440. (c) Li, Y.; Pattenden, G. 
Tetrahedron 2011, 67, 10045–10052.	  
22. Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. 
Organometallics 1996, 15, 1518–1520. 
23. No clean HRMS peak for the parent mass of lactol 403 could be observed, despite 
screening all instruments and ionization sources available to us. The acid required 
for most ionization methods is likely causing decomposition of the free lactol. 
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The major mass peaks observed for this compound by ES+ were: 253.1585, 
299.1633, 317.1746, 318.1780. 
24. No clean HRMS peak for the parent mass of lactol 404 could be observed, despite 
screening all instruments and ionization sources available to us. The acid required 
for most ionization methods is likely causing decomposition of the free lactol. 
The major mass peaks observed for this compound by ES+ were: 281.1531, 
282.1579, 322.1805, 334.2023, 335.2060. 






Synthetic Summary for Chapter 4: 
Revised Plan for the Synthesis of Ineleganolide: 
Alternative Advancement Toward the Asymmetric Total Synthesis  














Appendix 9 – Synthetic Summary for Chapter 4   484 
Scheme A9.1. Synthesis of 2H-Ineleganolide (373) Through Conjugate Reduction of Diene 324 
 
 
Scheme A9.2. Formation of Translactonized Polycycle 378 
 
 
Scheme A9.3. 1,2-Reduction of Isoineleganolide A (328) and Subsequent Silyl Ether Formation with 








































1) Cp2TiCl2 , Zn0
    H2O, THF
    –78 °C → 23 °C, 22 h
2) DMP
    ClCH2CH2Cl










































    THF, –78 °C,  15 min
2. TBSCl, DMAP
    imidazole, CH2Cl2
    0 °C → 23 °C, 25 h
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(26% yield) (74% yield)
328
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Scheme A9.4. Advancement of Isomeric Allylic Silyl Ether 389 and Unsaturated Lactone 390 
 
 
Scheme A9.5. Construction and Transformation of Lactol 403  
 
 



























































































































































     CH2Cl2 , 2h
2. Pd(OAc)2
    DMSO, 2 h









23 °C  → 100 °C
35 h
O
(75% yield) 423Isoineleganolide A
328
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Figure A10.2. Infrared spectrum (Thin Film, NaCl) of compound 372. 
 
Figure A10.3. 13C NMR (126 MHz, CDCl3) of compound 372. 
 













































































































Figure A10.5. Infrared spectrum (Thin Film, NaCl) of compound 371. 
 
Figure A10.6. 13C NMR (126 MHz, CDCl3) of compound 371. 
 
















































































































Figure A10.8. Infrared spectrum (Thin Film, NaCl) of compound 374. 
 
Figure A10.9. 13C NMR (126 MHz, CDCl3) of compound 374. 
 

























































































































Figure A10.11. Infrared spectrum (Thin Film, NaCl) of compound 373. 
 
Figure A10.12. 13C NMR (126 MHz, CDCl3) of compound 373. 
 
















































































































Figure A10.14. Infrared spectrum (Thin Film, NaCl) of compound 375. 
 
Figure A10.15. 13C NMR (126 MHz, CDCl3) of compound 375. 
 















































































































Figure A10.17. Infrared spectrum (Thin Film, NaCl) of compound 376. 
 
Figure A10.18. 13C NMR (101 MHz, CDCl3) of compound 376. 
 
















































































































Figure A10.20. Infrared spectrum (Thin Film, NaCl) of compound 377. 
 
Figure A10.21. 13C NMR (101 MHz, CDCl3) of compound 377. 
 

















































































































Figure A10.23. Infrared spectrum (Thin Film, NaCl) of compound 378. 
 
Figure A10.24. 13C NMR (101 MHz, CDCl3) of compound 378. 
 













































































































Figure A10.26. Infrared spectrum (Thin Film, NaCl) of compound 383. 
 
Figure A10.27. 13C NMR (126 MHz, CDCl3) of compound 383. 
 















































































































Figure A10.29. Infrared spectrum (Thin Film, NaCl) of compound 384. 
 
Figure A10.30. 13C NMR (126 MHz, CDCl3) of compound 384. 
 
















































































































Figure A10.32. Infrared spectrum (Thin Film, NaCl) of compound 385. 
 
Figure A10.33. 13C NMR (126 MHz, CDCl3) of compound 385. 
 















































































































Figure A10.35. Infrared spectrum (Thin Film, NaCl) of compound 389. 
 
Figure A10.36. 13C NMR (101 MHz, CDCl3) of compound 389. 
 















































































































Figure A10.38. Infrared spectrum (Thin Film, NaCl) of compound 390. 
 
Figure A10.39. 13C NMR (101 MHz, CDCl3) of compound 390. 
 















































































































Figure A10.41. Infrared spectrum (Thin Film, NaCl) of compound 391. 
 
Figure A10.42. 13C NMR (101 MHz, CDCl3) of compound 391. 
 
















































































































Figure A10.44. Infrared spectrum (Thin Film, NaCl) of compound 393. 
 
Figure A10.45. 13C NMR (101 MHz, CDCl3) of compound 393. 
 

















































































































Figure A10.47. Infrared spectrum (Thin Film, NaCl) of compound 396. 
 
Figure A10.48. 13C NMR (101 MHz, CDCl3) of compound 396. 
 















































































































Figure A10.50. Infrared spectrum (Thin Film, NaCl) of compound 394. 
 
Figure A10.51. 13C NMR (101 MHz, CDCl3) of compound 394. 
 
















































































































Figure A10.53. Infrared spectrum (Thin Film, NaCl) of compound 397. 
 
Figure A10.54. 13C NMR (101 MHz, CDCl3) of compound 397. 
 




















































































































Figure A10.56. Infrared spectrum (Thin Film, NaCl) of compound 399. 
 
Figure A10.57. 13C NMR (101 MHz, CDCl3) of compound 399. 
 
















































































































Figure A10.59. Infrared spectrum (Thin Film, NaCl) of compound 401. 
 
 Figure A10.60. 13C NMR (101 MHz, C6D6) of compound 401. 
 














































































































Figure A10.62. Infrared spectrum (Thin Film, NaCl) of compound 403. 
 
Figure A10.63. 13C NMR (101 MHz, CDCl3) of compound 403. 
 















































































































Figure A10.65. Infrared spectrum (Thin Film, NaCl) of compound 404. 
 
Figure A10.66. 13C NMR (101 MHz, CDCl3) of compound 404. 
 














































































































Figure A10.68. Infrared spectrum (Thin Film, NaCl) of compound 405. 
 
Figure A10.69. 13C NMR (101 MHz, CDCl3) of compound 405. 
 

















































































































Figure A10.71. Infrared spectrum (Thin Film, NaCl) of compound 406. 
 
Figure A10.72. 13C NMR (101 MHz, CDCl3) of compound 406. 
 














































































































Figure A10.74. Infrared spectrum (Thin Film, NaCl) of compound 407. 
 
Figure A10.75. 13C NMR (101 MHz, CDCl3) of compound 407. 
 

















































































































Figure A10.77. Infrared spectrum (Thin Film, NaCl) of compound 408. 
 
Figure A10.78. 13C NMR (101 MHz, CDCl3) of compound 408. 
 















































































































Figure A10.80. Infrared spectrum (Thin Film, NaCl) of compound 412. 
 
Figure A10.81. 13C NMR (126 MHz, CDCl3) of compound 412. 
 















































































































Figure A10.83. Infrared spectrum (Thin Film, NaCl) of compound 413. 
 
Figure A10.84. 13C NMR (101 MHz, CDCl3) of compound 413. 
 














































































































Figure A10.86. Infrared spectrum (Thin Film, NaCl) of compound 415. 
 
Figure A10.87. 13C NMR (101 MHz, CDCl3) of compound 415. 
 














































































































Figure A10.89. Infrared spectrum (Thin Film, NaCl) of compound 416. 
 
Figure A10.90. 13C NMR (101 MHz, CDCl3) of compound 416. 
 














































































































Figure A10.92. Infrared spectrum (Thin Film, NaCl) of compound 420. 
 
Figure A10.93. 13C NMR (101 MHz, CDCl3) of compound 420. 
 
























































































































Figure A10.95. Infrared spectrum (Thin Film, NaCl) of compound 422. 
 
Figure A10.96. 13C NMR (101 MHz, CDCl3) of compound 422. 
 



























































































































Figure A10.98. Infrared spectrum (Thin Film, NaCl) of compound 423. 
 
Figure A10.99. 13C NMR (101 MHz, CDCl3) of compound 423. 
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A11.1   X-Ray Crystal Structure Analysis of Epoxide 371 
 
Contents 
Table A11.1.1. Experimental Details 
Table A11.1.2. Crystal Data 
Table A11.1.3. Atomic Coordinates  
Table A11.1.4. Full Bond Distances and Angles 
Table A11.1.5. Anisotropic Displacement Parameters 
Table A11.1.6. Hydrogen Atomic Coordinates 
Table A11.1.7. Torsion Angles 
Table A11.1.8. Hydrogen Bond Distances and Angle 
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Table A11.1.1. Experimental Details for X-Ray Structure Determination of Epoxide 371. 
Low-temperature diffraction data (φ-and ω-scans) were collected on a Bruker AXS 
KAPPA APEX II diffractometer coupled to a APEX II CCD detector with graphite 
monochromated Mo Kα radiation (λ = 0.71073 Å) for the structure of epoxide 371 and on 
a Bruker AXS D8 VENTURE KAPPA diffractometer coupled to a PHOTON 100 CMOS 
detector with Cu Kα radiation (λ = 1.54178 Å) from an IµS micro-source for the structure 
of compound P15149 and P15156. The structure was solved by direct methods using 
SHELXS1 and refined against F2 on all data by full-matrix least squares with SHELXL-
20142 using established refinement techniques.3 All non-hydrogen atoms were refined 
anisotropically. Unless otherwise noted, all hydrogen atoms were included into the model 
at geometrically calculated positions and refined using a riding model. The isotropic 
displacement parameters of all hydrogen atoms were fixed to 1.2 times the U value of the 
atoms they are linked to (1.5 times for methyl groups).  
Epoxide 371 crystallizes in the orthorhombic space group P212121 with one 
molecule in the asymmetric unit. The coordinates for all hydrogen atoms were located in 
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Table A11.1.2. Crystal Data and Structure Refinement for Epoxide 371. 
Caltech Identification code  a14286 
CCDC Deposition Number 1061014 
Empirical formula  C19 H24 O5 
Formula weight  332.38 
Temperature  100 K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P 21 21 21 
Unit cell dimensions a = 6.2703(9) Å α= 90° 
 b = 11.2931(16) Å β= 90° 
 c = 23.177(4) Å γ = 90° 
Volume 1641.2(4) Å3 
Z 4 
Density (calculated) 1.345 Mg/m3 
Absorption coefficient 0.097 mm-1 
F(000) 712 
Crystal size 0.57 x 0.25 x 0.03 mm3 
Theta range for data collection 1.757 to 33.933°. 
Index ranges –9 ≤ h ≤ 9, –17 ≤ k ≤ 17, –36 ≤ l ≤ 35 
Reflections collected 42176 
Independent reflections 6378 [R(int) = 0.0463] 
Completeness to theta = 25.000° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.0000 and 0.8611 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6378 / 0 / 313 
Goodness-of-fit on F2 1.447 
Final R indices [I>2sigma(I)] R1 = 0.0413, wR2 = 0.0809 
R indices (all data) R1 = 0.0538, wR2 = 0.0831 
Absolute structure parameter -0.6(2) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.392 and -0.199 e.Å-3 
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Table A11.1.3.       Atomic coordinates (x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for Epoxide 371.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor.  
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 60147(17) 38434(9) 46552(5) 183(2) 
O(2) 76160(20) 34388(10) 35657(5) 243(3) 
O(3) 43551(17) 62722(10) 44133(4) 179(2) 
O(4) 26855(17) 58723(10) 52373(5) 212(2) 
O(5) 82780(20) 28834(10) 65931(5) 252(3) 
C(1) 78760(20) 45191(12) 44797(6) 146(3) 
C(2) 78900(20) 57950(12) 46746(6) 134(2) 
C(3) 66120(20) 60975(12) 52169(5) 121(2) 
C(4) 71270(20) 55487(12) 58083(6) 124(2) 
C(5) 69870(20) 41806(12) 58441(6) 161(3) 
C(6) 86020(30) 35128(14) 54757(7) 229(3) 
C(7) 81550(30) 34815(13) 48377(6) 202(3) 
C(8) 81980(20) 45267(13) 38266(6) 175(3) 
C(9) 67800(30) 55912(15) 36501(6) 203(3) 
C(10) 65480(20) 63631(13) 41907(6) 161(3) 
C(11) 43420(20) 60300(12) 49886(6) 153(3) 
C(12) 57290(20) 61462(13) 62695(6) 153(3) 
C(13) 62610(20) 57484(13) 68893(6) 156(3) 
C(14) 59610(30) 44006(14) 69216(6) 192(3) 
C(15) 72060(30) 37435(13) 64686(6) 179(3) 
C(16) 105320(30) 47240(15) 36731(7) 214(3) 
C(17) 84150(20) 61913(14) 70905(6) 161(3) 
C(18) 85030(30) 74981(15) 72048(8) 263(3) 
C(19) 101020(30) 55096(17) 71833(8) 247(3) 
________________________________________________________________________________ 
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Table A11.1.4.      Bond lengths [Å] and angles [°] for Epoxide 371. 
_____________________________________________________  
O(1)-C(1)  1.4523(18) 
O(1)-C(7)  1.465(2) 
O(2)-H(2)  0.87(3) 
O(2)-C(8)  1.4172(18) 
O(3)-C(10)  1.4725(18) 
O(3)-C(11)  1.3611(17) 
O(4)-C(11)  1.2015(18) 
O(5)-C(15)  1.2160(19) 
C(1)-C(2)  1.5101(19) 
C(1)-C(7)  1.446(2) 
C(1)-C(8)  1.527(2) 
C(2)-H(2A)  0.97(2) 
C(2)-C(3)  1.5290(19) 
C(2)-C(10)  1.542(2) 
C(3)-H(3)  0.970(17) 
C(3)-C(4)  1.5385(19) 
C(3)-C(11)  1.5205(19) 
C(4)-H(4)  0.987(18) 
C(4)-C(5)  1.5497(19) 
C(4)-C(12)  1.5383(19) 
C(5)-H(5)  1.010(19) 
C(5)-C(6)  1.524(2) 
C(5)-C(15)  1.5356(19) 
C(6)-H(6A)  1.00(2) 
C(6)-H(6B)  0.944(19) 
C(6)-C(7)  1.505(2) 
C(7)-H(7)  0.990(18) 
C(8)-C(9)  1.550(2) 
C(8)-C(16)  1.522(2) 
C(9)-H(9A)  0.970(19) 
C(9)-H(9B)  0.95(2) 
C(9)-C(10)  1.533(2) 
C(10)-H(10)  0.952(18) 
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Table A11.1.4. (cont’d) 
C(12)-H(12A)  0.961(19) 
C(12)-H(12B)  0.97(2) 
C(12)-C(13)  1.542(2) 
C(13)-H(13)  0.981(18) 
C(13)-C(14)  1.536(2) 
C(13)-C(17)  1.514(2) 
C(14)-H(14A)  0.991(18) 
C(14)-H(14B)  1.05(2) 
C(14)-C(15)  1.504(2) 
C(16)-H(16A)  0.96(2) 
C(16)-H(16B)  0.98(2) 
C(16)-H(16C)  0.93(2) 
C(17)-C(18)  1.500(2) 
C(17)-C(19)  1.326(2) 
C(18)-H(18A)  0.96(2) 
C(18)-H(18B)  1.00(2) 
C(18)-H(18C)  0.99(2) 
C(19)-H(19A)  0.95(2) 
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Symmetry transformations used to generate equivalent atoms:  
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Table A11.1.5.  Anisotropic displacement parameters  (Å2x103) for Epoxide 371.  The anisotropic 
displacement factor exponent takes the form: -2π2[ h2a*2U11  + ... + 2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 194(5)  141(5) 216(5)  -23(4) 1(4)  -37(4) 
O(2) 261(6)  241(6) 228(5)  -109(4) 20(5)  -44(5) 
O(3) 135(5)  224(5) 176(5)  -14(4) -40(4)  36(4) 
O(4) 115(5)  294(6) 226(5)  -25(4) -17(4)  11(4) 
O(5) 362(7)  157(5) 238(5)  21(4) -73(5)  38(5) 
C(1) 123(6)  145(6) 169(6)  -27(5) -3(5)  3(5) 
C(2) 111(6)  138(6) 152(6)  0(5) -26(5)  -14(5) 
C(3) 98(5)  99(6) 167(6)  -5(5) -20(5)  1(5) 
C(4) 103(6)  115(6) 154(6)  -11(5) -19(5)  2(5) 
C(5) 197(7)  118(6) 170(6)  2(5) -23(6)  17(5) 
C(6) 309(9)  172(7) 207(7)  3(5) -1(6)  128(7) 
C(7) 244(8)  148(6) 213(7)  -27(5) 10(6)  50(6) 
C(8) 176(7)  186(7) 164(6)  -39(5) -15(5)  -15(6) 
C(9) 192(7)  265(8) 152(6)  -20(5) -33(6)  16(6) 
C(10) 154(6)  159(7) 170(6)  21(5) -20(5)  -6(5) 
C(11) 146(6)  131(6) 183(6)  -29(5) -34(5)  31(5) 
C(12) 130(6)  161(6) 168(6)  -19(5) -10(5)  29(5) 
C(13) 139(6)  177(7) 153(6)  1(5) 5(5)  10(5) 
C(14) 195(7)  201(7) 179(6)  19(6) 4(6)  -37(6) 
C(15) 210(7)  128(6) 199(6)  -1(5) -32(6)  -49(6) 
C(16) 177(7)  264(8) 202(7)  -39(6) 23(6)  4(6) 
C(17) 186(7)  178(7) 119(5)  6(5) 6(5)  -23(6) 
C(18) 330(9)  184(7) 276(8)  -7(6) -68(7)  -44(7) 
C(19) 185(7)  263(9) 294(8)  -41(7) -57(6)  -7(6) 
______________________________________________________________________________ 
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Table A11.1.6.      Hydrogen coordinates (x104) and isotropic  displacement parameters (Å2x103)  
for Epoxide 371. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 6290(50) 3280(20) 3652(11) 50(7) 
H(2A) 9360(40) 6063(19) 4700(10) 37(6) 
H(3) 6760(30) 6945(15) 5272(7) 13(4) 
H(4) 8620(30) 5757(15) 5899(7) 8(4) 
H(5) 5490(30) 3966(16) 5724(8) 18(5) 
H(6A) 10040(30) 3871(16) 5545(8) 21(5) 
H(6B) 8650(30) 2724(17) 5610(8) 24(5) 
H(7) 8570(30) 2753(16) 4627(7) 14(4) 
H(9A) 7380(30) 6011(17) 3323(8) 24(5) 
H(9B) 5420(40) 5320(19) 3527(9) 29(5) 
H(10) 6820(30) 7182(16) 4126(7) 13(4) 
H(12A) 5870(30) 6992(17) 6239(8) 18(4) 
H(12B) 4240(30) 5975(16) 6195(8) 20(5) 
H(13) 5190(30) 6103(15) 7144(7) 14(4) 
H(14A) 6340(30) 4104(16) 7310(8) 19(4) 
H(14B) 4330(40) 4230(20) 6848(10) 40(6) 
H(16A) 11450(40) 4137(19) 3839(9) 31(5) 
H(16B) 11090(30) 5461(18) 3832(8) 24(5) 
H(16C) 10680(30) 4740(16) 3273(9) 23(5) 
H(18A) 8190(30) 7938(19) 6859(10) 36(6) 
H(18B) 9970(40) 7730(18) 7331(10) 34(6) 
H(18C) 7410(40) 7700(20) 7496(10) 42(6) 
H(19A) 11370(40) 5870(20) 7323(9) 35(5) 
H(19B) 10090(40) 4700(20) 7118(9) 36(6) 
________________________________________________________________________________ 
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Symmetry transformations used to generate equivalent atoms:  
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Table A11.1.8.      Hydrogen bonds for Epoxide 371 [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(2)-H(2)...O(5)#1 0.87(3) 2.37(3) 3.1244(19) 145(2) 
 C(2)-H(2A)...O(4)#2 0.97(2) 2.44(2) 3.2790(18) 144.5(17) 
 C(3)-H(3)...O(3)#3 0.970(17) 2.688(17) 3.5378(17) 146.5(13) 
 C(6)-H(6B)...O(1)#4 0.944(19) 2.39(2) 3.0758(19) 129.3(15) 
 C(16)-H(16B)...O(3)#2 0.98(2) 2.61(2) 3.427(2) 140.8(16) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 x-1/2,-y+1/2,-z+1    #2 x+1,y,z    #3 x+1/2,-y+3/2,-z+1       
#4 x+1/2,-y+1/2,-z+1       
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A11.2   X-Ray Crystal Structure Analysis of 2H-Ineleganolide (373) 
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Table A11.2.1. Experimental Details for X-Ray Structure Determination of 2H-Ineleganolide (373). 
Low-temperature diffraction data (φ-and ω-scans) were collected on a Bruker AXS 
KAPPA APEX II diffractometer coupled to a APEX II CCD detector with graphite 
monochromated Mo Kα radiation (λ = 0.71073 Å) for the structure of 2H-ineleganolide 
(373) and on a Bruker AXS D8 VENTURE KAPPA diffractometer coupled to a 
PHOTON 100 CMOS detector with Cu Kα radiation (λ = 1.54178 Å) from an IµS micro-
source for the structure of compound P15149 and P15156. The structure was solved by 
direct methods using SHELXS1 and refined against F2 on all data by full-matrix least 
squares with SHELXL-20142 using established refinement techniques.3 All non-hydrogen 
atoms were refined anisotropically. Unless otherwise noted, all hydrogen atoms were 
included into the model at geometrically calculated positions and refined using a riding 
model. The isotropic displacement parameters of all hydrogen atoms were fixed to 1.2 
times the U value of the atoms they are linked to (1.5 times for methyl groups).  
2H-Ineleganolide (373) crystallizes in the orthorhombic space group P212121 with 
two molecules in the asymmetric unit. The coordinates for all hydrogen atoms were 
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Table A11.2.2. Crystal Data and Structure Refinement for of 2H-Ineleganolide (373). 
Caltech Identification code  p15149 
CCDC Deposition Number 1061016 
Empirical formula  C19 H24 O5 
Formula weight  332.38 
Temperature  100 K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 10.4079(3) Å α= 90° 
 b = 14.7042(4) Å β= 90° 
 c = 21.8592(6) Å γ = 90° 
Volume 3345.33(16) Å3 
Z 8 
Density (calculated) 1.320 Mg/m3 
Absorption coefficient 0.776 mm-1 
F(000) 1424 
Crystal size 0.11 x 0.10 x 0.05 mm3 
Theta range for data collection 3.623 to 79.108°. 
Index ranges –12 ≤ h ≤ 13, –18 ≤ k ≤ 18, –27 ≤ l ≤ 27 
Reflections collected 46504 
Independent reflections 7174 [R(int) = 0.0796] 
Completeness to theta = 66.500° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9591 and 0.8890 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7174 / 0 / 625 
Goodness-of-fit on F2 1.059 
Final R indices [I>2sigma(I)] R1 = 0.0395, wR2 = 0.0780 
R indices (all data) R1 = 0.0533, wR2 = 0.0832 
Absolute structure parameter 0.00(9) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.164 and -0.204 e.Å-3 
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Table A11.2.3.       Atomic coordinates (x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for 2H-Ineleganolide (373).  U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor.  
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(5) -3492(18) 56047(13) 60617(9) 257(4) 
O(2) 5550(20) 41629(12) 48143(9) 272(5) 
O(1) 15419(18) 40753(12) 57144(8) 224(4) 
O(4) 8710(20) 60085(16) 71685(10) 344(5) 
O(3) -5710(20) 77121(13) 43577(10) 317(5) 
C(15) 26550(30) 54941(17) 57380(12) 186(5) 
C(11) 18080(30) 61455(18) 61256(12) 217(6) 
C(10) 4620(30) 61450(18) 58779(12) 215(6) 
C(9) 1640(30) 67917(19) 53641(13) 239(6) 
C(8) 4060(30) 63525(18) 47397(13) 209(6) 
C(3) 17970(30) 60187(17) 46347(12) 183(5) 
C(2) 22450(30) 52704(17) 50825(11) 189(5) 
C(1) 13390(30) 44637(17) 51635(12) 205(5) 
C(14) 25330(30) 45637(18) 60602(12) 216(5) 
C(13) 20580(30) 47320(20) 67087(13) 270(6) 
C(12) 19300(30) 57710(20) 67840(12) 253(6) 
C(19) 31090(40) 61710(30) 70917(15) 386(8) 
C(7) -280(30) 70064(19) 42368(13) 236(6) 
C(6) 2140(30) 67000(20) 35906(13) 258(6) 
C(5) 16110(30) 63940(18) 34952(12) 228(6) 
C(4) 19450(30) 56703(18) 39723(12) 225(6) 
C(16) 25680(30) 71734(18) 34857(12) 216(6) 
C(18) 22410(30) 80350(20) 35596(13) 255(6) 
C(17) 39360(30) 69060(20) 33625(15) 283(6) 
O(5B) 59070(20) 50022(12) 60452(9) 262(4) 
O(2B) 40407(18) 34681(13) 49667(9) 239(4) 
O(1B) 48604(18) 29282(13) 58299(8) 230(4) 
O(4B) 76480(20) 44953(14) 70004(9) 308(5) 
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Table A11.2.3. (cont’d) 
O(3B) 73160(20) 59914(14) 40281(9) 348(5) 
C(15B) 71090(30) 30487(17) 56261(12) 189(5) 
C(11B) 76280(30) 39347(18) 59232(12) 207(5) 
C(10B) 68140(30) 47391(17) 57380(12) 214(5) 
C(9B) 71380(30) 51781(19) 51349(13) 257(6) 
C(8B) 64360(30) 47390(18) 45923(12) 197(5) 
C(3B) 67320(30) 37204(18) 44942(12) 196(5) 
C(2B) 63390(30) 30974(17) 50267(12) 184(5) 
C(1B) 49680(30) 31980(16) 52432(12) 198(5) 
C(14B) 61090(30) 26871(18) 60892(13) 216(6) 
C(13B) 63060(30) 31860(20) 66917(13) 237(6) 
C(12B) 75770(30) 37126(18) 66164(12) 224(6) 
C(19B) 87110(30) 31200(20) 68043(15) 315(7) 
C(7B) 67240(30) 52828(18) 40098(12) 232(6) 
C(6B) 61770(30) 49090(20) 34202(13) 250(6) 
C(5B) 64620(30) 38920(20) 33323(12) 247(6) 
C(4B) 60490(30) 33846(19) 39122(13) 229(6) 
C(16B) 78200(30) 36610(20) 31480(12) 292(7) 
C(18B) 87410(30) 42570(30) 30882(16) 402(8) 
C(17B) 80480(40) 26660(20) 30363(15) 382(8) 
________________________________________________________________________________ 
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Table A11.2.4.      Bond lengths [Å] and angles [°] for 2H-Ineleganolide (373). 
_____________________________________________________  
O(5)-C(10)  1.227(3) 
O(2)-C(1)  1.201(3) 
O(1)-C(1)  1.349(3) 
O(1)-C(14)  1.467(3) 
O(4)-H(4)  0.94(5) 
O(4)-C(12)  1.429(3) 
O(3)-C(7)  1.211(3) 
C(15)-H(15)  0.96(3) 
C(15)-C(11)  1.553(4) 
C(15)-C(2)  1.531(4) 
C(15)-C(14)  1.544(3) 
C(11)-H(11)  0.97(3) 
C(11)-C(10)  1.503(4) 
C(11)-C(12)  1.546(4) 
C(10)-C(9)  1.504(4) 
C(9)-H(9A)  1.00(4) 
C(9)-H(9B)  0.96(3) 
C(9)-C(8)  1.531(4) 
C(8)-H(8)  0.94(3) 
C(8)-C(3)  1.545(4) 
C(8)-C(7)  1.529(4) 
C(3)-H(3)  1.00(3) 
C(3)-C(2)  1.545(3) 
C(3)-C(4)  1.544(4) 
C(2)-H(2)  0.96(3) 
C(2)-C(1)  1.526(4) 
C(14)-H(14)  0.97(3) 
C(14)-C(13)  1.522(4) 
C(13)-H(13A)  0.99(3) 
C(13)-H(13B)  0.96(3) 
C(13)-C(12)  1.542(4) 
C(12)-C(19)  1.518(4) 
C(19)-H(19A)  0.98(4) 
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Table A11.2.4. (cont’d) 
C(19)-H(19B)  1.02(4) 
C(19)-H(19C)  0.98(4) 
C(7)-C(6)  1.504(4) 
C(6)-H(6A)  1.03(4) 
C(6)-H(6B)  0.94(4) 
C(6)-C(5)  1.536(4) 
C(5)-H(5)  1.03(3) 
C(5)-C(4)  1.530(4) 
C(5)-C(16)  1.519(4) 
C(4)-H(4A)  1.00(3) 
C(4)-H(4B)  1.00(3) 
C(16)-C(18)  1.322(4) 
C(16)-C(17)  1.501(4) 
C(18)-H(18A)  0.98(3) 
C(18)-H(18B)  1.02(3) 
C(17)-H(17A)  1.03(4) 
C(17)-H(17B)  1.07(4) 
C(17)-H(17C)  0.99(4) 
O(5B)-C(10B)  1.221(3) 
O(2B)-C(1B)  1.206(3) 
O(1B)-C(1B)  1.347(3) 
O(1B)-C(14B)  1.461(3) 
O(4B)-H(4BA)  0.90(4) 
O(4B)-C(12B)  1.426(3) 
O(3B)-C(7B)  1.211(3) 
C(15B)-H(15B)  0.96(3) 
C(15B)-C(11B)  1.552(4) 
C(15B)-C(2B)  1.538(4) 
C(15B)-C(14B)  1.547(4) 
C(11B)-H(11B)  0.91(3) 
C(11B)-C(10B)  1.510(4) 
C(11B)-C(12B)  1.551(4) 
C(10B)-C(9B)  1.506(4) 
C(9B)-H(9BA)  0.95(3) 
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Table A11.2.4. (cont’d) 
C(9B)-H(9BB)  0.99(3) 
C(9B)-C(8B)  1.535(4) 
C(8B)-H(8B)  0.97(3) 
C(8B)-C(3B)  1.544(4) 
C(8B)-C(7B)  1.533(4) 
C(3B)-H(3B)  1.00(3) 
C(3B)-C(2B)  1.537(4) 
C(3B)-C(4B)  1.539(4) 
C(2B)-H(2B)  0.99(3) 
C(2B)-C(1B)  1.511(4) 
C(14B)-H(14B)  0.98(3) 
C(14B)-C(13B)  1.522(4) 
C(13B)-H(13C)  1.02(3) 
C(13B)-H(13D)  1.02(3) 
C(13B)-C(12B)  1.541(4) 
C(12B)-C(19B)  1.523(4) 
C(19B)-H(19D)  0.92(4) 
C(19B)-H(19E)  0.98(4) 
C(19B)-H(19F)  1.00(3) 
C(7B)-C(6B)  1.512(4) 
C(6B)-H(6BA)  1.00(3) 
C(6B)-H(6BB)  1.00(4) 
C(6B)-C(5B)  1.537(4) 
C(5B)-H(5B)  0.98(3) 
C(5B)-C(4B)  1.532(4) 
C(5B)-C(16B)  1.508(4) 
C(4B)-H(4BB)  0.94(3) 
C(4B)-H(4BC)  1.05(3) 
C(16B)-C(18B)  1.305(5) 
C(16B)-C(17B)  1.503(5) 
C(18B)-H(18C)  1.03(4) 
C(18B)-H(18D)  0.89(3) 
C(17B)-H(17D)  1.07(3) 
C(17B)-H(17E)  1.00(4) 
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Table A11.2.4. (cont’d) 
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Table A11.2.4. (cont’d) 
H(17E)-C(17B)-H(17F) 104(3) 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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Table A11.2.5.  Anisotropic displacement parameters  (Å2x103) for 2H-Ineleganolide (373).  The 
anisotropic displacement factor exponent takes the form: -2π2[ h2a*2U11  + ... + 2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(5) 208(10)  281(10) 281(10)  1(9) 44(8)  2(8) 
O(2) 355(12)  181(9) 278(11)  -13(8) -41(8)  -37(8) 
O(1) 284(10)  179(9) 208(9)  7(8) 18(8)  -22(8) 
O(4) 364(13)  446(13) 222(11)  -58(10) 89(9)  54(11) 
O(3) 312(12)  266(11) 373(13)  61(9) 22(9)  104(9) 
C(15) 167(13)  185(12) 207(13)  15(10) 36(10)  -4(10) 
C(11) 259(15)  191(13) 201(13)  -42(11) 42(11)  -20(11) 
C(10) 226(13)  200(12) 219(13)  -58(11) 74(10)  30(11) 
C(9) 229(16)  221(13) 267(15)  8(11) 64(11)  47(12) 
C(8) 213(14)  176(12) 237(14)  7(11) 27(10)  -22(11) 
C(3) 190(13)  155(11) 203(13)  3(10) 21(10)  12(10) 
C(2) 219(13)  148(11) 199(13)  3(10) 63(10)  15(10) 
C(1) 265(15)  150(11) 201(13)  -12(10) 52(11)  37(10) 
C(14) 227(14)  211(12) 210(13)  29(11) 10(11)  12(11) 
C(13) 305(16)  301(15) 204(14)  39(12) 26(11)  -14(13) 
C(12) 255(15)  309(15) 196(13)  -45(11) 31(11)  -8(12) 
C(19) 410(20)  480(20) 267(17)  -45(16) -71(14)  -89(17) 
C(7) 167(13)  232(13) 310(15)  41(12) 3(11)  -26(11) 
C(6) 252(16)  263(14) 260(16)  21(12) -45(11)  -15(12) 
C(5) 317(16)  183(12) 183(13)  -16(11) 6(11)  -8(12) 
C(4) 283(15)  185(12) 207(13)  1(11) 24(11)  20(11) 
C(16) 254(15)  227(13) 166(13)  19(10) -11(11)  6(11) 
C(18) 252(16)  218(13) 296(15)  1(12) -19(11)  -21(12) 
C(17) 300(16)  279(15) 272(16)  -15(13) 8(12)  30(14) 
O(5B) 318(11)  205(9) 264(10)  -40(8) 20(8)  50(8) 
O(2B) 179(10)  255(9) 282(10)  -41(8) -45(7)  -18(8) 
O(1B) 200(10)  267(10) 223(10)  1(8) 10(8)  -25(8) 
O(4B) 413(13)  305(11) 205(10)  -40(8) -60(9)  -18(10) 
O(3B) 443(13)  300(11) 299(11)  48(9) 18(9)  -128(10) 
C(15B) 189(13)  167(12) 210(13)  -19(11) 18(10)  33(11) 
Appendix 11 – X-Ray Crystallography Reports Relevant to Chapter 4 586 
 
Table A11.2.5. (cont’d) 
C(11B) 163(13)  241(13) 216(13)  -12(10) 17(10)  -11(11) 
C(10B) 256(14)  170(12) 217(13)  -59(11) -29(11)  -55(11) 
C(9B) 333(17)  211(13) 227(14)  -1(11) -21(12)  -72(12) 
C(8B) 194(13)  189(13) 208(13)  -5(11) -12(10)  -21(11) 
C(3B) 192(14)  205(13) 192(13)  -16(10) 2(10)  6(11) 
C(2B) 217(14)  153(12) 181(13)  -30(10) -5(10)  9(10) 
C(1B) 232(14)  142(11) 220(13)  -56(10) 16(11)  -44(11) 
C(14B) 224(14)  189(13) 234(14)  22(11) -6(11)  9(11) 
C(13B) 258(15)  260(14) 194(14)  26(11) 23(11)  4(12) 
C(12B) 226(14)  249(13) 198(13)  -24(11) -9(10)  4(11) 
C(19B) 254(17)  402(19) 289(17)  34(15) -36(12)  43(14) 
C(7B) 228(14)  224(13) 244(14)  19(11) 11(11)  5(11) 
C(6B) 296(16)  275(15) 180(14)  4(12) -2(11)  50(13) 
C(5B) 256(15)  307(15) 179(13)  -24(12) -49(11)  43(12) 
C(4B) 287(16)  213(14) 188(13)  -33(11) -34(11)  -2(11) 
C(16B) 313(16)  423(17) 139(13)  -7(12) -26(11)  107(14) 
C(18B) 336(19)  520(20) 347(18)  -35(17) 49(14)  9(17) 
C(17B) 460(20)  449(19) 240(16)  -29(14) -45(15)  209(17) 
______________________________________________________________________________ 
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Table A11.2.6.      Hydrogen coordinates (x104) and isotropic  displacement parameters (Å2x103)  
for 2H-Ineleganolide (373). 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(4) 170(40) 5710(30) 6990(20) 75(15) 
H(15) 3530(30) 5708(19) 5753(13) 17(7) 
H(11) 2140(30) 6760(20) 6082(13) 23(8) 
H(9A) 700(30) 7350(20) 5401(15) 36(9) 
H(9B) -720(30) 6980(20) 5393(14) 26(8) 
H(8) -110(30) 5833(19) 4697(13) 19(7) 
H(3) 2400(30) 6536(19) 4701(12) 18(7) 
H(2) 2970(30) 4986(18) 4893(12) 14(7) 
H(14) 3310(30) 4190(20) 6025(13) 21(7) 
H(13A) 2650(30) 4460(20) 7015(14) 26(8) 
H(13B) 1240(30) 4460(20) 6779(14) 29(9) 
H(19A) 3000(30) 6830(20) 7103(15) 38(9) 
H(19B) 3940(40) 6020(30) 6863(19) 54(12) 
H(19C) 3160(30) 5920(20) 7510(17) 42(10) 
H(6A) -30(40) 7210(30) 3291(17) 54(12) 
H(6B) -330(40) 6210(20) 3506(16) 38(10) 
H(5) 1700(30) 6090(20) 3072(14) 24(8) 
H(4A) 2850(30) 5460(20) 3924(13) 20(7) 
H(4B) 1360(30) 5130(20) 3910(14) 23(8) 
H(18A) 2870(30) 8530(20) 3529(14) 28(8) 
H(18B) 1310(30) 8230(20) 3630(14) 28(8) 
H(17A) 4340(40) 6650(30) 3753(18) 56(12) 
H(17B) 4540(40) 7470(20) 3236(16) 44(10) 
H(17C) 4030(40) 6470(30) 3024(18) 51(11) 
H(4BA) 6990(40) 4840(30) 6858(18) 50(12) 
H(15B) 7820(30) 2630(17) 5594(11) 10(6) 
H(11B) 8460(30) 4023(19) 5804(13) 18(7) 
H(9BA) 8040(30) 5140(19) 5062(13) 21(8) 
H(9BB) 6870(30) 5820(20) 5157(14) 29(8) 
H(8B) 5510(30) 4784(19) 4640(13) 19(7) 
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Table A11.2.6. (cont’d) 
H(3B) 7680(30) 3641(19) 4428(12) 18(7) 
H(2B) 6320(30) 2470(20) 4867(13) 24(8) 
H(14B) 6150(30) 2020(20) 6113(15) 37(9) 
H(13C) 6320(30) 2770(20) 7065(15) 29(9) 
H(13D) 5590(30) 3649(18) 6748(12) 12(7) 
H(19D) 9470(40) 3410(20) 6706(15) 34(9) 
H(19E) 8710(40) 2510(30) 6616(17) 45(11) 
H(19F) 8690(30) 3040(20) 7259(15) 28(8) 
H(6BA) 6500(30) 5310(20) 3082(14) 25(8) 
H(6BB) 5220(40) 4950(20) 3449(15) 37(9) 
H(5B) 5920(30) 3680(20) 2994(15) 32(9) 
H(4BB) 6220(30) 2760(20) 3867(13) 23(8) 
H(4BC) 5050(30) 3464(19) 3980(12) 19(7) 
H(18C) 9650(40) 4090(30) 2945(18) 59(12) 
H(18D) 8630(30) 4860(20) 3113(14) 21(8) 
H(17D) 8130(30) 2300(20) 3454(15) 39(9) 
H(17E) 8870(40) 2560(20) 2804(16) 35(9) 
H(17F) 7350(40) 2410(20) 2756(17) 50(11) 
________________________________________________________________________________ 
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Symmetry transformations used to generate equivalent atoms:  
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Table A11.2.8.      Hydrogen bonds for 2H-Ineleganolide (373) [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(4)-H(4)...O(5) 0.94(5) 2.11(5) 2.796(3) 129(4) 
 C(15)-H(15)...O(3)#1 0.96(3) 2.52(3) 3.227(3) 131(2) 
 C(8)-H(8)...O(2) 0.94(3) 2.57(3) 3.228(3) 128(2) 
 C(2)-H(2)...O(2B) 0.96(3) 2.50(3) 3.253(3) 136(2) 
 C(14)-H(14)...O(1B) 0.97(3) 2.50(3) 3.450(3) 164(2) 
 O(4B)-H(4BA)...O(5B) 0.90(4) 2.12(4) 2.863(3) 139(3) 
 C(15B)-H(15B)...O(2B)#2 0.96(3) 2.39(3) 3.270(3) 151(2) 
 C(8B)-H(8B)...O(2B) 0.97(3) 2.57(3) 3.222(3) 125(2) 
 C(2B)-H(2B)...O(2)#2 0.99(3) 2.62(3) 3.440(3) 140(2) 
 C(2B)-H(2B)...O(1)#2 0.99(3) 2.61(3) 3.588(3) 169(2) 
 C(13B)-H(13D)...O(5B) 1.02(3) 2.54(3) 3.049(3) 110.7(18) 
 C(6B)-H(6BA)...O(4B)#3 1.00(3) 2.54(3) 3.449(4) 150(2) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 x+1/2,-y+3/2,-z+1    #2 x+1/2,-y+1/2,-z+1    #3 -x+3/2,-y+1,z-1/2       
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A11.3   X-Ray Crystal Structure Analysis of Diketone 375 
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Table A11.3.1. Experimental Details for X-Ray Structure Determination of Diketone 375. 
Low-temperature diffraction data (φ-and ω-scans) were collected on a Bruker AXS 
D8 VENTURE KAPPA diffractometer coupled to a PHOTON 100 CMOS detector with 
Mo Kα radiation (λ = 0.71073 Å) or Cu Kα radiation (λ = 1.54178 Å) from an IµS micro-
source for the structure of diketone 375. The structure was solved by direct methods 
using SHELXS1 and refined against F2 on all data by full-matrix least squares with 
SHELXL-20142 using established refinement techniques.3 All non-hydrogen atoms were 
refined anisotropically. All hydrogen atoms were included into the model at 
geometrically calculated positions and refined using a riding model. The isotropic 
displacement parameters of all hydrogen atoms were fixed to 1.2 times the U value of the 
atoms they are linked to (1.5 times for methyl groups).  
Diketone 375 crystallizes in the orthorhombic space group P212121 with one 
molecule in the asymmetric unit. The carbon atom C18 was refined a mixture of CH3 and 
CH2Cl. The ratio of the components was refined freely and converged to 757(3):0.243(3). 
The coordinates for the hydrogen atom bound to O4 was located in the difference Fourier 









Appendix 11 – X-Ray Crystallography Reports Relevant to Chapter 4 596 
 
Table A11.3.2. Crystal Data and Structure Refinement for Diketone 375. 
Caltech Identification code  P14028 
CCDC Deposition Number 1061015  
Empirical formula  C19 H23.76 Cl0.24 O5 
Formula weight  340.56 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 6.6417(3) Å α= 90°. 
 b = 10.7582(5) Å β= 90°. 
 c = 22.9878(11) Å γ = 90°. 
Volume 1642.54(13) Å3 
Z 4 
Density (calculated) 1.377 Mg/m3 
Absorption coefficient 1.151 mm-1 
F(000) 727 
Crystal size 0.350 x 0.150 x 0.050 mm3 
Theta range for data collection 3.846 to 74.625°. 
Index ranges –8 ≤ h ≤ 7, –13 ≤ k ≤ 11, –28 ≤ l ≤ 28 
Reflections collected 18385 
Independent reflections 3362 [R(int) = 0.0393] 
Completeness to theta = 67.679° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7538 and 0.6487 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3362 / 1 / 232 
Goodness-of-fit on F2 1.002 
Final R indices [I>2sigma(I)] R1 = 0.0336, wR2 = 0.0822 
R indices (all data) R1 = 0.0351, wR2 = 0.0831 
Absolute structure parameter 0.042(17) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.223 and -0.189 e.Å-3 
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Table A11.3.3.       Atomic coordinates (x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for Diketone 375.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor.  
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 6910(2) 2659(1) 4395(1) 14(1) 
C(1) 8571(3) 3120(2) 4143(1) 13(1) 
O(2) 10204(2) 2731(2) 4290(1) 19(1) 
C(2) 8248(3) 4076(2) 3670(1) 13(1) 
C(3) 7555(3) 3408(2) 3103(1) 14(1) 
C(4) 9356(3) 2968(2) 2745(1) 18(1) 
C(5) 8713(3) 2419(2) 2154(1) 21(1) 
C(16) 7921(4) 3408(3) 1745(1) 28(1) 
C(17) 6089(5) 3400(3) 1508(1) 47(1) 
C(18) 9323(4) 4471(3) 1626(1) 34(1) 
Cl(1) 11943(4) 4100(2) 1619(1) 27(1) 
C(6) 7236(3) 1342(2) 2258(1) 22(1) 
C(7) 5511(3) 1689(2) 2657(1) 19(1) 
O(3) 3773(2) 1466(2) 2540(1) 27(1) 
C(8) 6152(3) 2287(2) 3228(1) 16(1) 
C(9) 4353(3) 2574(2) 3621(1) 18(1) 
C(10) 4943(3) 3148(2) 4212(1) 14(1) 
C(11) 4959(3) 4564(2) 4214(1) 14(1) 
C(12) 5086(3) 5184(2) 4830(1) 17(1) 
O(4) 6490(2) 4544(2) 5196(1) 20(1) 
C(20) 3034(4) 5305(2) 5117(1) 23(1) 
C(13) 6126(4) 6418(2) 4707(1) 21(1) 
C(14) 7684(3) 6082(2) 4255(1) 18(1) 
O(5) 9351(3) 6511(2) 4192(1) 28(1) 
C(15) 6758(3) 5076(2) 3867(1) 14(1) 
________________________________________________________________________________ 
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Table A11.3.4.      Bond lengths [Å] and angles [°] for Diketone 375. 
_____________________________________________________  
O(1)-C(1)  1.341(2) 
O(1)-C(10)  1.470(2) 
C(1)-O(2)  1.210(3) 
C(1)-C(2)  1.513(3) 
C(2)-C(15)  1.530(3) 
C(2)-C(3)  1.558(3) 
C(2)-H(2)  1.0000 
C(3)-C(4)  1.527(3) 
C(3)-C(8)  1.551(3) 
C(3)-H(3)  1.0000 
C(4)-C(5)  1.541(3) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-C(16)  1.514(3) 
C(5)-C(6)  1.537(3) 
C(5)-H(5)  1.0000 
C(16)-C(17)  1.333(4) 
C(16)-C(18)  1.500(4) 
C(17)-H(17A)  0.9500 
C(17)-H(17B)  0.9500 
C(18)-Cl(1)  1.786(4) 
C(18)-H(18A)  0.9800 
C(18)-H(18B)  0.9800 
C(18)-H(18C)  0.9800 
C(18)-H(18D)  0.9900 
C(18)-H(18E)  0.9900 
C(6)-C(7)  1.515(3) 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(7)-O(3)  1.210(3) 
C(7)-C(8)  1.522(3) 
C(8)-C(9)  1.529(3) 
C(8)-H(8)  1.0000 
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Table A11.3.4. (cont’d) 
C(9)-C(10)  1.544(3) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(10)-C(11)  1.523(3) 
C(10)-H(10)  1.0000 
C(11)-C(15)  1.539(3) 
C(11)-C(12)  1.567(3) 
C(11)-H(11)  1.0000 
C(12)-O(4)  1.432(3) 
C(12)-C(20)  1.520(3) 
C(12)-C(13)  1.523(3) 
O(4)-H(4O)  0.86(2) 
C(20)-H(20A)  0.9800 
C(20)-H(20B)  0.9800 
C(20)-H(20C)  0.9800 
C(13)-C(14)  1.510(3) 
C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 
C(14)-O(5)  1.208(3) 
C(14)-C(15)  1.531(3) 
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Symmetry transformations used to generate equivalent atoms:  
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Table A11.3.5.  Anisotropic displacement parameters  (Å2x103) for Diketone 375.  The anisotropic 
displacement factor exponent takes the form: -2π2[ h2a*2U11  + ... + 2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 14(1)  13(1) 16(1)  2(1) 1(1)  2(1) 
C(1) 15(1)  14(1) 12(1)  -2(1) 0(1)  0(1) 
O(2) 15(1)  24(1) 17(1)  4(1) -2(1)  4(1) 
C(2) 14(1)  14(1) 12(1)  0(1) -2(1)  -2(1) 
C(3) 15(1)  15(1) 12(1)  -1(1) -3(1)  1(1) 
C(4) 16(1)  22(1) 15(1)  -2(1) 1(1)  -2(1) 
C(5) 22(1)  24(1) 16(1)  -6(1) 2(1)  2(1) 
C(16) 42(1)  31(1) 12(1)  -5(1) -1(1)  1(1) 
C(17) 66(2)  38(2) 37(2)  5(1) -28(2)  -7(2) 
C(18) 40(1)  39(2) 24(1)  7(1) 4(1)  1(1) 
Cl(1) 33(1)  26(1) 22(1)  -1(1) 10(1)  -12(1) 
C(6) 24(1)  24(1) 20(1)  -8(1) -2(1)  2(1) 
C(7) 20(1)  17(1) 21(1)  -4(1) -2(1)  -1(1) 
O(3) 21(1)  33(1) 29(1)  -13(1) -4(1)  -5(1) 
C(8) 15(1)  17(1) 17(1)  -3(1) -1(1)  -1(1) 
C(9) 14(1)  20(1) 21(1)  -6(1) 0(1)  -3(1) 
C(10) 12(1)  14(1) 17(1)  0(1) 0(1)  0(1) 
C(11) 14(1)  14(1) 14(1)  0(1) -2(1)  1(1) 
C(12) 23(1)  14(1) 14(1)  -1(1) -1(1)  1(1) 
O(4) 24(1)  19(1) 16(1)  1(1) -4(1)  -2(1) 
C(20) 26(1)  19(1) 24(1)  -2(1) 6(1)  4(1) 
C(13) 31(1)  14(1) 19(1)  -3(1) 2(1)  -1(1) 
C(14) 27(1)  12(1) 16(1)  3(1) -2(1)  -2(1) 
O(5) 31(1)  26(1) 25(1)  -6(1) 2(1)  -12(1) 
C(15) 17(1)  13(1) 12(1)  2(1) -2(1)  1(1) 
______________________________________________________________________________ 
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Table A11.3.6.      Hydrogen coordinates (x104) and isotropic  displacement parameters (Å2x103)  
for Diketone 375. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 9568 4489 3589 16 
H(3) 6785 4021 2863 17 
H(4A) 10101 2329 2968 21 
H(4B) 10277 3677 2678 21 
H(5) 9945 2058 1970 25 
H(17A) 5676 4066 1264 57 
H(17B) 5197 2729 1582 57 
H(18A) 8930 4881 1263 51 
H(18B) 10703 4157 1591 51 
H(18C) 9252 5069 1948 51 
H(18D) 9093 5118 1925 41 
H(18E) 8964 4836 1245 41 
H(6A) 6681 1068 1879 27 
H(6B) 7978 632 2429 27 
H(8) 6986 1657 3438 19 
H(9A) 3596 1796 3692 22 
H(9B) 3443 3156 3415 22 
H(10) 3925 2870 4505 17 
H(11) 3695 4858 4022 16 
H(4O) 5980(40) 3830(20) 5286(13) 29 
H(20A) 2460 4476 5179 35 
H(20B) 2138 5789 4865 35 
H(20C) 3180 5729 5492 35 
H(13A) 5162 7038 4553 25 
H(13B) 6768 6753 5062 25 
H(15) 6215 5492 3511 17 
________________________________________________________________________________ 
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Symmetry transformations used to generate equivalent atoms:  
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Table A11.3.8.      Hydrogen bonds for Diketone 375 [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 C(18)-H(18E)...O(4)#1 0.99 2.52 3.498(3) 169.0 
 C(6)-H(6B)...Cl(1)#2 0.99 2.74 3.576(3) 142.2 
 C(8)-H(8)...Cl(1)#2 1.00 2.84 3.671(3) 140.5 
 C(10)-H(10)...O(2)#3 1.00 2.52 3.184(2) 123.2 
 O(4)-H(4O)...O(2)#4 0.86(2) 2.01(2) 2.849(2) 164(3) 
 C(20)-H(20A)...O(1)#4 0.98 2.52 3.462(3) 160.2 
 C(20)-H(20B)...O(5)#3 0.98 2.53 3.491(3) 165.2 
 C(20)-H(20C)...Cl(1)#5 0.98 2.60 3.512(3) 155.1 
 C(15)-H(15)...O(3)#6 1.00 2.63 3.580(2) 158.1 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+3/2,-y+1,z-1/2    #2 -x+2,y-1/2,-z+1/2    #3 x-1,y,z       
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